



(51) International Patent Classification:

A61K 31/4196 (2006.01) C07D 403/14 (2006.01)

(21) International Application Number:

PCT/US2018/032368

(22) International Filing Date:

11 May 2018 (11.05.2018)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/505,384 12 May 2017 (12.05.2017) US

(71) Applicant: BOARD OF TRUSTEES OF THE SOUTHERN ILLINOIS UNIVERSITY ON BEHALF OF SOUTHERN ILLINOIS UNIVERSITY EDWARDSVILLE [US/US]; Campus Box 1046, Edwardsville, Illinois 62026 (US).

(72) Inventors: WITT, Kenneth A.; c/o BOARD OF TRUSTEES OF THE SOUTHERN ILLINOIS UNIVERSITY ON BEHALF OF SOUTHERN ILLINOIS UNIVERSITY EDWARDSVILLE, Campus Box 1046, Edwardsville, Illinois 62026 (US). CRIDER, Albert M.; c/o BOARD OF TRUSTEES OF THE SOUTHERN ILLINOIS UNIVERSITY ON BEHALF OF SOUTHERN ILLINOIS UNIVERSITY EDWARDSVILLE, Campus Box 1046, Edwardsville, Illinois 62026 (US). NEUMANN, William; c/o BOARD OF TRUSTEES OF THE SOUTHERN ILLINOIS UNIVERSITY ON BEHALF OF SOUTHERN ILLINOIS UNIVERSITY EDWARDSVILLE, Campus Box 1046, Edwardsville, Illinois 62026 (US). HOSPITAL, Audrey; c/o BOARD OF TRUSTEES OF THE SOUTHERN ILLINOIS UNIVERSITY ON BEHALF OF SOUTHERN ILLINOIS UNIVERSITY EDWARDSVILLE, Campus Box 1046, Edwardsville, Illinois 62025 (US). SANDOVAL, Karin; c/o BOARD OF TRUSTEES OF THE SOUTHERN ILLINOIS UNIVERSITY ON BEHALF OF SOUTHERN ILLINOIS UNIVERSITY EDWARDSVILLE, Campus Box 1046, Edwardsville, Illinois 62025 (US). KONTOYIANNI, Maria; c/o BOARD OF TRUSTEES OF THE SOUTHERN ILLINOIS UNIVERSITY ON BEHALF OF SOUTHERN ILLINOIS UNIVERSITY EDWARDSVILLE, Campus Box 1046, Edwardsville, Illinois 62025 (US).

(74) Agent: NEALEY, Tara A. et al.; POLSINELLI SHUGHART PC, 100 South Fourth Street, Suite 1100, St. Louis, Missouri 63102-1825 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,

HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report (Rule 48.2(g))

(54) Title: 3,4,5-TRISUBSTITUTED-1,2,4-TRIAZOLES AND 3,4,5-TRISUBSTITUTED-3-THIO-1,2,4-TRIAZOLES AND USES THEREOF

(57) Abstract: The present disclosure describes novel compounds that are somatostatin receptor type 4 agonists.



WO 2018/209267 A2

3,4,5-TRISUBSTITUTED-1,2,4-TRIAZOLES AND 3,4,5-TRISUBSTITUTED-3-THIO-1,2,4-TRIAZOLES AND USES THEREOF

GOVERNMENTAL RIGHTS


[0001] This invention was made with government support under grant number AG047858 awarded by the National Institutes of Health. The government has certain rights in the invention.

TECHNICAL FIELD

[0002] The present disclosure relates to compounds that are somatostatin receptor type 4 agonists.

BACKGROUND


[0003] Somatostatin, also known as somatostatin release inhibitory factor (SRIF) is a cyclic peptide distributed throughout the human body, and is involved in numerous physiological processes. SRIF occurs as a tetradecapeptide and an N-terminally extended form (SST-28).



[0004] There are six somatostatin receptor (SSTR) subtypes; SSTR 1-5, including the alternatively spliced SSTR2A and SSTR2B receptors. The somatostatin receptors were originally divided into two families based on binding studies with iodinated synthetic analogues of somatostatin; a high affinity family (SRIF-1) and a lower affinity family (SRIF-2). When SRIF binds to its receptors, it produces changes in intracellular signaling pathways. SSTRs are all G-protein coupled receptors (GPCRs). Through receptor action, SRIF produces primarily inhibitory effects on endocrine and exocrine secretions throughout the body, regulates cellular differentiation and proliferation, and acts as a neurotransmitter/neuromodulator in the central nervous system. Given SRIF has shown to exhibit inhibitory actions on endocrine and exocrine secretions, as well as numerous modulatory effects on neuronal activity in the periphery and central nervous system (CNS), the respective receptors have become primary therapeutic targets.

SUMMARY

[0005] One aspect of the disclosure encompasses a compound comprising Formula (I):



wherein

$\diagdown$ are independently a single bond or is absent;

A, B, and C are independently C, N, O, or S;

R¹ and R⁷ are independently hydrogen, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted C₁-C₆ alkyl, substituted or unsubstituted cycloalkyl, or substituted or unsubstituted fused ring system;

R² is substituted or unsubstituted C₁-C₆ alkyl;


R³, R⁴, and R⁵ are independently hydrogen, F, Cl, Br, I, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted amine, sulfoxide, sulfone, thiosulfinate, thiosulfonate, thioamide, sulfimide, sulfoximide, sulfonediimine, or sulfur halide;

R⁶ and R⁸ are independently hydrogen, F, Cl, Br, I, substituted or unsubstituted C₁-C₆ alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted cycloalkyl; and

R⁹ is a substituted or unsubstituted C₁-C₃ alkyl;

with the proviso that when R⁹ is C₂ alkyl, R⁷ is not a 3,4-dichlorobenzene; or a pharmaceutically acceptable salt thereof.

[0006] Another aspect of the disclosure encompasses a compound of Formula (II):



wherein

$\diagup \diagdown$ are independently a bond or is absent;

A, B, and C are independently C, N, O, or S;

D is S, O, NR^{16} , or P;

R^1 and R^7 are independently hydrogen, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted $\text{C}_1\text{-C}_6$ alkyl, substituted or unsubstituted cycloalkyl or substituted or unsubstituted fused ring system;

R^2 is substituted or unsubstituted $\text{C}_1\text{-C}_6$ alkyl;

R^3 , R^4 , and R^5 are independently hydrogen, F, Cl, Br, I, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted amine, sulfoxide, sulfone, thiosulfinate, thiosulfonate, thioamide, sulfimide, sulfoximide, sulfonediimine, or sulfur halide;

R^6 and R^8 are independently hydrogen, F, Cl, Br, I, substituted or unsubstituted $\text{C}_1\text{-C}_6$ alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted cycloalkyl;

R^9 and R^{15} are independently substituted or unsubstituted $\text{C}_1\text{-C}_6$ alkyl; and

R^{16} is hydrogen, $\text{C}_1\text{-C}_6$ alkyl, aryl, or benzyl;

or a pharmaceutically acceptable salt thereof.


DETAILED DESCRIPTION

[0007] The present disclosure provides compounds of Formula (I) and Formula (II), which have been found to be somatostatin receptor type 4 agonists.

[0008] Various aspects of the disclosure are described in greater detail below.

I. COMPOUNDS OF FORMULA (I)

[0009] Provided herein are compounds comprising Formula (I)



wherein

$\diagup$ and $\diagdown$ are independently a single bond or is absent;

A, B, and C are independently C, N, O, or S;

R^1 and R^7 are independently hydrogen, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted C_1 - C_6 alkyl, substituted or unsubstituted cycloalkyl, or substituted or unsubstituted fused ring system;

R^2 is substituted or unsubstituted C_1 - C_6 alkyl;

R^3 , R^4 , and R^5 are independently hydrogen, F, Cl, Br, I, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted amine, sulfoxide, sulfone, thiosulfinate, thiosulfonate, thioamide, sulfimide, sulfoximide, sulfonediimine, or sulfur halide;

R^6 and R^8 are independently hydrogen, F, Cl, Br, I, substituted or unsubstituted C_1 - C_6 alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted cycloalkyl; and

R^9 is a substituted or unsubstituted C_1 - C_3 alkyl;

with the proviso that when R^9 is C_2 alkyl, R^7 is not a 3,4-dichlorobenzene; or a pharmaceutically acceptable salt thereof.

[0010] In one aspect, a compound of Formula (I) comprises any of the preceding compounds of Formula (I), wherein $\backslash$ are each a single bond and A, B, and C are N.

[0011] In another aspect, a compound of Formula (I) comprises any of the preceding compounds of Formula (I), wherein R^6 and R^8 are independently hydrogen or substituted or unsubstituted C_1 - C_3 alkyl.

[0012] In another aspect, a compound of Formula (I) comprises any of the preceding compounds of Formula (I), wherein R^6 and R^8 are hydrogen.

[0013] In another aspect, a compound of Formula (I) comprises any of the preceding compounds of Formula (I), wherein R^6 and R^8 are substituted or unsubstituted C_1 - C_2 alkyl.


[0014] In another aspect, a compound of Formula (I) comprises any of the preceding compounds of Formula (I), wherein R^1 and R^7 are independently substituted or unsubstituted aryl or substituted or unsubstituted fused ring system.

[0015] In another aspect, a compound of Formula (I) comprises any of the preceding compounds of Formula (I), wherein R^1 is substituted or unsubstituted fused ring system.

[0016] In another aspect, a compound of Formula (I) comprises any of the preceding compounds of Formula (I), wherein R^1 is substituted or unsubstituted indole.

[0017] In another aspect, a compound of Formula (I) comprises any of the preceding compounds of Formula (I), wherein R^9 is substituted or unsubstituted aryl.

[0018] In another aspect, a compound of Formula (I) comprises any of the



preceding compounds of Formula (I), wherein R^9 is

[0019] In another aspect, a compound of Formula (I) comprises any of the preceding compounds of Formula (I), wherein R^{10} , R^{11} , R^{12} , R^{13} , and R^{14} is independently hydrogen, F, Cl, Br, I, substituted or unsubstituted alkyl, substituted or

unsubstituted alkoxy, substituted or unsubstituted amine, sulfoxide, sulfone, thiosulfinate, thiosulfonate, thioamide, sulfimide, sulfoximide, sulfonediimine, or sulfur halide.

[0020] In another aspect, a compound of Formula (I) comprises any of the preceding compounds of Formula (I), wherein R^{10} , R^{11} , R^{12} , R^{13} , and R^{14} is independently hydrogen, F, Cl, Br, I, CF_3 , OCH_3 , NO_2 , $OCH_2(C_6H_4)$, C_6H_4 , SO_2CH_3 , or OCF_3 .

[0021] In another aspect, a compound of Formula (I) comprises any of the preceding compounds of Formula (I), wherein R^2 is substituted or unsubstituted C_1 - C_3 alkyl.

[0022] In another aspect, a compound of Formula (I) comprises any of the preceding compounds of Formula (I), wherein R^2 is substituted or unsubstituted propyl.

[0023] In another aspect, a compound of Formula (I) comprises any of the preceding compounds of Formula (I), wherein R^2 is unsubstituted propyl.


[0024] In another aspect, a compound of Formula (I) comprises any of the preceding compounds of Formula (I), wherein R^3 , R^4 , and R^5 are independently hydrogen, F, Cl, Br, I, substituted or unsubstituted alkyl.


[0025] In another aspect, a compound of Formula (I) comprises any of the preceding compounds of Formula (I), wherein R^3 , R^4 , and R^5 are hydrogen.


[0026] In another aspect, a compound of Formula (I) comprises any of the preceding compounds of Formula (I), wherein R^9 is methyl.


[0027] In another aspect, a compound of Formula (I) comprises any of the preceding compounds of Formula (I), wherein R^9 is ethyl.


[0028] In another aspect, a compound of Formula (I) comprises any of the preceding compounds of Formula (I), may be selected from the group consisting of:











[0029] In another aspect, a compound of the disclosure comprises Formula (I), wherein $\diagup$ and $\diagdown$ are single bonds; A, B, and C are nitrogen; R^1 is 3-indole; R^2 is propyl; R^3 , R^4 , and R^5 are hydrogen; R^6 and R^8 are hydrogen; R^9 is methyl; R^7 is benzene; R^{10} , R^{11} , R^{13} , and R^{14} are hydrogen; and R^{12} is fluoro.

[0030] In another aspect, a compound of the disclosure comprises Formula (I), wherein $\diagup$ and $\diagdown$ are single bonds; A, B, and C are nitrogen; R^1 is 3-indole; R^2 is propyl; R^3 , R^4 , and R^5 are hydrogen; R^6 and R^8 are hydrogen; R^9 is ethyl; R^7 is benzene; R^{11} , R^{12} , R^{13} , and R^{14} are hydrogen; and R^{10} is chloro.

[0031] In another aspect, a compound of the disclosure comprises Formula (I), wherein $\diagup$ and $\diagdown$ are single bonds; A, B, and C are nitrogen; R^1 is 3-indole; R^2 is propyl; R^3 , R^4 , and R^5 are hydrogen; R^6 and R^8 are hydrogen; R^9 is ethyl; R^7 is benzene; and R^{10} , R^{11} , R^{12} , R^{13} , and R^{14} are hydrogen.

[0032] In another aspect, a compound of the disclosure comprises Formula (I), wherein $\diagup$ and $\diagdown$ are single bonds; A, B, and C are nitrogen; R^1 is 3-indole; R^2 is propyl; R^3 , R^4 , and R^5 are hydrogen; R^6 and R^8 are hydrogen; R^9 is ethyl; R^7 is benzene; R^{10} , R^{11} , R^{13} , and R^{14} are hydrogen; and R^{12} is chloro.

[0033] In another aspect, a compound of the disclosure comprises Formula (I), wherein $\diagup$ and $\diagdown$ are single bonds; A, B, and C are nitrogen; R^1 is 3-indole; R^2 is propyl; R^3 , R^4 , and R^5 are hydrogen; R^6 and R^8 are hydrogen; R^9 is ethyl; R^7 is benzene; R^{10} , R^{12} , R^{13} , and R^{14} are hydrogen; and R^{11} is chloro.

[0034] In another aspect, a compound of the disclosure comprises Formula (I), wherein $\diagup$ and $\diagdown$ are single bonds; A, B, and C are nitrogen; R^1 is 3-indole; R^2 is propyl; R^3 , R^4 , and R^5 are hydrogen; R^6 and R^8 are hydrogen; R^9 is 1-aminoethyl; R^7 is benzene; R^{10} , R^{12} , R^{13} , and R^{14} are hydrogen; and R^{11} is chloro.

[0035] In another aspect, a compound of the disclosure comprises Formula (I), wherein $\diagup$ and $\diagdown$ are single bonds; A, and C are nitrogen; B is carbon; R^1 is 3-indole; R^2 is propyl; R^3 , R^4 , and R^5 are hydrogen; R^6 and R^8 are hydrogen; R^9 is ethyl; R^7 is benzene; R^{10} , R^{11} , R^{13} , and R^{14} are hydrogen; and R^{12} is chloro.

[0036] In another aspect, a compound of the disclosure comprises Formula (I), wherein $\diagup$ and $\diagdown$ are single bonds; A, B, and C are nitrogen; R¹ is 3-indole; R² is propyl; R³, R⁴, and R⁵ are hydrogen; R⁶ and R⁸ are hydrogen; R⁹ is ethyl; R⁷ is benzene; R¹⁰, R¹¹, R¹³, and R¹⁴ are hydrogen; and R¹² is methoxy.

[0037] In another aspect, a compound of the disclosure comprises Formula (I), wherein $\diagup$ and $\diagdown$ are single bonds; A, B, and C are nitrogen; R¹ is 3-indole; R² is propyl; R³, R⁴, and R⁵ are hydrogen; R⁶ and R⁸ are hydrogen; R⁹ is ethyl; R⁷ is benzene; R¹⁰, R¹², R¹³, and R¹⁴ are hydrogen; and R¹¹ is bromo.

[0038] In another aspect, a compound of the disclosure comprises Formula (I), wherein $\diagup$ and $\diagdown$ are single bonds; A, B, and C are nitrogen; R¹ is 3-indole; R² is propyl; R³, R⁴, and R⁵ are hydrogen; R⁶ and R⁸ are hydrogen; R⁹ is ethyl; R⁷ is benzene; R¹⁰, R¹², R¹³, and R¹⁴ are hydrogen; and R¹¹ is fluoro.

[0039] In another aspect, a compound of the disclosure comprises Formula (II), wherein $\diagup$ and $\diagdown$ are single bonds; A, B, and C are nitrogen; R¹ is 3-indole; R² is propyl; R³, R⁴, and R⁵ are hydrogen; R⁶ and R⁸ are hydrogen; R⁹ is ethyl; R⁷ is benzene; R¹⁰, R¹², R¹³, and R¹⁴ are hydrogen; and R¹¹ is trifluoromethyl.

[0040] In another aspect, a compound of the disclosure comprises Formula (I), wherein $\diagup$ and $\diagdown$ are single bonds; A, B, and C are nitrogen; R¹ is 1-methyl-3-indole; R² is propyl; R³, R⁴, and R⁵ are hydrogen; R⁶ and R⁸ are hydrogen; R⁹ is ethyl; R⁷ is benzene; R¹⁰, R¹², R¹³, and R¹⁴ are hydrogen; and R¹¹ is trifluoromethyl.

[0041] In another aspect, a compound of the disclosure comprises Formula (I), wherein $\diagup$ and $\diagdown$ are single bonds; A, B, and C are nitrogen; R¹ is 3-indole; R² is propyl; R³, R⁴, and R⁵ are hydrogen; R⁶ and R⁸ are hydrogen; R⁹ is ethyl; R⁷ is benzene; R¹⁰, R¹², R¹³, and R¹⁴ are hydrogen; and R¹¹ is methoxy.

[0042] In another aspect, a compound of the disclosure comprises Formula (I), wherein $\diagup$ and $\diagdown$ are single bonds; A, B, and C are nitrogen; R¹ is 3-indole; R² is propyl; R³, R⁴, and R⁵ are hydrogen; R⁶ and R⁸ are hydrogen; R⁹ is ethyl; R⁷ is benzene; R¹⁰, R¹², and R¹⁴ are hydrogen; and R¹¹ and R¹³ are chloro.

[0043] In another aspect, a compound of the disclosure comprises Formula (I), wherein $\diagup$ and $\diagdown$ are single bonds; A, B, and C are nitrogen; R^1 is 1-methyl-3-indole; R^2 is propyl; R^3 , R^4 , and R^5 are hydrogen; R^6 and R^8 are hydrogen; R^9 is ethyl; R^7 is benzene; R^{10} , R^{13} , and R^{14} are hydrogen; and R^{11} and R^{12} are chloro.

[0044] In another aspect, a compound of the disclosure comprises Formula (I), wherein $\diagup$ and $\diagdown$ are single bonds; A, B, and C are nitrogen; R^1 is 3-indole; R^2 is propyl; R^3 , R^4 , and R^5 are hydrogen; R^6 and R^8 are hydrogen; R^9 is ethyl; R^7 is benzene; R^{10} , R^{11} , R^{13} , and R^{14} are hydrogen; and R^{12} is benzyl.

[0045] In another aspect, a compound of the disclosure comprises Formula (I), wherein $\diagup$ and $\diagdown$ are single bonds; A, B, and C are nitrogen; R^1 is 3-indole; R^2 is propyl; R^3 , R^4 , and R^5 are hydrogen; R^6 and R^8 are hydrogen; R^9 is ethyl; R^7 is benzene; R^{10} , R^{12} , R^{13} , and R^{14} are hydrogen; and R^{11} is oxomethylbenzene.

[0046] In another aspect, a compound of the disclosure comprises Formula (I), wherein $\diagup$ and $\diagdown$ are single bonds; A, B, and C are nitrogen; R^1 is 3-indole; R^2 is propyl; R^3 , R^4 , and R^5 are hydrogen; R^6 and R^8 are hydrogen; R^9 is ethyl; R^7 is benzene; R^{10} , R^{12} , R^{13} , and R^{14} are hydrogen; and R^{11} is sulfonylmethane.

[0047] In another aspect, a compound of the disclosure comprises Formula (I), wherein $\diagup$ and $\diagdown$ are single bonds; A, B, and C are nitrogen; R^1 is 3-indole; R^2 is propyl; R^3 , R^4 , and R^5 are hydrogen; R^6 and R^8 are hydrogen; R^9 is ethyl; R^7 is benzene; R^{10} , R^{12} , R^{13} , and R^{14} are hydrogen; and R^{11} is trifluoromethoxy.

[0048] In another aspect, a compound of the disclosure comprises Formula (I), wherein $\diagup$ and $\diagdown$ are single bonds; A, B, and C are nitrogen; R^1 is 3-indole; R^2 is propyl; R^3 , R^4 , and R^5 are hydrogen; R^6 and R^8 are hydrogen; R^9 is ethyl; R^7 is benzene; R^{11} , R^{12} , R^{13} , and R^{14} are hydrogen; and R^{10} is methoxy.

[0049] In another aspect, a compound of the disclosure comprises Formula (I), wherein $\diagup$ and $\diagdown$ are single bonds; A, B, and C are nitrogen; R^1 is 3-indole; R^2 is propyl; R^3 , R^4 , and R^5 are hydrogen; R^6 and R^8 are hydrogen; R^9 is ethyl; R^7 is benzene; R^{10} , R^{12} , and R^{14} are hydrogen; and R^{11} and R^{13} are fluoro.

[0050] In another aspect, a compound of the disclosure comprises Formula (I), wherein $\backslash \backslash$ are single bonds; A, B, and C are nitrogen; R¹ is 3-indole; R² is propyl; R³, R⁴, and R⁵ are hydrogen; R⁶ and R⁸ are hydrogen; R⁹ is ethyl; R⁷ is benzene; R¹⁰, R¹², R¹³, and R¹⁴ are hydrogen; and R¹¹ is nitro.

[0051] In another aspect, a compound of the disclosure comprises Formula (I), wherein $\backslash \backslash$ are single bonds; A, B, and C are nitrogen; R¹ is 3-indole; R² is propyl; R³, R⁴, and R⁵ are hydrogen; R⁶ and R⁸ are hydrogen; R⁹ is ethyl; R⁷ is benzene; R¹⁰, R¹², R¹³, and R¹⁴ are hydrogen; and R¹¹ is cyano.

[0052] In another aspect, a compound of the disclosure comprises Formula (I), wherein $\backslash \backslash$ are single bonds; A, B, and C are nitrogen; R¹ is 3-indole; R² is propyl; R³, R⁴, and R⁵ are hydrogen; R⁶ and R⁸ are hydrogen; R⁹ is methyl; R⁷ is benzene; R¹⁰, R¹¹, R¹³, and R¹⁴ are hydrogen; and R¹² is methoxy.

[0053] In another aspect, a compound of the disclosure comprises Formula (I), wherein $\backslash \backslash$ are single bonds; A, B, and C are nitrogen; R¹ is 5-methoxy-3-indole; R² is propyl; R³, R⁴, and R⁵ are hydrogen; R⁶ and R⁸ are hydrogen; R⁹ is methyl; R⁷ is benzene; R¹⁰, R¹¹, R¹³, and R¹⁴ are hydrogen; and R¹² is fluoro.

[0054] In another aspect, a compound of the disclosure comprises Formula (I), wherein $\backslash \backslash$ are single bonds; A, B, and C are nitrogen; R¹ is 5-methoxy-3-indole; R² is propyl; R³, R⁴, and R⁵ are hydrogen; R⁶ and R⁸ are hydrogen; R⁹ is methyl; R⁷ is benzene; R¹⁰, R¹¹, R¹², R¹³, and R¹⁴ are hydrogen.

[0055] In another aspect, a compound of the disclosure comprises Formula (I), wherein $\backslash \backslash$ are single bonds; A, B, and C are nitrogen; R¹ is 5-methoxy-3-indole; R² is propyl; R³, R⁴, and R⁵ are hydrogen; R⁶ and R⁸ are hydrogen; R⁹ is methyl; R⁷ is benzene; R¹⁰, R¹¹, R¹³, and R¹⁴ are hydrogen; and R¹² is methoxy.

[0056] In another aspect, a compound of the disclosure comprises Formula (I), wherein $\backslash \backslash$ are single bonds; A, B, and C are nitrogen; R¹ is 5-methoxy-3-indole; R² is propyl; R³, R⁴, and R⁵ are hydrogen; R⁶ and R⁸ are hydrogen; R⁹ is methyl; R⁷ is benzene; R¹⁰, R¹², R¹³, and R¹⁴ are hydrogen; and R¹¹ is trifluoromethyl.

[0057] In another aspect, a compound of the disclosure comprises Formula (I), wherein $\diagup$ are single bonds; A, B, and C are nitrogen; R¹ is 6-fluoro-3-indole; R² is propyl; R³, R⁴, and R⁵ are hydrogen; R⁶ and R⁸ are hydrogen; R⁹ is methyl; R⁷ is benzene; R¹⁰, R¹¹, R¹³, and R¹⁴ are hydrogen; and R¹² is fluoro.

[0058] In another aspect, a compound of the disclosure comprises Formula (I), wherein $\diagup$ are single bonds; A, B, and C are nitrogen; R¹ is 6-fluoro-3-indole; R² is propyl; R³, R⁴, and R⁵ are hydrogen; R⁶ and R⁸ are hydrogen; R⁹ is methyl; R⁷ is benzene; R¹⁰, R¹¹, R¹³, and R¹⁴ are hydrogen; and R¹² is methoxy.

[0059] In another aspect, a compound of the disclosure comprises Formula (I), wherein $\diagup$ are single bonds; A, B, and C are nitrogen; R¹ is 6-fluoro-3-indole; R² is propyl; R³, R⁴, and R⁵ are hydrogen; R⁶ and R⁸ are hydrogen; R⁹ is methyl; R⁷ is 6-fluoro-3-indole.

[0060] In another aspect, a compound of the disclosure comprises Formula (I), wherein $\diagup$ are single bonds; A, B, and C are nitrogen; R¹ is 3-indole; R² is propyl; R³, R⁴, and R⁵ are hydrogen; R⁶ and R⁸ are hydrogen; R⁹ is methyl; R⁷ is benzene; R¹⁰, R¹¹, R¹³, and R¹⁴ are hydrogen; and R¹² is fluoro.

[0061] In another aspect, a compound of the disclosure comprises Formula (I), wherein $\diagup$ are single bonds; A, B, and C are nitrogen; R¹ is 3-indole; R² is propyl; R³, R⁴, and R⁵ are hydrogen; R⁶ and R⁸ are hydrogen; R⁹ is methyl; R⁷ is benzene; R¹⁰, R¹¹, R¹², R¹³, and R¹⁴ are hydrogen.

[0062] In another aspect, a compound of the disclosure comprises Formula (I), wherein $\diagup$ are single bonds; A, B, and C are nitrogen; R¹ is 3-indole; R² is propyl; R³, R⁴, and R⁵ are hydrogen; R⁶ and R⁸ are hydrogen; R⁹ is methyl; R⁷ is benzene; R¹⁰, R¹¹, R¹³, and R¹⁴ are hydrogen; and R¹² is chloro.

[0063] In another aspect, a compound of the disclosure comprises Formula (I), wherein $\diagup$ are single bonds; A, B, and C are nitrogen; R¹ is 3-indole; R² is propyl; R³, R⁴, and R⁵ are hydrogen; R⁶ and R⁸ are hydrogen; R⁹ is methyl; R⁷ is benzene; R¹⁰, R¹², R¹³, and R¹⁴ are hydrogen; and R¹¹ is trifluoromethyl.

[0064] In another aspect, a compound of the disclosure comprises Formula (I), wherein $\diagup$ are single bonds; A, B, and C are nitrogen; R¹ is 6-fluoro-3-indole; R² is propyl; R³, R⁴, and R⁵ are hydrogen; R⁶ and R⁸ are hydrogen; R⁹ is methyl; R⁷ is benzene; R¹⁰, R¹², R¹³, and R¹⁴ are hydrogen; and R¹¹ is trifluoromethyl.

[0065] In another aspect, a compound of the disclosure comprises Formula (I), wherein $\diagup$ are single bonds; A, B, and C are nitrogen; R¹ is 3-indole; R² is propyl; R³, R⁴, and R⁵ are hydrogen; R⁶ and R⁸ are hydrogen; R⁹ is methyl; R⁷ is benzene; R¹⁰, R¹², R¹³, and R¹⁴ are hydrogen; and R¹¹ is sulfonylmethane.


[0066] In another aspect, a compound of the disclosure comprises Formula (I), wherein $\diagup$ are single bonds; A, B, and C are nitrogen; R¹ is 6-fluoro-3-indole; R² is propyl; R³, R⁴, and R⁵ are hydrogen; R⁶ and R⁸ are hydrogen; R⁹ is methyl; R⁷ is benzene; R¹⁰, R¹¹, R¹², R¹³, and R¹⁴ are hydrogen.

[0067] In another aspect, a compound of the disclosure comprises Formula (I), wherein $\diagup$ are single bonds; A, B, and C are nitrogen; R¹ is 6-fluoro-3-indole; R² is propyl; R³, R⁴, and R⁵ are hydrogen; R⁶ and R⁸ are hydrogen; R⁹ is methyl; R⁷ is benzene; R¹⁰, R¹², R¹³, and R¹⁴ are hydrogen; and R¹¹ is bromo.

[0068] In another aspect, a compound of the disclosure comprises Formula (I), wherein $\diagup$ are single bonds; A, B, and C are nitrogen; R¹ is 6-fluoro-3-indole; R² is propyl; R³, R⁴, and R⁵ are hydrogen; R⁶ and R⁸ are hydrogen; R⁹ is methyl; R⁷ is *tert*-butyl.

II. COMPOUNDS OF FORMULA (II)

[0069] Also provided herein are compounds comprising Formula (II)



wherein

$\diagup \diagdown$ are independently a single bond or is absent;

A, B, and C are independently C, N, O, or S;

D is S, O, NR^{16} , or P;

R^1 and R^7 are independently hydrogen, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted $\text{C}_1\text{-C}_6$ alkyl, substituted or unsubstituted cycloalkyl or substituted or unsubstituted fused ring system;

R^2 is substituted or unsubstituted $\text{C}_1\text{-C}_6$ alkyl;

R^3 , R^4 , and R^5 are independently hydrogen, F, Cl, Br, I, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted amine, sulfoxide, sulfone, thiosulfinate, thiosulfonate, thioamide, sulfimide, sulfoximide, sulfonediimine, or sulfur halide.

R^6 and R^8 are independently hydrogen, F, Cl, Br, I, substituted or unsubstituted $\text{C}_1\text{-C}_6$ alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted cycloalkyl;

R^9 and R^{15} are independently substituted or unsubstituted $\text{C}_1\text{-C}_6$ alkyl; and

R^{16} is hydrogen, $\text{C}_1\text{-C}_6$ alkyl, aryl, or benzyl;

or a pharmaceutically acceptable salt thereof.

[0070] In one aspect, a compound of Formula (II) comprises any of the preceding compounds of Formula (II), wherein $\diagup$ and $\diagdown$ are each a single bond and A, B, and C are N.

[0071] In another aspect, a compound of Formula (II) comprises any of the preceding compounds of Formula (II), wherein D is S.

[0072] In another aspect, a compound of Formula (II) comprises any of the preceding compounds of Formula (II), wherein R⁹ is a bond.

[0073] In another aspect, a compound of Formula (II) comprises any of the preceding compounds of Formula (II), wherein R¹⁵ is unsubstituted C₁-C₃ alkyl.

[0074] In another aspect, a compound of Formula (II) comprises any of the preceding compounds of Formula (II), wherein R¹⁵ is unsubstituted C₁-C₂ alkyl.

[0075] In another aspect, a compound of Formula (II) comprises any of the preceding compounds of Formula (II), wherein R⁶ and R⁸ are independently hydrogen or substituted or unsubstituted C₁-C₃ alkyl.

[0076] In another aspect, a compound of Formula (II) comprises any of the preceding compounds of Formula (II), wherein R⁶ and R⁸ are hydrogen.


[0077] In another aspect, a compound of Formula (II) comprises any of the preceding compounds of Formula (II), wherein R¹ and R⁷ are independently substituted or unsubstituted aryl or substituted or unsubstituted fused ring system.

[0078] In another aspect, a compound of Formula (II) comprises any of the preceding compounds of Formula (II), wherein R¹ is substituted or unsubstituted fused ring system.

[0079] In still another aspect, a compound of Formula (II) comprises any of the preceding compounds of Formula (II), wherein R¹ is substituted or unsubstituted indole, substituted or unsubstituted naphthalene, or substituted or unsubstituted quinolone.

[0080] In another aspect, a compound of Formula (II) comprises any of the preceding compounds of Formula (II), wherein R⁷ is substituted or unsubstituted aryl or substituted or unsubstituted indole.

[0081] In another aspect, a compound of Formula (II) comprises any of the



preceding compounds of Formula (II), wherein R^7 is

[0082] In another aspect, a compound of Formula (II) comprises any of the preceding compounds of Formula (II), wherein R^{10} , R^{11} , R^{12} , R^{13} , and R^{14} is independently hydrogen, F, Cl, Br, I, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted amine, sulfoxide, sulfone, thiosulfinate, thiosulfonate, thioamide, sulfimide, sulfoximide, sulfonediimine, or sulfur halide.

[0083] In another aspect, a compound of Formula (II) comprises any of the preceding compounds of Formula (II), wherein R^{10} , R^{11} , R^{12} , R^{13} , and R^{14} is independently hydrogen, F, Cl, Br, I, CF_3 , OCH_3 , NO_2 , $OCH_2(C_6H_4)$, C_6H_4 , SO_2CH_3 , or OCF_3 .

[0084] In another aspect, a compound of Formula (II) comprises any of the preceding compounds of Formula (II), wherein R^2 is substituted or unsubstituted C_1 - C_3 alkyl.


[0085] In another aspect, a compound of Formula (II) comprises any of the preceding compounds of Formula (II), wherein R^2 is substituted or unsubstituted propyl.

[0086] In yet another aspect, a compound of Formula (II) comprises any of the preceding compounds of Formula (II), wherein R^2 is unsubstituted propyl.

[0087] In another aspect, a compound of Formula (II) comprises any of the preceding compounds of Formula (II), wherein R^3 , R^3 , and R^4 are independently hydrogen, F, Cl, Br, I, substituted or unsubstituted alkyl.

[0088] In another aspect, a compound of Formula (II) comprises any of the preceding compounds of Formula (II), wherein R^3 , R^3 , and R^4 are hydrogen.

[0089] In another aspect, a compound of Formula (II) comprises any of the preceding compounds of Formula (II), may be selected from the group consisting of:



[0090] In another aspect, a compound of the disclosure comprises Formula (II), wherein $\diagup$ are single bonds; A, B, and C are nitrogen; D is sulfur; R^1 is 2-quinoline; R^2 is propyl; R^3 , R^4 , R^5 , R^6 and R^8 are hydrogen; R^7 is aryl; R^9 is absent; R^{15} is methyl; and R^{10} , R^{11} , R^{12} , R^{13} , and R^{14} are hydrogen.

[0091] In another aspect, a compound of the disclosure comprises Formula (II), wherein $\diagup$ are single bonds; A, B, and C are nitrogen; D is sulfur; R^1 is 2-quinoline;

R² is propyl; R³, R⁴, R⁵, R⁶ and R⁸ are hydrogen; R⁷ is 3-indole; R⁹ is absent; R¹⁵ is ethyl; and R¹⁰, R¹¹, R¹², R¹³, and R¹⁴ are hydrogen.

[0092] In another aspect, a compound of the disclosure comprises Formula (II), wherein  are single bonds; A, B, and C are nitrogen; D is sulfur; R¹ is 2-naphthalene; R² is propyl; R³, R⁴, R⁵, R⁶ and R⁸ are hydrogen; R⁷ is benzene; R⁹ is absent; R¹⁵ is methyl; and R¹⁰, R¹¹, R¹², R¹³, and R¹⁴ are hydrogen.

[0093] In another aspect, a compound of the disclosure comprises Formula (II), wherein  are single bonds; A, B, and C are nitrogen; D is sulfur; R¹ is 5-fluoro-3-indole; R² is propyl; R³, R⁴, R⁵, R⁶ and R⁸ are hydrogen; R⁷ is benzene; R⁹ is absent; R¹⁵ is methyl; and R¹⁰, R¹¹, R¹², R¹³, and R¹⁴ are hydrogen.

[0094] In another aspect, a compound of the disclosure comprises Formula (II), wherein  are single bonds; A, B, and C are nitrogen; D is sulfur; R¹ is 1-naphthalene; R² is propyl; R³, R⁴, R⁵, R⁶ and R⁸ are hydrogen; R⁷ is benzene; R⁹ is absent; R¹⁵ is methyl; and R¹⁰, R¹¹, R¹², R¹³, and R¹⁴ are hydrogen.

[0095] In another aspect, a compound of the disclosure comprises Formula (II), wherein  are single bonds; A, B, and C are nitrogen; D is sulfur; R¹ is 3-indole; R² is propyl; R³, R⁴, R⁵, R⁶ and R⁸ are hydrogen; R⁷ is benzene; R⁹ is absent; R¹⁵ is methyl; and R¹⁰, R¹¹, R¹², R¹³, and R¹⁴ are hydrogen.

[0096] In another aspect, a compound of the disclosure comprises Formula (II), wherein  are single bonds; A, B, and C are nitrogen; D is sulfur; R¹ is aryl; R² is propyl; R³, R⁴, R⁵, R⁶ and R⁸ are hydrogen; R⁷ is benzene; R⁹ is absent; R¹⁵ is methyl; and R¹⁰, R¹¹, R¹², R¹³, and R¹⁴ are hydrogen.

[0097] In another aspect, a compound of the disclosure comprises Formula (II), wherein  are single bonds; A, B, and C are nitrogen; D is sulfur; R¹ is 3-methoxy-aryl; R² is propyl; R¹⁵ is carbon; and R³, R⁴, R⁵, R⁶, R⁷, and R⁸ are hydrogen.

[0098] In another aspect, a compound of the disclosure comprises Formula (II), wherein  are single bonds; A, B, and C are nitrogen; D is sulfur; R¹ is 2-indole; R² is propyl; R³, R⁴, and R⁵ are hydrogen; R⁷ is benzene; R⁹ is absent; R¹⁵ is methyl; and R¹⁰, R¹¹, R¹², R¹³, and R¹⁴ are hydrogen.

[0099] In another aspect, a compound of the disclosure comprises Formula (II), wherein $\backslash$ are single bonds; A, B, and C are nitrogen; D is sulfur; R^1 is benzene; R^2 is propyl; R^{15} is carbon; and R^3 , R^4 , R^5 , R^6 , R^7 , and R^8 are hydrogen.

[0100] In another aspect, a compound of Formula (II) comprises any of the preceding compounds of Formula (II), wherein R^{12} is an unsubstituted C_1 - C_3 alkyl.

[0101] In another aspect, a compound of Formula (II) comprises any of the preceding compounds of Formula (II), wherein R^{15} is unsubstituted C_1 - C_6 alkyl.

[0102] In another aspect, a compound of Formula (II) comprises any of the preceding compounds of Formula (II), wherein R^{15} is unsubstituted C_1 - C_3 alkyl.

[0103] In another aspect, a compound of Formula (II) comprises any of the preceding compounds of Formula (II), wherein R^6 and R^8 are independently hydrogen or substituted or unsubstituted C_1 - C_3 alkyl.

[0104] In another aspect, a compound of Formula (II) comprises any of the preceding compounds of Formula (II), wherein R^6 and R^8 are hydrogen.


[0105] In another aspect, a compound of Formula (II) comprises any of the preceding compounds of Formula (II), wherein R^1 and R^7 are independently substituted or unsubstituted aryl or substituted or unsubstituted fused ring system.

[0106] In another aspect, a compound of Formula (II) comprises any of the preceding compounds of Formula (II), wherein R^1 is substituted or unsubstituted fused ring system.

[0107] In still another aspect, a compound of Formula (II) comprises any of the preceding compounds of Formula (II), wherein R^1 is substituted or unsubstituted indole.

[0108] In another aspect, a compound of Formula (II) comprises any of the preceding compounds of Formula (II), wherein R^7 is substituted or unsubstituted aryl.

[0109] In still another aspect, a compound of Formula (II) comprises any of



the preceding compounds of Formula (II), wherein R^7 is

[0110] In another aspect, a compound of Formula (II) comprises any of the preceding compounds of Formula (II), wherein R^{10} , R^{11} , R^{12} , R^{13} , and R^{14} is independently hydrogen, F, Cl, Br, I, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted amine, sulfoxide, sulfone, thiosulfinate, thiosulfonate, thioamide, sulfimide, sulfoximide, sulfonediimine, or sulfur halide.

[0111] In another aspect, a compound of Formula (II) comprises any of the preceding compounds of Formula (II), wherein R^{10} , R^{11} , R^{12} , R^{13} , and R^{14} is independently hydrogen, F, Cl, Br, I, CF_3 , OCH_3 , NO_2 , $OCH_2(C_6H_4)$, C_6H_4 , SO_2CH_3 , or OCF_3 .


[0112] In another aspect, a compound of Formula (II) comprises any of the preceding compounds of Formula (II), wherein R^2 is substituted or unsubstituted propyl.


[0113] In another aspect, a compound of Formula (II) comprises any of the preceding compounds of Formula (II), wherein R^2 is unsubstituted propyl.

[0114] In another aspect, a compound of Formula (II) comprises any of the preceding compounds of Formula (II), wherein R^3 , R^3 , and R^4 are independently hydrogen, F, Cl, Br, I, substituted or unsubstituted alkyl.

[0115] In another aspect, a compound of Formula (II) comprises any of the preceding compounds of Formula (II), wherein R^3 , R^3 , and R^4 are hydrogen.

[0116] In another aspect, a compound of Formula (II) comprises any of the preceding compounds of Formula (II), may be selected from the group consisting of:





[0117] In another aspect, a compound of the disclosure comprises Formula (II), wherein $\diagup$ are single bonds; A, B, and C are nitrogen; D is sulfur; R¹ is 3-indole; R² is propyl; and R³, R⁴, and R⁵ are hydrogen; R⁶ and R⁸ are hydrogen; R⁹ is ethyl; R¹⁵ is methyl; R⁷ is benzene; and R¹⁰, R¹¹, R¹², R¹³, and R¹⁴ are hydrogen.

[0118] In another aspect, a compound of the disclosure comprises Formula (II), wherein $\diagup$ are single bonds; A, B, and C are nitrogen; D is sulfur; R¹ is 3-indole; R² is propyl; and R³, R⁴, and R⁵ are hydrogen; R⁶ and R⁸ are hydrogen; R⁹ is ethyl; R¹⁵ is methyl; R⁷ is benzene; R¹⁰, R¹¹, R¹², and R¹⁴ are hydrogen; and R¹³ is chloro.

[0119] In another aspect, a compound of the disclosure comprises Formula (II), wherein $\diagup$ are single bonds; A, B, and C are nitrogen; D is sulfur; R¹ is 3-indole; R² is propyl; and R³, R⁴, and R⁵ are hydrogen; R⁶ and R⁸ are hydrogen; R⁹ is ethyl; R¹⁵ is methyl; R⁷ is benzene; R¹⁰, R¹¹, R¹², and R¹⁴ are hydrogen; and R¹³ is fluoro.

[0120] In another aspect, a compound of the disclosure comprises Formula (II), wherein $\diagup$ are single bonds; A, B, and C are nitrogen; D is sulfur; R¹ is 3-indole; R² is propyl; and R³, R⁴, and R⁵ are hydrogen; R⁶ and R⁸ are hydrogen; R⁹ is ethyl; R¹⁵ is methyl; R⁷ is benzene; R¹⁰, R¹¹, and R¹⁴ are hydrogen; and R¹² and R¹³ are chloro.

[0121] In another aspect, a compound of the disclosure comprises Formula (II), wherein $\diagup$ are single bonds; A, B, and C are nitrogen; D is sulfur; R¹ is benzene; R² is propyl; and R³, R⁴, and R⁵ are hydrogen; R⁶ and R⁸ are hydrogen; R⁹ is ethyl; R¹⁵ is methyl; R⁷ is benzene; and R¹⁰, R¹¹, R¹², R¹³, and R¹⁴ are hydrogen.

[0122] In another aspect, a compound of the disclosure comprises Formula (II), wherein $\diagup$ are single bonds; A, B, and C are nitrogen; D is sulfur; R¹ is 3-indole; R² is propyl; and R³, R⁴, and R⁵ are hydrogen; R⁶ and R⁸ are hydrogen; R⁹ is methyl; R¹⁵ is methyl; R⁷ is benzene; and R¹⁰, R¹¹, R¹², R¹³, and R¹⁴ are hydrogen.

[0123] In another aspect, a compound of the disclosure comprises Formula (II), wherein $\diagup$ are single bonds; A, B, and C are nitrogen; D is sulfur; R¹ is 3-indole; R² is propyl; and R³, R⁴, and R⁵ are hydrogen; R⁶ and R⁸ are hydrogen; R⁹ is methyl; R¹⁵ is methyl; R⁷ is benzene; R¹⁰, R¹¹, R¹², and R¹⁴ are hydrogen; and R¹³ is trifluoromethyl.

[0124] In another aspect, a compound of the disclosure comprises Formula (II), wherein  are single bonds; A, B, and C are nitrogen; D is sulfur; R¹ is 3-indole; R² is propyl; and R³, R⁴, and R⁵ are hydrogen; R⁶ and R⁸ are hydrogen; R⁹ is methyl; R¹⁵ is methyl; R⁷ is benzene; R¹⁰, R¹¹, R¹², and R¹⁴ are hydrogen; and R¹³ is fluoro.

[0125] In another aspect, a compound of the disclosure comprises Formula (II), wherein  are single bonds; A, B, and C are nitrogen; D is sulfur; R¹ is 3-indole; R² is propyl; and R³, R⁴, and R⁵ are hydrogen; R⁶ and R⁸ are hydrogen; R⁹ is methyl; R¹⁵ is methyl; R⁷ is benzene; R¹⁰, R¹¹, and R¹⁴ are hydrogen; and R¹² and R¹³ chloro.

[0126] In another aspect, a compound of the disclosure comprises Formula (II), wherein  are single bonds; A, B, and C are nitrogen; D is sulfur; R¹ is 3-indole; R² is propyl; and R³, R⁴, and R⁵ are hydrogen; R⁶ and R⁸ are hydrogen; R⁹ is methyl; R¹⁵ is methyl; R⁷ is benzene; R¹⁰, R¹¹, R¹², and R¹⁴ are hydrogen; and R¹³ is bromo.

[0127] In another aspect, a compound of the disclosure comprises Formula (II), wherein  are single bonds; A, B, and C are nitrogen; D is sulfur; R¹ is 3-fluorobenzene; R² is propyl; and R³, R⁴, and R⁵ are hydrogen; R⁶ and R⁸ are hydrogen; R⁹ is methyl; R¹⁵ is methyl; R⁷ is benzene; and R¹⁰, R¹¹, R¹², R¹³, and R¹⁴ are hydrogen.

[0128] In another aspect, a compound of the disclosure comprises Formula (II), wherein  are single bonds; A, B, and C are nitrogen; D is sulfur; R¹ is 3-indole; R² is propyl; and R³, R⁴, and R⁵ are hydrogen; R⁶ and R⁸ are hydrogen; R⁹ is methyl; R¹⁵ is methyl; R⁷ is benzene; and R¹⁰, R¹¹, R¹², R¹³, and R¹⁴ are hydrogen.

[0129] In another aspect, a compound of the disclosure comprises Formula (II), wherein  are single bonds; A, B, and C are nitrogen; D is sulfur; R¹ is 3-indole; R² is propyl; and R³, R⁴, and R⁵ are hydrogen; R⁶ and R⁸ are hydrogen; R⁹ is methyl; R¹⁵ is methyl; R⁷ is benzene; R¹⁰, R¹³, and R¹⁴ are hydrogen; and R¹¹ and R¹² is chloro.

[0130] In another aspect, a compound of the disclosure comprises Formula (II), wherein  are single bonds; A, B, and C are nitrogen; D is sulfur; R¹ is 3-indole; R² is propyl; and R³, R⁴, and R⁵ are hydrogen; R⁶ and R⁸ are hydrogen; R⁹ is methyl; R¹⁵ is methyl; R⁷ is benzene; R¹⁰, R¹¹, R¹³, and R¹⁴ are hydrogen; and R¹² is chloro.

[0131] In another aspect, a compound of the disclosure comprises Formula (II), wherein  are single bonds; A, B, and C are nitrogen; D is sulfur; R¹ is 3-indole; R² is propyl; and R³, R⁴, and R⁵ are hydrogen; R⁶ and R⁸ are hydrogen; R⁹ is methyl; R¹⁵ is methyl; R⁷ is benzene; R¹⁰, R¹¹, R¹³, and R¹⁴ are hydrogen; and R¹² is fluoro.

[0132] In another aspect, a compound of the disclosure comprises Formula (II), wherein  are single bonds; A, B, and C are nitrogen; D is sulfur; R¹ is 6-fluoro-3-indole; R² is propyl; and R³, R⁴, and R⁵ are hydrogen; R⁶, R⁷, and R⁸ are absent; R⁹ is methyl; R¹⁵ is methyl; R⁷ is benzene; R¹⁰, R¹¹, R¹³, and R¹⁴ are hydrogen; and R¹² is fluoro.

[0133] In another aspect, a compound of the disclosure comprises Formula (II), wherein  are single bonds; A, B, and C are nitrogen; D is sulfur; R¹ is 6-fluoro-3-indole; R² is propyl; and R³, R⁴, and R⁵ are hydrogen; R⁶, R⁷, and R⁸ are absent; R⁹ is methyl; R¹⁵ is benzene; R¹⁰, R¹¹, R¹³, and R¹⁴ are hydrogen; and R¹² is methyl.

[0134] In another aspect, a compound of the disclosure comprises Formula (II), wherein  are single bonds; A, B, and C are nitrogen; D is sulfur; R¹ is 6-fluoro-3-indole; R² is propyl; and R³, R⁴, and R⁵ are hydrogen; R⁶, R⁷, and R⁸ are absent; R⁹ is methyl; R¹⁵ is benzene; R¹⁰, R¹², R¹³, and R¹⁴ are hydrogen; and R¹¹ is methoxy.

[0135] In another aspect, a compound of the disclosure comprises Formula (II), wherein  are single bonds; A, B, and C are nitrogen; D is sulfur; R¹ is 6-fluoro-3-indole; R² is propyl; and R³, R⁴, and R⁵ are hydrogen; R⁶, R⁷, and R⁸ are absent; R⁹ is methyl; R¹⁵ is 5-pyridinyl.

[0136] It will be understood that depending upon the selection of certain substituents, certain compounds within the scope of general Formula (I) may be more readily synthesizable than other compounds also within the scope within Formula (I). Similarly, certain compounds within the scope of general Formula (II) are more readily synthesizable than other compounds also within the scope of general Formula (II). Art-recognized principles and routine methods can be used for identifying the most readily synthesized compounds within the scope of the disclosure.

[0137] In another aspect, the present disclosure provides processes of manufacture of the novel compounds as disclosed herein, and of any prodrug forms thereof.

[0138] In another aspect, the present disclosure provides a pharmaceutically acceptable salt, hydrate or solvate of any of the compounds disclosed herein, which are encompassed by general Formula (I) or Formula (II). Pharmaceutically acceptable salts include for example salts of inorganic or organic acids as well known in the art. Any compound of general Formula (I) or Formula (II), or a pharmaceutically acceptable salt, hydrate, solvate or prodrug of any thereof, is optionally combined with one or more pharmaceutically acceptable carriers or excipients to provide a pharmaceutical composition.

[0139] In another aspect, the present disclosure provides methods of using the 3,4,5-trisubstituted-1,2,4-triazoles and 3,4,5-trisubstituted-3-thio-1,2,4-triazole analogues disclosed herein as somatostatin receptor subtype-4 (SSTR4) agonists for use in the prevention and/or treatment of diseases or disorders related to SSTR4, *e.g.*, disorders caused or influenced by activation of SSTR4. Such disorders include but are not limited to various forms of pain, including chronic, acute, visceral and neuropathic pain; and inflammation and inflammation-related disorders. Thus, any of the novel compounds disclosed herein can be used as a medicament for the treatment of pain, inflammation or inflammation-related disorders. Inflammation-related disorders include disorders of the cardiovascular, respiratory, gastrointestinal, nervous and skeletal systems which involve inflammation. Such disorders include, for example, atherosclerosis; thrombosis; diseases of the lungs and airways such as asthma, bronchitis, chronic obstructive lung disease (COPD) and emphysema; diseases of the gastrointestinal system including pancreatitis, Crohn's disease, irritable bowel syndrome, and ulcerative colitis; diabetes-associated disorders such as diabetic nephropathy, neuropathy, retinopathy, and vasculopathy; disorders of the eye including conjunctivitis, blepharitis, iritis, uveitis and glaucoma; disorders of skeletal joints and connective tissue including arthritis and back pain; diseases and disorders of the central nervous system including epilepsy, dementia, Alzheimer's disease, learning disorders, neurodegenerative diseases such as Parkinson's Disease, multiple sclerosis, and

amyotrophic lateral sclerosis, and psychiatric disorders such as anxiety and depression; morbid obesity; and cancer including benign and malignant tumors.

[0140] Any of the compounds of Formula (I) or Formula (II) are useful for the prevention and/or treatment of pain or inflammation, such as pain or inflammation associated with any one of the diseases or disorders disclosed herein. According to the present disclosure, a method of treatment for pain or inflammation comprises administering a therapeutically effective amount of a compound of Formula (I) or Formula (II) to a subject in need thereof. The subject is a mammal, for example, a human. A therapeutically effective amount of the compound of Formula (I) or Formula (II) will vary with the compound, the subject, the degree and severity of the disorder being treated, and the route of administration, and can be readily determined according to guidance generally available to those of skill in the art, using routine methods of optimization as needed. Usually an effective amount is a range of about 0.01 milligrams (mg) to about 100 mg/kilogram (kg) of body weight of the subject, which may be contained in a single dose or in doses formulated for administration multiple (e.g., 2, 3 or 4) times per day. The therapeutically effective amount of the compound may be contained together with a pharmaceutically acceptable carrier or excipient in a pharmaceutical composition as described herein.

DEFINITIONS

[0141] When introducing elements of the different aspects as described herein, the articles "a," "an," "the," and "said" are intended to mean that there are one or more of the elements. The terms "comprising," "including," and "having" are intended to be inclusive and mean that there may be additional elements other than the listed elements.

[0142] As used herein, the following definitions shall apply unless otherwise indicated. For purposes of this invention, the chemical elements are identified in accordance with the Periodic Table of the Elements, CAS version, and the Handbook of Chemistry and Physics, 75th Ed. 1994. Additionally, general principles of organic chemistry are described in "Organic Chemistry," Thomas Sorrell, University Science Books, Sausalito: 1999, and "March's Advanced Organic Chemistry," 5th Ed., Smith, M.

B. and March, J., eds. John Wiley & Sons, New York: 2001, the entire contents of which are hereby incorporated by reference.

[0143] "Alkyl" as used herein alone or as part of a group refers to saturated monovalent hydrocarbon radicals having straight or branched hydrocarbon chains or, in the event that at least 3 carbon atoms are present, cyclic hydrocarbons or combinations thereof and contains 1 to 20 carbon atoms (C_{1-20} alkyl), 1 to 10 carbon atoms (C_{1-10} alkyl), 1 to 8 carbon atoms (C_{1-8} alkyl), 1 to 6 carbon atoms (C_{1-6} alkyl), or 1 to 4 carbon atoms (C_{1-4} alkyl). Examples of alkyl radicals include methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isoamyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and the like.

[0144] "Alkenyl" as used herein alone or as part of a group refers to monovalent hydrocarbon radicals having a straight or branched hydrocarbon chains having one or more double bonds and containing from 2 to about 18 carbon atoms, from 2 to about 8 carbon atoms, or from 2 to about 5 carbon atoms. Examples of suitable alkenyl radicals include ethenyl, propenyl, alkyl, 1,4-butadienyl and the like.

[0145] "Alkynyl" as used herein alone or as part of a group refers to monovalent hydrocarbon radicals having a straight or branched hydrocarbon chains having one or more triple bonds and containing from 2 to about 10 carbon atoms, or from 2 to about 5 carbon atoms. Examples of alkynyl radicals include ethynyl, propynyl, (propargyl), butynyl and the like.

[0146] "Aryl" as used herein, alone or as part of a group, includes an organic radical derived from an aromatic hydrocarbon by removal of one hydrogen, and includes monocyclic and polycyclic radicals, such as phenyl, biphenyl, naphthyl.

[0147] "Alkoxy" as used herein, alone or as part of a group, refers to an alkyl ether radical wherein the term alkyl is as defined above. Examples of alkyl ether radical include methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy and the like.

[0148] "Cycloalkyl" as used herein, alone or in combination, means a saturated or partially saturated monocyclic, bicyclic or tricyclic alkyl radical wherein each cyclic moiety contains from 3 to 8 carbon atoms, or from 3 to 6 carbon atoms.

Examples of such cycloalkyl radicals include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and the like.

[0149] "Cycloalkylalkyl" as used herein, alone or in combination, means an alkyl radical as defined above which is substituted by a cycloalkyl radical as defined above. Examples of such cycloalkylalkyl radicals include cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl, 1-cyclopentylethyl, 1-cyclohexylethyl, 2-cyclopentylethyl, 2-cyclohexylethyl, cyclobutylpropyl, cyclopentylpropyl, cyclohexylbutyl and the like.

[0150] "Substituted" means that one or more of the hydrogen atoms bonded to carbon atoms in the chain or ring have been replaced with other substituents. Suitable substituents include monovalent hydrocarbon groups including alkyl groups such as methyl groups and monovalent heterogeneous groups including alkoxy groups such as methoxy groups. "Unsubstituted" means that the carbon chain or ring contains no other substituents other than carbon and hydrogen.

[0151] "Hydrocarbon group" means a chain of 1 to 25 carbon atoms, 1 to 12 carbon atoms, 1 to 10 carbon atoms, or 1 to 8 carbon atoms. Hydrocarbon groups may have a linear or branched chain structure. Suitably the hydrocarbon groups have one branch.

[0152] "Carbocyclic group" means a saturated or unsaturated hydrocarbon ring. Carbocyclic groups are not aromatic. Carbocyclic groups are monocyclic or polycyclic. Polycyclic carbocyclic groups can be fused, spiro, or bridged ring systems. Monocyclic carbocyclic groups contain 4 to 10 carbon atoms, 4 to 7 carbon atoms, or 5 to 6 carbon atoms in the ring. Bicyclic carbocyclic groups contain 8 to 12 carbon atoms, or 9 to 10 carbon atoms in the rings.

[0153] "Heteroatom" means an atom other than carbon e.g., in the ring of a heterocyclic group or the chain of a heterogeneous group. Heteroatoms may be selected from the group consisting of sulfur, phosphorous, nitrogen, and oxygen atoms. Groups containing more than one heteroatom may contain different heteroatoms.

[0154] "Heterocyclic group" means a saturated or unsaturated ring structure containing carbon atoms and 1 or more heteroatoms in the ring. Heterocyclic groups are not aromatic. Heterocyclic groups are monocyclic or polycyclic. Polycyclic

heteroaromatic groups can be fused, spiro, or bridged ring systems. Monocyclic heterocyclic groups contain 4 to 10 member atoms (*i.e.*, including both carbon atoms and at least 1 heteroatom), 4 to 7, or 5 to 6 in the ring. Bicyclic heterocyclic groups contain 8 to 18 member atoms, 9 or 10 in the rings.

[0155] "Isomer," "isomeric form," "stereochemically isomeric forms," or "stereoisomeric forms", as used herein, defines all possible isomeric as well as conformational forms, made up of the same atoms bonded by the same sequence of bonds but having different three-dimensional structures which are not interchangeable, which compounds or intermediates obtained during said process may possess. Unless otherwise mentioned or indicated, the chemical designation of a compound encompasses the mixture of all possible stereochemically isomeric forms which said compound may possess. Said mixture may contain all diastereoisomers, epimers, enantiomers and/or conformers of the basic molecular structure of said compound. More in particular, stereogenic centers may have the R- or S-configuration, diastereoisomers may have a syn- or anti-configuration, substituents on bivalent cyclic saturated radicals may have either the cis- or trans-configuration and alkenyl radicals may have the E- or Z-configuration. All stereochemically isomeric forms of said compound both in pure form or in admixture with each other are intended to be embraced within the scope of the present disclosure.

EXAMPLES

[0156] The following examples are included to demonstrate various aspects of the present disclosure. It should be appreciated by those of skill in the art that the techniques disclosed in the examples that follow represent techniques discovered by the inventors to function well in the practice of the disclosure, and thus can be considered to constitute preferred modes for its practice. However, those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific examples which are disclosed and still obtain a like or similar result without departing from the spirit and scope of the disclosure.

[0157] The compounds of the present disclosure may be prepared in a number of ways well known to one skilled in the art of organic synthesis. More specifically, the

novel compounds of this disclosure may be prepared using the reactions and techniques described herein. In the description of the synthetic methods described below, it is to be understood that all proposed reaction conditions, including choice of solvent, reaction atmosphere, reaction temperature, duration of the experiment and workup procedures, are chosen to be the conditions standard for that reaction. It is understood by one skilled in the art of organic synthesis that the functionality present on various portions of the molecule must be compatible with the reagents and reactions proposed. Such restrictions to the substituents, which are not compatible with the reaction conditions, will be apparent to one skilled in the art and alternate methods must then be used. Unless otherwise stated, the starting materials for the examples contained herein are either commercially available or are readily prepared by standard methods from known materials. The compounds of Formula (I) or (II) may be synthesized through standard organic chemistry methodology and purification known to those trained in the art of organic synthesis by using commercially available starting materials and reagents.


[0158] All reactions were performed under a positive pressure of dry argon unless otherwise indicated. Analytical thin layer chromatography (TLC) was performed on ANALTECH 0.15 mm silica gel 60-GF254 plates. Visualization was accomplished with exposure to UV light, exposure to Iodine or by dipping in an ethanolic phosphomolybdic acid solution followed by heating. Solvents for extraction were HPLC or ACS grade. Flash chromatography was performed with DYNAMIC ADSORBENTS silica gel 60A (32-63 μ , 230-400 mesh) with the indicated solvent system. NMR spectra were collected on a JEOL ECS-400 NMR spectrometer. ^1H NMR spectra were reported in ppm from tetramethylsilane (TMS) on the δ scale. Data are reported as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, quint = quintet, etc.; m = multiplet, complex multiplets used where overlapping multiplets are not resolved, b = broadened, obs = obscured, ABq = AB quartet, "apparent" used (e.g. apparent t) when spin systems are distorted due to non-first order effects), coupling constants (Hz), and assignments or relative integration where appropriate. ^{13}C NMR spectra were reported in ppm from the central deuterated solvent peak (multiplicities indicated when determined). Grouped shifts are provided where an ambiguity has not

been resolved. LCMS were run on a WATERS ALLIANCE – SQ 3100 system using a Thermo Scientific HYPERSIL GOLD (C18, 4.6 x 150 mm, 5-Micron) column and acetonitrile-water (0.05% trifluoroacetic acid) gradients.

[0159] The following abbreviations are used herein: ACN = acetonitrile; CH₂Cl₂ = dichloromethane; DCC = *N,N*-Dicyclohexylcarbodiimide; DIAD = diisopropyl azodicarboxylate; DMF = dimethylformamide; DMSO = dimethylsulfoxide; EDC = *N*'-ethylcarbodiimide hydrochloride; HCl = hydrochloric acid; HOBt·H₂O = 1-hydroxybenzotriazole hydrate; HRMS = high resolution mass spectroscopy; Hz = hertz; LCMS = liquid chromatography mass spectroscopy; LiAlH₄ = lithium aluminum hydride; MeOH = methanol; Na₂SO₄ = sodium sulfate; TEA = triethylamine; TFA = trifluoroacetic acid; THF = tetrahydrofuran; Trt-Cl = trityl chloride; Pd/C = palladium on carbon; PPh₃ = triphenylphosphine; ppm = parts per million; and SiO₂ = silicon dioxide.


Example 1: Synthesis of 3,4,5-Trisubstituted-1,2,4-Triazoles

Synthesis of (E)-methyl 3-(1H-imidazol-4-yl)acrylate hydrochloride (2)




[0160] Urocanic acid **1** (25.0 g, 181 mmol) was suspended in MeOH (700 mL) and treated with 4N HCl/Dioxane (118 mL). The resulting mixture was stirred overnight at room temperature. Concentration of the reaction afforded 34.0 g (100% yield) of compound **2** as a white solid: ¹H NMR (400 MHz, DMSO-d₆) δ 9.17 (s, 1H), 8.01 (s, 1H), 7.54 (d, *J* = 16.0 Hz, 1H), 6.81 (d *J* = 16.0 Hz, 1H), 3.69 (s, 3H). LCMS (5-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 4.77 minutes, ESI *m/z* = 153, [M+H]⁺.

Synthesis of methyl 3-(1H-imidazol-4-yl)propanoate hydrochloride (3)




[0161] (E)-Methyl 3-(1H-imidazol-4-yl)acrylate hydrochloride (**2**) (29.4 g, 156 mmol) was dissolved in MeOH (700 mL) in an argon filled glovebox. To this solution was added 5% Pd/C (4 g). The mixture was brought out of the glovebox and fitted with a balloon of H₂ gas. The mixture was stirred for 48 hours at room temperature. During this time the balloon was periodically refilled with H₂. When the reaction was complete (as judged by LCMS analysis), the mixture was purged with argon and filtered through a pad of CELITE. Concentration of the filtrate afforded 28.9 g (98% yield) of compound **3** as a white solid: ¹H NMR (400 MHz, DMSO-d₆) δ 8.94 (s, 1H), 7.37 (s, 1H), 3.57 (s, 3H), 2.87 (t, *J* = 7.30 Hz, 2H), 2.71 (t, *J* = 7.30 Hz, 2H). ¹³C (100 MHz, DMSO-d₆) δ 172.58 (s), 133.92 (d), 132.55 (s), 116.13 (d), 52.08(q), 32.42 (t), 20.01 (t). LCMS (5-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 3.67 minutes, ESI *m/z* = 155, [M+H]⁺.


Synthesis of methyl 3-(1-trityl-1H-imidazol-4-yl)propanoate (4)



[0162] Methyl 3-(1H-imidazol-4-yl)propanoate hydrochloride (**3**) (15.0 g, 78.7 mmol) was dissolved in CH₂Cl₂ (400 mL) and treated with trimethylamine (23.0 mL, 165 mmol). To this stirred mixture was added a solution of triphenylmethyl chloride (21.9 g, 78.7 mmol) in CH₂Cl₂ (200 mL) dropwise. After stirring for 16 hours at room temperature, the mixture was transferred to a separatory funnel and washed with water (2 x 250 mL). The organic layer was dried (Na₂SO₄), filtered and concentrated. The residue was recrystallized from methanol-water to afford 24.1 g (77% yield) of compound **4** as a white solid: ¹H NMR (400 MHz, CHCl₃) δ 7.30-7.34 (complex multiplets, 10H), 7.08 – 7.13 (m, 5H), 6.53 (s, 1H), 3.60 (s, 3H), 2.86 (t, *J* = 7.80 Hz, 2H), 2.64 (t, *J* = 7.30 Hz, 2H). ¹³C NMR (100 MHz, CHCl₃) δ 173.70 (s), 142.51 (s), 139.97 (d), 138.46 (s), 129.86 (d), 128.08 (d), 118.18 (d), 75.61 (s), 51.61 (q), 33.97 (t), 23.93 (t). LCMS (50-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 3.78 minutes, ESI *m/z* = 397, [M+H]⁺.

Synthesis of 3-(1-trityl-1H-imidazol-4-yl)propan-1-ol (5)


[0163] To a solution of methyl 3-(1-trityl-1H-imidazol-4-yl)propanoate (**4**) (56.6 g, 143 mmol) in THF (300 mL) cooled in an ice-salt bath, was added LiAlH_4 (100 mL of a 2.4 M solution in THF, 240 mmol) drop-wise at a rate which maintained the temperature under 5 °C. The reaction was stirred at 0-5 °C for 10 minutes post-addition, allowed to warm to room temperature (~1 hour) and heated to reflux for 1 hour. The mixture was then cooled to 0-5 °C and carefully quenched by the drop-wise addition of 0.5 N NaOH (20 mL). The mixture was then filtered and the solids washed with CH_2Cl_2 . The filtrate was concentrated to afford 41.2 g (78% yield) of compound **5** as a white solid: ^1H NMR (400 MHz, CHCl_3) δ 7.37 (d, J = 1.40 Hz, 1H), 7.31 – 7.34 (m, 10H), 7.09 – 7.14 (m, 5H), 6.54 (s, 1H), 3.72 (t, J = 6.00 Hz, 2H), 2.68 (t, J = 6.90 Hz, 2H), 1.85 (quint., J = 6.8 Hz, 2H). ^{13}C NMR (100 MHz, CHCl_3) δ 142.92 (s), 141.57 (d), 138.10 (s), 129.72 (d), 128.69 (d), 128.46 (d), 117.85 (d), 74.84 (s), 60.79 (t), 32.75 (t), 24.96 (t). LCMS (50-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 2.97 minutes, ESI m/z = 369, $[\text{M}+\text{H}]^+$.

Synthesis of 2-(3-(1-trityl-1H-imidazol-4-yl)propyl)isoindoline-1,3-dione (6)

[0164] To a solution of 3-(1-trityl-1H-imidazol-4-yl)propan-1-ol (**5**) (11.0 g, 29.9 mmol) in THF (200 mL) was added phthalimide (6.51 g, 44.2 mmol) and triphenylphosphine (11.7 g, 44.6 mmol). The resulting mixture was cooled to 0-5 °C and treated with a solution of diisopropylazodicarboxylate (12.6 mL, 63.8 mmol) in THF (50 mL) dropwise over 2.5 hours. The reaction was allowed to stir for 16 hours and warm to room temperature. The solid product was filtered and washed with cold THF (100 mL).


The solid was triturated with hot ACN (~500 mL) and filtered to afford 13.1 g (88% yield) of compound **6** as a fine white powder: ^1H NMR (400 MHz, CHCl_3) δ 7.80 (ddd, J = 8.20, 5.00, 1.40 Hz, 2H), 7.68 (ddd, J = 8.20, 5.00, 1.40 Hz, 2H), 7.36 (d, J = 0.90 Hz, 1H), 7.29 – 7.33 (m, 10H), 7.09 – 7.14 (m, 5H), 6.57 (s, 1H), 3.71 (t, J = 6.90 Hz, 2H), 2.60 (t, J = 7.40 Hz, 2H), 1.99 (quint., J = 7.30 Hz, 2H). LCMS (50-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 5.35 minutes, ESI m/z = 498, $[\text{M}+\text{H}]^+$.

Synthesis of 3-(1-Trityl-1H-imidazol-4-yl)propan-1-amine (7)



[0165] A suspension of 2-(3-(1-trityl-1H-imidazol-4-yl)propyl)isoindoline-1,3-dione (**6**) (10.2 g, 20.6 mmol) in ethanol (500 mL) was treated with hydrazine hydrate (8.00 mL of 98%, 162 mmol) and heated to reflux for 5 hours. The reaction mixture was allowed to cool and stir over night. The mixture was filtered to remove the precipitated phthalhydrazide and triturated with CH_2Cl_2 (400 mL) for 5 hours. Filtration to remove the remaining phthalhydrazide and concentration of the filtrate afforded 7.66 g (100% yield) of pure amine **7** as an off white foam: ^1H NMR (400 MHz, CHCl_3) δ 7.29 – 7.32 (m, 10H), 7.09 – 7.13 (m, 6H), 6.51 (s, 1H), 2.73 (t, J = 6.90 Hz, 2H), 2.57 (t, J = 7.80 Hz, 2H), 2.41 (bs, 2H), 1.77 (quint., J = 6.90 Hz, 2H). ^{13}C NMR (100 MHz, CHCl_3) δ 142.60 (s), 141.23 (d), 138.37 (s), 129.86 (d), 128.08 (d), 117.92 (s), 75.17 (s), 41.67 (t), 32.77 (t), 25.88 (t). LCMS (25-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 5.75 minutes, ESI m/z = 368, $[\text{M}+\text{H}]^+$.


Synthesis of 3-(1H-indol-3-yl)-N-(3-(1-trityl-1H-imidazol-4-yl)propyl) propanamide (9)



[0166] To a solution of 3-(1H-indol-3-yl)propanoic acid (**8**) (5.66g, 29.9 mmol) in DMF (80 mL) was added EDC·HCl (8.60 g, 44.9 mmol) and HOBT·H₂O (5.70 g, 37.2 mmol). The resulting mixture was stirred at room temperature for 45 minutes. A

solution of the amine **7** (11.0 g, 29.9 mmol) in DMF (80 mL) and TEA (6.00 mL, 43.0 mmol) was added and the reaction was stirred for 16 hours at room temperature. The mixture was poured into water (500 mL) in a large beaker and stirred for 30 minutes at room temperature. The solid was collected by filtration. Recrystallization from ACN afforded 11.8 g (73% yield) of pure amide **9**: ^1H NMR (400 MHz, DMSO- d_6) δ 10.70 (bs, 1H), 7.78 (t, J = 5.50 Hz, 1H), 7.46 (d, J = 7.80 Hz, 1H), 7.31 – 7.38 (complex multiplets, 9H), 7.25 (d, J = 7.80 Hz, 1H), 7.20 (s, 1H), 7.02 – 7.05 (m, 7H), 6.99 (t, J = 8.20 Hz, 1H), 6.56 (s, 1H), 2.99 (q, J = 5.9 Hz, 2H), 2.85 (t, J = 7.70 Hz, 2H), 2.34 – 2.38 (m, 4H), 1.58 (quint., J = 7.40 Hz, 2H). ^{13}C NMR (100 MHz, DMSO- d_6) δ 172.20 (s), 142.90 (s), 141.17 (d), 138.14 (s), 136.71 (s), 129.72 (d), 128.71 (d), 128.47 (d), 127.54 (s), 122.57 (d), 121.36 (d), 118.87 (d), 118.60 (d), 118.11 (d), 114.3 (s), 111.78 (d), 74.85 (s), 38.58 (t), 36.89 (t), 29.37 (t), 25.79 (t), 21.61 (t). LCMS (50-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 4.87 minutes, ESI m/z = 539, $[\text{M}+\text{H}]^+$.


Synthesis of 3-(1H-indol-3-yl)-N-(3-(1-trityl-1H-imidazol-4-yl)propyl) propanethioamide (10)



[0167] A mixture of 3-(1H-indol-3-yl)-N-(3-(1-trityl-1H-imidazol-4-yl)propyl)propanamide (**9**) (6.46 g, 12.0 mmol) and Lawesson's reagent (3.15 g, 7.80 mmol) in THF (100 mL) was heated to 65 °C for 4 hours. The reaction was cooled and concentrated. The residue was purified by flash column chromatography (SiO₂, 10/1 CH₂Cl₂/MeOH) to afford 3.34 g (50% yield) of thioamide **10** as a tan foam: ^1H NMR (400 MHz, DMSO- d_6) contains a small amount of inseparable imidothioic phosphonate intermediate adduct of the starting amide with Lawesson's reagent (ESI m/z = 741, $[\text{M}+\text{H}]^+$); desired thioamide component: δ 10.73 (bs, 1H), 9.96 (t, J = 5.10 Hz, 1H), 7.50 (d, J = 7.80 Hz, 1H), 7.34 – 7.40 (complex multiplets, 10H), 7.26 (d, J = 7.80 Hz, 1H), 7.05 – 7.09 (m, 6H), 6.99 (t, J = 7.70 Hz, 1H), 6.90 (t, J = 7.70 Hz, 1H), 3.43 (apparent q, J = 6.00 Hz, 2H), 3.02 (apparent t, J = 7.80 Hz, 2H), 2.82 (apparent t, J = 7.75 Hz,


2H), 2.42 (t, $J = 6.80$ Hz, 2H), 1.76 (quint, $J = 7.30$ Hz, 2H). ^{13}C NMR (100 MHz, DMSO- d_6) δ 203.79 (s), 142.45 (s), 137.93 (s), 136.70 (d), 129.74 (d), 128.83 (d), 128.63 (d), 127.54 (s), 122.75 (d), 121.41 (d), 118.91 (d), 118.64 (d), 113.86 (s), 111.83 (s), 75.53 (s), 46.51 (t), 45.22 (t), 27.15 (t), 25.67 (t), 25.02 (t). LCMS (50-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 5.85 minutes, ESI $m/z = 555$, $[\text{M}+\text{H}]^+$

Synthesis of 3-(1-methyl-1H-indol-3-yl)propanoic acid (12)




[0168] To a solution of 3-(1H-indol-3-yl)propanoic acid (**8**) (3.00 g, 15.9 mmol) in acetone (70 mL) was added methyl iodide (5.00 mL, 80.3 mmol) and KOH (5.30 g, 94.4 mmol) at 0 °C. The reaction was stirred for 4 hours and the solvent was evaporated. The residue was dissolved in H₂O (100 mL) and treated with KOH (4.50 g, 80.2 mmol). The resulting mixture was refluxed for 2 hours, cooled to 0 °C, and acidified to pH ~ 1 with 6N HCl. The product was isolated by filtration and washed with heptane (~100 mL) to afford 3.20 g (99 % yield) of compound **12** as a yellow solid: ^1H NMR (400 MHz, DMSO- d_6) δ 12.06 (bs, 1H), 7.48 (d, $J = 7.80$ Hz, 1H), 7.33 (d, $J = 8.20$ Hz, 1H), 7.09 (t, $J = 8.20$ Hz, 1H), 7.05 (s, 1H), 6.96 (t, $J = 7.80$ Hz, 1H), 3.68 (s, 3H), 2.87 (t, $J = 7.80$ Hz, 2H), 2.53 (t, $J = 7.40$ Hz, 2H). ^{13}C NMR (100 MHz, DMSO- d_6) δ 174.68, 137.13, 127.75, 127.23, 121.59, 118.85, 113.26, 110.06, 35.11, 32.75, 20.66. LCMS (50-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 3.50 minutes, ESI $m/z = 204$, $[\text{M}+\text{H}]^+$.

Synthesis of 3-(1-methyl-1H-indol-3-yl)-N-(3-(1-trityl-1H-imidazol-4-yl)propyl)propanamide (13)



[0169] To a solution of 3-(1-methyl-1H-indol-3-yl)propanoic acid (**12**) (503 mg, 2.47 mmol) in DMF (30 mL) was added EDC·HCl (592 mg, 3.09 mmol) and HOBT·H₂O (476 mg, 3.09 mmol). The resulting mixture was stirred at room temperature for 45 minutes. A solution of the amine **7** (908 mg, 2.47 mmol) in DMF (20 mL) and TEA (700 μ L, 5.00 mmol) was added and the reaction was stirred for 16 hours at room temperature. The DMF was evaporated and the residue was partitioned with CH₂Cl₂ (150 mL) and water (150 mL). The layers were separated and the organic solution was washed with saturated NaHCO₃ (150 mL) and brine (150 mL). The organic layer was then dried (Na₂SO₄), filtered and concentrated to afford 650 mg (48% yield) of compound **13** as a tan solid: ¹H NMR (400 MHz, CDCl₃) δ 7.54 (d, *J* = 7.80 Hz, 1H), 7.30 – 7.34 (complex multiplets, 10H), 7.28 (d, *J* = 4.50 Hz, 1 H), 7.22 – 7.25 (m, 1H), 7.17 (dt, *J* = 6.80, 0.90 Hz, 1H), 7.08 – 7.11 (m, 5H), 7.02 (dt, *J* = 6.90, 0.90 Hz, 1H), 6.83 (s, 1H), 6.47 (s, 1H), 6.25 (bt, *J* = 4.60 Hz, 1H), 3.66 (t, 3H), 3.22 (apparent q, *J* ~ 6.00 Hz, 2H), 3.07 (t, *J* = 7.30 Hz, 2H), 2.51 (t, *J* = 7.80 Hz, 2H), 2.44 (t, *J* = 7.30 Hz, 2H), 1.72 (quint, *J* = 6.80 Hz, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 172.85, 142.40, 140.61, 138.17, 137.05, 129.81, 128.15, 128.01, 126.57, 121.57, 118.93, 118.76, 118.25, 113.72, 109.24, 75.36, 39.11, 37.75, 32.63, 28.55, 25.46, 21.45. LCMS (50-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 6.40 minutes, ESI *m/z* = 553, [M+H]⁺.


Synthesis of 3-(1-methyl-1H-indol-3-yl)-N-(3-(1-trityl-1H-imidazol-4-yl)propyl)propane-thioamide (**14**)



[0170] A solution of 3-(1-methyl-1H-indol-3-yl)-N-(3-(1-trityl-1H-imidazol-4-yl)propyl)-propanamide (**13**) (azeotropically dried by coevaporation with toluene, 620 mg, 1.12 mmol) and Lawesson's reagent (295 mg, 0.73 mmol) in THF (30 mL) was heated to 65 °C for 4 hours. The resulting mixture was allowed to cool to room temperature and concentrated. Purification by flash column chromatography (SiO₂, 40:1 to 20:1 CH₂Cl₂/MeOH) afforded 470 mg (78% yield) of compound **14** as a yellow


foam: ^1H NMR (400 MHz, DMSO-d_6) δ 9.92 (bt, $J \sim 5.00$ Hz, 1H), 7.51 (d, $J = 8.20$ Hz, 1H), 7.30 – 7.39 (complex multiplets, 10H), 7.27 (t, $J = 8.20$ Hz, 1H), 7.02 – 7.06 (m, 7H), 6.93 (t, $J = 7.30$ Hz, 1H), 6.60 (s, 1H), 3.62 (s, 3H), 3.42 (apparent q, $J \sim 6.20$ Hz, 2H), 3.01 (t, $J = 7.40$ Hz, 2H), 2.79 (t, $J = 7.30$ Hz, 2H), 2.36 (t, $J = 7.30$ Hz, 2H), 1.73 (quint, $J = 7.30$ Hz, 2H). ^{13}C NMR (100 MHz, DMSO-d_6) δ 203.59, 142.71, 140.29, 138.09, 137.08, 129.73, 128.77, 128.53, 127.85, 127.25, 121.53, 119.16, 118.73, 118.39, 113.15, 109.98, 75.13, 46.56, 45.33, 40.69, 32.70, 27.27, 25.45. LCMS (50-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 6.40 minutes, ESI m/z = 569, $[\text{M}+\text{H}]^+$.

Synthesis of tert-butyl (2-(3-(1H-indol-3-yl)propanamido)ethyl) carbamate (16)



[0171] To a solution of 3-(1H-indol-3-yl)propanoic acid (**8**) (3.00 g, 15.9 mmol) in DMF (80 mL) was added EDC·HCl (4.56 g, 23.8 mmol) and HOBT·H₂O (3.64 g, 23.8 mmol). The resulting mixture was stirred at room temperature for 30 minutes. A solution of the amine **15** (3.00 g, 18.7 mmol) in DMF (20 mL) and TEA (3.50 mL, 25.1 mmol) was added and the reaction was stirred for 16 hours at room temperature. The DMF was evaporated and the residue was partitioned with EtOAc (150 mL) and water (150 mL). The layers were separated and the organic solution was washed with 1N NaHSO₄ (150 mL), saturated NaHCO₃ (150 mL) and brine (150 mL). The organic layer was then dried (Na₂SO₄), filtered and concentrated to afford 5.12 g (97% yield) of compound **16** as a white foam: LCMS (50-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 2.87 minutes, ESI m/z = 332, $[\text{M}+\text{H}]^+$.


Synthesis of tert-butyl (2-(3-(1H-indol-3-yl)propanethioamido)ethyl) carbamate (17)



[0172] A solution of tert-butyl (2-(3-(1H-indol-3-yl)propanamido)ethyl)carbamate (**16**) (azeotropically dried by coevaporation with


toluene, 4.74 g, 14.3 mmol) and Lawesson's reagent (3.18 g, 7.86 mmol) in THF (50 mL) was heated to 65 °C for 4 hours. The resulting mixture was allowed to cool to room temperature and concentrated. Purification by flash column chromatography (SiO₂, 3:1 hexanes/EtOAc to 1:1) afforded 3.86 g (78% yield) of compound **17** as an orange foam: LCMS (50-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 5.45 minutes, ESI m/z = 348, [M+H]⁺.

Synthesis of tert-butyl (4-(3-(1H-indol-3-yl)propanamido)butyl) carbamate (19)




[0173] To a solution of 3-(1H-indol-3-yl)propanoic acid (**8**) (1.00 g, 5.29 mmol) in DMF (40 mL) was added EDC·HCl (1.52 g, 7.93 mmol) and HOBT·H₂O (1.21 g, 7.93 mmol). The resulting mixture was stirred at room temperature for 30 minutes. A solution of the amine **18** (1.10 g, 5.82 mmol) in DMF (10 mL) and TEA (1.50 mL, 10.8 mmol) was added and the reaction was stirred for 16 hours at room temperature. The DMF was evaporated and the residue was partitioned with EtOAc (150 mL) and water (150 mL). The layers were separated and the organic solution was washed with 1N NaHSO₄ (150 mL), saturated NaHCO₃ (150 mL) and brine (150 mL). The organic layer was then dried (Na₂SO₄), filtered and concentrated to afford 1.90 g (100% yield) of compound **19** as a white foam: ¹H NMR (400 MHz, CDCl₃) δ 8.59 (bs, 1H), 7.59 (d, *J* = 7.80 Hz, 1H), 7.36 (d, *J* = 8.20 Hz, 1H), 7.17 (t, *J* = 7.30 Hz, 1H), 7.09 (t, *J* = 7.20 Hz, 1H), 6.99 (d, *J* = 1.40 Hz, 1H), 5.47 (bs, 1H), 4.59 (bs, 1H), 3.09 – 3.13 (m, 4H), 2.97 – 3.02 (m, 2H), 2.54 (t, *J* = 6.90 Hz, 2H), 1.45 (s, 9H), 1.17 – 1.31 (complex multiplets, 4H). ¹³C NMR (100 MHz, CDCl₃) δ 173.05, 156.39, 136.51, 127.09, 122.33, 121.98, 118.71, 114.53, 111.47, 79.51, 40.30, 39.12, 37.60, 28.57, 27.69, 26.79, 21.68. LCMS (40-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 3.83 minutes, ESI m/z = 360, [M+H]⁺.

Synthesis of tert-butyl (4-(3-(1H-indol-3-yl)propanethioamido)butyl) carbamate (20)



[0174] A solution of tert-butyl (4-(3-(1H-indol-3-yl)propanamido)butyl)carbamate (**19**) (azeotropically dried by coevaporation with toluene, 654 mg, 1.82 mmol) and Lawesson's reagent (404 mg, 1.00 mmol) in THF (50 mL) was heated to 65 °C for 1 hour. The resulting mixture was allowed to cool to room temperature and concentrated. Purification by flash column chromatography (SiO₂, 1:1 hexanes/EtOAc) afforded 471 mg (69% yield) of compound **20** as a yellow foam: ¹H NMR (400 MHz, CDCl₃) δ 8.58 (bs, 1H), 7.61 (d, *J* = 7.80 Hz, 1H), 7.39 (d, *J* = 8.30 Hz, 1H), 7.32 (bs, 1H), 7.18 (dt, *J* = 7.10, 0.90 Hz, 1H), 7.10 (dt, *J* = 7.80, 0.90 Hz, 1H), 7.01 (s, 1H), 4.56 (bs, 1H), 3.46 (apparent q, *J* = 5.95 Hz, 2H), 3.25 (t, *J* = 6.90 Hz, 2H), 3.02 (t, *J* = 6.90 Hz, 2H), 2.95 (bt, *J* ~ 6.40 Hz, 1H), 1.46 (s, 9H), 1.27 – 1.34 (m, 2H), 1.10 – 1.18 (m, 2H). LCMS (40-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 5.78 minutes, ESI *m/z* = 376, [M+H]⁺.


Synthesis of tert-butyl (5-(3-(1H-indol-3-yl)propanamido)pentyl) carbamate (22)



[0175] To a solution of 3-(1H-indol-3-yl)propanoic acid (**8**) (1.00 g, 5.29 mmol) in DMF (30 mL) was added EDC·HCl (1.52 g, 7.93 mmol) and HOBT·H₂O (1.21 g, 7.93 mmol). The resulting mixture was stirred at room temperature for 30 minutes. A solution of the amine **21** (1.18 g, 5.82 mmol) in DMF (10 mL) and TEA (2.00 mL, 14.3 mmol) was added and the reaction was stirred for 16 hours at room temperature. The DMF was evaporated and the residue was partitioned with EtOAc (150 mL) and water (150 mL). The layers were separated and the organic solution was washed with 1N NaHSO₄ (150 mL), saturated NaHCO₃ (150 mL) and brine (150 mL). The organic layer was then dried (Na₂SO₄), filtered and concentrated to afford 1.99 g (100% yield) of compound **22** as a tan foam: ¹H NMR (400 MHz, CDCl₃) δ 9.06 (bs, 1H), 7.58 (d, *J* =


7.80 Hz, 1H), 7.38 (d, J = 7.80 Hz, 1H), 7.17 (dt, J = 6.90, 1.00 Hz, 1H), 7.09 (dt, J = 7.80, 0.90 Hz, 1H), 7.00 (d, J = 2.30 Hz, 1H), 5.34 (bs, 1H), 4.62 (bs, 1H), 3.07 – 3.13 (m, 4H), 3.02 (apparent q, J ~ 6.75 Hz, 2H), 2.54 (t, J = 7.30 Hz, 2H), 1.46 (s, 9H), 1.33 (quint, J = 7.30 Hz, 2H), 1.20 – 1.26 (m, 2H), 0.93 – 1.01 (m, 2H). ^{13}C NMR (100 MHz, CDCl_3) δ 173.05, 156.49, 136.67, 127.02, 122.42, 121.86, 119.17, 118.60, 114.21, 111.57, 79.57, 40.50, 39.16, 37.59, 30.05, 29.15, 28.55, 23.70, 21.72. LCMS (40-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 4.12 minutes, ESI m/z = 374, $[\text{M}+\text{H}]^+$.

Synthesis of tert-butyl (5-(3-(1H-indol-3-yl)propanethioamido)pentyl) carbamate (23)



[0176] A solution of tert-butyl (5-(3-(1H-indol-3-yl)propanamido)pentyl) carbamate (**22**) (azeotropically dried by coevaporation with toluene, 1.99 g, 5.33 mmol) and Lawesson's reagent (1.19 g, 2.93 mmol) in THF (50 mL) was heated to 65 °C for 1 hour. The resulting mixture was allowed to cool to room temperature and concentrated. Purification by flash column chromatography (SiO_2 , 1:1 hexanes/EtOAc) afforded 1.20 g (58% yield) of compound **23** as a yellow foam: LCMS (40-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 6.17 minutes, ESI m/z = 390, $[\text{M}+\text{H}]^+$.


Synthesis of (R)-tert-butyl (3-(1H-indol-3-yl)-1-oxo-1-((3-(1-trityl-1H-imidazol-4-yl)propyl)-amino)propan-2-yl)carbamate (25)




[0177] To a solution of N-Boc-D-Tryptophan (597 mg, 1.96 mmol, purchased from Chem-Impex International, Cat. #01387) (**24**) in DMF (50 mL) was added EDC·HCl (470 mg, 2.45 mmol) and HOBT·H₂O (375 mg, 2.45 mmol). The resulting mixture was stirred at room temperature for 30 minutes. A solution of the amine **7** (721 mg, 1.96

mmol) in DMF (30 mL) and TEA (400 μ L, 2.87 mmol) was added and the reaction was stirred for 16 hours at room temperature. The DMF was evaporated and the residue was partitioned with EtOAc (75 mL) and water (75 mL). The layers were separated and the organic solution was washed with 1N NaHSO₄ (75 mL), saturated NaHCO₃ (75 mL) and brine (75 mL). The organic layer was then dried (Na₂SO₄), filtered and concentrated to afford 1.02 g (80% yield) of compound **25** as a tan solid: ¹H NMR (400 MHz DMSO-d₆) δ 10.75 (bs, 1H), 7.84 (t, *J* = 6.00 Hz, 1H), 7.71 (d, *J* = 8.30 Hz, 1H), 7.32 – 7.39 (complex m, 10H), 7.27 – 7.27 (m, 2H), 7.20 (d, *J* = 0.90 Hz, 1H), 7.03 – 7.06 (m, 3H), 6.97 (t, *J* = 7.30 Hz, 1H), 6.89 (t, *J* = 6.80 Hz, 1H), 6.69 (d, *J* = 8.20 Hz, 1H), 6.54 (s, 1H), 4.08 (dt, *J* = 8.70, 5.00 Hz, 1H), 2.95 – 3.02 (m, 3H), 2.80 – 2.86 (m, 1H), 2.33 (t, *J* = 7.30 Hz, 2H), 1.56 (quint, *J* = 7.30 Hz, 2H). LCMS (50-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 5.88 minutes, ESI *m/z* = 654, [M+H]⁺.


Synthesis of (R)-tert-butyl (3-(1H-indol-3-yl)-1-thioxo-1-((3-(1-trityl-1H-imidazol-4-yl)propyl)amino)propan-2-yl)carbamate (26)



[0178] A solution of (R)-tert-butyl (3-(1H-indol-3-yl)-1-oxo-1-((3-(1-trityl-1H-imidazol-4-yl)propyl)-amino)propan-2-yl)carbamate (**25**) (azeotropically dried by coevaporation with toluene, 450 mg, 0.69 mmol) and Lawesson's reagent (240 mg, 0.59 mmol) in THF (40 mL) was heated to 65 °C for 4 hours. The resulting mixture was allowed to cool to room temperature and concentrated. Purification by flash column chromatography (SiO₂, 1:1 hexanes/EtOAc) afforded 289 mg (58% yield) of compound **26** as an orange-brown foam: LCMS (50-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 6.81 minutes, ESI *m/z* = 670, [M+H]⁺.


General Procedure 1A: Boc-Protected Hydrazides

[0179] A mixture of the carboxylic acid (1.00 mmol), EDC·HCl (1.25 equiv.), HOBT·H₂O (1.25 equiv.) in DMF (50 mL) was stirred at room temperature for 30 minutes. The resulting mixture was treated with tert-butyl hydrazinecarboxylate (1.25 equiv.) and TEA (5 mL) and stirred for 16 hours. The solvent was evaporated and the residue was partitioned between EtOAc (150 mL) and 1N Na₂SO₄ (150 mL). The layers were separated and organic layer was washed with H₂O (150 mL), saturated NaHCO₃ (150 mL) and brine (150 mL). The organic layer was dried (anhydrous Na₂SO₄), filtered, and concentrated.

Synthesis of tert-Butyl 2-(2-(4-chlorophenyl)acetyl) hydrazine carboxylate (28a)

28a

[0180] Prepared according to the **General Procedure 1A** from 2-(4-chlorophenyl)acetic acid (**27a**) (3.00 g, 17.6 mmol) and tert-butyl hydrazinecarboxylate (2.91 g, 22.0 mmol) to afford 4.91 g (98% yield) of compound **28a** as a white solid: ¹H NMR (400 MHz, DMSO-d₆) δ 9.79 (bs, 1H), 8.75 (bs, 1H), 7.33 (d, *J* = 8.70 Hz, 2H), 7.25 (d, *J* = 8.70 Hz, 2H), 3.30 (s, 2H), 1.34 (s, 9H). LCMS (50-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 3.65 minutes, ESI *m/z* = 285, [M+H]⁺.


Synthesis of tert-Butyl 2-(2-(3-chlorophenyl)acetyl) hydrazine carboxylate (28b)

28b

[0181] Prepared according to the **General Procedure 1A** from 2-(3-chlorophenyl)acetic acid (**27b**) (3.17 g, 18.6 mmol) and tert-butyl hydrazinecarboxylate (3.07 g, 23.3 mmol) to afford 5.25 g (99% yield) of compound **28b** as a white solid: ¹H

NMR (400 MHz, CDCl_3) δ 7.81 (bs, 1H), 7.24 (m, 2H), 7.17 – 7.19 (m, 1H), 6.64 (bs, 1H), 3.55 (s, 2H), 1.43 (s, 9H). ^{13}C NMR (100 MHz, CDCl_3) δ 169.71 (s), 155.60 (s), 135.75 (s), 134.72 (s), 130.23 (d), 129.55 (d), 127.77 (d), 127.63 (d), 82.21 (s), 40.84 (t), 28.20 (q). LCMS (50-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 3.73 minutes, ESI m/z = 285, $[\text{M}+\text{H}]^+$, m/z = 569 $[2\text{M} + \text{H}]^+$.


Synthesis of tert-Butyl 2-(2-(2-chlorophenyl)acetyl) hydrazine carboxylate (28c)



28c


[0182] Prepared according to the **General Procedure 1A** from 2-(2-chlorophenyl)acetic acid (**27c**) (3.01 g, 17.6 mmol) and tert-butyl hydrazinecarboxylate (2.91 g, 22.1 mmol) to afford 2.30 g (46% yield) of compound **28c** as a white solid: ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 9.78 (bs, 1H), 8.77 (bs, 1H), 7.36 – 7.39 (m, 2H), 7.22 – 7.27 (m, 2H), 3.53 (s, 2H), 1.35 (s, 9H). ^{13}C NMR (100 MHz, $\text{DMSO}-d_6$) δ 169.17 (s), 155.74 (s), 134 (s), 132.31 (d), 129.49 (d), 129.05 (d), 127.53 (d), 127.45 (s), 79.60 (s), 38.03 (t), 28.57 (q). LCMS (50-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 3.30 minutes, ESI m/z = 285, $[\text{M}+\text{H}]^+$, m/z = 569 $[2\text{M} + \text{H}]^+$.

Synthesis of tert-Butyl 2-(2-(4-methoxyphenyl)acetyl) hydrazine carboxylate (28d)




28d

[0183] Prepared according to the **General Procedure 1A** from 2-(4-methoxyphenyl)acetic acid (**27d**) (3.00 g, 18.0 mmol) and tert-butyl hydrazinecarboxylate (2.98 g, 22.5 mmol) to afford 4.97 g (98% yield) of compound **28d** as white solid: ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 9.70 (bs, 1H), 8.70 (bs, 1H), 7.14 (d, J = 8.70 Hz, 2H), 6.82 (d, J = 8.70 Hz, 2H), 3.68 (s, 3H), 3.29 (s, 2H), 1.35 (s, 9H). ^{13}C NMR (100 MHz, $\text{DMSO}-d_6$) δ 171.07, 158.89, 155.76, 130.51, 126.00, 114.34, 81.83, 55.03, 40.39, 28.21. LCMS (40-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 3.88 minutes, ESI m/z = 281, $[\text{M}+\text{H}]^+$, m/z = 561 $[2\text{M} + \text{H}]^+$.

Synthesis of tert-Butyl 2-(2-(3-methoxyphenyl)acetyl)hydrazine carboxylate (28e)


28e

[0184] Prepared according to the **General Procedure 1A** from 2-(3-methoxyphenyl)acetic acid (**27e**) (2.43 g, 14.6 mmol) and tert-butyl hydrazine carboxylate (2.41 g, 18.3 mmol) to afford 4.16 g (100% yield) of compound **28e** as white solid: ^1H NMR (400 MHz, CDCl_3) δ 7.40 (bs, 1H), 7.25 (t, $J = 8.3$ Hz, 1H), 6.81 – 6.87 (m, 3H), 6.51 (bs, 1H), 3.79 (s, 3H), 3.58 (s, 2H), 1.43 (s, 9H). ^{13}C NMR (100 MHz, CDCl_3) δ 170.24 (s), 160.06 (s), 155.39 (s), 135.10 (s), 130.17 (d), 121.74 (d), 115.00 (d), 113.28 (d), 82.00 (s), 55.33 (q), 41.71 (t), 28.19 (q). LCMS (40-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 4.13 minutes, ESI $m/z = 281$, $[\text{M}+\text{H}]^+$, $m/z = 561$ $[2\text{M} + \text{H}]^+$.

Synthesis of tert-Butyl 2-(2-(2-methoxyphenyl)acetyl)hydrazine carboxylate (28f)

28f


[0185] Prepared according to the **General Procedure 1A** from 2-(2-methoxyphenyl)acetic acid (**27f**) (3.00 g, 18.0 mmol) and tert-butyl hydrazinecarboxylate (2.98 g, 22.5 mmol) to afford 4.62 g (91% yield) of compound **28f** as white solid: ^1H NMR (400 MHz, CDCl_3) rotational isomers observed, δ 7.52 (bd, $J \sim 2.80$ Hz, 1H), 7.24 – 7.29 (m, 2H), 6.93 (dt, $J = 7.70, 1.30$ Hz, 1H), 6.90 (d, $J = 8.20$ Hz, 1H). ^{13}C NMR (100 MHz, CDCl_3) rotational isomers observed, δ 170.53, 157.09, 155.30, 131.35, 129.14, 122.50, 121.27, 110.86, 81.74, 55.69, 36.74, 28.16. LCMS (50-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 3.07 minutes, ESI $m/z = 281$, $[\text{M}+\text{H}]^+$, $m/z = 561$ $[2\text{M} + \text{H}]^+$.

Synthesis of tert-Butyl 2-(2-(3-fluorophenyl)acetyl)hydrazine carboxylate (28g)

28g


[0186] Prepared according to the **General Procedure 1A** from 2-(3-fluorophenyl)acetic acid (**27g**) (3.07 g, 19.9 mmol) and tert-butyl hydrazinecarboxylate (3.29 g, 24.9 mmol) to afford 5.14 g (96% yield) of compound **28g** as a white solid: ^1H NMR (400 MHz, DMSO- d_6) δ 9.81 (bs, 1H), 8.77 (bs, 1H), 7.31 (apparent q, $J_{\text{H,F}} \sim 6.90$, $J_{\text{H,H}} \sim 6.90$ Hz, 1H), 7.01 – 7.08 (m, 3H), 3.41 (s, 2H), 1.35 (s, 9H). LCMS (50-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 2.98 minutes, ESI m/z = 269, $[\text{M}+\text{H}]^+$, m/z = 537 $[2\text{M} + \text{H}]^+$.

Synthesis of tert-Butyl 2-(2-(3-bromophenyl)acetyl)hydrazine carboxylate (28h)



[0187] Prepared according to the **General Procedure 1A** from 2-(3-bromophenyl)acetic acid (**27h**) (5.00 g, 23.2 mmol) and tert-butyl hydrazinecarboxylate (3.84 g, 29.0 mmol) to afford 7.14 g (97% yield) of compound **28h** as a white solid: ^1H NMR (400 MHz, CDCl_3) δ 7.71 (bs, 1H), 7.45 (bs, 1H), 7.40 (d, $J = 6.00$ Hz, 1H), 7.17 – 7.23 (m, 2H), 6.60 (bs, 1H), 3.55 (s, 2H), 1.44 (s, 9H). ^{13}C NMR (100 MHz, CDCl_3) δ 169.68, 155.56, 136.00, 132.43, 130.73, 130.54, 128.10, 122.95, 82.23, 40.83, 28.21. LCMS (50-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 3.97 minutes, ESI m/z = 329, $[\text{M}+\text{H}]^+$, m/z = 657 $[2\text{M} + \text{H}]^+$.


Synthesis of tert-Butyl 2-(2-(3-(trifluoromethyl)phenyl)acetyl) hydrazine carboxylate (28i)



[0188] Prepared according to the **General Procedure 1A** from 2-(3-bromophenyl)acetic acid (**27i**) (3.00 g, 14.7 mmol) and tert-butyl hydrazinecarboxylate (1.94 g, 14.7 mmol) to afford 4.52 g (97% yield) of compound **28i** as a white solid: ^1H NMR (400 MHz, CDCl_3) δ 8.01 (bs, 1H), 7.49 – 7.54 (m, 3H), 7.41 – 7.45 (m, 1H), 3.61 (s, 2H), 1.43 (s, 9H). ^{13}C NMR (100 MHz, CDCl_3) δ 169.64, 155.65, 134.81, 132.82, 131.18 (q, $J_{\text{C,F}} = 32.6$ Hz), 129.39, 126.15 (q, $J_{\text{C,F}} = 3.80$ Hz), 124.38 (q, $J_{\text{C,F}} = 3.90$ Hz), 124.00 (q, $J_{\text{C,F}} = 272.2$ Hz), 82.30, 40.78, 28.16. LCMS (50-95% acetonitrile in 0.05%


TFA over 10 minutes) retention time = 4.43 minutes, ESI m/z = 319, $[M+H]^+$, m/z = 637 $[2M + H]^+$.

Synthesis of tert-Butyl 2-(2-(3,5-difluorophenyl)acetyl)hydrazine carboxylate (28j)




[0189] Prepared according to the **General Procedure 1A** from 2-(3,5-difluorophenyl)acetic acid (**27j**) (3.00 g, 17.4 mmol) and tert-butyl hydrazinecarboxylate (2.88 g, 21.8 mmol) to afford 3.05 g (61% yield) of compound **28j** as a white solid: LCMS (50-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 3.45 minutes, ESI m/z = 287, $[M+H]^+$, m/z = 573 $[2M + H]^+$.

Synthesis of tert-Butyl 2-(2-(3,5-dichlorophenyl)acetyl)hydrazine carboxylate (28k)



[0190] Prepared according to the **General Procedure 1A** from 2-(3,5-dichlorophenyl)acetic acid (**27k**) (5.06 g, 24.7 mmol) and tert-butyl hydrazinecarboxylate (3.26 g, 24.7 mmol) to afford 6.81 g (86% yield) of compound **28k** as a white solid: LCMS (50-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 4.90 minutes, ESI m/z = 319, $[M+H]^+$; m/z = 639, $[2M + H]^+$.


Synthesis of tert-Butyl 2-(2-(3,4-dichlorophenyl)acetyl)hydrazine carboxylate (28l)



[0191] Prepared according to the **General Procedure 1A** from 2-(3,4-dichlorophenyl)acetic acid (**27l**) (2.43 g, 11.9 mmol) and tert-butyl hydrazinecarboxylate (1.97 g, 14.9 mmol) to afford 3.61g (95% yield) of compound **28l** as a white solid: ^1H NMR (400 MHz, $CDCl_3$) δ 7.95 (bs, 1H), 7.39 (d, J = 2.30 Hz, 1H), 7.38 (d, J = 8.30 Hz,


1H), 7.14 (dd, $J = 8.30, 2.30$ Hz, 1H), 6.67 (bs, 1H), 3.51 (s, 2H), 1.44 (s, 9H). LCMS (40-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 2.10 minutes, ESI $m/z = 319$, $[M+H]^+$.

Synthesis of tert-Butyl 2-(2-([1,1'-biphenyl]-4-yl)acetyl)hydrazine carboxylate (AH.2.182)




[0192] Prepared according to the **General Procedure 1A** from 2-([1,1'-biphenyl]-4-yl)acetic acid (**27m**) (3.00 g, 14.1 mmol) and tert-butyl hydrazinecarboxylate (3.39 g, 17.7 mmol) to afford 3.96g (86% yield) of compound **28m** as a white solid: ^1H NMR (400 MHz, DMSO- d_6) δ 9.80 (bs, 1H), 8.72 (bs, 1H), 7.55 – 7.62 (m, 4H), 7.41 (t, $J = 7.30$ Hz, 2H), 7.31 – 7.34 (m, 3H), 3.42 (s, 2H), 1.35 (s, 9H). ^{13}C NMR (100 MHz, DMSO- d_6) δ 170.16, 155.79, 140.49, 138.95, 135.44, 130.16, 129.44, 127.83, 127.08, 127.05, 79.62, 28.57. LCMS (50-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 5.23 minutes, ESI $m/z = 327$, $[M+H]^+$, 653 $[2M + H]^+$.


General Procedure 1B: Synthesis of Hydrazide Free Bases




[0193] To the Boc-hydrazide (1.00 mmol) in CH_2Cl_2 was added 4N HCl/Dioxane (10 mL) and the reaction was stirred at room temperature. After 1.5 hours a white precipitate was formed. The precipitated HCl salt was filtered and washed with CH_2Cl_2 and dried under high vacuum. The salt (1.00 mmol) was suspended in CH_2Cl_2 (75 mL) or dissolved in methanol (or methanol/water) and treated with TEA (6 mL). The resulting mixture was stirred at room temperature for 30 minutes, transferred to a separatory funnel and partitioned with additional CH_2Cl_2 (75 mL) and water (150 mL). The layers were separated and the organic solution was dried (anhydrous Na_2SO_4), filtered, and concentrated. This compound was used in the next step without further purification.

Synthesis of 2-(4-Chlorophenyl)acetic hydrazide (29a)

[0194] Prepared according to the **General Procedure 1B** from tert-Butyl 2-(2-(4-chlorophenyl)acetyl)hydrazinecarboxylate (**28a**) (4.90 g, 17.2 mmol) to afford 3.18 g (84% yield) of the intermediate HCl salt as a white solid. The HCl salt was then converted to 860 mg (32% yield) of freebase **29a** (27% for two steps), isolated as a white solid: LCMS (50-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 2.08 minutes, ESI m/z = 185, $[M+H]^+$.

Synthesis of 2-(3-Chlorophenyl)acetic hydrazide (29b)


[0195] Prepared according to the **General Procedure 1B** from tert-butyl 2-(2-(3-chlorophenyl)acetyl)hydrazinecarboxylate (**28b**) (5.00 g, 17.6 mmol) to afford 3.02 g (78% yield) of the intermediate HCl salt as a white solid. The HCl salt was then converted to 1.73 g (69% yield) of freebase **29b** (54% for two steps), isolated as a white solid: ^1H NMR (400 MHz, DMSO- d_6) δ 9.20 (bs, 1H), 7.23 – 7.30 (complex m, 3H), 1.15 – 7.18 (complex m, 1H), 4.20 (bs, 2H), 3.32 (s, 2H). ^{13}C NMR (100 MHz, CDCl_3) δ 171.00 (s), 135.92 (s), 134.83 (s), 130.30 (d), 129.52 (d), 127.82 (d), 127.60 (d), 41.4 (t). LCMS (50-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 1.95 minutes, ESI m/z = 185, $[M+H]^+$; m/z = 369, $[2M + H]^+$; m/z = 391, $[2M + \text{Na}]^+$.

Synthesis of 2-(2-Chlorophenyl)acetic hydrazide (29c)

[0196] Prepared according to the **General Procedure 1B** from tert-butyl 2-(2-(2-chlorophenyl)acetyl)hydrazinecarboxylate (**28c**) (2.10 g, 7.37 mmol) to afford 1.63 g (100% yield) of the intermediate HCl salt as a white solid. The HCl salt (1.23 g, 5.56


mmol) was then converted to 830 mg (81% yield) of freebase **29c** (81% for two steps), isolated as a white solid: ^1H NMR (400 MHz, DMSO- d_6) δ 9.17 (bs, 1H), 7.31 – 7.38 (complex m, 2H), 7.20 – 7.26 (complex m, 2H), 4.20 (bs, 2H), 3.47 (s, 2H). ^{13}C NMR (100 MHz, DMSO- d_6) δ 168.95 (s), 134.54 (s), 133.94 (s), 132.32 (d), 129.50 (d), 128.90 (d), 127.51 (d), 38.34 (t). LCMS (50-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 2.08 minutes, ESI m/z = 185, $[\text{M}+\text{H}]^+$; m/z = 369, $[2\text{M} + \text{H}]^+$; m/z = 391, $[2\text{M} + \text{Na}]^+$.

Synthesis of 2-(4-Methoxyphenyl)acetic hydrazide (29d)



[0197] Prepared according to the **General Procedure 1B** from tert-butyl 2-(2-(4-methoxyphenyl)acetyl)hydrazinecarboxylate (**28d**) (4.67 g, 16.7 mmol) to afford 2.78 g (77% yield) of the intermediate HCl salt as a white solid. The HCl salt (2.68 g, 12.4 mmol) was then converted to 1.18 g (53% yield) of freebase **29d** (41% for two steps), isolated as a white solid: ^1H NMR (400 MHz, DMSO- d_6) δ 9.12 (bs, 2H), 7.12 (d, J = 6.40 Hz, 2H), 6.81 (d, J = 6.90 Hz, 2H), 4.15 (bs, 2H), 3.67 (s, 3H), 3.22 (s, 2H).


Synthesis of 2-(3-Methoxyphenyl)acetic hydrazide (29e)



[0198] Prepared according to the **General Procedure 1B** from tert-butyl 2-(2-(3-methoxyphenyl)acetyl)hydrazinecarboxylate (**28e**) (4.09 g, 14.6 mmol) to afford 3.10 g (98% yield) of the intermediate HCl salt as a white solid. The HCl salt (2.50 g, 11.5 mmol) was then converted to 1.10 g (53% yield) of freebase **29e** (52% for two steps), isolated as a white solid: ^1H NMR (400 MHz, DMSO- d_6) δ 9.15 (bs, 1H), 7.15 (t, J = 7.8 Hz, 1H), 6.79 (s, 1H), 6.74 – 6.77 (complex m, 2H), 4.17 (bs, 2H), 3.68 (s, 3H), 3.26 (s, 2H). ^{13}C NMR (100 MHz, DMSO- d_6) δ 169.93 (s), 159.63 (s), 138.23 (s), 129.69 (d), 121.71 (d), 115.20 (d), 112.27 (d), 55.45 (q), 41.03 (t). LCMS (50-95% acetonitrile in


0.05% TFA over 10 minutes) retention time = 1.85 minutes, ESI m/z = 181, $[M+H]^+$; m/z = 361, $[2M + H]^+$.

Synthesis of 2-(2-Methoxyphenyl)acetic hydrazide (29f)




[0199] Prepared according to the **General Procedure 1B** from tert-butyl 2-(2-(2-methoxyphenyl)acetyl)hydrazinecarboxylate (**28f**) (4.61 g, 16.4 mmol) to afford 3.08 g (86% yield) of the intermediate HCl salt as a white solid. The HCl salt (3.08 g, 14.2 mmol) was then converted to 1.88 g (73% yield) of freebase **29f** (63% for two steps), isolated as a white solid: ^1H NMR (400 MHz, DMSO- d_6) δ 8.98 (bs, 1H), 7.16 (dt, J = 7.80, 1.90 Hz, 1H), 7.11 (d, J = 7.30 Hz, 1H), 6.90 (d, J = 7.80 Hz, 1H), 6.82 (t, J = 7.30 Hz, 1H), 4.15 (bs, 1H), 3.70 (s, 3H), 3.28 (s, 2H). ^{13}C NMR (100 MHz, DMSO- d_6) δ 170.13 (s), 157.59 (s), 130.98 (d), 128.33 (d), 124.73 (s), 120.57 (d), 111.10 (d), 55.86 (q), 35.02 (t). LCMS (50-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 1.85 minutes, ESI m/z = 181, $[M+H]^+$; m/z = 361, $[2M + H]^+$.

Synthesis of 2-(3-Fluorophenyl)acetic hydrazide (29g)




[0200] Prepared according to the **General Procedure 1B** from tert-butyl 2-(2-(3-fluorophenyl)acetyl)hydrazinecarboxylate (**28g**) (5.06 g, 18.9 mmol) to afford 2.59 g (67% yield) of the intermediate HCl salt as a white solid. The HCl salt (2.47 g, 12.1 mmol) was then converted to 882 mg (43% yield) of freebase **29g** (29% for two steps), isolated as a white solid: ^1H NMR (400 MHz, DMSO- d_6) δ 8.98 (bs, 1H), 7.29 (dt, J = 6.90, 6.00 Hz, 1H), 6.99 – 7.05 (complex m, 3H), 4.20 (s, 2H). ^{13}C NMR (100 MHz, DMSO- d_6) δ 169.55 (s), 162.52 (d, $J_{\text{C,F}}$ = 243 Hz), 139.55 (d, $J_{\text{C,F}}$ = 7.60 Hz), 130.57 (d, $J_{\text{C,F}}$ = 8.60 Hz), 125.64 (d, $J_{\text{C,F}}$ = 2.90 Hz), 116.19 (d, $J_{\text{C,F}}$ = 22.1 Hz), 113.72 (d, $J_{\text{C,F}}$ = 20.2 Hz), 40.55 (d, $J_{\text{C,F}}$ = 1.90 Hz). LCMS (50-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 1.90 minutes, ESI m/z = 169, $[M+H]^+$.

Synthesis of 2-(3-Bromophenyl)acetic hydrazide (29h)


29h

[0201] Prepared according to the **General Procedure 1B** tert-butyl 2-(2-(3-bromophenyl)acetyl)hydrazinecarboxylate (**X28h**) (7.41 g, 22.5 mmol) to afford 4.00 g (67% yield) of the intermediate HCl salt as a white solid. The HCl salt (4.00 g, 15.1 mmol) was then converted to 2.73 g (79% yield) of freebase **29h** (53% for two steps), isolated as a white solid: ^1H NMR (400 MHz, DMSO- d_6) δ 9.22 (bs, 1H), 7.43 – 7.44 (m, 1H), 7.37 – 7.40 (complex m, 1H), 7.20 – 7.23 (complex m, 2H), 4.26 (bs, 2H). ^{13}C NMR (100 MHz, CDCl_3) δ 171.01 (s), 136.28 (s), 132.40 (d), 130.71 (d), 130.55 (d), 128.07 (d), 122.99 (s), 41.32 (t). LCMS (50-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 1.98 minutes, ESI m/z = 229, $[\text{M}+\text{H}]^+$; 270, $[\text{M}+\text{H}+\text{ACN}]^+$; 459, $[2\text{M}+\text{H}]^+$.


Synthesis of 2-(3-(Trifluoromethyl)phenyl)acetic hydrazide (29i)

29i


[0202] Prepared according to the **General Procedure 1B** from tert-butyl 2-(2-(3-(trifluoromethyl)phenyl)acetyl)hydrazinecarboxylate (**28i**) (4.20 g, 13.2 mmol) to afford 3.26 g (97% yield) of the intermediate HCl salt as a white solid. The HCl salt (3.26 g, 12.8 mmol) was then converted to 2.14 g (77% yield) of freebase **29i** (75% for two steps), isolated as a white solid: ^1H NMR (400 MHz, CD_3OD) δ 7.59 (bs, 1H), 7.45 – 7.54 (m, 3H), 3.53 (s, 2H). ^{13}C NMR (100 MHz, CD_3OD) δ 170.92, 136.72, 132.61, 130.42 (q, $J_{\text{C},\text{F}}$ = 32.6 Hz), 128.95, 125.42 (q, $J_{\text{C},\text{F}}$ = 3.80 Hz), 124.30 (q, $J_{\text{C},\text{F}}$ = 271 Hz), 123.37 (q, $J_{\text{C},\text{F}}$ = 3.90 Hz), 39.93. LCMS (50-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 2.00 minutes, ESI m/z = 219, $[\text{M}+\text{H}]^+$; 437 $[2\text{M} + \text{H}]^+$.

Synthesis of 2-(3,5-Difluorophenyl)acetic hydrazide (29j)

[0203] Prepared according to the **General Procedure 1B** from tert-butyl 2-(2-(3,5-difluorophenyl)acetyl)hydrazinecarboxylate (**28j**) (3.05 g, 10.7 mmol) to afford 2.02 g (85% yield) of the intermediate HCl salt as a white solid. The HCl salt (1.91 g, 8.58 mmol) was then converted to 740 mg (46% yield) of freebase **29j** (39% for two steps), isolated as a white solid: ^1H NMR (400 MHz, DMSO- d_6) δ 9.21 (bs, 1H), 7.05 (tt, J = 9.20, 2.30 Hz, 1 H), 6.91 – 6.96 (m, 2H), 4.21 (bs, 1H), 3.36 (s, 2H). ^{13}C NMR (100 MHz, CDCl_3) δ 170.39 (s), 163.64 (dd, $J_{\text{C,F}}$ = 249, 13.4 Hz), 137.63 (t, $J_{\text{C,F}}$ = 8.60 Hz), 112.39 (dd, $J_{\text{C,F}}$ = 25.9, 7.70 Hz), 103.13 (t, $J_{\text{C,F}}$ = 24.9 Hz), 41.29 (t, CH_2). LCMS (50-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 1.98 minutes, ESI m/z = 229, $[\text{M}+\text{H}]^+$; 270, $[\text{M} + \text{H} + \text{ACN}]^+$; 459 $[2\text{M} + \text{H}]^+$.


Synthesis of 2-(3,5-Dichlorophenyl)acetic hydrazide (29k)

[0204] Prepared according to the **General Procedure 1B** from tert-butyl 2-(2-(3,5-dichlorophenyl)acetyl)hydrazinecarboxylate (**28k**) (6.00 g, 18.8 mmol) to afford 4.34 g (90% yield) of the intermediate HCl salt as a white solid. The HCl salt (4.34 g, 17.0 mmol) was then converted to 2.65 g (71% yield) of freebase **29k** (64% for two steps), isolated as a white solid: ^1H NMR (400 MHz, DMSO- d_6) δ 9.18 (bs, 1H), 7.42 (t, J = 1.90 Hz, 1H), 7.27 (d, J = 1.90 Hz, 2H), 4.20 (bs, 2H), 3.35 (s, 2H). ^{13}C NMR (100 MHz, CDCl_3) δ 170.21, 137.21, 135.44, 127.86, 127.83, 40.93. LCMS (50-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 2.10 minutes, ESI m/z = 219, $[\text{M}+\text{H}]^+$.

Synthesis of 2-(3,4-Dichlorophenyl)acetic hydrazide (29l)


29l

[0205] Prepared according to the **General Procedure 1B** from tert-butyl 2-(2-(3,4-dichlorophenyl)acetyl)hydrazinecarboxylate (**28l**) (3.00 g, 9.40 mmol) to afford 2.40 g (100% yield) of the intermediate HCl salt as a white solid. The HCl salt (549 mg, 2.15 mmol) was then converted to 473 mg (100 % yield) of freebase **29l** (100% for two steps), isolated as a white solid: LCMS (40-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 2.38 minutes, ESI m/z = 219, $[M+H]^+$.

Synthesis of 2-([1,1'-Biphenyl]-4-yl)acetic hydrazide (29m)


29m

[0206] Prepared according to the **General Procedure 1B** from tert-butyl 2-(2-([1,1'-biphenyl]-4-yl)acetyl)hydrazinecarboxylate (**AH.2.182**) (3.83 g, 11.7 mmol) to afford 2.75 g (89% yield) of the intermediate HCl salt as a white solid. The HCl salt (2.75 g, 10.5 mmol) was then converted to 1.84 g (77 % yield) of freebase **29m** (69% for two steps), isolated as a white solid: ^1H NMR (400 MHz, DMSO- d_6) δ 9.21 (bs, 1H), 7.53 – 7.61 (m, 4H), 7.41 (t, J = 7.30 Hz, 2H), 7.29 – 7.32 (m, 3H), 4.19 (bs, 2H), 3.35 (s, 2H). ^{13}C NMR (100 MHz, DMSO- d_6) δ 170.03, 140.53, 138.86, 136.07, 130.05, 129.44, 127.81, 127.08, 127.04, 40.68. LCMS (15-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 6.25 minutes, ESI m/z = 227, $[M+H]^+$; 453, $[2M + H]$.

Synthesis of 2-phenylacetic hydrazide (29n)


[0207] To a solution of methyl phenylacetate (**30**) (1.00 g, 6.66 mmol) in ethanol (50 mL) was added hydrazine hydrate (66.6 mmol). The resulting mixture was heated to reflux for 4 hours. The reaction was cooled and partitioned with water (200 mL) and EtOAc (200 mL). The EtOAc solution was washed again with water (2 x 200 mL), dried (Na_2SO_4), filtered and concentrated to afford 370 mg (37% yield) of compound **29n** as a viscous oil: ^1H NMR (400 MHz, DMSO-d_6) δ 9.18 (bs, 1H), 7.15 – 7.27 (m, 5H), 4.17 (bs, 2H), 3.30 (s, 2H). ^{13}C NMR (100 MHz, DMSO-d_6) δ 170.07, 136.81, 129.47, 128.70, 126.88, 40.99. LCMS (15-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 3.43 minutes, ESI m/z = 151, $[\text{M}+\text{H}]^+$.

General Procedure 1C: Synthesis of Triazoles




[0208] A mixture of thioamide (1 mmol) and hydrazide (1.2 mmol) was dissolved in CH_2Cl_2 (30 mL) and treated with silver benzoate (2 mmol) followed immediately with acetic acid (3 mmol). The black solution was stirred at room temperature overnight. The solution was concentrated and the residue was dissolved in 1:1 MeOH/ CH_2Cl_2 and treated with 1N HCl (2 mmol). The mixture was stirred for 5 minutes, treated with diisopropylethylamine (~10 mmol) and concentrated. The residue was suspended in MeOH (50 mL), filtered through CELITE (1 inch pad) and concentrated. The final residue was purified by flash chromatography.

Synthesis of 3-(2-(5-(4-Chlorobenzyl)-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazol-3-yl)ethyl)-1H-indole (31a)



[0209] Prepared according to the **General Procedure 1C** from 3-(1H-indol-3-yl)-N-(3-(1-trityl-1H-imidazol-4-yl)propyl)propanethioamide (**10**) (475 mg, 0.86 mmol) and 2-(4-chlorophenyl)acetic hydrazide (**29a**) (190 mg, 1.03 mmol). Purification by flash chromatography (SiO₂, 20:1 CH₂Cl₂/methanol) afforded 360 mg (61% yield) of compound **31a** as a white solid: LCMS (50-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 4.35 minutes, ESI m/z = 687, [M+H]⁺.


Synthesis of 3-(2-(5-(3-Chlorobenzyl)-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazol-3-yl)ethyl)-1H-indole (31b)



[0210] Prepared according to the **General Procedure 1C** from 3-(1H-indol-3-yl)-N-(3-(1-trityl-1H-imidazol-4-yl)propyl)propanethioamide (**10**) (200 mg, 0.36 mmol) and 2-(3-chlorophenyl)acetic hydrazide (80.0 mg, 0.45 mmol). Purification by flash chromatography (SiO₂, 20:1 CH₂Cl₂/methanol) afforded 147 mg (60% yield) of compound **31b** as a white solid: ¹H NMR (400 MHz, DMSO-d₆) δ 10.83 (bs, 1H), 8.73


(bs, 1H), 7.44 (d, $J = 8.20$ Hz, 1H), 7.37 – 7.42 (m, 10H), 7.21– 7.33 (complex multiplets, 4H), 7.05 – 7.15 (complex multiplets, 8H), 7.01 (t, $J = 8.20$ Hz, 1H), 6.90 (t, $J = 8.20$ Hz, 1H), 4.20 (s, 2H), 3.89 (distorted triplet, $J = 7.30$ Hz, 2H), 3.07 – 3.16 (m, 4H), 2.53 (distorted t, $J = 7.30$ Hz, 2H), 1.63 (quint, $J = 7.40$ Hz, 2H). ^{13}C NMR (100 MHz, DMSO- d_6) δ 155.21 (s), 153.37 (s), 140.85 (s), 138.27 (s), 137.71 (s), 133.69 (s), 131.03 (d), 129.68 (d), 129.21 (d), 128.14 (d), 127.59 (d), 127.31 (s), 123.42 (d), 121.57 (d), 119.97 (s), 118.89 (d), 118.65 (d), 113.07 (s), 111.99 (d), 77.85 (s), 43.04 (t), 29.90 (t), 28.15 (t), 25.66 (t), 22.39 (t), 21.88 (t). LCMS (50-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 4.38 minutes, ESI $m/z = 687$, $[\text{M}+\text{H}]^+$.

Synthesis of 3-(2-(5-(2-Chlorobenzyl)-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazol-3-yl)ethyl)-1H-indole (31c)




[0211] Prepared according to the **General Procedure 1C** from 3-(1H-indol-3-yl)-N-(3-(1-trityl-1H-imidazol-4-yl)propyl)propanethioamide (**10**) (500 mg, 0.90 mmol) and 2-(2-chlorophenyl)acetic hydrazide (199 mg, 1.08 mmol). Purification by flash chromatography (SiO_2 , 20:1 CH_2Cl_2 /methanol) afforded 286 mg (46% yield) of compound **31c** as a white solid: LCMS (50-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 3.90 minutes, ESI $m/z = 687$, $[\text{M}+\text{H}]^+$.

Synthesis of 3-(2-(5-(4-Methoxybenzyl)-4-(3-(1-trityl-1H-imidazol-5-yl)propyl)-4H-1,2,4-triazol-3-yl)-ethyl)-1H-indole (31d)




[0212] Prepared according to the **General Procedure 1C** from 3-(1H-indol-3-yl)-N-(3-(1-trityl-1H-imidazol-4-yl)propyl)propanethioamide (**10**) (540 mg, 0.97 mmol) and 2-(4-methoxy-phenyl)acetic hydrazide (209 mg, 1.16 mmol). Purification by flash chromatography (SiO₂, 30:1 to 20:1 CH₂Cl₂/methanol) afforded 250 mg (38% yield) of compound **31d** as a white solid: ¹H NMR (400 MHz, DMSO-d₆) δ 10.74 (bs, 1H), 6.73 – 7.91 (complex multiplets, 25H), 6.51 (s), 3.93 (s, 2H), 3.63 (apparent t, *J* = 7.40 Hz, 2H), 3.61 (s, 3H), 3.05 (apparent t, *J* = 7.40 Hz, 2H), 2.89 (apparent t, *J* = 6.90 Hz, 2H), 2.29 (t, *J* = 6.90 Hz, 2H), 1.54 (quint, *J* = 7.30 Hz, 2H). ¹³C NMR (100 MHz, DMSO-d₆) δ 158.44 (s), 154.46 (s), 153.21 (s), 142.82 (s), 140.16, 138.30, 136.67, 130.51, 129.90, 129.66 (d), 128.95, 128.69 (d), 128.46, 127.43, 123.08, 121.40, 118.72, 118.19, 114.38, 114.14, 113.87, 111.84, 74.88 (s), 55.49 (q), 42.43 (t), 29.92 (t), 29.55 (t), 25.88 (t), 25.05 (t), 23.22 (t). LCMS (25-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 6.75 minutes, ESI *m/z* = 683, [M+H]⁺.

Synthesis of 3-(2-(5-(3-Methoxybenzyl)-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazol-3-yl)ethyl)-1H-indole (31e)




[0213] Prepared according to the **General Procedure 1C** from 3-(1H-indol-3-yl)-N-(3-(1-trityl-1H-imidazol-4-yl)propyl)propanethioamide (**10**) (500 mg, 0.90 mmol) and 2-(3-methoxyphenyl)acetic hydrazide (195 mg, 1.08 mmol). Purification by flash chromatography (SiO₂, 20:1 to 10:1 CH₂Cl₂/methanol) afforded 190 mg (31% yield) of compound **31e** as a white solid: ¹H NMR (400 MHz, CDCl₃) δ 7.99 (bs, 1H), 7.49 (d, *J* = 7.80 Hz, 1H), 7.27 – 7.34 (complex multiplets, 10H), 7.21 (d, *J* = 8.30 Hz, 1H), 6.99 – 7.11 (complex multiplets, 9H), 6.86 (d, *J* = 2.30 Hz, 1H), 6.65 – 6.68 (m, 3H), 6.36 (s, 1H), 4.05 (s, 2H), 3.32 (apparent t, *J* = 7.80 Hz, 2H), 3.26 (t, *J* = 7.80 Hz, 2H), 2.97 (t, *J* = 7.80 Hz, 2H), 2.25 (t, *J* = 7.30 Hz, 2H), 1.51 (quint, *J* = 7.80 Hz, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 159.91 (s), 155.16 (s), 152.17 (s), 142.41 (s), 138.49, 137.61, 136.22, 129.79, 129.77, 128.20, 128.17, 122.08, 122.00, 120.92, 119.50, 118.62, 118.14, 114.77, 114.16, 112.52, 111.24, 75.33 (s), 55.35 (q), 42.72 (t), 31.70 (t), 29.42 (t), 26.20 (t), 25.20 (t), 23.68 (t). LCMS (25-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 6.78 minutes, ESI *m/z* = 683, [M+H]⁺.

Synthesis of 3-(2-(5-(2-Methoxybenzyl)-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazol-3-yl)ethyl)-1H-indole (31f)



[0214] Prepared according to the **General Procedure 1C** from 3-(1H-indol-3-yl)-N-(3-(1-trityl-1H-imidazol-4-yl)propyl)propanethioamide (**10**) (500 mg, 0.90 mmol) and 2-(2-methoxyphenyl)acetic hydrazide (195 mg, 1.08 mmol). Purification by flash chromatography (SiO₂, 30:1 to 20:1 CH₂Cl₂/methanol) afforded 203 mg (33% yield) of compound **31f** as a white solid: LCMS (50-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 3.70 minutes, ESI m/z = 683, [M+H]⁺.


Synthesis of 3-(2-(5-(3-Fluorobenzyl)-4-(3-(1-trityl-1H-imidazol-5-yl)propyl)-4H-1,2,4-triazol-3-yl)ethyl)-1H-indole (31g)



[0215] Prepared according to the **General Procedure 1C** from 3-(1H-indol-3-yl)-N-(3-(1-trityl-1H-imidazol-4-yl)propyl)propanethioamide (**10**) (514 mg, 0.93 mmol) and 2-(3-fluorophenyl)acetic hydrazide (188 mg, 1.11 mmol). Purification by flash chromatography (SiO₂, 20:1 CH₂Cl₂/methanol) afforded 300 mg (49% yield) of


compound **31g** as a white solid: ^1H NMR (400 MHz, DMSO- d_6) contains minor inseparable aromatic impurity related to the previous use of Lawesson's reagent, hydrogen-bonded forms observed, major form: δ 10.74 (bs, 1H), 9.20 (bs, 0.5 H), 7.90 (d, J = 6.40 Hz, 1H), 7.58 (t, J = 6.40 Hz, 0.5H), 6.90 – 7.46 (complex multiplets, 23H), 6.84 (t, J = 7.70 Hz, 1H), 6.48 (s, 1H), 4.05 (s, 2H), 3.69 (apparent t, J = 8.20 Hz, 2H), 3.06 (apparent t, J = 7.55 Hz, 2H), 2.91 (apparent, t, J = 7.55 Hz, 2H), 2.30 (apparent t, J = 6.90 Hz, 1H), 1.52 (quint., J = 7.30 Hz, 2H). LCMS (25-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 6.82 minutes, ESI m/z = 671, $[\text{M}+\text{H}]^+$.

Synthesis of 3-(2-(5-(3-Bromobenzyl)-4-(3-(1-trityl-1H-imidazol-5-yl)propyl)-4H-1,2,4-triazol-3yl)ethyl)-1H-indole (31h)




[0216] Prepared according to the **General Procedure 1C** from 3-(1H-indol-3-yl)-N-(3-(1-trityl-1H-imidazol-4-yl)propyl)propanethioamid (**10**) (748 mg, 1.40 mmol) and 2-(3-bromophenyl)acetic hydrazide (371 mg, 1.62 mmol). Purification by flash chromatography (SiO_2 , 20:1 CH_2Cl_2 /methanol) afforded 492 mg (48% yield) of compound **31h** as a white solid: ^1H NMR (400 MHz, DMSO- d_6) contains minor inseparable aromatic impurity related to the previous use of Lawesson's reagent, hydrogen-bonded forms observed, major form: δ 10.75 (bs, 1H), 7.90 (d, J = 6.80 Hz, 1H), 6.98 – 7.47 (complex multiplets, 23H), 6.84 (t, J = 8.00 Hz, 1H), 6.49 (s, 1H), 4.03 (s, 2H), 3.70 (apparent t, J = 8.20 Hz, 2H), 3.05 – 3.07 (m, 2H), 2.89 – 2.933 (m, 2H), 2.28 – 2.32 (m, 2H), 1.51 (quint., J = 7.30 Hz, 2H). LCMS (50-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 4.30 minutes, ESI m/z = 731, $[\text{M}+\text{H}]^+$.

Synthesis of 3-(2-(5-(3-(Trifluoromethyl)benzyl)-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazol-3-yl)ethyl)-1H-indole (31i)



[0217] Prepared according to the **General Procedure 1C** from 3-(1H-indol-3-yl)-N-(3-(1-trityl-1H-imidazol-4-yl)propyl)propanethioamide (**10**) (500 mg, 0.90 mmol) and 2-(3,5-difluorophenyl)acetic hydrazide (236 mg, 1.08 mmol). Purification by flash chromatography (SiO₂, 40:1 CH₂Cl₂/methanol to 20:1) afforded 279 mg (36% yield) of compound **31i** as a white solid: LCMS (50-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 4.90 minutes, ESI m/z = 721, [M+H]⁺.


Synthesis of 3-(2-(5-(3,5-Difluorobenzyl)-4-(3-(1-trityl-1H-imidazol-5-yl)propyl)-4H-1,2,4-triazol-3-yl)ethyl)-1H-indole (31j)



[0218] Prepared according to the **General Procedure 1C** from 3-(1H-indol-3-yl)-N-(3-(1-trityl-1H-imidazol-4-yl)propyl)propanethioamide (**10**) (500 mg, 0.90 mmol) and 2-(3,5-difluorophenyl)acetic hydrazide (206 mg, 1.10 mmol). Purification by flash chromatography (SiO₂, 20:1 CH₂Cl₂/methanol) afforded 300 mg (47% yield) of

compound **31j** as a white solid: ^1H NMR (400 MHz, DMSO- d_6) conformational forms present; major form: δ 10.74 (bs, 1H), 7.89 – 7.91 (m, 1H), 7.40 (d, J = 8.20 Hz, 1H), 7.29 – 7.33 (complex multiplets, 9H), 7.26 (d, J = 7.80 Hz, 1H), 7.19 (d, J = 1.30 Hz, 1H), 7.08 (d, J = 2.30 Hz, 1H), 6.07 – 7.01 (complex multiplets, 8H), 6.86 – 6.89 (m, 1H), 6.83 (t, J = 6.80 Hz, 1H), 6.51 (s, 1H), 4.07 (s, 2H), 3.72 (apparent t, J = 6.30 Hz, 2H), 3.06 (apparent t, J = 6.90 Hz, 2H), 2.92 (apparent t, J = 6.40 Hz, 2H), 2.33 (t, J = 6.90 Hz, 2H), 1.58 (quint, J = 7.80 Hz, 2H). ^{13}C NMR (100 MHz, DMSO- d_6) δ 162.79 (dd, $J_{\text{C,F}}$ = 246, 13.4 Hz), 154.70 (s), 152.14 (s), 142.81 (s), 141.82 (t, $J_{\text{C,F}}$ = 9.50 Hz), 140.15, 138.30, 136.68, 129.77, 129.65 (d), 129.06, 128.69 (d), 128.45, 127.43, 123.08, 121.40, 118.71, 118.68, 118.13, 113.88, 112.35 (dd, $J_{\text{C,F}}$ = 18.2, 6.70 Hz), 111.85, 102.70 (t, $J_{\text{C,F}}$ = 24.9 Hz), 74.87 (s), 42.51 (t), 30.17 (t), 29.67 (t), 25.91 (t), 24.99 (t), 23.17 (t). LCMS (50-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 4.13 minutes, ESI m/z = 689, $[\text{M}+\text{H}]^+$.


Synthesis of 3-(2-(5-(3,5-Dichlorobenzyl)-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazol-3-yl)ethyl)-1H-indole (31k)



31k


[0219] Prepared according to the **General Procedure 1C** from 3-(1H-indol-3-yl)-N-(3-(1-trityl-1H-imidazol-4-yl)propyl)propanethioamide (**10**) (500 mg, 0.90 mmol) and 2-(3,5-difluorophenyl)acetic hydrazide (237 mg, 1.08 mmol). Purification by flash chromatography (SiO_2 , 20:1 CH_2Cl_2 /methanol) afforded 378 mg (58% yield) of compound **31k** as a white solid: LCMS (50-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 5.25 minutes, ESI m/z = 721, $[\text{M}+\text{H}]^+$.

Synthesis of 3-(2-(5-([1,1'-Biphenyl]-4-ylmethyl)-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazol-3-yl)ethyl)-1H-indole (31m)




[0220] Prepared according to the **General Procedure 1C** from 3-(1H-indol-3-yl)-N-(3-(1-trityl-1H-imidazol-4-yl)propyl)propanethioamide (**10**) (500 mg, 0.90 mmol) and 2-([1,1'-biphenyl]-4-yl)acetic hydrazide (244 mg, 1.08 mmol). Purification by flash chromatography (SiO₂, 20:1 CH₂Cl₂/methanol) and recrystallization of the product from ACN afforded 235 mg (36% yield) of compound **31m** as a white solid: ¹H NMR (400 MHz, DMSO-d₆) δ 10.71 (bs, 1H), 7.54 (d, *J* = 7.40 Hz, 2H), 7.48 (d, *J* = 8.20 Hz, 2H), 7.35 – 7.43 (m, 3H), 7.25 – 7.31 (complex m, 11H), 7.16 – 7.19 (complex m, 3H), 7.07 (d, *J* = 2.30 Hz, 1H), 6.96 – 6.98 (m, 7H), 6.85 (t, *J* = 7.30 Hz, 1H), 6.50 (s, 1H), 4.05 (s, 2H), 3.68 (apparent t, *J* = 8.20 Hz, 2H), 3.07 (apparent t, *J* ~ 7.55 Hz, 2H), 2.92 (apparent t, *J* ~ 7.80 Hz, 2H), 2.32 (t, *J* = 6.90 Hz, 2H), 1.61 (quint, *J* = 7.80 Hz, 2H). ¹³C NMR (100 MHz, DMSO-d₆) δ 154.54, 152.84, 142.81, 140.34, 140.18, 139.05, 138.31, 136.72, 136.47, 130.11, 129.65, 129.48, 129.39, 128.65, 128.42, 127.85, 127.47, 127.28, 127.06, 123.10, 121.39, 118.73, 118.69, 118.20, 113.90, 111.85, 74.90, 42.53, 30.40, 29.60, 25.95, 25.06, 23.28. LCMS (50-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 5.40 minutes, ESI *m/z* = 729, [M+H]⁺.

Synthesis of 3-(2-(5-Benzyl-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazol-3-yl)ethyl)-1H-indole (31n)



[0221] Prepared according to the **General Procedure 1C** from 3-(1H-indol-3-yl)-N-(3-(1-trityl-1H-imidazol-4-yl)propyl)propanethioamide (**10**) (580 mg, 1.04 mmol) and 2-phenylacetic hydrazide (187 mg, 1.24 mmol). Purification by flash chromatography (SiO₂, 20:1 CH₂Cl₂/methanol) afforded 310 mg (46% yield) of compound **31n** as a white solid: ¹H NMR (400 MHz, DMSO-d₆) δ 10.74 (bs, 1H), 9.18 (bs, 1H), 7.90 (d, *J* = 6.90 Hz, 1H), 6.98 – 7.55 (complex multiplets, 24H), 6.84 (t, *J* = 6.80 Hz, 1H), 6.45 (s, 1H), 4.01 (s, 2H), 3.65 (apparent t, *J* = 8.30 Hz, 2H), 3.06 (apparent t, *J* = 8.20 Hz, 2H), 2.90 (apparent t, *J* = 7.80 Hz, 2H), 2.27 (t, *J* = 7.30 Hz, 2H), 1.47 (quint., *J* = 7.40 Hz, 2H). ¹³C NMR (100 MHz, DMSO-d₆) δ 154.54 (s), 152.95 (s), 142.83 (s), 140.17, 138.26, 137.28, 136.81, 136.69, 133.35, 129.79, 129.68 (d), 129.47, 129.09, 128.98, 128.90, 128.70 (d), 128.48, 127.45, 127.08, 126.88, 123.10, 121.41, 118.74, 118.71, 118.16, 113.90, 111.86, 74.88 (s), 42.51 (t), 40.99 (t), 30.77 (t), 29.58 (t), 25.91 (t), 25.09 (t), 23.22 (t). LCMS (50-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 3.97 minutes, ESI *m/z* = 653, [M+H]⁺.


Synthesis of (R)-tert-butyl (1-(5-(3-chlorobenzyl)-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazol-3-yl)-2-(1H-indol-3-yl)ethyl)carbamate (33)



33

[0222] Prepared according to the **General Procedure 1C** from (R)-tert-butyl (3-(1H-indol-3-yl)-1-thioxo-1-((3-(1-trityl-1H-imidazol-4-yl)propyl)amino)propan-2-yl)carbamate (**26**) (289 mg, 0.43 mmol) and 2-(3-chlorophenyl)acetic hydrazide (95.6 mg, 0.52 mmol). Purification by flash chromatography (SiO₂, 20:1 CH₂Cl₂/methanol) afforded 80 mg (23% yield) of compound 33 as a tan foam: LCMS (50-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 5.90 minutes, ESI m/z = 802, [M+H]⁺.

Synthesis of 3-(2-(5-(3,4-Dichlorobenzyl)-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazol-3-yl)ethyl)-1-methyl-1H-indole (35)




35

[0223] Prepared according to the **General Procedure 1C** from 3-(1-methyl-1H-indol-3-yl)-N-(3-(1-trityl-1H-imidazol-4-yl)propyl)propanethioamide (**14**) (440 mg, 0.77 mmol) and 2-(3,4-Dichlorophenyl)acetic hydrazide (**29I**) (203 mg, 0.93 mmol).

Purification by flash chromatography (SiO₂, 40:1 CH₂Cl₂/methanol to 20:1) and recrystallization of the product from ACN afforded 390 mg (67% yield) of compound **35** as a white solid: LCMS (50-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 5.62 minutes, ESI m/z = 735, [M+H]⁺.


Synthesis of 1-Methyl-3-(2-(5-(3-(trifluoromethyl)benzyl)-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazol-3-yl)ethyl)-1H-indole (37)



37


[0224] Prepared according to the **General Procedure 1C** from 3-(1-methyl-1H-indol-3-yl)-N-(3-(1-trityl-1H-imidazol-4-yl)propyl)propanethioamide (**14**) (720 mg, 1.26 mmol) and 2-(3-(trifluoromethyl)phenyl)acetic hydrazide (29i) (331 mg, 1.52 mmol). Purification by flash chromatography (SiO₂, 40:1 CH₂Cl₂/methanol to 20:1) afforded 463 mg (50% yield) of compound **37** as a white solid: LCMS (50-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 5.47 minutes, ESI m/z = 735, [M+H]⁺.

General Procedure 1D: Trityl Deprotection




[0225] A mixture of the trityl-protected compound (1 mmol) in ethanol (50 mL) was added 2N HCl (25 mL) and the mixture was heated to 70 °C for 2-4 hours. The reaction was cooled, transferred to a separatory funnel, and diluted with water (50 mL). The solution was washed with CH₂Cl₂ (3 x 50 mL). The resulting aqueous solution was made basic with 2N NaOH (checked with pH paper) and extracted with CH₂Cl₂ (3 x 50 mL). The combined extracts were dried (Na₂SO₄), filtered and concentrated. The residue was purified by recrystallization, flash chromatography, or used as is.

Synthesis of 3-(2-(4-(3-(1H-imidazol-4-yl)propyl)-5-(4-chlorobenzyl)-4H-1,2,4-triazol-3-yl)ethyl)-1H-indole (BN-VI-62)



[0226] Prepared according to the **General Procedure 1D** from 3-(2-(5-(2-chlorobenzyl)-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazol-3-yl)ethyl)-1H-indole (**31a**) (257 mg, 0.37 mmol) to afford 114 mg (69% yield) of **BN-VI-62** as a white solid: LCMS (25-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 5.43 minutes, ESI m/z = 445, [M+H]⁺.


Synthesis of 3-(2-(4-(3-(1H-Imidazol-4-yl)propyl)-5-(3-chlorobenzyl)-4H-1,2,4-triazol-3-yl)ethyl)-1H-indole (BN-VI-56)



BN-VI-56

[0227] Prepared according to the **General Procedure 1D** from 3-(2-(5-(3-chlorobenzyl)-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazol-3-yl)ethyl)-1H-indole (**31b**) (48.0 mg, 0.07 mmol) to afford 27.0 mg (87% yield) of **BN-VI-56** as a white solid: LCMS (25-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 5.38 minutes, ESI m/z = 445, $[M+H]^+$.

Synthesis of 3-(2-(4-(3-(1H-Imidazol-4-yl)propyl)-5-(2-chlorobenzyl)-4H-1,2,4-triazol-3-yl)ethyl)-1H-indole (MM-I-17)




MM-I-17

[0228] Prepared according to the **General Procedure 1D** from 3-(2-(5-(2-chlorobenzyl)-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazol-3-yl)ethyl)-1H-indole (**31c**) (234 mg, 0.34 mmol). Recrystallization from ACN afforded 76.0 mg (50% yield) of **MM-I-17** (Example 3) as a white solid: ^1H NMR (400 MHz, DMSO- d_6) imidazole tautomers observed: δ 11.77 and 11.70 (two overlapping bs, 1H overall), 10.78 (bs, 1H),

7.41 – 7.44 (m, 3H), 7.29 (d, $J = 8.20$ Hz, 1H), 7.22 – 7.27 (m, 2H), 7.06 – 7.10 (complex multiplet, 2H), 7.02 (t, $J = 7.30$ Hz, 1H), 6.92 (t, $J = 7.30$ Hz, 1H), 6.71 and 6.51 (two broadened singlets, 1H overall), 4.08 (s, 2H), 3.68 – 3.78 (m, 2H), 3.05 – 3.08 (m, 2H), 2.94 – 2.98 (m, 2H), 2.36 (t, $J = 6.90$ Hz, 2H), 1.71 (quint, $J = 7.30$ Hz, 2H). LCMS (15-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 5.98 minutes, ESI $m/z = 445$, $[M+H]^+$.


Synthesis of 3-(2-(4-(3-(1H-imidazol-4-yl)propyl)-5-(4-methoxybenzyl)-4H-1,2,4-triazol-3-yl)ethyl)-1H-indole (SM-I-29)



[0229] Prepared according the **General Procedure 1D** from 3-(2-(5-(4-methoxybenzyl)-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazol-3-yl)ethyl)-1H-indole (**31d**) (210 mg, 0.30 mmol) to afford 110 mg (83% yield) of **SM-I-29** as a white solid: ^1H NMR (400 MHz, DMSO- d_6) imidazole tautomers observed: δ 11.73 (bs, 1H), 10.77 (bs, 1H), 7.49 and 7.45 (2 bs, 1H overall), 7.42 (d, $J = 7.40$ Hz, 1H), 7.11 – 7.34 (complex multiplets, 5H), 7.09 (d, $J = 2.30$ Hz, 1H), 7.02 (dt, $J = 6.60, 0.90$ Hz, 1H), 6.97 (d, $J = 8.30$ Hz, 2H), 6.92 (t, $J = 6.90$ Hz, 1H), 6.78 – 6.81 (m, 2H), 6.69 and 6.50 (2 bs, 1H overall), 3.93 (s, 2H), 3.66 (s, 3H), 3.60 – 3.66 (m, 2H), 3.06 (apparent t, $J = 8.20$ Hz, 2H), 2.91 (apparent t, $J = 6.90$ Hz, 2H), 2.29 – 2.38 (m, 2H), 1.53 – 1.62 (m, 2H). ^{13}C NMR (100 MHz, DMSO- d_6) imidazole tautomers observed: δ 158.48 (s), 154.53 (s), 153.24 (s), 148.29, 144.63, 139.80, 136.68, 135.20, 130.43, 129.91, 128.93, 128.65, 128.41, 128.29, 128.06, 127.45, 127.17, 123.11, 121.43, 118.80, 118.71, 114.45, 114.2, 113.90, 112.55, 111.86, 55.54 (q), 42.49 (t), 42.34 (t), 29.99 (t), 29.90 (t), 29.52 (t),


25.88 (t), 25.00 (t), 23.26 (t), 23.18 (t). LCMS (5-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 6.30 minutes, ESI m/z = 441, $[M+H]^+$.

Synthesis of 3-(2-(4-(3-(1H-imidazol-4-yl)propyl)-5-(3-methoxybenzyl)-4H-1,2,4-triazol-3-yl)ethyl)-1H-indole (BN-VI-61)



[0230] Prepared according to the **General Procedure 1D** from 3-(2-(5-(3-methoxybenzyl)-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazol-3-yl)ethyl)-1H-indole (**31e**) (177 mg, 0.26 mmol) to afford 96 mg (84% yield) of **BN-VI-61** as a white solid: ^1H NMR (400 MHz, DMSO-d_6) δ 11.80 (bs, 1H), 10.78 (bs, 1H), 7.49 (s, 1H), 7.43 (d, J = 7.80 Hz, 1H), 7.29 (d, J = 7.80 Hz, 1H), 7.15 (t, J = 7.80 Hz, 1H), 7.10 (d, J = 1.80 Hz, 1H), 7.02 (t, J = 7.40 Hz, 1H), 6.92 (t, J = 7.40 Hz, 1H), 6.72 – 6.76 (m, 2H), 6.62 – 6.68 (m, 2H), 3.99 (s, 2H), 3.69 (apparent t, J = 7.40 Hz, 2H), 3.07 (apparent t, J = 6.90 Hz, 2H), 2.92 (apparent t, J = 6.90 Hz, 2H), 2.34 (t, J = 6.80 Hz, 2H), 1.59 (quint, J = 7.80 Hz, 2H). ^{13}C NMR (100 MHz, DMSO-d_6) δ 159.88 (s), 154.57 (s), 152.91 (s), 138.74, 136.71, 135.19, 130.13, 127.47, 123.10, 121.45, 121.11, 118.81, 118.73, 114.69, 113.94, 112.55, 111.88, 55.50 (q), 42.50 (t), 30.79 (t), 29.74 (t), 25.91 (t), 23.19 (t). LCMS (25-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 4.02 minutes, ESI m/z = 441, $[M+H]^+$.


Synthesis of 3-(2-(4-(3-(1H-imidazol-4-yl)propyl)-5-(2-methoxybenzyl)-4H-1,2,4-triazol-3-yl)ethyl)-1H-indole (MM-I-21)



MM-I-21

[0231] Prepared according to the **General Procedure 1D** from 3-(2-(5-(2-methoxybenzyl)-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazol-3-yl)ethyl)-1H-indole (**31f**) (102 mg, 0.15 mmol) to afford 21 mg (74% yield) of **MM-I-21** as a white solid: ^1H NMR (400 MHz, DMSO- d_6) imidazole tautomers observed: δ 11.75 and 11.69 (two overlapping bs, 1H overall), 10.77 (bs, 1H), 7.41 – 7.44 (m, 2H), 7.29 (d, J = 8.30 Hz, 1H), 7.18 (broadened dt, J = 6.40, 1.80 Hz, 1H), 7.09 (d, J = 1.80 Hz, 1H), 7.02 (dt, J = 6.90, 0.9 Hz, 1H), 6.90 – 6.95 (m, 2H), 6.80 – 6.88 (m, 3H), 6.69 and 6.50 (two bs, 1H overall), 3.92 and 3.91 (two overlapping s, 2H overall), 3.73 and 3.72 (two overlapping s, 3H overall), 3.64 – 3.73 (m, 2H), 3.04 – 3.09 (m, 2H), 2.91 – 2.95 (m, 2H), 2.38 and 2.33 (two t, J = 7.80 and 6.90 Hz, respectively, 2H overall), 1.61 – 1.70 (m, 2H). LCMS (15-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 5.95 minutes, ESI m/z = 441, $[\text{M}+\text{H}]^+$.


Synthesis of 3-(2-(4-(3-(1H-imidazol-4-yl)propyl)-5-(3-fluorobenzyl)-4H-1,2,4-triazol-3-yl)ethyl)-1H-indole (SM-I-38)



SM-I-38

[0232] Prepared according to the **General Procedure 1D** from 3-(2-(5-(3-fluorobenzyl)-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazol-3-yl)ethyl)-1H-indole (**31g**) (290 mg, 0.43 mmol) to afford 120 mg (65% yield) of **SM-I-38** as a white solid: ^1H NMR (400 MHz, DMSO- d_6) imidazole tautomers observed: δ 11.75 and 9.21 (two bs, 1H overall), 10.78 (bs, 1H), 7.47 (s, 1H), 7.42 (d, $J = 7.70$ Hz, 1H), 7.29 (apparent q, $J = 7.80$ Hz, 2H), 7.10 (bs, 1H), 6.97 – 7.05 (m, 3H), 6.89 – 6.95 (m, 2H), 6.65 (bs, 1H), 4.05 (s, 2H), 3.70 (apparent t, $J = 7.80$ Hz, 2H), 3.07 (apparent t, $J = 7.55$ Hz, 2H), 2.93 (apparent t, $J = 7.55$ Hz, 2H), 2.35 (t, $J = 6.90$ Hz, 2H), 1.61 (quint, $J = 7.30$ Hz, 2H). ^{13}C NMR (100 MHz, DMSO- d_6) imidazole tautomers observed: δ 162.68 (d, $J_{\text{C,F}} = 243$ Hz), 162.68 (d, $J_{\text{C,F}} = 243$ Hz), (s), 154.68 (s), 152.56 (s), 140.07 (d, $J_{\text{C,F}} = 7.60$ Hz), 139.54 (d, $J_{\text{C,F}} = 7.60$ Hz), 136.60, 135.21, 130.99 (d, $J_{\text{C,F}} = 8.70$ Hz), 130.55 (d, $J_{\text{C,F}} = 8.70$ Hz), 127.45, 125.63, 125.09, 123.11, 121.44, 118.79, 118.70, 116.18 (d, $J_{\text{C,F}} = 22.1\text{Hz}$), 115.82 (d, $J_{\text{C,F}} = 21.1\text{Hz}$), 114.12, 113.91, 113.71 (d, $J_{\text{C,F}} = 21.1\text{Hz}$), 111.87, 42.27 (t), 31.22 (t), 30.35 (t), 29.81 (t), 25.92 (t), 23.2 (t). LCMS (40-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 1.88 minutes, ESI $m/z = 429$, $[\text{M}+\text{H}]^+$.


Synthesis of 3-(2-(4-(3-(1H-imidazol-4-yl)propyl)-5-(3-bromobenzyl)-4H-1,2,4-triazol-3-yl)ethyl)-1H-indole (SM-I-50)



SM-I-50


[0233] Prepared according to the **General Procedure 1D** from 3-(2-(5-(3-bromobenzyl)-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazol-3-yl)ethyl)-1H-indole (**31h**) (270 mg, 0.37 mmol) to afford 100 mg (55% yield) of **SM-I-50** as a white solid: ^1H NMR (400 MHz, DMSO- d_6) major tautomer δ 11.75 (bs, 1H), 10.77 (bs, 1H), 7.48 (s, 1H), 7.42 (d, J = 8.30 Hz, 1H), 7.38 – 7.40 (m, 2H), 7.15 – 7.34 (complex multiplets, 5H), 7.08 – 7.11 (m, 2H), 7.02 (t, J = 6.90 Hz, 1H), 6.91 (t, J = 7.30 Hz, 1H), 6.66 (bs), 4.04 (s, 2H), 3.71 (apparent t, J = 7.70 Hz, 2H), 3.07 (apparent t, J = 7.55 Hz, 2H), 2.93 (apparent t, J = 7.55 Hz, 2H), 2.36 (t, J = 7.30 Hz, 2H), 1.62 (quint, J = 7.80 Hz, 2H). ^{13}C NMR (100 MHz, DMSO- d_6) major tautomer δ 154.67 (s), 152.57 (s), 140.02, 136.69, 135.20, 131.81, 131.16, 130.08, 128.40, 128.29, 128.17, 128.06, 127.45, 123.11, 122.24, 121.44, 118.80, 118.70, 113.90, 111.87, 42.48 (t), 30.18 (t), 29.94 (t), 25.91 (t), 23.20 (t). LCMS (5-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 6.47 minutes, ESI m/z = 489, $[\text{M}+\text{H}]^+$.

Synthesis of 3-(2-(4-(3-(1H-Imidazol-4-yl)propyl)-5-(3-(trifluoromethyl) benzyl)-4H-1,2,4-triazol-3-yl)ethyl)-1H-indole (BN-VI-97)



[0234] Prepared according to the **General Procedure 1D** from 3-(2-(5-(3-(trifluoromethyl)benzyl)-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazol-3-yl)ethyl)-1H-indole (**31i**) (268 mg, 0.37 mmol) to afford 121 mg (68% yield) of **BN-VI-97** as a white solid: ^1H NMR (400 MHz, DMSO- d_6 , 80 °C) imidazole tautomers observed δ 11.54 and 9.06 (2 bs, 1H overall), 10.56 (bs, 1H), 7.58 (s, 1H), 7.48 – 7.55 (m, 3H), 7.41 – 7.44 (m, 2H), 7.30 (d, J = 8.20 Hz, 1H), 7.07 (s, 1H), 7.02 (t, J = 6.80 Hz, 1H), 6.92 (t, J = 7.80 Hz, 1H), 6.66 (bs, 1H), 4.14 (s, 2H), 3.71 – 3.79 (m, 2H), 3.10 (apparent t, J = 6.80 Hz, 2H), 2.96 (apparent t, J = 7.30 Hz, 2H), 2.36 – 2.41 (m, 2H), 1.69 (b quint, J ~ 6.50 Hz, 2H). ^{13}C NMR (100 MHz, DMSO- d_6 , 80 °C) imidazole tautomers observed δ 156.06, 152.63, 136.92, 136.67, 134.83, 131.88, 130.72 (q, $J_{\text{C,F}}$ = 32.6 Hz), 129.46, 126.97, 124.91 (q, $J_{\text{C,F}}$ = 3.80 Hz), 124.14 (q, $J_{\text{C,F}}$ = 271 Hz), 123.68 (q, $J_{\text{C,F}}$ = 3.80 Hz), 122.13, 121.10, 118.46, 117.62, 112.91, 111, 42.08, 29.93, 28.79, 25.81, 23.66. LCMS (5-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 6.58 minutes, ESI m/z = 479, $[\text{M}+\text{H}]^+$.


Synthesis of 3-(2-(4-(3-(1H-Imidazol-4-yl)propyl)-5-(3,5-difluorobenzyl)-4H-1,2,4-triazol-3-yl)ethyl)-1H-indole (SM-I-55)



SM-I-55


[0235] Prepared according to the **General Procedure 1D** from 3-(2-(5-(3,5-difluorobenzyl)-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazol-3-yl)ethyl)-1H-indole (**31j**) (250 mg, 363 μ mol) to afford 130 mg (80 % yield) of **SM-I-55** as a white solid. A small fraction was recrystallized from ACN to afford pure material: ^1H NMR (400 MHz, DMSO- d_6) imidazole tautomers observed δ 11.74 (bs, 1H), 10.77 (bs, 1H), 7.48 (bs, 1H), 7.41 (d, J = 7.70 Hz, 1H), 7.28 (d, J = 8.30 Hz, 1H), 7.05 – 7.11 (m, 2H), 7.01 (t, J = 7.40 Hz, 1H), 6.86 – 6.92 (m, 3H), 6.72 and 6.51 (two bs, 1H overall), 4.07 (s, 2H), 3.66 – 3.76 (m, 2H), 3.05 – 3.08 (m, 2H), 2.92 – 2.95 (m, 2H), 2.33 – 2.37 (m, 2H), 1.59 – 1.68 (m, 2H). LCMS (5-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 6.40 minutes, ESI m/z = 447, $[\text{M}+\text{H}]^+$.

Synthesis of 3-(2-(4-(3-(1H-Imidazol-4-yl)propyl)-5-(3,5-dichlorobenzyl)-4H-1,2,4-triazol-3-yl)ethyl)-1H-indole (BN-VI-89)



[0236] Prepared according to the **General Procedure 1D** from 3-(2-(5-(3,5-dichlorobenzyl)-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazol-3-yl)ethyl)-1H-indole (**31k**) (328 mg, 0.45 mmol) to afford 179 mg (83 % yield) of **BN-VI-89** as an off white solid: ^1H NMR (400 MHz, DMSO- d_6) imidazole tautomers observed δ 11.73 and 9.19 (2 bs, 1H overall), 10.74 (bs, 1H), 7.40 – 7.47 (m, 3H), 7.25 – 7.30 (m, 3H), 7.10 (s, 1H), 7.02 (t, J = 6.90 Hz, 1H), 6.91 (t, J = 6.90 Hz, 1H), 6.72 and 6.58 (2 bs, 1H overall), 4.07 (s, 2H), 3.73 – 3.79 (bm, 2H), 3.08 (apparent t, J = 7.40 Hz, 2H), 2.94 (apparent t, J = 7.40 Hz, 2H), 2.35 – 2.42 (bm, 2H), 1.67 (bquint, J = 6.80 Hz, 2H). LCMS (25-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 5.82 minutes, ESI m/z = 479, $[\text{M}+\text{H}]^+$.


Synthesis of 3-(2-(4-(3-(1H-imidazol-4-yl)propyl)-5-([1,1'-biphenyl]-4-ylmethyl)-4H-1,2,4-triazol-3-yl)ethyl)-1H-indole (MM-I-26)



MM-I-26

[0237] Prepared according to the **General Procedure 1D** from 3-(2-(5-([1,1'-biphenyl]-4-ylmethyl)-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazol-3-yl)ethyl)-1H-indole (**31k**) (204 mg, 0.28 mmol) to afford 36 mg (26 % yield) of **MM-I-26** as a white solid: ^1H NMR (400 MHz, CD_3OD) δ 7.51 – 7.54 (complex m, 3H), 7.47 (d, $J = 7.30$ Hz, 2H), 7.39 (t, $J = 7.40$ Hz, 2H), 7.28 – 7.32 (m, 2H), 7.26 (d, $J = 7.80$ Hz, 1H), 7.01 – 7.06 (m, 1H), 7.00 (d, $J = 8.30$ Hz, 2H), 6.92 (dt, $J = 7.80$ Hz, 1H), 6.89 (s, 1H), 6.53 (bs, 1H), 4.03 (s, 2H), 3.31 (apparent t, $J = 7.30$ Hz, 2H), 3.81 (apparent t, $J = 6.90$ Hz, 2H), 3.01 (apparent t, $J = 6.90$ Hz, 2H), 2.25 (t, $J = 7.30$ Hz, 2H), 1.38 (apparent quint, $J \sim 7.80$ Hz, 2H). ^{13}C NMR (100 MHz, CD_3OD) δ 156.03, 153.15, 140.44, 140.06, 136.67, 135.99 (broadened), 134.73, 134.38, 129.21, 128.53, 128.46, 127.13, 127.09, 126.55, 122.19, 121.10, 118.50, 117.68, 115.68, 112.90, 111.00, 42.19, 30.05, 28.68, 25.77, 23.68, 23.13. LCMS (15-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 6.30 minutes, ESI $m/z = 487$, $[\text{M}+\text{H}]^+$.


Synthesis of 3-(2-(4-(3-(1H-imidazol-4-yl)propyl)-5-benzyl-4H-1,2,4-triazol-3-yl)ethyl)-1H-indole (SM-I-26)



SM-I-26

[0238] Prepared according to the **General Procedure 1D** from 3-(2-(5-benzyl-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazol-3-yl)ethyl)-1H-indole (**31n**) (250 mg, 0.38 mmol). Recrystallization from ACN afforded 46.0 mg (30% yield) of **SM-I-26** as a white solid: ^1H NMR (400 MHz, DMSO- d_6) imidazole tautomers observed: δ 11.74 and 9.18 (2 bs, 1H overall), 10.77 (bs, 1H), 7.47 (s, 1H), 7.42 (d, J = 8.20 Hz, 1H), 7.15 – 7.30 (complex m, 5H), 7.06 – 7.10 (m, 3H), 7.02 (t, J = 7.30 Hz, 1H), 6.91 (t, J = 7.40 Hz, 1H), 6.67 and 6.53 (2 bs, 1H overall), 4.01 (s, 2H), 3.62 – 3.69 (bm, 2H), 3.06 (apparent t, J ~ 7.55 Hz, 2H), 2.92 (apparent t, J ~ 7.80 Hz, 2H), 2.30 – 2.35 (bm, 2H), 1.53 – 1.64 (bm, 2H). ^{13}C NMR (100 MHz, DMSO- d_6) imidazole tautomers observed: δ 154.58, 152.95, 137.18, 136.68, 135.19, 129.46, 129.05, 128.91, 128.69, 127.45, 127.13, 126.87, 123.11, 121.43, 118.80, 118.71, 113.90, 111.87, 42.45, 30.81, 29.78 (broadened), 25.90, 24.86 (broadened), 23.22. LCMS (15-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 5.88 minutes, ESI m/z = 411, $[\text{M}+\text{H}]^+$.


Synthesis of (R)-1-(4-(3-(1H-imidazol-4-yl)propyl)-5-(3-chlorobenzyl)-4H-1,2,4-triazol-3-yl)-2-(1H-indol-3-yl)ethanamine (BN-VI-87)



BN-VI-87

[0239] Prepared according to the **General Procedure 1D** from (R)-tert-butyl (1-(5-(3-chlorobenzyl)-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazol-3-yl)-2-(1H-indol-3-yl)ethyl)carbamate (**33**) (80.0 mg, 0.10 mmol) to afford **32** mg (72 % yield) of **BN-VI-87** as a tan foam: LCMS (25-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 3.00 minutes, ESI m/z = 460, $[M+H]^+$.

Synthesis of 3-(2-(4-(3-(1H-imidazol-4-yl)propyl)-5-(3,4-dichlorobenzyl)-4H-1,2,4-triazol-3-yl)ethyl)-1-methyl-1H-indole (SM-I-60)




SM-I-60

[0240] Prepared according to the **General Procedure 1D** from 3-(2-(5-(3,4-dichlorobenzyl)-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazol-3-yl)ethyl)-1-methyl-1H-indole (**35**) (320 mg, 0.44 mmol) to afford 120 mg (56 % yield) of **SM-I-60** as a white foam: ^1H NMR (400 MHz, DMSO- d_6) imidazole tautomers observed δ 11.75 and

9.20 (2 bs, 1H overall), 7.52 (d, $J = 8.20$ Hz, 1H), 7.47 – 7.49 (bm, 1H), 7.45 (d, $J = 1.80$ Hz, 1H), 7.41 (d, $J = 7.80$ Hz, 1H), 7.32 (d, $J = 8.20$ Hz, 1H), 7.05 – 7.12 (complex m, 3H), 6.94 (t, $J = 7.40$ Hz, 1H), 6.66 (bs, 1H), 4.05 (s, 2H), 3.65 – 3.72 (m, 2H), 3.66 (s, 3H), 3.05 (apparent t, $J \sim 7.55$ Hz, 2H), 2.91 (apparent t, $J \sim 7.55$ Hz, 2H), 2.36 (t, $J = 7.30$ Hz, 2H), 1.61 (quint, $J = 7.30$ Hz, 2H). LCMS (15-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 6.45 minutes, ESI $m/z = 493$, $[M+H]^+$.


Synthesis of 3-(2-(4-(3-(1H-imidazol-4-yl)propyl)-5-(3-(trifluoromethyl)benzyl)-4H-1,2,4-triazol-3-yl)ethyl)-1-methyl-1H-indole (SM-I-76)



SM-I-76


[0241] Prepared according to **General Procedure 1D** from 1-methyl-3-(2-(5-(3-(trifluoromethyl)benzyl)-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazol-3-yl)ethyl)-1H-indole (**37**) (0.620 g, 0.843 mmol) to afford 0.220 g (77% yield) of compound **SM-I-76** as a yellow solid: ^1H NMR (400 MHz, CD_3OD) δ 7.53 – 7.51 (m, 2H), 7.46 – 7.42 (m, 2H), 7.28 (d, $J = 8.00$ Hz, 1H), 7.24 – 7.22 (m, 2H), 7.10 (dt, $J = 7.00, 0.84$ Hz, 1H), 6.93 (dt, $J = 7.23, 0.78$ Hz, 1H), 6.77 (s, 1H), 6.55 (bs, 1H), 4.09 (s, 2H), 3.60 (s, 3H), 3.35 – 3.31 (m, 2H), 3.15 (t, $J = 7.15$ Hz, 2H), 3.00 (t, $J = 6.79$ Hz, 2H), 2.26 (t, $J = 7.07$ Hz, 2H), 1.41 (quint., $J = 7.18$ Hz, 2H). ^{13}C NMR (100 MHz, CD_3OD) δ 155.98, 152.66, 137.13, 136.96, 134.85, 131.97, 130.74 (q, $J_{\text{C,F}} = 32.2$ Hz), 129.48, 127.48, 126.56, 124.92 (q, $J_{\text{C,F}} = 3.76$ Hz), 124.14 (q, $J_{\text{C,F}} = 271.3$ Hz), 123.71 (q, $J_{\text{C,F}} = 3.73$ Hz), 121.24, 118.53, 117.96, 112.42, 108.93, 42.13, 31.25, 29.94, 28.75, 25.87, 23.47, 23.15. LCMS (25-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 5.98 minutes, ESI $m/z = 493$, $[M+H]^+$.

Synthesis of 3-((4-(3-(1H-imidazol-4-yl)propyl)-5-benzyl-4H-1,2,4-triazol-3-yl)methyl)-1H-indole (SK-I-25)




[0242] Prepared according to **General Procedure 1D** from 3-((5-benzyl-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazol-3-yl)methyl)-1H-indole (237 mg, 0.37 mmol) to afford 113 mg (77% yield) of compound **SK-I-25** as a white solid: ^1H NMR (400 MHz, CD_3OD) δ 7.53 (s, 1H), 7.35 (d, J = 7.92 Hz, 1H), 7.30 (d, J = 8.21 Hz, 1H), 7.23 – 7.14 (complex m, 3H), 7.06 (dt, J = 7.11, 0.66 Hz, 1H), 7.02 (d, J = 6.89, 2H), 6.94 (apparent t, J = 6.83 Hz, 2H), 6.51 (s, 1H), 4.25 (s, 2H), 4.06 (s, 2H), 3.59 (apparent t, J = 8.33 Hz, 2H), 2.24 (t, J = 7.07 Hz, 2H), 1.35 (quint., J = 7.21 Hz, 2H). ^{13}C NMR (100 MHz, CD_3OD) δ 154.82, 154.21, 136.84, 135.41, 134.66, 128.59, 128.01, 126.89, 126.66, 122.96, 121.51, 118.83, 117.88, 111.16, 107.93, 42.75, 30.37, 28.88, 23.18, 21.55. LCMS (50-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 1.75 minutes, ESI m/z = 397, $[\text{M}+\text{H}]^+$.

Synthesis of 3-((4-(3-(1H-imidazol-4-yl)propyl)-5-(4-fluorobenzyl)-4H-1,2,4-triazol-3-yl)methyl)-1H-indole (SK-I-16)




[0243] Prepared according to **General Procedure 1D** from 3-((5-(4-fluorobenzyl)-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazol-3-yl)methyl)-1H-indole (150 mg, 0.23 mmol) to afford 86 mg (91% yield) of compound **SK-I-16** as a white solid: ^1H NMR (400 MHz, CD_3OD) δ 7.53 (s, 1H), 7.34 (d, J = 8.02 Hz, 1H), 7.30 (d, J = 8.23 Hz, 1H), 7.28 – 7.25 (m, 1H), 4.26 (s, 2H), 4.04 (s, 2H), 3.63 – 3.59 (m, 2H), 2.27 (t, J = 7.07 Hz, 2H), 1.39 (t, J = 7.10 Hz, 2H). LCMS (50-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 1.78 minutes, ESI m/z = 415, $[\text{M}+\text{H}]^+$

Synthesis of 3-((4-(3-(1H-imidazol-4-yl)propyl)-5-(4-chlorobenzyl)-4H-1,2,4-triazol-3-yl)methyl)-1H-indole (SK-I-22)




[0244] Prepared according to **General Procedure 1D** from 3-((5-(4-chlorobenzyl)-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazol-3-yl)methyl)-1H-indole (220 mg, 0.33 mmol) to afford 115 mg (83% yield) of compound **SK-I-22** as a white solid: ^1H NMR (400 MHz, CD_3OD) δ 7.54 (s, 1H), 7.34 (d, J = 7.91 Hz, 1H), 7.30 (d, J = 8.07 Hz, 1H), 7.26 – 7.20 (m, 4H), 7.07 (dt, J = 8.01, 0.97 Hz, 1H), 7.01 (d, J = 8.43 Hz, 2H), 6.96 - 6.92 (m, 2H), 4.26 (s, 2H), 4.04 (s, 2H), 3.63 – 3.59 (m, 2H), 2.26 (t, J = 7.10 Hz, 2H), 1.38 (t, J = 7.02 Hz, 2H). LCMS (50-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 1.82 minutes, ESI m/z = 431, $[\text{M}+\text{H}]^+$.

Synthesis of 3-((4-(3-(1H-imidazol-4-yl)propyl)-5-(3-(trifluoromethyl)benzyl)-4H-1,2,4-triazol-3-yl)methyl)-1H-indole (MM-I-66)




[0245] Prepared according to **General Procedure 1D** from 3-((5-(3-(trifluoromethyl)benzyl)-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazol-3-yl)methyl)-1H-indole (242 mg, 0.34 mmol) to afford 120 mg (75% yield) of compound **MM-I-66** as a white solid: ^1H NMR (400 MHz, CD_3OD) δ 7.53 – 7.49 (m, 2H), 7.45 – 7.41 (m, 2H), 7.32 (m, 3H), 7.06 (dt, J = 8.05, 0.79 Hz, 1H), 6.95 (s, 1H), 6.93 (t, J = 7.30 Hz, 1H), 6.53 (bs, 1H), 4.27 (s, 2H), 4.16 (s, 2H), 3.68 – 3.64 (m, 2H), 2.27 (t, J = 7.10 Hz, 2H), 1.40 (quint., J = 7.20 Hz, 2H). ^{13}C NMR (100 MHz, CD_3OD) δ 154.93, 153.61, 136.97, 136.85, 134.73, 132.60, 131.99, 130.78 (q, $J_{\text{C,F}}$ = 31.9 Hz), 129.40, 128.95, 126.65, 124.80 (q, $J_{\text{C,F}}$ = 3.58 Hz), 124.1 (q, $J_{\text{C,F}}$ = 271.3 Hz), 123.71 (q, $J_{\text{C,F}}$ = 3.69 Hz), 122.96, 121.51, 118.86, 117.82, 111.17, 107.88, 42.78, 29.93, 28.76, 23.22, 21.58. LCMS (50-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 2.05 minutes, ESI m/z = 465, $[\text{M}+\text{H}]^+$.

Synthesis of 3-((4-(3-(1H-imidazol-4-yl)propyl)-5-(3-(trifluoromethyl)benzyl)-4H-1,2,4-triazol-3-yl)methyl)-6-fluoro-1H-indole (MM-I-87)




[0246] Prepared according to **General Procedure 1D** from 6-fluoro-3-((5-(3-(trifluoromethyl)benzyl)-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazol-3-yl)methyl)-1H-indole (125 mg, 0.17 mmol) to afford 60 mg (72% yield) of compound **MM-I-87** as a white solid: ^1H NMR (400 MHz, CD_3OD) δ 7.54 (s, 1H), 7.51 (d, $J = 7.79$ Hz, 1H), 7.44 (t, $J = 7.61$ Hz, 1H), 7.42 (s, 1H), 7.34 – 7.28 (m, 2H), 6.99 (dd, $J = 9.98$, 2.22 Hz, 1H), 6.95 (s, 1H), 6.72 (dt, $J = 9.63$, 2.32 Hz, 1H), 6.57 (bs, 1H), 4.25 (s, 2H), 4.17 (s, 2H), 3.70 – 3.66 (m, 2H), 2.31 (t, $J = 7.08$ Hz, 2H), 1.42 (quint., $J = 7.12$ Hz, 2H). ^{13}C NMR (100 MHz, CD_3OD) δ (d, $J_{\text{C,F}} = 235.96$ Hz), 154.71, 153.67, 136.95, 136.80 (d, $J_{\text{C,F}} = 12.54$ Hz), 134.77, 132.60, 132.02, 130.78 (q, $J_{\text{C,F}} = 32.24$ Hz), 129.42, 128.95, 124.80 (q, $J_{\text{C,F}} = 3.70$ Hz), 124.10 (q, $J_{\text{C,F}} = 271.45$ Hz), 123.71 (q, $J_{\text{C,F}} = 3.68$ Hz), 123.50 (d, $J_{\text{C,F}} = 2.84$ Hz), 123.37, 122.74, 118.86, 118.76, 108.20, 107.34 (d $J_{\text{C,F}} = 24.93$ Hz), 97.06 (d, $J_{\text{C,F}} = 26.00$ Hz), 42.75, 29.92, 29.42, 28.78, 21.51. LCMS (50-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 2.07 minutes, ESI $m/z = 483$, $[\text{M}+\text{H}]^+$.

Synthesis of 3-((4-(3-(1H-imidazol-4-yl)propyl)-5-(3-(methylsulfonyl)benzyl)-4H-1,2,4-triazol-3-yl)methyl)-1H-indole (MM-I-72)




[0247] Prepared according to **General Procedure 1D** from 3-((5-(3-(methylsulfonyl)benzyl)-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazol-3-yl)methyl)-1H-indole (65 mg, 0.09 mmol) to afford 37 mg (86% yield) of compound **MM-I-72** as a white solid: ^1H NMR (400 MHz, CD_3OD) δ 7.79 (d, $J = 7.79$ Hz, 1H), 7.71 (s, 1H), 7.54 (bs, 1H), 7.51 (t, $J = 7.75$ Hz, 1H), 7.42 (d, $J = 7.73$ Hz, 1H), 7.36 (d, $J = 7.91$ Hz, 1H), 7.30 (d, $J = 8.23$ Hz, 1H), 7.06 (dt, $J = 8.08, 0.84$ Hz, 1H), 6.97 (s, 1H), 6.95 (dt, $J = 8.03, 0.77$ Hz, 1H), 6.55 (bs, 1H), 4.28 (s, 2H), 4.19 (s, 2H), 3.69 – 3.65 (m, 2H), 2.98 (s, 3H), 2.29 (t, $J = 7.07$ Hz, 2H), 1.41 (t, $J = 6.95$ Hz, 2H). ^{13}C NMR (100 MHz, CD_3OD) δ 154.97, 153.51, 141.35, 137.51, 136.85, 134.81, 133.64, 129.75, 126.91, 126.67, 125.92, 123.02, 121.52, 118.91, 117.85, 111.19, 107.89, 42.89, 42.80, 29.93, 28.84, 23.34, 21.59. LCMS (50-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 1.72 minutes, ESI $m/z = 475$, $[\text{M}+\text{H}]^+$.

Synthesis of 3-(2-(4-(3-(1H-imidazol-4-yl)propyl)-5-(3-(methylsulfonyl)benzyl)-4H-1,2,4-triazol-3-yl)ethyl)-1H-indole (SM-I-92)




[0248] Prepared according to **General Procedure 1D** from 3-(2-(5-(3-(methylsulfonyl)benzyl)-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazol-3-yl)ethyl)-1H-indole (80 mg, 0.11 mmol) to afford **39** mg (73% yield) of compound SM-I-92 as a white solid: ^1H NMR (400 MHz, CD_3OD) δ 7.81 (d, J = 7.80 Hz, 1H), 7.70 (s, 1H), 7.54 – 7.50 (m, 2H), 7.30 – 7.25 (m, 4H), 7.04 (t, J = 7.31 Hz, 1H), 6.92 (t, J = 7.69 Hz, 1H), 6.88 (s, 1H), 6.57 (s, 1H), 4.10 (s, 2H), 3.31 – 3.26 (obscured m, 2H), 3.17 (t, J = 7.00 Hz, 2H), 3.08 – 3.01 (m, 1H), 3.05 (s, 3H), 2.26 (t, J = 7.04 Hz, 2H), 1.44 (quint., J = 7.26 Hz, 2H). ^{13}C NMR (100 MHz, CD_3OD) δ 156.13, 152.45, 141.30, 137.47, 136.64, 134.90, 133.53, 129.80, 126.98, 126.91, 125.88, 122.20, 121.13, 118.51, 117.62, 112.85, 111.02, 42.90, 42.08, 29.94, 28.81, 25.77, 23.72, 23.15. LCMS (50-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 1.73 minutes, ESI m/z = 489, $[\text{M}+\text{H}]^+$

Synthesis of 3-((4-(3-(1H-imidazol-4-yl)propyl)-5-benzyl-4H-1,2,4-triazol-3-yl)methyl)-6-fluoro-1H-indole (MM-I-89)



[0249] Prepared according to **General Procedure 1D** from 3-((5-benzyl-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazol-3-yl)methyl)-6-fluoro-1H-indole (180 mg, 0.27 mmol) to afford 89 mg (78% yield) of compound **MM-I-89** as a white solid: ^1H NMR (400 MHz, CD_3OD) δ 7.55 (bs, 1H), 7.31 – 7.15 (complex m, 5H), 7.03 (d, J = 6.95 Hz, 2H), 7.99 (dd, J = 9.89, 2.32 Hz, 1H), 6.93 (s, 1H), 6.73 (dt, J = 9.69, 2.31 Hz, 1H), 6.55 (bs, 1H), 4.23 (s, 2H), 4.07 (s, 2H), 3.63 – 3.59 (m, 2H), 2.28 (t, J = 7.04 Hz, 2H), 1.38 (quint., J = 7.09 Hz, 1H). LCMS (50-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 1.78 minutes, ESI m/z = 415, $[\text{M}+\text{H}]^+$.


Synthesis of 3-((4-(3-(1H-imidazol-4-yl)propyl)-5-(3-bromobenzyl)-4H-1,2,4-triazol-3-yl)methyl)-6-fluoro-1H-indole (MM-I-83)



[0250] Prepared according to **General Procedure 1D** from 3-((5-benzyl-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazol-3-yl)methyl)-6-fluoro-1H-indole (180

mg, 0.24 mmol) to afford 94 mg (78% yield) of compound **MM-I-83** as a white solid: ^1H NMR (400 MHz, CD_3OD) δ 7.56 (bs, 1H), 7.35 (d, $J = 8.85$ Hz, 1H), 7.29 (dd, $J = 8.72$, 5.27 Hz, 1H), 7.25 (m, 1H), 7.15 (t, $J = 7.84$ Hz, 1H), 7.03 – 6.09 (m, 2H), 6.95 (s, 1H), 6.74 (dt, $J = 9.59$, 2.30 Hz, 1H), 6.59 (bs, 1H), 4.24 (s, 2H), 4.06 (s, 2H), 3.66 – 3.62 (m, 2H), 2.31 (t, $J = 7.04$ Hz, 2H), 1.38 (quint., $J = 7.13$ Hz, 1H). ^{13}C NMR (100 MHz, CD_3OD) δ 159.95 (d, $J_{\text{C,F}} = 235.84$ Hz), 154.70, 153.71, 138.04, 136.82 (d, $J_{\text{C,F}} = 12.54$ Hz), 134.80, 131.71, 131.07, 130.34, 130.08, 126.97, 123.53 (d, $J_{\text{C,F}} = 2.91$ Hz), 123.38, 122.44, 118.87, 118.77, 108.20, 107.39 (d, $J_{\text{C,F}} = 24.81$ Hz), 97.06 (d, $J_{\text{C,F}} = 25.93$ Hz), 42.75, 29.80, 28.79, 23.37, 21.52. LCMS (15-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 6.18 minutes, ESI $m/z = 493, 495$ $[\text{M}+\text{H}]^+$.


Synthesis of tert-butyl 2-(2-(3-(trifluoromethoxy)phenyl)acetyl)hydrazine carboxylate (28n)



28n

[0251] Prepared according to **General Procedure 1A** from 2-(2-trifluoromethoxyphenyl)acetic acid (**27n**) (3.00 g, 18.05 mmol) and *tert*-butyl hydrazinecarboxylate (2.98 g, 22.6 mmol) to afford 4.62 g (91% yield) of compound **28n** as yellow solid: ^1H NMR (400 MHz, CDCl_3) δ 7.71 (bd, $J = 2.62$ Hz, 1H), 7.29 – 7.24 (m, 3H), 6.95 – 6.89 (m, 2H), 6.43 (bs, 1H), 3.86 (s, 3H), 3.60 (s, 2H), 1.41 (bs, 9H). ^{13}C NMR (100 MHz, CDCl_3) δ 170.53, 157.09, 155.30, 131.35, 129.14, 122.50, 121.27, 110.86, 81.74, 55.69, 36.74, 28.16. LCMS (50-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 3.07 min, ESI $m/z = 281, [\text{M}+\text{H}]^+$.


Synthesis of tert-butyl 2-(2-(3-nitrophenyl)acetyl)hydrazinecarboxylate (28o)



28o

[0252] Prepared according to **General Procedure 1A** from 2-(3-nitrophenyl)acetic acid (**27o**) (3.00 g, 16.6 mmol) and *tert*-butyl hydrazinecarboxylate (2.74 g, 20.7 mmol) to afford 2.32 g (47% yield) of compound **28o** as yellow solid: ^1H NMR (400 MHz, CD_3OD) δ 8.18-8.23 (m, 1H), 8.07-8.14 (m, 1H), 7.71 (d, J = 7.84 Hz, 1H), 7.54 (t, J = 7.93 Hz, 1H), 3.66 (bs, 2H), 1.44 (s, 9H). ^{13}C NMR (100 MHz, CD_3OD) δ 171.04, 156.39, 148.35, 137.09, 135.46, 129.30, 123.89, 121.61, 80.58, 39.34, 27.16. LCMS (50-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 3.00 min, ESI m/z = 196, $[\text{M}-\text{Boc}]^+$.


Synthesis of *tert*-butyl 2-(2-(3-(benzyloxy)phenyl)acetyl)hydrazinecarboxylate (28p)



28p

[0253] Prepared according to **General Procedure 1A** from 2-(3-(benzyloxy)phenyl)acetic acid (**27p**) (3.00 g, 12.4 mmol) and *tert*-butyl hydrazinecarboxylate (2.05 g, 15.5 mmol) to afford 4.06 g (92% yield) of compound **28p** as yellow solid: ^1H NMR (400 MHz, CD_3OD) δ 7.44 – 7.36 (m, 2H), 7.35 – 7.25 (complex m, 3H), 7.18 (t, J = 7.93 Hz, 1H), 6.99 (bs, 1H), 6.90 – 6.80 (m, 2H), 5.04 (s, 2H), 3.48 (bs, 2H), 1.44 (bs, 9 H). ^{13}C NMR (100 MHz, CD_3OD) δ 172.15, 159.05, 156.39, 137.40, 136.31, 129.17, 128.13, 127.50, 127.26, 121.46, 115.34, 113.22, 80.47, 69.56, 40.20, 27.19. LCMS (50-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 5.32 min, ESI m/z = 357, $[\text{M}+\text{H}]^+$.

Synthesis of *tert*-butyl 2-(2-(3-cyanophenyl)acetyl)hydrazinecarboxylate (28q)




28q

[0254] Prepared according to **General Procedure 1A** from 2-(3-cyanophenyl)acetic acid (**27q**) (4.95 g, 30.7 mmol) and *tert*-butyl hydrazinecarboxylate

(5.07 g, 38.4 mmol) to afford 4.42 g (52% yield) of compound **28q** as yellow solid: ^1H NMR (400 MHz, DMSO- d_6) δ 9.83 (bs, 1H), 8.77 (bs, 1H), 7.69 – 7.67 (m, 1H), 7.67 (s, 1H), 7.57 (d, J = 7.62 Hz, 1H), 7.49 (t, J = 7.94 Hz, 1H), 3.48 (bs, 2H), 1.35 (bs, 9H). ^{13}C NMR (100 MHz, DMSO- d_6) δ 169.53, 155.76, 137.80, 134.69, 133.11, 130.94, 130.03, 119.29, 111.68, 79.72, 28.55. LCMS (25-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 5.70 min, ESI m/z = 276, $[\text{M}+\text{H}]^+$.


Synthesis of *tert*-butyl 2-(2-(4-fluorophenyl)acetyl)hydrazinecarboxylate (**28r**)



28r

[0255] Prepared according to **General Procedure 1A** from 2-(4-fluorophenyl)acetic acid (2.00 g, 12.9 mmol) and *tert*-butyl hydrazinecarboxylate (2.13 g, 16.1 mmol) to afford 3.34 g of compound **28r** (97% yield) as a white solid. ^1H NMR (400 MHz, DMSO- d_6) δ 9.74 (s, 1H), 8.71 (s, 1H), 7.26 (dd, $^3J_{\text{HF}}$ = 8.20, J_{HH} = 5.50 Hz, 2H), 7.08 (apparent t, $^3J_{\text{HF}}$ = 9.10, J_{HH} = 9.10 Hz, 2H), 3.36 (s, 2H), 1.35 (s, 9H). ^{13}C NMR (100 MHz, DMSO- d_6) δ 170.08, 161.61 (d, $^1J_{\text{CF}}$ = 241 Hz), 155.78, 132.34 (d, $^4J_{\text{CF}}$ = 2.80 Hz), 131.4 (d, $^3J_{\text{CF}}$ = 7.60 Hz), 115.4 (d, $^2J_{\text{CF}}$ = 21.1 Hz), 79.62, 28.56. LCMS (50-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 3.08 minutes, ESI m/z = 269, $[\text{M}+\text{H}]^+$.

Synthesis of 2-(3-(trifluoromethoxy)phenyl)acetic hydrazide (**29n**)




29n

[0256] Prepared according to the **General Procedure 1B** from *tert*-butyl 2-(2-(3-(trifluoromethoxy)phenyl)acetyl)hydrazinecarboxylate (**28n**) (3.76 g, 11.2 mmol) to afford 2.54 g (83% yield) of the intermediate HCl salt as a white solid. The HCl salt (2.54 g, 9.37 mmol) was then converted to 1.88 g (71 % yield) of freebase **29n** (69% for

two steps), isolated as a white solid: ^1H NMR (400 MHz, CDCl_3) δ 7.36 (t, J = 5.86 Hz, 1H), 7.19 (bd, J = 7.73 Hz, 1H), 7.16 – 7.11 (m, 2H), 5.54 (s, 2H). ^{13}C NMR (100 MHz, CDCl_3) δ 170.86, 149.62, 136.22, 130.37, 127.77, 121.93, 120.47 (q, $J_{\text{C,F}}$ = 257.48 Hz), 119.96, 41.39. LCMS (15-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 6.17 minutes, ESI m/z = 235, $[\text{M}+\text{H}]^+$; 276, $[\text{M}+\text{H}+\text{ACN}]^+$.


Synthesis of 2-(3-nitrophenyl)acetic hydrazide (29o)



29o

[0257] Prepared according to the **General Procedure 1B** from *tert*-butyl 2-(2-(3-nitrophenyl)acetyl)hydrazinecarboxylate (**28o**) (2.27 g, 7.69 mmol) to afford 1.66 g (93% yield) of the intermediate HCl salt as a white solid. The HCl salt (1.66 g, 7.17 mmol) was then converted to 1.31 g (94 % yield) of freebase **29o** (87% for two steps), isolated as a light yellow solid: ^1H NMR (400 MHz, CD_3OD) δ 8.19 – 8.17 (m, 1H), 8.12 – 8.10 (m, 1H), 7.68 (d, J = 7.10 Hz, 1H), 7.54 (t, J = 8.01 Hz, 1H), 3.59 (s, 2H). ^{13}C NMR (100 MHz, CD_3OD) δ 170.57, 148.35, 137.60, 135.24, 129.33, 123.59, 121.56, 39.65. LCMS (50-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 2.05 minutes, ESI m/z = 196, $[\text{M}+\text{H}]^+$; 237, $[\text{M}+\text{H}+\text{ACN}]^+$.

Synthesis of 2-(3-(benzyloxy)phenyl)acetic hydrazide (29p)




29p

[0258] Prepared according to the **General Procedure 1B** from *tert*-butyl 2-(2-(3-(benzyloxy)phenyl)acetyl)hydrazinecarboxylate (**28p**) (4.02 g, 11.3 mmol) to afford 2.65 g (81% yield) of the intermediate HCl salt as a white solid. The HCl salt (2.65 g, 9.07 mmol) was then converted to 2.00 g (86 % yield) of freebase **29p** (70% for two steps), isolated as a white solid: ^1H NMR (400 MHz, CD_3OD) δ 7.42 – 7.25 (complex m, 5H), 7.18 (t, J = 8.00 Hz, 1H), 6.93 (apparent t, J = 1.90 Hz, 1H), 6.85 (dd, J = 8.10,

2.06 Hz, 2H), 5.04 (s, 2H), 3.40 (s, 2H). ^{13}C NMR (100 MHz, CD_3OD) δ 171.69, 159.05, 137.37, 136.73, 129.21, 128.14, 127.51, 127.25, 121.27, 115.37, 113, 69.54, 40.45. LCMS (25-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 5.43 minutes (broad), ESI m/z = 257, $[\text{M}+\text{H}]^+$; 535, $[2\text{M}+\text{Na}]^+$.


Synthesis of 2-(3-cyanophenyl)acetic hydrazide (29q)



29q

[0259] Prepared according to the **General Procedure 1B** from *tert*-butyl 2-(2-(3-cyanophenyl)acetyl)hydrazinecarboxylate (**28q**) (4.32 g, 15.7 mmol) to afford 2.60 g (79% yield) of the intermediate HCl salt as a white solid. The HCl salt (2.60 g, 12.3 mmol) was then converted to 1.41 g (75 % yield) of freebase **29q** (59% for two steps), isolated as a white solid: ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 9.23 (bs, 1H), 7.68 – 7.65 (m, 2H), 7.57 – 7.54 (m, 1H), 7.47 (t, J = 7.79 Hz, 1H), 4.21 (bs, 2H), 3.39 (s, 2H). ^{13}C NMR (100 MHz, $\text{DMSO}-d_6$) δ 169.29, 138.41, 134.59, 132.98, 130.82, 129.98, 119.32, 111.64, benzyl carbon obscured by $\text{DMSO}-d_6$ solvent peaks. LCMS (25-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 2.07 minutes, ESI m/z = 176, $[\text{M}+\text{H}]^+$.

Synthesis of 2-(4-fluorophenyl)acetic hydrazide (29r)




29r

[0260] Produced according to **General Procedure B** from *tert*-butyl 2-(2-(4-fluorophenyl)acetyl)hydrazinecarboxylate **28r** (3.23 g, 12.0 mmol) to afford 2.18 g of the intermediate HCl salt (89% yield) as a white solid. The HCl salt was converted to freebase afford 1.57 g of compound **29r** (90%yield) (78% yield over two steps) as a white solid. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 9.15 (s, 1H), 7.24 (dd, $^4J_{\text{HF}}$ = 8.80, J_{HH} = 5.50 Hz, 2H), 7.07 (apparent t, $^3J_{\text{HF}}$ = 8.70, J_{HH} = 8.70 Hz, 2H), 4.17 (s, 2H). ^{13}C NMR

(100 MHz, DMSO- d_6) δ 169.95, 161.54 (d, $^1J_{CF}$ = 243 Hz), 132.96, 131.25 (d, $^3J_{CF}$ = 7.60 Hz), 115.39 (d, $^2J_{CF}$ = 21.1 Hz), 40.73 (partially obscured by DMSO solvent peak). LCMS (50-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 1.85 minutes, ESI m/z = 169, $[M+H]^+$.


Synthesis of 3-(2-(5-(3-(trifluoromethoxy)benzyl)-4-(3-(1-trityl-1H-imidazol-4-yl) propyl)-4H-1,2,4-triazol-3-yl)ethyl)-1H-indole (31o)



31o

[0261] Prepared according to the **General Procedure 1C** from 3-(1H-indol-3-yl)-N-(3-(1-trityl-1H-imidazol-4-yl)propyl)propanethioamide (**10**) (325 mg, 0.59 mmol) and 2-(3-(trifluoromethoxy)phenyl)acetic hydrazide (**29n**) (165.8 mg, 0.71 mmol). Purification by flash chromatography (SiO₂, 30:1 CH₂Cl₂/methanol) afforded 203 mg (47% yield) of compound **31o** as a tan solid: ^1H NMR (400 MHz, CD₃OD) δ 7.98 (dd, J = 8.51, 1.45 Hz, 1H), 7.41 (t, J = 7.85 Hz, 1H), 7.33 – 7.30 (m, 9H), 7.28 (t, J = 7.85 Hz, 1H), 7.18 (d, J = 8.16 Hz, 1H), 7.05 – 7.02 (m, 8 H), 6.98 – 6.93 (m, 2H), 6.89 (s, 1H), 6.84 (t, J = 7.65 Hz, 1H), 6.44 (bs, 1H), 4.07 (s, 2H), 3.38 – 3.34 (m, 2H), 3.17 (t, J = 7.03 Hz, 2H), 3.00 (t, J = 7.06 Hz, 2H), 2.19 (t, J = 7.09 Hz, 1H), 1.36 – 1.32 (m, 4H). ^{13}C NMR (100 MHz, CD₃OD) δ 155.97, 152.63, 149.38, 142.24, 138.98, 138.28, 138.14, 136.67, 130.29, 129.44, 129.26, 127.99, 127.92, 126.97, 126.90, 122.13, 121.10, 120.88, 120.46 (q, $J_{C,F}$ = 255.77 Hz), 119.41, 118.45, 117.71, 112.95, 111.05, 75.42, 42.26, 29.85, 28.63, 25.79, 24.13, 23.57. LCMS (50-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 5.25 minutes, ESI m/z = 737, $[M+H]^+$.


Synthesis of 3-(2-(5-(3-nitrobenzyl)-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazol-3-yl)ethyl)-1H-indole (31p)



31p

[0262] Prepared according to the **General Procedure 1C** from 3-(1H-indol-3-yl)-N-(3-(1-trityl-1H-imidazol-4-yl)propyl)propanethioamide (**10**) (500 mg, 0.90 mmol) and 2-(3-nitrophenyl)acetic hydrazide (**29o**) (211 mg, 1.08 mmol). Purification by flash chromatography (SiO₂, 40:1 CH₂Cl₂/methanol to 10/1) afforded 328 mg (52% yield) of compound **31p** as a tan solid: ¹H NMR (400 MHz, CD₃OD) δ 8.02 – 7.97 (m, 1H), 8.00 (s, 1H), 7.47 – 7.42 (m, 1H), 7.40 – 7.35 (m, 1H), 7.34 – 7.28 (m, 11H), 7.15 (d, *J* = 8.20 Hz, 1H), 7.05 – 7.01 (m, 6H), 6.92 (t, *J* = 7.63 Hz, 1H), 6.89 (s, 1H), 6.83 (t, *J* = 7.70 Hz, 1H), 6.43 (s, 1H), 4.13 (s, 2H), 3.35 – 3.31 (m, 2H), 3.17 (t, *J* = 7.14 Hz, 2H), 3.02 (t, *J* = 6.92 Hz, 2H), 2.21 (t, *J* = 7.01 Hz, 2H), 1.38 (quint., *J* = 7.17 Hz, 2H). ¹³C NMR (100 MHz, CD₃OD) δ 156.06, 152.36, 148.46, 142.23, 138.90, 138.20, 137.86, 136.65, 134.45, 132.34, 129.79, 129.44, 129.31, 128.00, 127.93, 126.99, 123.10, 122.20, 121.88, 121.10, 118.46, 117.68, 112.91, 111.07, 75.42, 42.23, 29.74, 28.61, 25.79, 24.08, 23.68. LCMS (50-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 3.87 minutes, ESI *m/z* = 698, [M+H]⁺.


Synthesis of 3-(2-(5-(3-(benzyloxy)benzyl)-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazol-3-yl)ethyl)-1H-indole (31q)



31q

[0263] Prepared according to the **General Procedure 1C** from 3-(1H-indol-3-yl)-N-(3-(1-trityl-1H-imidazol-4-yl)propyl)propanethioamide (**10**) (500 mg, 0.90 mmol) and 2-(3-(benzyloxy)phenyl)acetic hydrazide (**29p**) (277 mg, 1.08 mmol). Purification by flash chromatography (SiO₂, 30:1 CH₂Cl₂/methanol to 20/1) afforded 335 mg (49% yield) of compound **31q** as a white foam: ¹H NMR (400 MHz, CD₃OD) δ 7.35 – 7.26 (m, 11H), 7.25 – 7.23 (m, 4H), 7.18 (d, *J* = 8.12 Hz, 1H), 7.13 – 7.10 (m, 1H), 7.04 – 7.00 (m, 7H), 6.95 (t, *J* = 7.01 Hz, 1H), 6.89 (s, 1H), 6.88 (t, *J* = 7.31 Hz, 1H), 6.68 – 6.64 (m, 2H), 6.55 (d, *J* = 7.61 Hz, 1H), 6.36 (s, 1H), 5.65 (s, 2H), 4.90 (s, 2H), 3.98 (bs, 2H), 3.16 (t, *J* = 7.24, 2H), 2.97 (t, *J* = 7.15 Hz, 2H), 2.10 (t, *J* = 7.23 Hz, 2H), 1.15 (quint., *J* = 7.45 Hz, 2H). ¹³C NMR (100 MHz, CD₃OD) δ 159.08, 155.83, 153.17, 142.24, 139.07, 138.05, 137.09, 137.01, 136.67, 129.70, 129.47, 128.18, 127.99, 127.94, 127.49, 127.18, 126.99, 122.12, 121.10, 120.43, 118.46, 118.41, 117.71, 114.52, 113.66, 112.98, 111.04, 75.41, 69.40, 42.33, 30.35, 28.45, 25.76, 24.29, 23.52. LCMS (50-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 5.50 minutes, ESI *m/z* = 759, [M+H]⁺.


Synthesis of 3-((5-(2-(1H-indol-3-yl)ethyl)-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazol-3-yl)methyl)benzonitrile (31r)



31r

[0264] Prepared according to the **General Procedure 1C** from 3-(1H-indol-3-yl)-N-(3-(1-trityl-1H-imidazol-4-yl)propyl)propanethioamide (**10**) (500 mg, 0.90 mmol) and 2-(3-cyanophenyl)acetic hydrazide (**29q**) (189 mg, 1.08 mmol). Purification by flash chromatography (SiO₂, 40:1 CH₂Cl₂/methanol to 20/1) afforded 330 mg (54% yield) of compound **31r** as a white foam: ¹H NMR (400 MHz, DMSO-d₆) δ 10.75 (bs, 1H), 7.90 (dd, *J* = 8.34, 1.46 Hz, 1H), 7.64 (s, 1H), 7.60 (dt, *J* = 7.23, 1.65 Hz, 1H), 7.48 – 7.45 (m, 1H), 7.43 (d, *J* = 7.50 Hz, 1H), 7.39 (d, *J* = 7.32 Hz, 1H), 7.35 – 7.29 (m, 9H), 7.26 (d, *J* = 8.15 Hz, 1H), 7.20 (d, *J* = 0.93 Hz, 1H), 7.08 (d, *J* = 2.19 Hz, 1H), 7.01–6.95 (m, 6H), 6.83 (t, *J* = 7.26 Hz, 1H), 6.50 (s, 1H), 4.08 (s, 2H), 3.71 (apparent t, *J* = 7.89 Hz, 2H), 3.05 (apparent t, *J* = 7.09 Hz, 2H), 2.92 (dd, *J* = 8.63, 6.70 Hz, 2H), 2.32 (t, *J* = 7.02 Hz, 2H), 1.56 (quint., *J* = 7.52 Hz, 2H). ¹³C NMR (100 MHz, DMSO-d₆) δ 154.70, 152.34, 142.81, 140.13, 138.96, 138.31, 136.68, 134.20, 133.39, 132.73, 130.99, 130.18, 129.78, 129.65, 129.10, 128.70, 128.46, 127.43, 123.10, 121.41, 119.20, 118.72, 118.67, 118.10, 113.85, 111.85, 74.85, 42.49, 30.10, 29.64, 25.90, 25.00, 23.20. LCMS (50–95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 3.58 minutes, ESI *m/z* = 678, [M+H]⁺.


Synthesis of 3-(2-(4-(3-(1H-imidazol-4-yl)propyl)-5-(3-(trifluoromethoxy)benzyl)-4H-1,2,4-triazol-3-yl)ethyl)-1H-indole (MM-I-36)



MM-I-36

[0265] Prepared according to the **General Procedure 1D** from 3-(2-(5-(3-(trifluoromethoxy)benzyl)-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazol-3-yl)ethyl)-1H-indole (**31o**) (172 mg, 0.23 mmol) to afford 82 mg (71 % yield) of **MM-I-36** as a white solid: ^1H NMR (400 MHz, CD_3OD) δ 7.52 (s, 1H), 7.34 (t, $J = 7.97$ Hz, 1H), 7.27 (t, $J = 7.74$ Hz, 2H), 7.10 (bd, $J = 8.24$ Hz, 1H), 7.03 (t, $J = 7.85$ Hz, 1H), 7.02 (bd, $J = 1.54$ Hz, 1H), 6.92 (d, $J = 7.65$ Hz, 2H), 6.89 – 6.87 (m, 1H), 6.57 (s, 1H), 4.04 (s, 2H), 3.34 – 3.30 (m, obscured by NMR solvent, 2H), 3.16 (t, $J = 7.13$ Hz, 2H), 3.01 (t, $J = 7.14$ Hz, 2H), 2.26 (t, $J = 7.03$ Hz, 2H), 1.43 (quint., $J = 7.12$ Hz, 2H). ^{13}C NMR (100 MHz, CD_3OD) δ 156.07, 152.61, 149.39, 138.16, 136.67, 134.81, 130.30, 126.97, 126.86, 122.13, 121.10, 120.83, 120.51 (q, $J_{\text{C,F}} = 255.66$ Hz), 119.36, 118.47, 117.62, 112.91, 111.00, 42.10, 29.85, 28.77, 25.81, 23.65, 23.12. LCMS (15-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 2.15 minutes, ESI $m/z = 495$, $[\text{M}+\text{H}]^+$, 989 $[\text{2M}+\text{H}]^+$.


Synthesis of 3-(2-(4-(3-(1H-imidazol-4-yl)propyl)-5-(3-nitrobenzyl)-4H-1,2,4-triazol-3-yl)ethyl)-1H-indole (MM-I-43)



MM-I-43


[0266] Prepared according to **General Procedure 1D** from 3-(2-(5-(3-nitrobenzyl)-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazol-3-yl)ethyl)-1H-indole (**31p**) (0.148 g, 0.212 mmol) to afford 0.085 g (88% yield) of **MM-I-43** as a white solid: ¹H NMR (400 MHz, CD₃OD) imidazole tautomers observed: δ 8.05 - 8.12 (m, 1H), 7.97 (bs, 1H), 7.44 - 7.55 (m, 2H), 7.21 - 7.37 (m, 4H), 6.98 - 7.05 (m, 1H), 6.85 - 6.95 (m, 2H), 6.57 (bs, 1H), 4.10 (s, 2H), 3.31 (obs s, 1H), 3.17 (apparent t, *J* = 6.9, 2H), 3.03 (apparent t, *J* = 8.08, 2H), 2.28 (apparent t, *J* = 7.1, 2H), 1.46 (quint., *J* = 7.71, 2H). ¹³C NMR (100 MHz, CD₃OD) imidazole tautomers observed: δ 156.14, 152.36, 148.50, 137.75, 136.66, 134.88, 134.42, 129.80, 126.98, 123.04, 122.19, 121.80, 121.09, 118.47, 117.59, 112.89, 111.00, 42.07, 32.42, 29.75, 28.80, 25.84, 23.74. LCMS (50-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 3.87 min, ESI *m/z* = 699, [M+H]⁺.

Synthesis of 3-(2-(4-(3-(1H-imidazol-4-yl)propyl)-5-(3-(benzyloxy)benzyl)-4H-1,2,4-triazol-3-yl)-ethyl)-1H-indole (MM-I-53)



[0267] Prepared according to **general procedure 1D** from 3-(2-(5-(3-(benzyloxy)benzyl)-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazol-3-yl)ethyl)-1H-indole (**31q**) (148 mg, 0.21 mmol) to afford 85.0 mg (88% yield) of **MM-I-53** as a white solid: ^1H NMR (400 MHz, CD_3OD), significant broadening observed at room temperature: δ 7.52 (bs, 1H), 7.34 – 7.22 (m, 5H), 7.14 (t, J = 7.90 Hz, 1H), 7.03 (t, J = 7.28 Hz, 1H), 6.92 (t, J = 7.45 Hz, 1H), 6.87 (s, 1H), 6.82 (dd, J = 8.13, 1.31 Hz, 1H), 6.67 (s, 1H), 6.54 (d, J = 7.41 Hz, 1H), 4.99 (s, 2H), 3.96 (s, 2H), 3.29 – 3.25 (m, obscured by NMR solvent, 2H), 3.16 (bt, J = 6.87 Hz, 2H), 2.98 (bt, J = 6.67 Hz, 2H), 2.22 – 2.15 (bm, 2H), 1.34 – 1.25 (bm, 2H). ^{13}C NMR (100 MHz, CD_3OD): δ 159.15, 137.19, 136.88, 136.67, 129.71, 128.18, 127.52, 127.22, 126.98, 122.11, 121.10, 120.47, 118.48, 117.64, 114.58, 113.52, 112.93, 111.00, 69.45, 42.23, 30.37, 28.63, 25.80, 23.57, 23.25 (broad). LCMS (50-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 2.20 min, ESI m/z = 517, $[\text{M}+\text{H}]^+$.


Synthesis of 3-((4-(3-(1H-imidazol-4-yl)propyl)-5-(2-(1H-indol-3-yl)ethyl)-4H-1,2,4-triazol-3-yl)methyl)benzonitrile (MM-I-63)



MM-I-63


[0268] Prepared according to **general procedure 1D** from 3-((5-(2-(1H-indol-3-yl) ethyl)-4-(3-(1-trityl-1H-imidazol-4-yl) propyl)-4H-1,2,4-triazol-3-yl)methyl)benzonitrile (**31r**) (292 mg, 0.43 mmol) to afford 135 mg (72% yield) of **MM-I-63** as a white solid: ^1H NMR (400 MHz, DMSO- d_6): δ 11.74 (bs, 1H), 10.77 (s, 1H), 7.68 (dt, J = 6.91, 1.58 Hz, 1H), 7.64 (s, 1H), 7.50 – 7.44 (m, 3H), 7.40 (d, J = 7.85 Hz, 1H), 7.28 (d, J = 8.11 Hz, 1H), 7.11 (d, J = 2.17 Hz, 1H), 7.01 (dt, J = 7.01, 0.76 Hz, 1H), 6.91 (t, J = 7.26 Hz, 1H), 6.70 (bs, 1H), 4.10 (bs, 2H), 3.72 (bt, J = 6.70 Hz, 2H), 3.07 (dd, J = 8.50, 5.42 Hz, 2H), 2.93 (dd, J = 8.66, 5.49 Hz, 2H), 2.36 (bt, J = 6.23 Hz, 2H), 1.63 (quint., J = 7.29 Hz, 2H). ^{13}C NMR (100 MHz, DMSO- d_6): δ 154.74, 152.36, 138.92, 136.68, 135.22, 134.20, 132.71, 131.08, 130.25, 127.45, 123.13, 121.44, 119.25, 118.80, 118.69, 113.88, 111.88, 42.49, 30.18, 29.87 (2 broadened carbons), 25.92, 23.22. LCMS (50-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 1.70 min, ESI m/z = 436, $[\text{M}+\text{H}]^+$.

Synthesis of 2-(5-methoxy-1H-indol-3-yl)-N-(3-(1-trityl-1H-imidazol-4-yl)propyl)-acetamide (B)



[0269] To a solution of 2-(5-methoxy-1*H*-indol-3-yl)acetic acid (**A**) (2.00 g, 4.87 mmol) in DMF (40 mL) was added EDC•HCl (1.40 g, 7.31 mmol) and HOBt•H₂O (933 mg, 6.09 mmol). The resulting mixture was stirred at RT for 45 min and treated with compound **7** (1.79 g, 4.87 mmol). The “pH” of the solution was adjusted ~9 by the addition of TEA (~1.35 mL) and the reaction was stirred at RT for 16 hours. After this time water (200 mL) was added and the resulting precipitate was collected by filtration and dried by azeotropic distillation with toluene to afford 2.38 g (88% yield) of compound **B** as a white solid: ¹H NMR (400 MHz, DMSO-*d*₆): δ 10.64 (bs, 1H), 7.85 (t, *J* = 5.50 Hz, 1H), 7.38 – 7.30 (m, 9H), 7.18 (s, 1H), 7.15 (d, *J* = 8.70 Hz, 1H), 7.07 – 6.98 (m, 8H), 6.63 (dd, *J* = 8.60, 2.80 Hz, 1H), 6.52 (s, 1H), 3.63 (s, 3H), 3.38 (s, 2H), 3.00 (q, *J* = 6.00 Hz, 2H), 2.36 (t, *J* = 7.30 Hz, 2H), 1.59 (quint. *J* = 7.30 Hz, 2H). ¹³C NMR (100 MHz, DMSO-*d*₆): δ 171.01, 153.46, 142.90, 141.17, 138.14, 131.75, 129.71, 128.70, 128.45, 128.00, 124.91, 118.02, 112.44, 111.59, 109.29, 100.96, 74.83, 55.75, 38.76, 33.42, 29.53, 25.83. LCMS (50-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 3.87 min, ESI *m/z* = 555, [M+H]⁺.


Synthesis of 2-(5-methoxy-1*H*-indol-3-yl)-*N*-(3-(1-trityl-1*H*-imidazol-4-yl)propyl)ethane-thioamide (**C**)



[0270] A solution of 2-(5-methoxy-1*H*-indol-3-yl)-*N*-(3-(1-trityl-1*H*-imidazol-4-yl)propyl)acetamide (**B**) (azeotropically dried by coevaporation with toluene, 2.00 g, 3.61 mmol) and Lawesson's reagent (946 mg, 2.34 mmol) in THF (35 mL) was heated to 70 °C for 3 hours. The resulting mixture was allowed to cool to room temperature and concentrated. Purification by flash column chromatography (SiO₂, 40:1 to 20:1 CH₂Cl₂/MeOH) afforded 1.82 g (88% yield) of compound **C** as a yellow foam: ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.69 (bs, 1H), 9.94 (bt, *J* ~ 5.0 Hz, 1H), 7.38 – 7.30 (m, 9H), 7.15 (d, *J* = 9.10 Hz, 1H), 7.13 (d, *J* = 2.30 Hz, 1H), 7.07 – 7.03 (m, 8H), 6.64 (d, *J* = 2.30 Hz, 1H), 6.61 (bs, 1H), 3.91 (s, 2H), 3.63 (s, 3H), 3.44 (q, *J* = 6.80 Hz, 2H), 2.40 (t,


$J = 7.40$ Hz, 2H), 1.76 (quint., $J = 7.30$ Hz, 2H). ^{13}C NMR (100 MHz, DMSO- d_6): δ 202.13, 153.50, 142.65, 138.07, 131.71, 129.71, 128.76, 128.53, 127.76, 125.20, 118.39, 112.50, 111.57, 110.33, 101.15, 75.19, 55.78, 45.49, 42.94, 27.43, 25.44. LCMS (50-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 5.32 min, ESI $m/z = 571$, $[\text{M}+\text{H}]^+$.

Synthesis of 2-(1H-indol-3-yl)-N-(3-(1-trityl-1H-imidazol-4-yl)propyl)acetamide (F)




[0271] To a solution of 2-(1H-indol-3-yl)acetic acid (**E**) (816 mg, 4.66 mmol) in DMF (50 mL) was added EDC·HCl (1.34 g, 6.99 mmol) and HOBT·H₂O (892 mg, 5.83 mmol). The resulting mixture was stirred at room temperature for 45 min. A solution of the amine **7** (1.71 g, 4.66 mmol) in DMF (50 mL) and TEA (1.70 mL) were added and the reaction was stirred for 16 hours at room temperature. The mixture was poured into water (150 mL) in a large beaker and stirred for 30 minutes at room temperature. The solid was collected by filtration. Trituration of the solid with hot ACN and filtration afforded 1.10 g (45% yield) of pure amide **F**: ^1H NMR (400 MHz, DMSO- d_6) δ 10.80 (bs, 1H), 7.84 (t, $J = 5.38$ Hz, 1H), 7.47 (d, $J = 7.88$ Hz, 1H), 7.38 – 7.38 (m, 8H), 7.27 (d, $J = 8.13$ Hz, 2H), 7.18 (d, $J = 1.03$ Hz, 1H), 7.11 (d, $J = 2.03$ Hz, 1H), 7.04 – 7.02 (m, 6H), 6.97 (t, $J = 7.23$ Hz, 1H), 6.84 (t, $J = 7.21$ Hz, 1H), 6.52 (s, 1H), 3.42 (s, 2H), 2.98 (apparent q, $J = 6.59$ Hz, 2H), 2.34 (t, $J = 7.42$ Hz, 2H), 1.59 (quint., $J = 7.06$ Hz, 2H). LCMS (50-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 4.33 min, ESI $m/z = 525$, $[\text{M}+\text{H}]^+$.

Synthesis of 2-(1H-indol-3-yl)-N-(3-(1-trityl-1H-imidazol-4-yl)propyl)ethanethioamide (G)



[0272] A mixture of 3-(1*H*-indol-3-yl)-*N*-(3-(1-trityl-1*H*-imidazol-4-yl)propyl)propanamide (**F**) (1.01 g, 1.90 mmol; previously dried by 3 azeotropic coevaporations with toluene, 30 mL each) and Lawesson's reagent (499.5 mg, 1.24 mmol) in THF (45 mL) was heated to 65 °C for 3.5 hours. After this time, the reaction was cooled and concentrated. The residue was purified by flash column chromatography (SiO₂, 30/1 CH₂Cl₂/MeOH) to afford 314 mg (31% yield) of thioamide **G** as a tan foam: ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.84 (bs, 1H), 9.90 (t, *J* = 5.03 Hz, 1H), 7.53 (d, *J* = 7.80 Hz, 1H), 7.38 – 7.28 (m, 10H), 7.26 (d, *J* = 7.99 Hz, 1H), 7.16 (d, *J* = 2.31 Hz, 1H), 7.05 – 7.02 (m, 6H), 6.97 (dt, *J* = 7.02, 0.58 Hz, 1H), 6.84 (dt, *J* = 7.89, 0.80 Hz, 1H), 6.57 (bs, 1H), 3.95 (s, 2H), 3.45 – 3.39 (m, 2H), 2.38 (t, *J* = 7.33 Hz, 2H), 1.75 (quint., *J* = 7.31, 2H). ¹³C NMR (100 MHz, DMSO-*d*₆) δ 202.11, 142.75, 140.40, 138.10, 136.59, 129.72, 128.74, 128.50, 127.45, 124.53, 121.43, 119.27, 118.82, 118.32, 111.86, 110.61, 75.04, 45.50, 42.84, 27.40, 25.57. LCMS (50-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 5.42 min, ESI *m/z* = 541, [M+H]⁺.


Synthesis of 2-(6-fluoro-1H-indol-3-yl)-N-(3-(1-trityl-1H-imidazol-4-yl)propyl) acetamide
(I)



[0273] To a solution of 2-(6-fluoro-1H-indol-3-yl)acetic acid (**H**) (1.00 g, 5.18 mmol) in DMF (50 mL) was added EDC·HCl (1.50 g, 7.77 mmol) and HOBt·H₂O (1.19 g, 7.77 mmol). The resulting mixture was stirred at room temperature for 1 h. A solution of the amine **7** (1.90 g, 5.18 mmol) and TEA (2.80 mL) were added and the reaction was stirred for 16 hours at room temperature. The mixture was partitioned with EtOAc (120 mL) and 1N NaHSO₄ (100 mL). The layers were separated and the EtOAc solution was washed with water (150 mL), sat. NaHCO₃ (150 mL) and brine (150 mL). The EtOAc layer was dried (Na₂SO₄), filtered and concentrated. Trituration of the solid with hot ACN and filtration afforded 1.58 g (56% yield) of pure amide **I**: ¹H NMR (400 MHz, DMSO-d₆) δ 10.88 (bs, 1H), 7.89 (t, *J* = 5.48 Hz, 1H), 7.45 (dd, *J* = 8.69, 5.53 Hz, 1H),


7.37 – 7.23 (complex m, 9H), 7.19 (d, $J = 1.20$ Hz, 1H), 7.11 (d, $J = 2.36$ Hz, 1H), 7.06 – 7.01 (m, 7H), 6.73 (ddd, $J = 11.04, 9.73, 2.33$ Hz, 1H), 6.53 (bs, 1H), 3.40 (s, 2H), 2.98 (apparent q, $J = 6.71$ Hz, 2H), 2.35 (t, $J = 7.44$ Hz, 2H), 1.58 (quint., $J = 7.19$ Hz, 2H). LCMS (50-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 4.38 min, ESI $m/z = 543$, $[M+H]^+$.

Synthesis of 2-(6-fluoro-1H-indol-3-yl)-N-(3-(1-trityl-1H-imidazol-4-yl)propyl)ethane-thioamide (J)




[0274] A mixture of 2-(6-fluoro-1H-indol-3-yl)-N-(3-(1-trityl-1H-imidazol-4-yl)propyl)-acetamide (**I**) (1.58 g, 2.91 mmol; previously dried by 3 azeotropic coevaporations with toluene, 30 mL each) and Lawesson's reagent (789 mg, 1.95 mmol) in THF (75 mL) was heated to 65 °C for 2.5 hours. After this time, the reaction was cooled and concentrated. The residue was purified by flash column chromatography (SiO₂, 40/1 CH₂Cl₂/MeOH to 20/1) to afford 1.18 g (73% yield) of thioamide **J** as a tan foam: ¹H NMR (400 MHz, DMSO-d₆) δ 10.88 (bs, 1H), 9.90 (t, $J = 4.95$ Hz, 1H), 7.52 (dd, $J = 8.70, 5.53$ Hz, 1H), 7.39 – 7.31 (complex m, 9H), 7.16 (d, $J = 2.30$ Hz, 1H), 7.08 – 7.03 (m, $J = 7$ Hz), 6.73 (ddd, $J = 11.05, 8.80, 2.32$ Hz, 1H), 3.93 (s, 2H), 3.42 (apparent q, $J = 6.65$ Hz, 2H), 2.42 (t, $J = 7.43$ Hz, 2H), 1.76 (quint., $J = 7.36$ Hz, 2H). ¹³C NMR (100 MHz, DMSO-d₆) δ 201.98, 159.30 (d, $J_{C,F} = 234.1$ Hz), 142.56, 139.73, 137.99, 136.44 (d, $J_{C,F} = 12.7$ Hz), 129.72, 128.78, 128.57, 125.11, 124.36, 120.30 (d, $J_{C,F} = 10.3$ Hz), 118.53, 110.95, 107.29 (d, $J_{C,F} = 24.3$ Hz), 97.80 (d, $J_{C,F} = 25.7$ Hz), 75.40, 45.44, 42.72, 27.26, 25.22. LCMS (50-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 5.83 min, ESI $m/z = 559$, $[M+H]^+$.

Synthesis of 3,3-dimethyl-N-(3-(1-trityl-1H-imidazol-4-yl)propyl)butanamide (L)




[0275] To a solution of 3,3-dimethylbutanoic acid **K** (1.00 g, 8.61 mmol) in DMF (50 mL) was added EDC•HCl (2.48 g, 12.9 mmol) and HOBt•H₂O (1.65 g, 10.8 mmol) and the resulting mixture was stirred for 30 minutes at room temperature. After this time, a solution of amine **7** (3.00 g, 8.61 mmol), and TEA (1.74 g, 2.40 mL, 17.2 mmol) in DMF (20 mL) was added and the reaction was stirred for 16 hours thereafter. Workup as described in the previous examples afforded 3.10 g of compound **L** (77% yield) as a white : ¹H NMR (400 MHz, DMSO-d₆) δ 7.65 (t, *J* = 5.10 Hz, 1H), 7.35 (m, 9H), 7.20 (apparent d, *J* = 1.40 Hz, 1H), 7.04 (dd, *J* = 8.90, *J* = 2.60 Hz, 6H), 6.56 (apparent d, *J* = 1.40 Hz, 1H), 2.96 (q, *J* = 6.90 Hz, 2H), 2.37 (t, *J* = 7.40 Hz, 2H), 1.87 (s, 2H), 1.58 (quint., *J* = 7.30 Hz, 2H), 0.88 (s, 9H). ¹³C NMR (100 MHz, DMSO-d₆) δ 171.07, 142.90, 141.15, 138.17, 129.71, 128.70, 128.46, 118.09, 74.84, 49.38, 38.37, 30.88, 30.21, 29.45, 25.81. LCMS (50-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 4.93 minutes, ESI *m/z* = 466, [M+H]⁺.

Synthesis of 3,3-dimethyl-N-(3-(1-trityl-1H-imidazol-4-yl)propyl)butanethioamide (**M**)



[0276] Produced following **General Procedure D** from amide **L** (2.95 g, 6.34 mmol) and Lawesson's reagent (1.67 g, 4.12 mmol), which afforded ~5.5 g crude material as a brown oil after 7 hours of reflux (reaction determined to be mostly complete by LCMS). The crude was purified by flash chromatography (SiO₂, 80:1 CH₂Cl₂:MeOH to 40:1) which afforded 1.32 g of **M** as a tan foam (43% purified yield): LCMS (50-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 6.13 minutes, ESI *m/z* = 482, [M+H]⁺.

Synthesis of 3-((5-(4-methoxybenzyl)-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazol-3-yl)methyl)-1H-indole (70)



[0277] Prepared according to the **General Procedure 1C** from 2-(1H-indol-3-yl)-N-(3-(1-trityl-1H-imidazol-4-yl)propyl)ethanethioamide **G** (500 mg, 0.93 mmol), 2-(4-methoxyphenyl)acetic hydrazide (208 mg, 1.16 mmol), silver benzoate (424 mg, 1.85 mmol), and acetic acid (167 mg, 159 μ L, 2.78 mmol), which formed ~1.4 g of crude material. The crude was purified by flash chromatography (SiO_2 , 40:1 CH_2Cl_2 :MeOH to 30:1, to 20:1) afforded 97 mg (16% yield) of compound **70** as a white solid: LCMS (50-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 3.63 minutes, ESI m/z = 669, $[\text{M}+\text{H}]^+$.


Synthesis of 3-((4-(3-(1H-imidazol-4-yl)propyl)-5-(4-methoxybenzyl)-4H-1,2,4-triazol-3-yl)methyl)-1H-indole (SK-I-23)



[0278] Prepared according to **general procedure 1D** from 3-((5-(4-methoxybenzyl)-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazol-3-yl)methyl)-1H-indole **70** (97 mg, 0.15 mmol) and afforded 48 mg (77% yield) of compound **SK-I-23** as

a tan solid: LCMS (50-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 1.72 minutes, ESI m/z = 427, $[M+H]^+$.


Synthesis of 3-((5-(4-fluorobenzyl)-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazol-3-yl)methyl)-5-methoxy-1H-indole (72)



72


[0279] Prepared according to **General Procedure 1C** from thioamide **C** (300 mg, 0.53 mmol), 2-(4-fluorophenyl)acetic hydrazide (111 mg, 0.66 mmol), silver benzoate (243 mg, 1.06 mmol), and acetic acid (95 mg, 90.9 μ L, 1.59 mmol), which afforded 735 mg of crude material. The crude was purified by flash chromatography (SiO_2 , 40:1 CH_2Cl_2 :MeOH to 20:1) to afford 159 mg (43% yield) of compound **72**: ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 10.70 (bs, 1H), 7.90 (d, J = 8.20 Hz, 1H), 7.46 (t, J = 8.10 Hz, 1H), 7.36 – 7.29 (m, 9H), 7.21 (bs, 1H), 7.14 – 7.10 (m, 3H), 7.06 (d, J = 1.80 Hz, 1H), 7.00 – 6.98 (m, 6H), 6.91 (d, J = 2.30 Hz, 1H), 6.62 (dd, J = 8.30, 2.30 Hz, 1H), 6.45 (bs, 1H), 4.08 (s, 2H), 3.97 (s, 2H), 3.68 (apparent t, J = 7.80 Hz, 2H), 2.24 (t, J = 7.60 Hz, 2H), 1.41 (quint., J = 7.50 Hz, 2h). ^{13}C NMR (100 MHz, $\text{DMSO}-d_6$) δ 161.47 (d, $^1J_{\text{CF}}$ = 242 Hz), 160.26, 153.80, 153.47, 153.19, 142.82, 140.17, 138.25, 133.39, 133.31 (d, $^4J_{\text{CF}}$ = 2.90 Hz), 131.85, 130.83 ($^3J_{\text{CF}}$ = 8.70 Hz), 129.78, 139.66, 129.10, 128.69, 128.46, 127.63, 124.63 118.11, 115.64 (d, $^2J_{\text{CF}}$ = 22.0 Hz), 112.57, 111.66, 109.02, 100.93, 74.87, 55.73, 42.70, 29.84, 29.44, 25.06, 21.87. LCMS (50-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 3.77 minutes, ESI m/z = 687, $[M+H]^+$.

Synthesis of 3-((4-(3-(1H-imidazol-4-yl)propyl)-5-(4-fluorobenzyl)-4H-1,2,4-triazol-3-yl)methyl)-5-methoxy-1H-indole (SK-I-55)




[0280] Prepared according to **General Procedure 1D** from 3-((5-(4-fluorobenzyl)-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazol-3-yl)methyl)-5-methoxy-1H-indole **72** (144 mg, 0.21 mmol) and afforded 66 mg (71% yield) of compound **SK-I-55** as a tan residue. ^1H NMR (400 MHz, MeOH- d_4) δ 7.55 (s, 1H), 7.19 (d, J = 8.70 Hz, 1H), 7.05 – 7.02 (m, 2H), 7.97 – 7.92 (m, 3H), 6.83 (d, J = 2.40 Hz, 1H), 6.72 (dd, J = 8.70, 2.30 Hz, 1H), 6.55 (s, 1H), 4.24 (s, 2H), 4.04 (s, 2H), 3.70 (s, 3H), 3.63 – 3.58 (m, 2H), 2.28 (t, J = 6.80 Hz, 2H), 1.38 (quint., J = 6.80 Hz, 2H). ^{13}C NMR (100 MHz, MeOH- d_4) δ 162.01 (d, $^1J_{\text{CF}}$ = 244 Hz), 154.87, 154.16, 153.92, 134.71, 131.99, 131.38 (d, $^4J_{\text{CF}}$ = 2.90 Hz), 129.84 (d, $^3J_{\text{CF}}$ = 8.60 Hz), 126.97, 123.61, 115.22 (d, $^2J_{\text{CF}}$ = 22.1 Hz), 111.89, 107.52, 99.54, 54.78, 42.75, 29.51, 28.69, 23.33 (broad), 21.72. LCMS (50-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 5.92 minutes, ESI m/z = 445, $[\text{M}+\text{H}]^+$.

Synthesis of 3-((5-benzyl-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazol-3-yl)methyl)-5-methoxy-1H-indole (74)



[0281] Prepared according to **General Procedure 1C** from thioamide **C** (300 mg, 0.53 mmol), phenylacetic hydrazide (**29n**) (99 mg, 0.66 mmol), silver benzoate (243 mg, 1.06 mmol), and acetic acid (95 mg, 90.9 μ L, 1.59 mmol), affording 738 mg of crude material. The crude was purified by flash chromatography (SiO_2 , 40:1 CH_2Cl_2 :MeOH to 20:1) to afford 118 mg (33% yield) of compound **74**. ^1H NMR (400 MHz, DMSO-d_6) δ 10.69 (bs 1H), 7.90 (d, J = 7.40 Hz, 1H), 7.46 (t, J = 7.80 Hz, 1H), 7.36 – 7.32 (m, 9H), 7.20 (s, 1H), 7.14 – 7.03 (complex m, 7H), 7.00 – 6.97 (m, 6H), 6.90 (d, J = 2.30 Hz, 1H), 6.62 (dd, J = 8.70, 2.30 Hz, 1H), 6.39 (s, 1H), 4.08 (s, 2H), 3.98 (s, 2H), 3.68 – 3.64 (m, 2H), 2.22 (apparent t, J = 6.90 Hz, 2H), 1.36 (apparent quint., J ~ 7.00 Hz, 2H). ^{13}C NMR (100 MHz, DMSO-d_6) δ 153.79, 153.47, 153.24, 142.81, 140.17, 138.17, 137.19, 133.39, 131.85, 129.78, 129.67, 129.09, 128.91, 128.87, 128.70, 128.47, 127.63, 127.01, 124.62, 118.10, 112.57, 111.68, 109.02, 100.90, 74.88, 55.73, 42.73, 30.71, 29.40, 25.11, 21.89. LCMS (50-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 3.43 minutes, ESI m/z = 669, $[\text{M}+\text{H}]^+$.

Synthesis of 3-((4-(3-(1H-imidazol-4-yl)propyl)-5-benzyl-4H-1,2,4-triazol-3-yl)methyl)-5-methoxy-1H-indole (SK-I-53)




SK-I-53

[0282] Synthesized according to **General Procedure 1D** from 3-((5-benzyl-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazol-3-yl)methyl)-5-methoxy-1H-indole **74** (118 mg, 0.18 mmol) to afford 64 mg (85% yield) of compound **SK-I-53** as a tan solid. ^1H NMR (400 MHz, MeOH-d_4) δ 7.54 (s, 1H), 7.23 – 7.14 (complex m, 4H), 7.02 (d, J = 6.80 Hz, 2H), 6.92 (s, 1H), 6.84 (d, J = 2.20 Hz, 1H), 6.72 (dd, J = 8.70 Hz, 2.70 Hz, 1H), 6.52 (s, 1H), 4.23 (s, 2H), 4.06 (s, 2H), 3.70 (s, 3H), 3.61 – 3.57 (m, 2H), 2.25 (t, J = 6.80 Hz, 2H), 1.35 (quint., J = 7.80 Hz, 2H). ^{13}C NMR (100 MHz, MeOH-d_4) δ 154.82,

154.27, 153.92, 135.43, 134.67, 131.98, 128.58, 127.99, 126.89, 123.58, 111.91, 107.54, 99.51, 54.77, 42.77, 30.04, 28.61, 23.24 (broad), 21.73. LCMS (50-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 5.80 minutes, ESI m/z = 427, $[M+H]^+$.


Synthesis of 5-methoxy-3-((5-(4-fluorobenzyl)-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazol-3-yl)methyl)-1H-indole (76)



76

[0283] Created according to **General Procedure 1C** from thioamide **C** (311 mg, 0.54 mmol), 2-(4-methoxyphenyl)acetic hydrazide (**29d**) (123 mg, 0.68 mmol), silver benzoate (247 mg, 1.08 mmol), and acetic acid (97 mg, 93 μ L, 1.62 mmol), which afforded 760 mg of crude material. The crude was purified by flash chromatography (SiO_2 , 40:1 $\text{CH}_2\text{Cl}_2/\text{MeOH}$ to 20:1) to afford 132 mg (39% yield) of compound **76**. ^1H NMR (400 MHz, DMSO-d_6) δ 10.7 (s, 1H), 7.90 (d, J = 6.80 Hz, 1H), 7.45 (t, J = 7.80 Hz, 1H), 7.33 (m, 9H), 7.21 (s, 1H), 7.11 (d, J = 8.70 Hz, 1H), 7.04 (apparent d, J = 1.80 Hz, 1H), 6.99 (m, 6H), 6.90 (apparent d, J = 2.30 Hz, 1H), 6.70 (d, J = 8.70 Hz, 2H), 6.62 (dd, J = 8.70, J = 2.30 Hz, 1H), 6.46 (s, 1H), 4.06 (s, 2H), 3.90 (s, 2H), 3.64 (partially obs. t, J = 7.30 Hz, 2H), 3.59 (s, 3H), 3.59 (s, 3H), 2.23 (t, J = 6.80 Hz, 2H), 1.41 (quint., J = 6.80 Hz, 2H). LCMS (50-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 3.38 minutes, ESI m/z = 699, $[M+H]^+$.


Synthesis of 3-((4-(3-(1H-imidazol-4-yl)propyl)-5-(4-methoxybenzyl)-4H-1,2,4-triazol-3-yl)methyl)-5-methoxy-1H-indole (SK-I-56)



SK-I-56

[0284] Prepared according to **General Procedure 1D** from 5-methoxy-3-((5-(4-methoxybenzyl)-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazol-3-yl)methyl)-1H-indole (**76**) (112 mg, 0.16 mmol) and afforded 67 mg (92% yield) of compound **SK-I-56** as a light tan solid. ^1H NMR (400 MHz, MeOH-d_4) δ 7.54 (s, 1H), 7.18 (d, J = 8.70 Hz, 1H), 6.94 – 6.90 (m, 3H), 6.83 (d, J = 2.70 Hz, 1H), 6.77 – 6.74 (m, 2H), 6.72 (dd, J = 8.70, 2.70 Hz, 1H), 6.53 (bs, 1H), 4.23 (s, 2H), 3.99 (s, 2H), 3.70 (s, 3H), 3.69 (s, 3H), 3.61 – 3.56 (m, 2H), 2.25 (t, J = 7.40 Hz, 2H), 1.33 (quint., J = 7.70 Hz, 2H). ^{13}C NMR (100 MHz, MeOH-d_4) δ 158.97, 154.78, 154.59, 153.92, 134.64, 131.99, 129.03, 127.12, 126.97, 123.58, 113.93, 111.89, 107.57, 99.54, 54.78, 54.31, 42.77, 29.56, 28.58, 23.59 (broad), 21.71. LCMS (50-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 1.75 minutes, ESI m/z = 457, $[\text{M}+\text{H}]^+$.


Synthesis of 5-methoxy-3-((5-(3-(trifluoromethyl)benzyl)-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazol-3-yl)methyl)-1H-indole (78)



78


[0285] Prepared according to **General Procedure 1C** from thioamide **C** (360 mg, 0.63 mmol), 3-(trifluoromethyl)phenylacetic hydrazide (**29i**) (172 mg, 0.79 mmol), silver benzoate (286 mg, 1.26 mmol), and acetic acid (113 mg, 108 μ L, 1.89 mmol), to afford 932 mg of crude material. The crude was purified by flash chromatography (SiO_2 , 20:1 $\text{CH}_2\text{Cl}_2/\text{MeOH}$ to 10:1) afforded 209 mg (45% yield) of compound **78**. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 10.7 (s, 1H), 7.90 (d, J = 8.20 Hz, 1H), 7.60-7.38 (complex m, 3H), 7.32 (m, 9H), 7.19 (s, 1H), 7.11 (d, J = 8.70 Hz, 1H), 7.06 (s, 1H), 6.99 (m, 6H), 6.91 (apparent d, J = 1.80 Hz, 1H), 6.62 (dd, J = 8.70, J = 2.30 Hz, 1H), 6.43 (s, 1H), 4.10 (s, 2H), 4.09 (s, 2H), 3.75 (t, J = 7.30 Hz, 2H), 3.59 (s, 3H), 2.25 (t, J = 6.90 Hz, 2H), 1.42 (J = 7.70 Hz, 2H). LCMS (50-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 7.98 minutes, ESI m/z = 737, $[\text{M}+\text{H}]^+$.

Synthesis of 3-((4-(3-(1H-imidazol-4-yl)propyl)-5-(3-(trifluoromethyl)benzyl)-4H-1,2,4-triazol-3-yl)methyl)-5-methoxy-1H-indole (SK-I-57)



[0286] Prepared according to **General Procedure 1D** from 5-methoxy-3-((5-(3-(trifluoromethyl)benzyl)-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazol-3-yl)methyl)-1H-indole (**78**) (209 mg, 0.28 mmol) to afford 105 mg (76% yield) of compound **SK-I-57** as a tan solid. ^1H NMR (400 MHz, $\text{MeOH}-d_4$) δ 7.59 – 7.41 (complex overlapping m, 5H), 7.31 (d, J = 7.80 Hz, 1H), 7.18 (d, J = 8.70 Hz, 1H), 6.93 (s, 1H), 6.85 (d, J = 2.30 Hz, 1H), 6.72 (dd, J = 8.70, 2.30 Hz, 1H), 6.54 (bs, 1H), 4.25 (s, 2H), 4.16 (s, 2H), 3.70 (s, 3H), 3.69 – 3.66 (m, 2H), 2.28 (t, J = 7.30 Hz, 2H), 1.39 (quint., J = 7.50 Hz, 2H). LCMS (50-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 1.85 minutes, ESI m/z = 495, $[\text{M}+\text{H}]^+$.


Synthesis of 6-fluoro-3-((5-(4-fluorobenzyl)-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazol-3-yl)methyl)-1H-indole (80)



80

[0287] Synthesized following **General Procedure 1C** from thioamide **J** (547 mg, 0.98 mmol), 2-(4-fluorophenyl)acetic hydrazide (206 mg, 1.22 mmol), silver benzoate (449 mg, 1.96 mmol), and acetic acid (177 mg, 168 μ L, 2.94 mmol), which afforded 1.37 mg of crude material. The crude was purified by flash chromatography (SiO_2 , 40:1 $\text{CH}_2\text{Cl}_2/\text{MeOH}$ to 20:1) afforded 327 mg (49% yield) of compound **80**. LCMS (50-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 4.42 minutes, ESI m/z = 675, $[\text{M}+\text{H}]^+$.

Synthesis of 3-((4-(3-(1H-imidazol-4-yl)propyl)-5-(4-fluorobenzyl)-4H-1,2,4-triazol-3-yl)methyl)-6-fluoro-1H-indole (SK-I-91)




SK-I-91

[0288] Prepared according to **General Procedure 1D** from 6-fluoro-3-((5-(4-fluorobenzyl)-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazol-3-yl)methyl)-1H-indole (**80**) (136 mg, 0.20 mmol) and afforded 51 mg (59% yield) of compound **SK-I-91** as a tan solid. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 11.75 (bs, 1H), 10.95 (s, 1H), 7.51 (s, 1H), 7.38 (dd, J = 8.70, 5.5 Hz, 1H), 7.26 – 7.21 (m, 1H), 7.14 – 7.02 (complex overlapping m, 7H), 6.77 (dt, J = 8.70, 2.30 Hz, 1H), 6.67 (bs, 1H), 4.09 (s, 2H), 3.97 (s,

2H), 3.71 – 3.65 (m, 2H), 2.32 – 2.26 (m, 2H), 1.49 – 1.40 (m, 2H). LCMS (50-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 1.83 minutes, ESI m/z = 433, $[M+H]^+$.


Synthesis of 6-fluoro-3-((5-(4-methoxybenzyl)-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazol-3-yl)methyl)-1H-indole (82)



82

[0289] Prepared according to **General Procedure 1C** from thioamide **C** (300 mg, 0.54 mmol), 2-(4-methoxyphenyl)acetic hydrazide (**29d**) (121 mg, 0.67 mmol), silver benzoate (247 mg, 1.08 mmol), and acetic acid (97 mg, 93 μ L, 1.62 mmol), which formed 737 mg of crude material. The crude was purified by flash chromatography (SiO_2 , 40:1 $\text{CH}_2\text{Cl}_2/\text{MeOH}$ to 20:1) afforded 234 mg (63% yield) of compound **82**. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 10.92 (bs, 1H), 7.91 – 7.89 (m, 2H), 7.45 (t, J = 7.80 Hz, 2H), 7.39 – 7.30 (complex overlapping m, 8H), 7.22 (d, J = 1.40 Hz, 1H), 7.11 (d, J = 2.30 Hz, 1H), 7.01 – 6.97 (m, 6H), 6.73 – 6.68 (m, 3H), 6.47 (bs, 1H), 4.08 (s, 2H), 3.90 (s, 2H), 3.59 (s, 3H), 3.67 – 3.63 (m, 2H), 2.25 (t, J = 7.30 Hz, 2H), 1.41 (apparent quint., J ~ 7.30 Hz, 2H). LCMS (50-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 3.43 minutes, ESI m/z = 687, $[M+H]^+$.


Synthesis of 3-((4-(3-(1H-imidazol-4-yl)propyl)-5-(4-methoxybenzyl)-4H-1,2,4-triazol-3-yl)methyl)-6-fluoro-1H-indole (SK-I-105)



SK-I-105


[0290] Synthesized according to **General Procedure 1D** from 6-fluoro-3-((5-(4-methoxybenzyl)-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazol-3-yl)methyl)-1H-indole (**82**) (224 mg, 0.33 mmol) and afforded 111 mg (76% yield) of compound **SK-I-105** as a tan solid. ^1H NMR (400 MHz, DMSO- d_6) δ 11.75 (bs, 1H), 10.95 (bs, 1H), 7.51 (s, 1H), 7.38 (dd, J = 8.20, 5.90 Hz, 1H), 7.06 – 7.03 (m, 2H), 6.97 (d, J = 8.20 Hz, 2H), 6.79 – 6.74 (m, 3H), 6.66 (s, 1H), 4.08 (s, 2H), 3.90 (s, 2H), 3.64 (s, 3H), 3.62 – 3.56 (bm, 2H), 2.32 – 2.24 (bm, 2H), 1.48 – 1.38 (bm, 2H). ^{13}C NMR (100 MHz, DMSO- d_6) δ 159.40 (d, $^1J_{\text{CF}}$ = 234 Hz), 158.47, 153.63, 153.53, 136.61 (d, J_{CF} = 13.4 Hz), 135.18, 130.42, 129.93, 128.79, 124.57 (d, J_{CF} = 2.80 Hz), 124.16, 120.15 (d, J_{CF} = 9.60 Hz), 114.41, 114.11, 109.59, 107.52 (d, J_{CF} = 24.9 Hz), 98.88 (d, J_{CF} = 25.8 Hz), 55.51, 42.61, 29.96, 29.59, 24.94 (broad), 21.84. LCMS (50-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 1.78 minutes, ESI m/z = 445, $[\text{M}+\text{H}]^+$.

Synthesis of 6-fluoro-3-((5-neopentyl-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazol-3-yl)methyl)-1H-indole (84)

**84**

[0291] (Prepared from the hydrazide hydrochloride; modification of **General Method 1C**) To a solution of thioamide **M** (300 mg, 0.62 mmol) and hydrazide (**3m**) (189 mg, 0.78 mmol), in CH₂Cl₂ (40 mL) was added silver benzoate (284 mg, 1.24 mmol) followed immediately with acetic acid (112 mg, 106 μ L, 1.86 mmol). The black solution (Ag₂S formation) was stirred at room temperature for 16 hrs. LCMS determined minimal reaction progress was made; TEA (78 mg, 108 μ L, 0.78 mmol) was added and the reaction was stirred at room temperature for 18 hrs. LCMS showed further reaction progress was made; silver benzoate (284 mg, 1.24 mmol) and acetic acid (112 mg, 106 μ L, 1.86 mmol) were added to the reaction, which was allowed to stir at room temperature for an additional 72 hours. The solution was concentrated and the residue was dissolved in 1:1 MeOH/CH₂Cl₂ and treated with 1N HCl (1.24 mmol, 1.24 mL). The mixture was stirred for 5 min, treated with diisopropylethylamine (~10 mmol, ~5 mL) and concentrated. The residue was suspended in MeOH (120 mL), filtered through celite (1 inch pad) and concentrated to afford 1.11 g of crude material. The crude residue was purified by flash chromatography (SiO₂, 40:1 CH₂Cl₂/MeOH to 20:1) to afford 200 mg (51% yield) of compound **84**. This compound was not pure but was taken on "as is." LCMS (50-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 4.62 minutes, ESI m/z = 637, [M+H]⁺.


Synthesis of 3-((4-(3-(1H-imidazol-4-yl)propyl)-5-neopentyl-4H-1,2,4-triazol-3-yl)methyl)-6-fluoro-1H-indole (SK-I-119)



[0292] Prepared according to **General Procedure 1D** from 6-fluoro-3-((5-neopentyl-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazol-3-yl)methyl)-1H-indole (**84**) (186 mg, 0.29 mmol) and afforded 112 mg (97% yield) of compound **SK-I-119** as a

pale yellow solid. LCMS (50-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 1.80 minutes, ESI m/z = 395, $[M+H]^+$.


Synthesis of 3,3'-((4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazol-3,5-diyl))bis(methylene))bis(6-fluoro-1H-indole) (86)



86

[0293] (Prepared from the hydrazide hydrochloride; modification of **General Method 1C**) To a solution of thioamide **J** (300 mg, 0.54 mmol) and hydrazide hydrochloride (**3m**) (164 mg, 0.68 mmol), in CH_2Cl_2 (40 mL) was added silver benzoate (247 mg, 1.08 mmol) followed immediately with acetic acid (97 mg, 93 μL , 1.62 mmol). The black solution (Ag_2S formation) was stirred at room temperature for 16 hours. LCMS determined minimal reaction progress was made; TEA (68 mg, 94 μL , 0.68 mmol) was added and the reaction was stirred at room temperature for 18 hours. LCMS showed further reaction progress was made; silver benzoate (247 mg, 1.08 mmol) and acetic acid (97 mg, 93 μL , 1.62 mmol) were added to the reaction, which was allowed to stir at room temperature for an additional 72 hours. The solution was concentrated and the residue was dissolved in 1:1 MeOH: CH_2Cl_2 and treated with 1N HCl (1.08 mmol, 1.08 mL). The mixture was stirred for 5 min, treated with diisopropylethylamine (~10 mmol, ~5 mL) and concentrated. The residue was suspended in MeOH (120 mL), filtered through celite (1 inch pad) and concentrated to afford 1.18 g of crude material. The crude residue was purified by flash chromatography (SiO_2 , 40:1 $\text{CH}_2\text{Cl}_2/\text{MeOH}$ to 20:1, to 10:1) afforded 68 mg (18% yield) of compound **86**. LCMS (50-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 4.32 minutes, ESI m/z = 714, $[M+H]^+$.

Synthesis of 3,3'-((4-(3-(1H-imidazol-4-yl)propyl)-4H-1,2,4-triazol-3,5-diyl)bis(methylene))bis(6-fluoro-1H-indole) (SK-I-124)




SK-I-124

[0294] Prepared following **General Procedure 1D** from 3,3'-((4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazol-3,5-diyl)bis(methylene))bis(6-fluoro-1H-indole) (**86**) (68 mg, 0.095 mmol) and afforded 33 mg (73% yield) of compound **SK-I-124** as a tan solid. ^1H NMR (400 MHz, DMSO- d_6) δ 11.71 (bs, 1H), 10.90 (bs, 1H), 7.48 (s, 1H), 7.36 – 7.32 (m, 2H), 7.04 – 7.01 (m, 4H), 6.74 – 6.69 (m, 2H), 6.64 (s, 1H), 4.07 (s, 4H), 3.69 (apparent t, $J \sim 7.30$ Hz, 2H), 2.30 – 2.24 (m, 2H), 1.53 – 1.44 (m, 2H). LCMS (50–95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 1.97 minutes, ESI m/z = 472, $[\text{M}+\text{H}]^+$.


Example 2: Synthesis of 3,4,5-Trisubstituted-3-Thio-1,2,4-Triazoles

Synthesis of 3-[1-(Triphenylmethyl)-1H-imidazol-4-yl] propyl Isothiocyanate (1)



[0295] A mixture of *N,N*-Dicyclohexylcarbodiimide (1.10 g, 5.3 mmol) and CS_2 (3.36 mL, 53 mmol) in THF (16 mL) was treated with a solution of commercially available *N*-*tert*-butoxycarbonyl-1,4-diaminobutane (1.0 g, 5.3 mmol) in THF (32 mL). The reaction mixture was stirred overnight under nitrogen. Removal of the solvent under reduce pressure afforded a white solid. The solid was triturated with Et_2O (150 mL) and the dicyclohexylthiourea was filtered. The filtrate was evaporated to afford a yellow solid. The residue was used in the next step without further purification.

Synthesis of *tert*-butyl (4-isothiocyanatobutyl) carbamate (2)



[0296] A mixture of DCC (3.37 g, 16.3 mmol) and CS₂ (13.3 g, 174 mmol) in THF (50 mL) was treated with a solution of 3-(1-Trityl-1H-imidazol-4-yl)propan-1-amine (6.0 g, 16.3 mmol) in THF (100 mL). The reaction mixture was stirred overnight under nitrogen. Removal of the solvent under reduced pressure afforded a white solid. The solid was triturated with Et₂O (300 mL) and the dicyclohexylthiourea was filtered. The filtrate was evaporated to afford an oil. Flash chromatography on silica gel using EtOAc/hexanes (2:8) gave the desired compound 2 (4.8 g, 72%) as a yellow solid.

General Procedure 2A: General Condensation Reactions

[0297] The isothiocyanate (1-2) (1 eq.) was added to the desired hydrazide (**3a-3l**) (1 eq.) in anhydrous THF (minimum for solubilization) and the reaction was stirred at room temperature under N₂ for 18 to 24 hours. The corresponding hydrazinecarbothioamides (**14a-l**) were obtained after evaporation of the solvent and appropriate purification.

General Procedure 2B: General Cyclization Reactions

[0298] The hydrazinecarbothioamide (**14a-l**) (1 eq.) was dissolved in EtOH (5mL/mmol), and NaOH 1 M (1.5 eq.) is added. The mixture is heated 85°C for 3 to 4 hours. At the end of the reaction, water was added. The aqueous layer was washed with DCM, acidified to pH 2 with conc. HCl 1M, and extracted twice with DCM. After evaporation, the 3-thiol-1,2,4-triazole (**15a-k**) was purified by precipitation, recrystallization, flash chromatography, or used without further purification.

General Procedure 2C: General Alkylation of the thiol Reactions


[0299] To a mixture of a benzyl bromide derivative (1 eq.) and a cyclized derivative (**15a-k**) (1 eq.) in DCM (8 mL/mmol) was added triethylamine (1 eq.). The reaction mixture was stirred 5 to 12 hours, and the solvent was evaporated and the residue was partitioned between EtOAc (150 mL) and brine (150 mL). The layers were separated, and the organic layer was dried (anhydrous MgSO₄), filtered, and concentrated. The reaction mixture was evaporated and purified by chromatography on silica column (gradient DCM to EtOAc or DCM to DCM/MeOH (9:1)).

General Procedure 2D: General N-Boc Deprotection Reactions

[0300] To a mixture of the N-Boc-protected compound (1 eq.) in DCM (5.5 mL/mmol) was added 6N HCl in *i*PrOH (5.5 mL/mmol) and the mixture was stirred at room temperature overnight. The reaction was co-evaporated three times with absolute EtOH. The desired deprotected compound was obtained after purification (recrystallization, or used without further purification).

General Procedure 2E: General Trityl Deprotection Reactions

[0301] A mixture of the trityl-protected compound (1 mmol) in DCM (26.5 mL/mmol) was added 1N HCl (10.6 mL/mmol) and the mixture was stirred at room temperature overnight. The reaction was co-evaporated three times with absolute ethanol, and the desired unprotected compound was obtained after purification (recrystallization, or used without further purification).



3a R = 3-indolyethyl

1

3b R = 2-quinolyl

3c R = 2-naphthalyl

3d R = phenylethyl

3e R = 3-indolyl

3f R = Ph

3g R = 3-indolylmethyl

3h R = 1-naphthalyl

3i R = 5-fluoro-2-indolyl

3j R = 4-fluoro-phenylethyl

3k R = 2-indolyl

3l R = 3-(5-fluoro)indolylmethyl

14a R = 3-indolyethyl

14b R = 2-quinolyl

14c R = 2-naphthalyl

14d R = phenylethyl

14e R = 3-indolyl

14f R = Ph

14g R = 3-indolylmethyl

14h R = 1-naphthalyl


14i R = 5-fluoro-2-indolyl

14j R = 4-fluoro-phenylethyl

14k R = 2-indolyl

14l R = 3-(5-fluoro)indolylmethyl


Synthesis of 2-(3-(1H-indol-3-yl)propanoyl)-N-(3-(1-trityl-1H-imidazol-4-yl)propyl)hydrazinecarbothioamide (14a)



14a

[0302] Prepared according to the **General Procedure 2A** from compound **1** (2.09 g, 5.1 mmol) and hydrazine **3a** (942 mg, 4.6 mmol) to afford 2.41 g (77%) of compound **14a** as a yellow foam: ^1H NMR (400 MHz, DMSO- d_6) δ 10.82 (s, 1H), 9.71 (s, 1H), 9.13 (s, 1H), 7.76 (m, 1H), 7.51 (d, J = 7.6 Hz, 1H), 7.40-7.31 (m, 11H), 7.25 (d, J = 1.4 Hz, 1H), 7.10-7.02 (m, 8H), 6.96 (t, J = 7.8 Hz, 1H), 3.33 (m, 2H, under H_2O peak), 2.94 (m, 2H), 2.46 (m, 2H under DMSO), 2.43 (m, 2H), 1.68 (m, 2H). ^{13}C NMR (100 MHz, DMSO- d_6) δ 171.70, 142.38, 140.66, 137.65, 136.27, 129.24, 128.22, 127.96, 126.95, 122.23, 120.98, 118.31, 118.22, 117.53, 113.49, 111.38, 74.39, 43.32, 34.14, 28.40, 25.17, 20.39. LCMS (50-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 3.28 minutes, ESI m/z = 613.36 $[\text{M}+\text{H}]^+$.


Synthesis of 2-(quinoline-2-carbonyl)-N-(3-(1-trityl-1H-imidazol-4-yl)propyl) hydrazine carbothioamide (14b)



14b


[0303] Prepared according to the **General Procedure 2A** from compound **3b** (415 mg, 2.2 mmol) and **1** (1.00 g, 2.4 mmol) to afford 873 mg (66%) of compound **10b** as a white solid: ^1H NMR (400 MHz, DMSO- d_6) δ 10.73 (s, 1H), 9.38 (s, 1H), 8.55 (d, J = 8.7 Hz, 1H), 8.29 (s, 1H), 8.11-8.07 (m, 3H), 7.89 (t, J = 6.9 Hz, 1H), 7.75 (t, J = 6.9 Hz, 1H), 7.40-7.33 (m, 9H), 7.13 (s, 1H), 7.08-7.03 (m, 6H), 6.61 (s, 1H), 3.47 (m, 2H), 2.45 (t, J = 7.3 Hz, 2H), 1.75 (m, 2H). ^{13}C NMR (100 MHz, DMSO- d_6) δ 181.25, 149.54, 145.91, 142.33, 140.68, 137.62, 137.54, 130.56, 129.26, 129.16, 128.84, 128.25, 128.17, 127.91, 119.00, 117.39, 74.30, 43.58, 28.26, 25.24.

Synthesis of 2-(2-naphthoyl)-N-(3-(1-trityl-1H-imidazol-4-yl)propyl) hydrazine carbothioamide (14c)



[0304] Prepared according to the **General Procedure 2A** from compound **3c** (413 mg, 2.2 mmol) and **1** (1.00 g, 2.4 mmol) to afford 1.26 g (95%) of compound **14c** as a white solid: ^1H NMR (400 MHz, DMSO- d_6) δ 10.49 (bs, 1H), 9.32 (bs, 1H), 8.52 (s, 1H), 8.33 (bs, 1H), 8.00-7.95 (m, 5H), 7.60 (m, 2H), 7.35 (m, 10H), 7.04 (m, 7H), 6.61 (s, 1H), 3.46 (m, 2H), 2.45 (m, 2H), 1.74 (m, 2H). ^{13}C NMR (100 MHz, DMSO- d_6) δ 165.97, 142.34, 140.67, 137.59, 134.33, 131.97, 129.92, 129.18, 128.92, 128.37, 128.19, 127.92, 127.77, 127.68, 126.84, 124.41, 117.45, 74.34, 43.51, 28.35, 25.23.


Synthesis of 2-(3-phenylpropanoyl)-N-(3-(1-trityl-1H-imidazol-4-yl)propyl)hydrazinecarbothioamide (14d)



[0305] Prepared according to the **General Procedure 2A** from compound **3d** (417 mg, 2.5 mmol) and **1** (1.04 g, 2.5 mmol) to afford 558 mg (38%) of compound **14d** as a white solid: ^1H NMR (400 MHz, DMSO- d_6) δ 9.68 (s, 1H), 9.12 (s, 1H), 7.82 (m, 1H), 7.41-7.33 (m, 9H), 7.27-7.23 (m, 3H), 7.19-7.14 (m, 3H), 7.08 (m, 6H), 6.63 (s, 1H), 3.41 (m, 2H), 2.80 (m, 2H), 2.41 (m, 2H), 1.72 (m, 2H). ^{13}C NMR (100 MHz, DMSO- d_6)

δ 171.17, 142.38, 141.08, 140.65, 137.64, 129.23, 128.37, 128.22, 127.97, 125.99, 117.54, 74.39, 43.31, 34.90, 30.35, 28.40, 25.15.


Synthesis of 2-(1H-indole-3-carbonyl)-N-(3-(1-trityl-1H-imidazol-4-yl)propyl) hydrazine carbothioamide (14e)



14e

[0306] Prepared according to the **General Procedure 2A** from compound **3e** (396 mg, 2.3 mmol) and **1** (1.02 g, 2.5 mmol) to afford 1.11 g (85% yield) of compound **14e** as a white solid: ^1H NMR (400 MHz, DMSO- d_6) δ 11.66 (s, 1H), 9.76 (s, 1H), 9.17 (s, 1H), 8.15-8.08 (m, 2H), 7.45 (d, J = 8.3 Hz, 1H), 7.40-7.33 (m, 9H), 7.18-7.06 (m, 10H), 6.62 (s, 1H), 3.47 (m, 2H), 2.42 (m, 2H), 1.75 (m, 2H). ^{13}C NMR (100 MHz, DMSO- d_6) δ 164.36, 142.38, 140.73, 137.61, 135.94, 129.22, 128.91, 128.20, 127.94, 126.35, 122.12, 120.95, 120.72, 117.45, 111.92, 108.03, 74.36, 67.05, 43.43, 28.48, 25.29, 25.16.

Synthesis of 2-benzoyl-N-(3-(1-trityl-1H-imidazol-4-yl)propyl) hydrazine carbothioamide (14f)




14f

[0307] Prepared according to the **General Procedure 2A** from phenylhydrazide (**3f**) (305 mg, 2.24 mmol) and **1** (1.009 g, 2.46 mmol) to afford 913 mg (75% yield) of compound **14f** as a white solid: ^1H NMR (400 MHz, DMSO- d_6) δ 10.34 (s, 1H), 9.27 (s, 1H), 8.26 (s, 1H), 7.91 (d, J = 6.8 Hz, 2H), 7.56 (d, J = 7.3 Hz, 1H), 7.47-


7.34 (m, 13H), 7.16 (s, 1H), 7.08-7.06 (m, 7H), 6.62 (s, 7H), 3.48-3.44 (m, 2H), 2.45 (d, $J = 7.3$ Hz, 2H), 1.74 (m, 2H). ^{13}C NMR (100 MHz, DMSO- d_6) δ 165.90, 142.36, 140.67, 137.61, 132.48, 131.82, 129.22, 128.22, 127.96, 127.80, 117.45, 74.37, 43.54, 28.34, 25.24.

Synthesis of 2-(2-(1H-indol-3-yl)acetyl)-N-(3-(1-trityl-1H-imidazol-4-yl)propyl)hydrazine carbothioamide (14g)



[0308] Prepared according to the **General Procedure 2A** from compound **3g** (424 mg, 2.24 mmol) and **1** (1.009 g, 2.48 mmol) to afford 1.002 g (75% yield) of compound **14g** as a white solid: ^1H NMR (400 MHz, DMSO- d_6) δ 10.90 (s, 1H), 9.87 (s, 1H), 9.18 (s, 1H), 7.95 (s, 1H), 7.55 (d, $J = 8.2$ Hz, 1H), 7.42-7.21 (m, 12H), 7.11-7.02 (m, 7H), 6.96 (m, 1H), 6.65 (s, 1H), 3.56 (s, 2H), 3.44 (m, 2H), 2.45 (t, $J = 7.3$ Hz, 2H), 1.72 (m, 2H). ^{13}C NMR (100 MHz, DMSO- d_6) δ 142.40, 140.66, 137.69, 136.06, 129.26, 128.24, 127.99, 127.23, 123.97, 121.00, 118.78, 118.34, 117.56, 111.31, 108.01, 74.42, 43.42, 30.66, 28.36, 25.22.


Synthesis of 2-(1-naphthoyl)-N-(3-(1-trityl-1H-imidazol-4-yl)propyl) hydrazine carbothioamide (14h)



[0309] Prepared according to the **General Procedure 2A** from compound **3h** (412 mg, 2.2 mmol) and **1** (997 mg, 2.43 mmol) to afford 1.27 g (96%) of compound **14h** as a white solid: ^1H NMR (400 MHz, DMSO- d_6) δ 10.30 (s, 1H), 9.39 (s, 1H), 8.29 (m,

2H), 8.06 (d, $J = 8.3$ Hz, 1H), 7.98 (d, $J = 7.8$ Hz, 1H), 7.90 (d, $J = 6.9$ Hz, 1H), 7.57-7.50 (m, 3H), 7.43-7.35 (m, 11H), 7.09 (m, 6H), 6.71 (s, 1H), 3.52 (m, 2H), 3.45-3.43 (m, 2H), 1.79 (m, 2H). ^{13}C NMR (100 MHz, DMSO- d_6) δ 168.19, 142.19, 140.07, 137.55, 133.15, 130.77, 130.05, 129.23, 128.27, 128.20, 128.04, 127.81, 127.58, 126.74, 126.45, 126.32, 125.73, 124.73, 117.75, 74.66, 43.43, 28.31, 24.85.


Synthesis of 2-(5-fluoro-1H-indole-2-carbonyl)-N-(3-(1-trityl-1H-imidazol-4-yl)propyl)hydrazinecarbothioamide (14i)



14i

[0310] Prepared according to the **General Procedure 2A** from compound **3i** (434 mg, 2.25 mmol) and **1** (920 mg, 2.25 mmol) to afford 1.09 g (81%) of compound **14i** as a white solid: ^1H NMR (400 MHz, DMSO- d_6) δ 11.81 (s, 1H), 10.38 (s, 1H), 9.32 (s, 1H), 8.35 (s, 1H), 7.41-7.32 (m, 11H), 7.15 (s, 1H), 7.05 (m, 7H), 6.60 (s, 1H), 3.44 (m, 2H), 2.42 (m, 2H), 1.73 (m, 2H). ^{13}C NMR (100 MHz, DMSO- d_6) δ 160.77, 158.34, 156.02, 142.37, 140.66, 137.61, 133.30, 131.37, 129.19, 128.20, 127.93, 127.01, 126.90, 117.39, 113.59, (d), 112.59 (d), 103.72, 74.34, 56.06, 54.96, 54.96, 43.62, 28.26, 25.29, 18.59.


Synthesis of 2-(3-(4-fluorophenyl)propanoyl)-N-(3-(1-trityl-1H-imidazol-4-yl)propyl)hydrazinecarbothioamide (14j)



14j

[0311] Prepared according to the **General Procedure 2A** from compound **3j** (356 mg, 1.95 mmol) and **1** (813 mg, 1.95 mmol) to afford 994 mg (85%) of compound **14j** as a white solid: ^1H NMR (400 MHz, DMSO- d_6) δ 9.64 (s, 1H), 9.08 (s, 1H), 7.83 (s, 1H), 7.37-7.30 (m, 9H), 7.22-7.16 (m, 3H), 7.04 (m, 7H), 6.59 (s, 1H), 3.33 (m, 2H, under H_2O), 2.75 (m, 2H), 2.36 (m, 2H), 1.67 (m, 2H). ^{13}C NMR (100 MHz, DMSO- d_6) δ 171.20, 161.96, 159.56, 142.41, 140.68, 137.71, 137.23, 130.10, 130.02, 129.30, 128.29, 128.05, 117.63, 115.18, 114.93, 74.46, 43.39, 35.02, 29.55, 25.19.


Synthesis of 2-(1H-indole-2-carbonyl)-N-(3-(1-trityl-1H-imidazol-4-yl)propyl)hydrazinecarbothioamide (14k)



14k

[0312] Prepared according to the **General Procedure 2A** from compound **3k** (349 mg, 1.99 mmol) and **1** (815 mg, 1.99 mmol) to afford 815 mg (70% yield) of compound **14k** as a white solid: ^1H NMR (400 MHz, DMSO- d_6) δ 11.64 (s, 1H), 10.29 (s, 1H), 9.26 (s, 1H), 8.28 (s, 1H), 7.53 (d, $J = 7.8$ Hz, 1H), 7.39-7.28 (m, 10H), 7.17-7.13 (m, 3H), 7.02-6.97 (m, 7H), 6.57 (s, 1H), 3.47 (m, 2H, under H_2O peak), 2.38 (m, 2H), 1.70 (m, 2H). ^{13}C NMR (100 MHz, DMSO- d_6) δ 164.45, 163.95, 150.26, 150.22, 142.38, 140.64, 140.30, 139.62, 137.64, 129.25, 128.25, 128.01, 121.67, 121.06, 117.53, 74.41, 43.56, 28.36, 25.22.


Synthesis of 2-(2-(5-Fluoro-1H-indol-3-yl)acetyl)-N-(3-(1-trityl-1H-imidazol-4-yl)propyl)hydrazinecarbothioamide (14l)



[0313] Prepared according to **General Procedure 2A** from compound **1** (1 g, 2.44 mmol) and hydrazide **3l** (506 mg, 2.44 mmol) to afford 1.38 g (92%) of compound **14l** as a yellow foam: ^1H NMR (400 MHz, DMSO- d_6) δ 11.00 (s, 1H), 9.87 (s, 1H), 9.18 (s, 1H), 8.02 (s, 1H), 7.43-7.26 (m, 13H), 7.10-7.07 (m, 6H), 6.89 (m, 1H), 6.64 (s, 1H),


3.44 (m, 2H), 2.43 (m, 2H), 1.73 (m, 2H). ^{13}C NMR (100 MHz, DMSO- d_6) δ 170.24, 157.86, 155.59, 142.40, 140.63, 137.67, 132.74, 129.25, 128.23, 127.98, 127.52 (d), 126.14, 117.55, 112.28, 109.22 (d), 108.34, 103.72 (d), 74.40, 67.05, 43.43, 30.59, 28.36, 25.17.

Synthesis of 2-(2-(6-fluoro-1H-indol-3-yl)acetyl)-N-3-(1-trityl-1H-imidazol-4-yl)propyl)hydrazinecarbo-thioamide (14m)




[0314] Prepared according to **General Procedure A** from compound **1** (1.12 g, 2.73 mmol) and hydrazide **3m** (567 mg, 2.73 mmol) to afford 1.20 g (71%) of compound **14m** as a yellow foam: ^1H NMR (400 MHz, DMSO- d_6) δ 10.94 (s, 1H), 9.85 (s, 1H), 9.14 (s, 1H), 7.97 (s, 1H), 7.50 (m, 1H), 7.41-7.33 (m, 9H), 7.25 (d, J = 1.4 Hz, 1H), 7.19 (d, J = 2.3 Hz, 1H), 7.10-7.04 (m, 6H), 6.82-6.76 (m, 1H), 6.63 (s, 1H), 3.51 (s, 2H), 2.41 (m, 2H), 1.75 (m, 2H). ^{13}C NMR (100 MHz, DMSO- d_6) δ 170.26, 160.01, 157.68, 142.39, 140.64, 137.68, 135.93 (d), 129.24, 128.22, 124.59 (d), 124.11, 119.93 (d), 117.55, 108.32, 106.90 (d), 97.36 (d), 74.40, 43.42, 30.58, 28.37, 25.21.


Synthesis of 2-(2-phenylacetyl)-N-(3-(1-trityl-1H-imidazol-4-yl)propyl)hydrazinecarbothioamide (14n)



[0315] Prepared according to **General Procedure A** from compound **1** (1.10 g, 2.69 mmol) and hydrazide **3n** (403 mg, 2.69 mmol) to afford 1.05 g (70%) of compound **14n** as a white solid: ^1H NMR (400 MHz, DMSO- d_6) δ 9.92 (s, 1H), 9.05 (s, 1H), 7.94 (s, 1H), 7.35-7.28 (m, 10H), 7.22 (m, 1H), 7.20-7.10 (m, 4H), 7.02-6.99 (m, 6H), 6.59 (s, 1H), 3.39 (s, 2H), 3.34 (m, 2H), 2.34 (m, 2H), 1.65 (m, 2H). ^{13}C NMR (100 MHz, DMSO- d_6) δ 142.38, 140.65, 137.65, 135.49, 129.23, 128.20, 128.15, 127.95, 117.50, 74.37, 43.39, 33.37, 28.35, 25.19.




Synthesis of 5-(2-(1H-indol-3-yl)ethyl)-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazole-3-thiol (15a)



[0316] Prepared according to the **General Procedure 2B** from derivative **14a** (2.41 g, 3.9 mmol). Flash chromatography on silica gel (gradient DCM/MeOH 9:1) afforded the desired product **15a** as a yellow foam (1.78 g, 76%): ^1H NMR (400 MHz, DMSO- d_6) δ 10.77 (s, 1H), 7.45 (d, J = 7.8 Hz, 1H), 7.37-7.26 (m, 11H), 7.17 (d, J = 1.4 Hz, 1H), 7.09 (s, 1H), 7.05-6.96 (m, 7H), 6.85 (t, J = 6.9 Hz, 1H), 3.83 (t, J = 8.2 Hz, 2H), 2.99 (m, 4H), 2.41 (t, J = 6.9 Hz, 2H), 1.82 (m, 2H). ^{13}C NMR (100 MHz, DMSO- d_6) δ 166.65, 152.61, 142.86, 140.37, 138.23, 136.69, 129.71, 128.70, 128.43, 127.35, 123.15, 121.48, 118.79, 118.70, 118.18, 113.27, 111.90, 74.87, 43.04, 27.80, 26.20, 25.39, 22.03. LCMS (25-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 7.08 minutes, ESI m/z = 595.41 $[\text{M}+\text{H}]^+$. HRMS (ESI $^+$): m/z calculated for $\text{C}_{37}\text{H}_{35}\text{N}_6\text{S}$ ($\text{M}+\text{H}$) + 595.2630, found 595.2638.


Synthesis of 5-(quinolin-2-yl)-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazole-3-thiol (15b)



15b

[0317] Prepared according to the **General Procedure 2B** from compound **14b** (873 mg, 1.46 mmol) to afford 800 mg (94%) of compound **15b** as a white solid: ^1H NMR (400 MHz, DMSO- d_6) δ 8.56 (d, J = 8.7 Hz, 1H), 8.13 (d, J = 8.2 Hz, 1H), 8.08-8.02 (m, 2H), 7.77-7.68 (m, 2H), 7.38-7.34 (m, 9H), 7.23 (s, 1H), 7.05-7.03 (m, 6H), 6.69 (s, 1H), 4.69 (t, J = 7.6 Hz, 2H), 2.63 (t, J = 7.3 Hz, CH_2), 2.14-2.07 (m, 2H). ^{13}C NMR (100 MHz, DMSO- d_6) δ 168.41, 148.57, 146.46, 145.85, 142.32, 140.13, 137.70, 130.55, 129.19, 128.13, 128.04, 127.90, 127.65, 119.76, 117.67, 74.36, 45.24, 27.99, 25.40.


Synthesis of 5-(naphthalen-2-yl)-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazole-3-thiol (15c)



15c

[0318] Prepared according to the **General Procedure 2B** from compound **14c** (1.25 g, 2.1 mmol) to afford 996 mg (82%) of compound **15c** as a white solid: ^1H NMR (400 MHz, DMSO- d_6) δ 8.23 (d, J = 0.9 Hz, 1H), 8.01 (d, J = 8.2 Hz, 1H), 7.95 (d, J = 8.2 Hz, 1H), 7.73 (dxd, J = 8.2, 1.4 Hz, 1H), 7.63 (t, J = 8.2 Hz, 1H), 7.55 (d, J = 7.3 Hz, 1H), 4.07 (m, 2H), 2.39 (m, 2H), 1.94 (m, 2H). ^{13}C NMR (100 MHz, DMSO- d_6) δ 167.25, 151.29, 137.67, 133.40, 132.33, 129.14, 128.73, 128.60, 128.49, 128.11, 127.89, 127.75, 127.70, 126.97, 125.17, 123.40, 118.01, 74.28, 56.07, 43.75, 27.31, 24.73, 18.59.


Synthesis of 5-phenethyl-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazole-3-thiol (15d)



15d

[0319] Prepared according to the **General Procedure 2B** from **14d** (464 mg, 0.81 mmol) to afford 418 mg (93%) of compound **15d** as a white solid: ^1H NMR (400 MHz, DMSO- d_6) δ 10.82 (s, 1H), 8.76 (s, 1H), 7.47-7.43 (m, 10H), 7.32-7.24 (m, 5H), 7.21-7.15 (m, 8H), 3.91 (t, J = 8.2 Hz, 2H), 3.01-2.93 (m, 4H), 2.68-2.64 (m, 2H), 1.95-1.88 (m, 2H). ^{13}C NMR (100 MHz, DMSO- d_6) δ 166.33, 166.24, 151.75, 147.77, 140.68, 140.31, 136.62, 133.66, 132.55, 129.23, 128.61, 128.56, 128.46, 128.37, 128.33, 127.78, 127.55, 126.67, 126.25, 119.64, 115.56, 80.57, 41.94, 31.17, 26.49, 26.27, 21.24.

Synthesis of 5-(3a,7a-dihydro-1H-indol-3-yl)-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazole-3-thiol (15e)




15e

[0320] Prepared according to the **General Procedure 2B** from compound **14e** (1.09 g, 1.90 mmol) to afford 1.00 g (93%) of compound **15e** as a white solid: ^1H NMR (400 MHz, DMSO- d_6) δ 11.88 (s, 1H), 8.02 (d, J = 2.8 Hz, 1H), 7.97 (d, J = 8.2 Hz, 1H), 7.51 (d, J = 7.8 Hz, 1H), 7.41-7.37 (m, 9H), 7.25-7.21 (m, 1H), 7.17-7.09 (m, 7H), 6.97 (s, 1H), 4.18 (m, 2H), 2.61 (m, 2H), 2.00 (m, 2H). ^{13}C NMR (100 MHz, DMSO- d_6) δ 166.11, 147.48, 141.54, 137.38, 135.91, 129.19, 128.36, 128.19, 127.77, 127.54,

126.38, 125.28, 122.64, 120.60, 120.48, 118.89, 112.03, 100.46, 75.57, 43.24, 26.60, 23.46.


Synthesis of 5-phenyl-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazole-3-thiol (15f)



15f

[0321] Prepared according to the **General Procedure 2B** from compound **14f** (890 mg, 1.63 mmol) to afford 851 mg (99%) of compound **15f** as a white solid: ^1H NMR (400 MHz, DMSO- d_6) δ 7.52 (m, 2H), 7.39-7.34 (m, 12H), 7.22 (s, 1H), 7.04-7.02 (m, 6H), 6.53 (s, 1H), 3.95 (t, J = 7.8 Hz, 2H), 2.37 (t, J = 7.3 Hz, 2H), 1.85 (m, 2H). ^{13}C NMR (100 MHz, DMSO- d_6) δ 167.70, 150.66, 142.32, 140.02, 137.73, 129.25, 128.73, 128.64, 128.20, 127.99, 127.58, 117.83, 74.37, 43.16, 28.17, 25.05.

Synthesis of 5-((1H-indol-3-yl)methyl)-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazole-3-thiol (15g)




15g

[0322] Prepared according to the **General Procedure 2B** from compound **14g** (1.00 g, 1.67 mmol) to afford 829 mg (85%) of compound **15g** as a white solid: ^1H NMR (400 MHz, DMSO- d_6) δ 11.07 (s, 1H), 8.47 (s, 1H), 7.47-7.39 (m, 10H), 7.31-7.28 (m, 2H), 7.14-7.09 (m, 7H), 7.03 (m, 1H), 6.93 (m, 1H), 4.19 (m, 2H), 3.86 (t, J = 7.3 Hz, 1H), 2.53 (m, 2H), 1.70 (m, 2H). ^{13}C NMR (100 MHz, DMSO- d_6) δ 166.46, 151.36, 140.80, 136.62, 136.22, 134.76, 129.22, 128.56, 128.49, 127.78, 127.54, 126.65,

124.21, 121.29, 119.33, 118.66, 118.29, 111.62, 107.11, 76.68, 42.16, 26.44, 22.19, 21.92.


Synthesis of 5-(naphthalen-1-yl)-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazole-3-thiol (15h)



15h

[0323] Prepared according to the **General Procedure 2B** from compound **14h** (1.11 g, 1.86 mmol) to afford 733 mg (69%) of **15h** as a white solid: ^1H NMR (400 MHz, DMSO- d_6) δ 8.76 (s, 1H), 8.11 (d, J = 8.2 Hz, 1H), 8.04 (d, J = 7.8 Hz, 1H) 7.80 (d, J = 7.1 Hz, 1H), 7.62-7.54 (m, 4H), 7.41-7.37 (m, 10H), 7.08 (s, 1H), 7.02 (m, 6H), 3.70 (m, 2H), 2.44 (m, 2H), 1.74 (m, 2H). ^{13}C NMR (100 MHz, DMSO- d_6) δ 166.84, 149.71, 140.16, 136.32, 132.98, 132.69, 131.30, 131.23, 129.33, 129.18, 128.71, 127.93, 126.98, 125.44, 124.28, 122.92, 120.22, 77.43, 42.55, 26.47, 20.87.

Synthesis of 5-(5-fluoro-1H-indol-2-yl)-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazole-3-thiol (15i)




15i

[0324] Prepared according to the **General Procedure 2B** from compound **14i** (1.09 g, 1.81 mmol) to afford 410 mg (39%) of **15i** as a white solid: ^1H NMR (400 MHz, DMSO- d_6) δ 11.96 (s, 1H), 7.44-7.41 (m, 1H), 7.36-7.34 (m, 10H), 7.19-7.16 (m, 1H), 7.09-7.05 (m, 8H), 6.95 (s, 1H), 6.72 (s, 1H), 4.23 (m, 2H), 2.58 (m, 2H), 2.02 (m, 2H). ^{13}C NMR (100 MHz, DMSO- d_6) δ 166.84, 149.71, 140.16, 136.32, 132.98, 132.69,


131.30, 131.23, 129.33, 129.18, 128.71, 127.93, 126.98, 125.44, 124.28, 122.92, 120.22, 77.43, 42.55, 26.47, 20.87.

Synthesis of 5-(4-fluorophenethyl)-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazole-3-thiol (15j)



[0325] Prepared according to the **General Procedure 2B** from compound **14j** (893 mg, 1.51 mmol) to afford 790 mg (91%) of **15j** as a white solid: ^1H NMR (400 MHz, DMSO- d_6) δ 7.97 (s, 1H), 7.34-7.28 (m, 9H), 7.20-7.16 (m, 2H), 7.04-6.92 (m, 9H), 3.78 (m, 2H), 2.47 (m, 2H), 1.79 (m, 2H). ^{13}C NMR (100 MHz, DMSO- d_6) δ 166.24, 162.05, 159.64, 151.61, 147.80, 141.21, 136.94, 136.43, 133.61, 132.38, 130.35 (d), 129.24, 128.50 (d), 127.81, 127.57, 126.68, 119.09, 115.09 (d), 76.14, 42.07, 30.26, 26.78, 26.33, 22.85.


Synthesis of 5-(1H-indol-2-yl)-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazole-3-thiol (15k)



[0326] Prepared according to the **General Procedure 2B** from **14k** (735 mg, 1.26 mmol) to afford 610 mg (86%) of compound **15k** as a white solid: ^1H NMR (400 MHz, DMSO- d_6) δ 11.87 (s, 1H), 8.79 (s, 1H), 7.55 (d, J = 8.3 Hz, 1H), 7.45-7.35 (m, 12H), 7.22-7.10 (m, 7H), 7.06-6.99 (m, 2H), 4.23 (m, 2H), 2.75 (m, 2H), 2.04 (m, 2H). ^{13}C NMR (100 MHz, DMSO- d_6) δ 167.28, 147.80, 145.17, 140.51, 136.80, 136.56,

133.63, 129.25, 128.65, 127.81, 127.58, 127.48, 126.69, 123.71, 122.43, 120.20, 120.04, 112.05, 103.31, 77.16, 43.13, 26.54, 25.17.


Synthesis of 5-((5-Fluoro-1H-indol-3-yl)methyl)-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazole-3-thiol (15l)



15l

[0327] Prepared according to **General Procedure 2B** from derivative **14l** (1.23 g, 2.00 mmol). Evaporation of the organic phase afforded the desired product **15l** as a yellow foam (860 mg, 72%): ^1H NMR (400 MHz, DMSO- d_6) δ 11.19 (s, 1H), 7.48-7.39 (m, 10H), 7.32-7.21 (m, 3H), 7.17-7.14 (m, 6H), 6.90 (s, 1H), 4.17 (s, 2H), 3.86 (d, $J = 7.4$ Hz, 2H), 2.61 (d, $J = 7.3$ Hz, 2H), 1.76 (m, 2H). ^{13}C NMR (100 MHz, DMSO- d_6) δ 166.49, 157.82, 155.52, 151.24, 147.78, 140.47, 136.39, 133.66, 132.89, 129.23, 128.66, 127.79, 127.55, 127.00 (d), 126.67, 126.34, 119.77, 112.71 (d), 109.58 (d), 107.40 (d), 103.21 (d), 77.20, 42.02, 26.36, 21.74, 21.62.

Synthesis of 5-((6-fluoro-1H-indol-3-yl)methyl)-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazole-3-thiol (15m)




15m

[0328] Prepared according to **General Procedure B** from derivative **14m** (1.50 g, 2.40 mmol) to afford the desired product **15m** as a yellow foam (1.46 g, quantitative yield): ^1H NMR (400 MHz, DMSO- d_6) δ 11.21 (s, 1H), 8.59 (s, 1H), 7.47-7.39 (m, 11H), 7.33 (s, 1H), 7.18-7.08 (m, 8H), 6.82 (s, 1H), 4.19 (s, 2H), 3.86 (m, 2H),

2.60 (m, 2H), 1.75 (m, 2H). ^{13}C NMR (100 MHz, DMSO- d_6) δ 166.48, 160.05, 157.72, 151.21, 140.73, 136.58, 136.17 (d), 129.21, 128.58, 128.51, 124.86 (d), 123.55, 119.45 (d), 107.42, 107.34 (d), 97.70, 97.44, 76.80, 42.11, 26.41, 22.05, 21.81.


Synthesis of 5-benzyl-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazole-3-thiol (15n)



15n

[0329] Prepared according to **General Procedure B** from derivative **14n** (879 mg, 1.55 mmol) to afford the desired product **15n** as a yellow foam (703 mg, 84%): ^1H NMR (400 MHz, DMSO- d_6) δ 8.09 (s, 1H), 7.45-7.39 (m, 9H), 7.27-7.22 (m, 4H), 7.17-7.11 (m, 7H), 6.92 (s, 1H), 4.10 (s, 2H), 3.83 (m, 2H), 2.53 (m, 2H), 1.68 (m, 2H). ^{13}C NMR (100 MHz, DMSO- d_6) δ 166.60, 151.15, 141.30, 136.98, 135.07, 129.21, 128.73, 128.63, 128.44, 128.32, 127.02, 118.75, 42.40, 30.72, 26.58, 23.08.

Synthesis of 6-fluoro-3-((5-(3-methylbenzylthio)-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazol-3-yl)methyl)-1H-indole (16m)




16m

[0330] Prepared according to **General Procedure C** from cyclized compound **15m** (690 mg, 1.15 mmol) and benzyl bromide (138 μL , 1.15 mmol) to afford 500 mg


(63%) of the desired product **16m** as a yellow foam: ^1H NMR (400 MHz, DMSO- d_6) δ 11.03 (s, 1H), 7.47-7.43 (m, 1H), 7.40-7.35 (m, 9H), 7.24 (s, 1H), 7.16-7.04 (m, 13H), 6.79 (m, 1H), 6.54 (s, 1H), 4.26 (s, 2H), 4.17 (s, 2H), 3.61 (t, J = 7.8 Hz, 2H), 2.27 (t, J = 7.1 Hz, 2H), 1.48 (m, 2H). ^{13}C NMR (100 MHz, DMSO- d_6) δ 160.05, 157.73, 154.40, 148.36, 142.31, 139.56, 137.72, 137.21, 136.19, 136.07, 129.17, 128.73, 128.31, 128.16, 127.93, 127.32, 124.18, 123.60, 119.62 (d), 117.53, 108.76 (d), 107.14 (d), 97.51 (d), 74.35, 42.66, 37.60, 28.66, 24.59, 21.56.

Synthesis of 6-fluoro-3-((5-(3-methylbenzylthio)-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazol-3-yl)methyl)-1H-indole (17m)



[0331] Prepared according to **General Procedure C** from cyclized compound **15m** (770 mg, 1.29 mmol) and 3-methylbenzyl bromide (174 μL , 1.29 mmol) to afford 545 mg (60%) of the desired product **17m** as a yellow foam: ^1H NMR (400 MHz, DMSO- d_6) δ 11.00 (s, 1H), 7.47-7.43 (m, 1H), 7.39-7.36 (m, 10H), 7.24 (m, 1H), 7.15 (m, 1H), 7.07-6.93 (m, 11H), 6.78 (m, 1H), 6.54 (s, 1H), 4.23 (s, 2H), 4.16 (s, 2H), 3.64 (t, J = 7.8 Hz, 2H), 2.28 (t, J = 6.9 Hz, 2H), 2.13 (s, 3H), 1.47 (m, 2H). ^{13}C NMR (100 MHz, DMSO- d_6) δ 160.07, 157.75, 154.40, 148.50, 142.31, 139.53, 137.73 (d), 137.02, 136.21 (d), 129.35, 129.18, 128.25, 128.18, 128.03, 127.95, 125.85, 124.17 (d), 123.61, 119.63 (d), 117.56, 108.81, 107.16 (d), 97.54 (d), 74.40, 42.72, 37.53, 28.69, 24.59, 21.54, 20.79.


Synthesis of 3-benzyl-5-(benzylthio)-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazole (17n)



17n

[0332] Prepared according to **General Procedure C** from cyclized compound **15n** (333 mg, 0.61 mmol) and 3-methoxybenzyl bromide (86 μ L, 0.61 mmol) to afford 266 mg (65%) of the desired product **17n** as a white foam: ^1H NMR (400 MHz, DMSO- d_6) δ 7.39-7.36 (m, 10H), 7.23-7.19 (m, 4H), 7.11-7.02 (m, 9H), 6.80-6.73 (m, 2H), 6.49 (s, 1H), 4.26 (s, 2H), 4.08 (s, 2H), 3.63 (s, 3H), 3.60 (m, 2H), 2.26 (m, 2H), 1.40 (m, 2H). ^{13}C NMR (100 MHz, DMSO- d_6) δ 159.16, 154.31, 148.66, 142.32, 139.50, 138.67, 137.73, 136.27, 129.46, 129.18, 128.51, 128.37, 128.18, 127.97, 126.70, 120.97, 117.55, 114.26, 113.05, 74.37, 42.80, 37.41, 30.39, 28.73, 24.64.


Synthesis of 3-(3-methoxybenzylthio)-5-phenethyl-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazole (17d)



17d

[0333] Prepared according to **General Procedure C** from cyclized compound **15d** (401 mg, 0.72 mmol) and 3-methoxybenzyl bromide (101 μ L, 0.72 mmol) to yield 420 mg (88%) of **17d** as a white solid: ^1H NMR (400 MHz, DMSO- d_6) δ 7.39-7.33 (m, 9H), 7.21 (d, J = 1.4 Hz, 1H), 7.20-7.11 (m, 6H), 7.04-7.02 (m, 6H), 6.81-6.75 (m, 3H), 6.58 (s, 1H), 4.25 (s, 2H), 3.66-3.62 (m, 2H), 3.65 (s, 3H), 2.97-2.86 (m, 4H), 2.36-2.33 (m, 2H), 1.67-1.63 (m, 2H). ^{13}C NMR (100 MHz, DMSO- d_6) δ 159.17, 154.90, 148.11, 142.31, 140.62, 139.55, 138.71, 137.76, 129.50, 129.18, 128.37, 128.24, 128.19,

127.96, 126.11, 121.02, 117.74, 114.33, 113.00, 74.37, 42.42, 37.29, 32.47, 28.79, 26.21, 24.50.




15a R = 3-indolylethyl
 15b R = 2-quinolyl
 15c R = 2-naphthalyl
 15d R = phenylethyl
 15e R = 3-indolyl
 15f R = Ph
 15g R = 3-indolymethyl
 15h R = 1-naphthalyl
 15i R = 5-fluoro-2-indolyl
 15j R = 4-fluoro-phenylethyl
 15k R = 2-indolyl
 15l R = 3-(5-fluoro)indolymethyl

16a R = 3-indolylethyl
 17a R = 3-indolylethyl
 18a R = 3-indolylethyl
 19a R = 3-indolylethyl
 16b R = 2-quinolyl
 17b R = 2-quinolyl
 18b R = 2-quinolyl
 16c R = 2-naphthalyl
 16d R = phenylethyl
 16e R = 3-indolyl
 16f R = Ph
 16g R = 3-indolymethyl
 17g R = 3-indolymethyl
 18g R = 3-indolymethyl
 19g R = 3-indolymethyl
 20g R = 3-indolymethyl
 21g R = 3-indolymethyl
 22g R = 3-indolymethyl
 16h R = 1-naphthalyl
 16i R = 5-fluoro-2-indolyl
 16j R = 4-fluoro-phenylethyl
 16k R = 2-indolyl
 16l R = 3-(5-fluoro)indolymethyl

R' = Ph
 R' = 3-chlorophenyl
 R' = 3-fluorophenyl
 R' = 3,4-dichlorophenyl
 R' = Ph
 R' = 3-indolylethyl
 R' = 3-bromophenyl
 R' = Ph
 R' = Ph
 R' = Ph
 R' = Ph
 R' = Ph
 R' = 3-trifluoromethylphenyl
 R' = 3-fluoro
 R' = 3,4-dichlorophenyl
 R' = 3-bromophenyl
 R' = 3-methoxyphenyl
 R' = 3-methylphenyl
 R' = Ph
 R' = Ph
 R' = Ph
 R' = Ph

Synthesis of 3-(2-(5-(benzylthio)-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazol-3-yl)ethyl)-1H-indole (S16a)




16a

[0334] Prepared according to the **General Procedure 2C** from cyclized compound **15a** (272 mg, 0.46 mmol) and benzyl bromide (55 μ L, 0.46 mmol) to afford 218 mg (70%) of **16a** as a yellow solid: ^1H NMR (400 MHz, DMSO- d_6) δ 10.78 (bs, 1H), 7.44 (d, J = 7.8 Hz, 2H), 7.36-7.32 (m, 9H), 7.30 (d, J = 8.2 Hz, 1H), 7.23-7.19 (m, 6H),


7.10 (m, 1H), 7.04-7.01 (m, 7 H), 6.89 (t, $J = 7.6$ Hz, 1H), 6.56 (s, 1H), 4.27 (s, 2H), 3.64 (t, $J = 7.8$ Hz, 2H), 3.06-2.95 (m, 4H), 2.33 (t, $J = 6.8$ Hz, 2H), 1.64 (m, 2H). ^{13}C NMR (100 MHz, DMSO- d_6) δ 155.41, 147.03, 142.31, 139.50, 137.78, 137.22, 136.18, 129.18, 128.86, 128.42, 128.17, 127.94, 127.42, 126.89, 122.61, 120.93, 118.25, 118.15, 117.66, 113.15, 111.35, 74.36, 42.51, 37.40, 28.87, 25.53, 24.59, 22.64. LCMS (50-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 5.28 minutes, ESI $m/z = 685.44$ $[\text{M}+\text{H}]^+$.

Synthesis of 3-(2-(5-(3-chlorobenzylthio)-4-(3-(1-*trityl*-1*H*-imidazol-4-yl)propyl)-4*H*-1,2,4-triazol-3-yl)ethyl)-1*H*-indole (17a)




[0335] Prepared according to the **General Procedure 2C** from cyclized compound **15a** (323 mg, 0.54 mmol) and 3-chlorobenzyl bromide (71 μL , 0.54 mmol) to afford 320 mg (82%) of **17a** as a white solid: ^1H NMR (400 MHz, DMSO- d_6) δ 10.79 (s, 1H), 7.44 (d, $J = 8.2$ Hz, 1H), 7.36-7.33 (m, 9H), 7.30-7.20 (m, 4H), 7.11 (d, $J = 3.5$ Hz, 1H), 7.04-7.01 (m, 8H), 6.87 (m, 1H), 6.58 (s, 1H), 4.29 (s, 2H), 3.64 (m, 2H), 3.06-2.96 (m, 4H), 2.32 (m, 2H), 1.66 (m, 2H). ^{13}C NMR (100 MHz, DMSO- d_6) δ 155.57, 147.82, 142.32, 140.05, 139.49, 137.83, 136.19, 132.89, 130.26, 129.19, 128.71, 128.19, 127.96, 127.61, 127.35, 126.89, 122.62, 120.94, 118.27, 118.15, 117.67, 113.16, 111.38, 74.37, 42.56, 36.42, 28.89, 25.55, 24.58, 22.65.

Synthesis of 3-(3-methoxybenzylthio)-5-phenethyl-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazole (17d)



[0336] Prepared according to **General Procedure C** from cyclized compound **15d** (401 mg, 0.72 mmol) and 3-methoxybenzyl bromide (101 μ L, 0.72 mmol) to yield 420 mg (88%) of **17d** as a white solid: ^1H NMR (400 MHz, DMSO-d_6) δ 7.39-7.33 (m, 9H), 7.21 (d, J = 1.4 Hz, 1H), 7.20-7.11 (m, 6H), 7.04-7.02 (m, 6H), 6.81-6.75 (m, 3H), 6.58 (s, 1H), 4.25 (s, 2H), 3.66-3.62 (m, 2H), 3.65 (s, 3H), 2.97-2.86 (m, 4H), 2.36-2.33 (m, 2H), 1.67-1.63 (m, 2H). ^{13}C NMR (100 MHz, DMSO-d_6) δ 159.17, 154.90, 148.11, 142.31, 140.62, 139.55, 138.71, 137.76, 129.50, 129.18, 128.37, 128.24, 128.19, 127.96, 126.11, 121.02, 117.74, 114.33, 113.00, 74.37, 42.42, 37.29, 32.47, 28.79, 26.21, 24.50.


Synthesis of 3-(2-(5-(3-fluorobenzylthio)-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazol-3-yl)ethyl)-1H-indole (18a)



[0337] Prepared according the **General Procedure 2C** from **15a** (300 mg, 0.51 mmol) and 3-fluorobenzyl bromide (62 μ L, 0.51mmol) to afford 250 mg (73%) of compound **18a** as a white solid: ^1H NMR (400 MHz, DMSO-d_6) δ 10.75 (s, 1H), 7.41 (d, J = 7.8 Hz, 1H), 7.34-7.19 (m, 12H), 7.18 (d, J = 1.4 Hz, 1H), 7.10-7.04 (m, 2H), 7.01-6.96 (m, 8H), 6.85 (m, 1H), 6.54 (s, 1H), 4.27 (s, 2H), 3.64 (d, J = 7.8 Hz, 2H), 3.05-2.83

(m, 4H), 2.31 (t, $J = 6.8$ Hz, 2H), 1.64 (m, 2H). ^{13}C NMR (100 MHz, DMSO- d_6) δ 207.10, 163.71, 161.24, 156.05, 148.36, 142.82, 140.76 (2), 140.00, 138.32, 136.69, 130.84 (2), 129.68, 128.68, 128.45, 127.39, 125.51, 123.11, 121.44, 118.76, 118.65, 118.18, 116.26, 116.04, 114.86, 114.65, 113.65, 111.88, 74.86, 43.06, 37.00, 31.23, 29.42, 26.05, 25.07, 23.15. LCMS (60-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 2.77 minutes, ESI $m/z = 703.38$ $[\text{M}+\text{H}]^+$.


Synthesis of 3-(2-(5-(3,4-dichlorobenzylthio)-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazol-3-yl)ethyl)-1H-indole (19a)



19a

[0338] Prepared according the **General Procedure 2C** from **15a** (526 mg, 0.88 mmol) and 3,4-dichlorobenzyl bromide (128 μL , 0.88 mmol) to afford 218 mg (70%) of compound **19a** as a white solid: ^1H NMR (400 MHz, DMSO- d_6) δ 10.75 (s, 1H), 7.52 (d, $J = 1.8$ Hz, 1H), 7.47 (d, $J = 8.2$ Hz, 1H), 7.41 (d, $J = 7.8$ Hz, 1H), 7.34-7.21 (m, 11H), 7.18 (d, $J = 1.4$ Hz, 1H), 7.08 (d, $J = 2.3$ Hz, 1H), 7.01-6.96 (m, 7H), 6.86 (t, $J = 7.3$ Hz, 1H), 6.56 (s, 1H), 4.27 (s, 2H), 3.66 (t, $J = 7.3$ Hz, 2H), 3.05-2.92 (m, 4H), 2.32 (t, $J = 6.8$ Hz, 2H), 1.66 (m, 2H). ^{13}C NMR (100 MHz, DMSO- d_6) δ 207.08, 156.14, 142.82, 139.99, 139.38*2, 138.34, 136.69, 131.34, 131.03, 130.51, 129.79, 129.72, 128.44, 128.16, 127.41*2, 123.15, 121.44, 118.78*2, 118.57, 118.19, 113.64, 74.87, 43.11, 36.10, 29.45, 26.02, 25.03, 23.10. LCMS (60-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 2.67 minutes, ESI $m/z = 753.36$ $[\text{M}+\text{H}]^+$.


Synthesis of 3-((5-(4-bromobenzylthio)-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazol-3-yl)methyl)-1H-indole (19o)



19o

[0339] Prepared according to **General Procedure C** from cyclized compound **15g** (500 mg, 0.86 mmol) and 4-bromobenzyl bromide (215 mg, 0.86 mmol) to afford 506 mg (78%) of **19o** as a yellow foam: ^1H NMR (400 MHz, DMSO- d_6) δ 10.94 (s, 1H), 7.46 (d, J = 7.8 Hz, 1H), 7.40-7.34 (m, 9H), 7.31 (d, J = 7.8 Hz, 1H), 7.24-7.22 (m, 2H), 7.19 (m, 1H), 7.10-7.01 (m, 9H), 6.91 (t, J = 7.8 Hz, 1H), 6.54 (s, 1H), 4.23 (s, 2H), 4.18 (s, 2H), 3.61 (t, J = 7.5 Hz, 2H), 2.26 (t, J = 6.8 Hz, 2H), 1.49 (m, 2H). ^{13}C NMR (100 MHz, DMSO- d_6) δ 154.68, 148.11, 142.31, 139.54, 137.73, 136.85, 136.27, 131.18, 130.88, 129.18, 128.17, 127.93, 126.71, 123.64, 121.16, 120.52, 118.51, 118.47, 117.57, 111.50, 108.32, 74.36, 42.66, 36.65, 28.73, 24.57, 21.70.

Synthesis of Methyl 4-((5-((1H-indol-3-yl)methyl)-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazol-3-ylthio)methyl)benzoate (20o)




20o

[0340] Prepared according to **General Procedure C** from cyclized compound **15g** (493 mg, 0.85 mmol) and methyl 4-(bromomethyl)benzoate (194 mg, 0.85 mmol) to afford 395 mg (64%) of **20o** as a yellow foam: ^1H NMR (400 MHz, DMSO- d_6) δ 10.87 (s,

1H), 7.65 (d, $J = 8.2$ Hz, 2H), 7.40 (d, $J = 8.2$ Hz, 1H), 7.35-7.31 (m, 9H), 7.26-7.23 (m, 3H), 7.18 (m, 1H), 7.14 (d, $J = 2.3$ Hz, 1H), 7.03-6.96 (m, 7H), 6.85 (t, $J = 7.3$ Hz, 1H), 6.49 (s, 1H), 4.29 (s, 2H), 4.13 (s, 2H), 3.78 (s, 3H), 3.58 (t, $J = 7.8$ Hz, 2H), 2.21 (t, $J = 6.8$ Hz, 2H), 1.44 (m, 2H). ^{13}C NMR (100 MHz, DMSO- d_6) δ 165.87, 154.72, 148.02, 142.95, 142.32, 139.54, 137.71, 136.26, 129.21, 129.17, 129.05, 128.51, 128.16, 127.92, 126.69, 123.63, 121.16, 118.47, 117.57, 111.48, 108.30, 74.35, 52.10, 42.68, 38.87, 36.94, 28.75, 24.55, 21.68.


Synthesis of 3-benzyl-5-(benzylthio)-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazole (16n)



16n

[0341] Prepared according to **General Procedure C** from cyclized compound **15n** (370 mg, 0.68 mmol) and benzyl bromide (82 μL , 0.68 mmol) to afford 252 mg (58%) of the desired product **16n** as a white foam: ^1H NMR (400 MHz, DMSO- d_6) δ 7.40-7.35 (m, 10H), 7.23-7.08 (m, 10H), 7.04-7.02 (m, 6H), 6.48 (s, 1H), 4.27 (s, 2H), 4.07 (s, 2H), 3.57 (t, $J = 7.6$ Hz, 2H), 2.28 (t, $J = 7.2$ Hz, 2H), 1.39 (m, 2H). ^{13}C NMR (100 MHz, DMSO- d_6) δ 154.32, 148.65, 142.32, 139.50, 137.73, 137.21, 136.26, 129.20, 128.80, 128.53, 128.39, 128.20, 128.00, 127.39, 126.71, 117.57, 74.39, 42.76, 37.57, 30.40, 28.67, 24.64.


Synthesis of 2-(5-(benzylthio)-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazol-3-yl)quinoline (16b)



16b

[0342] Prepared according to the **General Procedure 2C** from **15b** (550 mg, 0.95 mmol) to afford 460 mg (72%) of compound **16b** as a white solid: ^1H NMR (400 MHz, DMSO- d_6) δ 8.54 (d, J = 8.7 Hz, 1H), 8.30 (d, J = 8.7 Hz, 1H), 8.05 (d, J = 6.9 Hz, 1H), 7.99 (d, J = 8.3 Hz, 1H), 7.75-7.55 (m, 5H), 7.37-7.19 (m, 13H), 7.05-7.01 (m, 5H), 6.62 (s, 1H), 4.49 (m, 2H), 4.48 (m, 2H), 2.54 (m, 2H), 1.97 (m, 2H). ^{13}C NMR (100 MHz, DMSO- d_6) δ 152.42, 152.26, 147.16, 146.59, 142.30, 139.77, 137.77, 137.42, 137.06, 130.33, 129.17, 128.97, 128.47, 128.11, 127.99, 127.92, 127.60, 127.53, 127.37, 119.93, 117.72, 74.35, 45.50, 36.80, 29.26, 25.13.

Synthesis of 2-(5-(2-(1H-indol-3-yl)ethylthio)-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazol-3-yl)quinoline (17b)




17b

[0343] The cyclized compound **15b** (515 mg, 0.89 mmol) was dissolved in DMF (7.1 mL) followed by the addition of K_2CO_3 (123 mg, 0.89 mmol) and 3-(2-bromoethyl)-1H-indole (199 mg, 0.89 mmol). The reaction was stirred at 40°C overnight and the precipitate was filtered and washed with cold diethyl ether to afford 496 mg (77%) of **17b** as a brown solid: ^1H NMR (400 MHz, DMSO- d_6) δ 10.91 (s, 1H), 8.53 (d, J = 8.7 Hz, 1H), 8.29 (d, J = 8.7 Hz, 1H), 8.04 (d, J = 6.9 Hz, 1H), 7.99 (d, J = 8.7 Hz, 1H),


7.74-7.60 (m, 3H) 7.35-7.32 (m, 10H), 7.25-7.23 (m, 2H), 7.08-6.95 (m, 8H), 6.66 (s, 1H), 4.57 (m, 2H), 3.55 (m, 2H), 3.16 (m, 2H), 2.59 (m, 2H), 2.10 (m, 2H). ^{13}C NMR (100 MHz, DMSO- d_6) δ 152.66, 150.01, 147.78, 146.40, 143.79, 143.65, 138.67, 133.63, 133.53, 133.53, 132.13, 131.38, 129.50, 129.22, 128.27, 127.91, 127.79, 127.55, 127.00, 126.66, 124.40, 120.63, 120.32, 119.58, 115.80, 112.00, 105.17, 80.57, 48.00, 30.43, 27.94, 27.81, 21.12.

Synthesis of 2-(5-(3-Bromobenzylthio)-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazol-3-yl)quinoline (18b)



[0344] Prepared according to **General Procedure 2C** from cyclized compound **15b** (480 mg, 0.83 mmol) and 3-bromobenzyl bromide (207 mg, 0.83 mmol) to afford 325 mg (52%) of 18b as a white foam: ^1H NMR (400 MHz, DMSO- d_6) δ 8.54 (d, J = 8.2 Hz, 1H), 8.30 (d, J = 8.7 Hz, 1H), 8.06 (d, J = 7.8 Hz, 1H), 7.99 (d, J = 7.8 Hz, 1H), 7.75-7.64 (m, 2H), 7.60 (m, 1H), 7.41-7.32 (m, 11H), 7.25-7.20 (m, 2H), 7.05-7.01 (m, 6H), 6.64 (s, 1H), 4.49 (m, 4H), 2.55 (m, 2H), 1.99 (m, 2H). ^{13}C NMR (100 MHz, DMSO- d_6) δ 152.51, 151.98, 147.11, 146.57, 142.29, 140.13, 139.73, 137.79, 137.40, 131.65, 130.54, 130.30, 129.16, 128.09, 127.96, 127.90, 127.58, 127.35, 121.52, 119.91, 117.70, 74.33, 45.53, 35.80, 29.26, 25.12.


Synthesis of 3-(benzylthio)-5-(naphthalen-2-yl)-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazole (16c)



16c

[0345] Prepared according to the **General Procedure 2C** from compound **15b** (417 mg, 0.72 mmol) to afford 270 mg (56%) of **16c** as a white solid: ^1H NMR (400 MHz, DMSO- d_6) δ 8.12 (s, 1H), 7.98 (d, J = 8.7 Hz, 1H), 7.92 (d, J = 8.2 Hz, 1H), 7.69 (dxd, J = 8.2, 1.4 Hz, 1H), 7.59 (t, J = 6.9 Hz, 1H), 7.51 (d, J = 6.9 Hz, 1H), 7.34-7.19 (m, 14H), 7.14 (d, J = 1.4 Hz, 1H), 7.14 (d, J = 1.4 Hz, 1H), 6.92-6.90 (m, 6H), 6.45 (s, 1H), 4.42 (s, 2H), 3.88 (t, J = 6.8 Hz, 2H), 2.31 (t, J = 6.4 Hz, 2H), 1.75 (m, 2H). ^{13}C NMR (100 MHz, DMSO- d_6) δ 154.95, 150.19, 142.20, 139.16, 137.85, 137.15, 133.11, 132.45, 129.19, 128.99, 128.58, 128.50, 128.10, 127.90, 127.66, 127.53, 127.40, 126.83, 125.39, 124.57, 117.97, 74.28, 43.82, 28.81, 24.50.

Synthesis of 3-(benzylthio)-5-phenethyl-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazole (16d)




16d

[0346] Prepared according to the **General Procedure 2C** from compound **15d** (388 mg, 0.70 mmol) to afford 335 mg (74%) of **16d** as a white solid: ^1H NMR (400 MHz, DMSO- d_6) δ 7.37 (m, 9H), 7.24-7.19 (m, 10H), 7.14 (m, 1H), 7.06-7.03 (m, 6H), 6.59 (s, 1H), 4.30 (s, 2H), 2.97-2.87 (m, 4H), 2.36 (m, 2H), 1.65 (m, 2H). ^{13}C NMR (100 MHz, DMSO- d_6) δ 154.88, 148.11, 142.30, 140.62, 139.55, 137.76, 137.25, 129.18,

128.85, 128.40, 128.38, 128.23, 128.18, 127.96, 127.42, 126.10, 117.74, 74.38, 42.41, 37.34, 32.46, 28.76, 26.20, 24.51.


Synthesis of 3-(5-(benzylthio)-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazol-3-yl)-1H-indole (16e)



16e

[0347] Prepared according to the **General Procedure 2C** from compound **15e** (457 mg, 0.81 mmol) to afford 423 mg (80%) of **16e** as a white solid: ^1H NMR (400 MHz, DMSO- d_6) δ 11.65 (s, 1H), 8.05 (d, J = 7.8 Hz, 1H), 7.81 (d, J = 2.8 Hz, 1H), 7.46 (d, J = 8.2 Hz, 1H), 7.34-7.30 (m, 11H), 7.28 (s, 1H), 7.25-7.10 (m, 4H), 7.04-7.02 (m, 6H), 6.59 (s, 1H), 4.37 (s, 2H), 3.88 (t, J = 8.2 Hz, 1H), 2.42 (t, J = 6.8 Hz, 2H), 1.77 (m, 2H). ^{13}C NMR (100 MHz, DMSO- d_6) δ 171.70, 142.38, 140.66, 137.65, 136.27, 129.24, 128.22, 127.96, 126.95, 122.23, 120.98, 118.31, 118.22, 117.53, 113.49, 111.38, 74.39, 43.32, 34.14, 28.40, 25.17, 20.39.

Synthesis of 3-(benzylthio)-5-phenyl-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazole (16f)




16f

[0348] Prepared according to the **General Procedure 2C** from **15f** (810 mg, 1.53 mmol) to afford 440 mg (46%) of **16f** as a white solid: ^1H NMR (400 MHz, DMSO- d_6) δ 7.55 (m, 2H), 7.47-7.42 (m, 3H), 7.37-7.19 (m, 15H), 7.04-7.00 (m, 6H), 6.48 (s, 1H), 4.41 (s, 2H), 3.81 (t, J = 7.8 Hz, 2H), 2.30 (t, J = 6.8 Hz, 2H), 1.70 (m, 2H). ^{13}C NMR (100 MHz, DMSO- d_6) δ 154.95, 149.99, 142.27, 139.13, 137.87, 137.14, 129.99,

129.22, 129.00, 128.93, 128.51, 128.36, 128.20, 128.02, 127.56, 127.27, 117.92, 74.39, 43.60, 37.34, 28.82, 24.48.


Synthesis of 3-((5-(benzylthio)-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazol-3-yl)methyl)-1H-indole (16g)



16g

[0349] Prepared according to the **General Procedure 2C** from **15g** (775 mg, 1.37 mmol) to afford 647 mg (72%) of compound **16g** as a white solid: ^1H NMR (400 MHz, DMSO- d_6) δ 10.93 (s, 1H), 7.47 (d, J = 7.8 Hz, 1H), 7.40-7.35 (m, 9H), 7.30-7.25 (m, 2H), 7.15-7.01 (m, 13H), 6.91 (s, 1H), 6.53 (s, 1H), 4.25 (s, 2H), 4.17 (s, 2H), 3.59 (t, J = 7.3 Hz, 2H), 2.24 (t, J = 7.3 Hz, 2H), 1.45 (m, 2H). ^{13}C NMR (100 MHz, DMSO- d_6) δ 154.62, 148.38, 142.30, 139.45, 137.72, 137.23, 136.30, 129.21, 128.75, 128.36, 128.22, 128.00, 127.36, 126.74, 123.61, 121.24, 118.53, 117.62, 111.47, 108.44, 74.45, 42.68, 37.68, 28.69, 24.57, 21.69.

Synthesis of 3-((5-(3-(trifluoromethyl)benzylthio)-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazol-3-yl)methyl)-1H-indole (17g)




17g

[0350] Prepared according to the **General Procedure 2C** from compound **15g** (468 mg, 0.81 mmol) and 3-trifluoromethylbenzyl bromide (123 μL , 0.81 mmol) to


afford 474mg (80%) of compound **17g** as a pale yellow foam: ^1H NMR (400 MHz, DMSO- d_6) δ 10.88 (d, J = 2.3 Hz, 1H), 7.60 (s, 1H), 7.39-6.97 (m, 24H), 6.46 (d, 1H), 4.34 (s, 2H), 4.12 (s, 2H), 3.61 (t, J = 7.4 Hz, 2H), 2.21 (t, J = 7.1 Hz, 2H), 1.40 (m, 2H). ^{13}C NMR (100 MHz, DMSO- d_6) δ 154.83, 148.13, 142.37, 139.55, 139.15, 137.81, 136.31, 132.97, 129.42, 129.24, 129.01, 128.25, 128.03, 126.76, 125.49 (d), 124.07 (d), 123.66, 122.76, 121.29, 118.53 (d), 117.64, 111.53, 108.44, 74.45, 42.82, 36.46, 28.76, 24.61, 21.65.

Synthesis of 3-((5-(3-fluorobenzylthio)-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazol-3-yl)methyl)-1H-indole (18g)



[0351] Prepared according to the **General Procedure 2C** from compound **15g** (529 mg, 0.91 mmol) and 3-fluorobenzyl bromide (112 μL , 0.91 mmol) to afford 610 mg (97%) of **18g** as a pale yellow foam: ^1H NMR (400 MHz, DMSO- d_6) δ 10.93 (s, 1H), 7.45 (d, J = 8.3 Hz, 1H), 7.40-7.34 (m, 10H), 7.29-7.23 (m, 2H), 7.14-6.98 (m, 12H), 6.90 (s, 1H), 6.53 (s, 1H), 4.30 (s, 2H), 4.18 (s, 2H), 3.66 (t, J = 7.8 Hz, 2H), 2.26 (t, J = 7.3 Hz, 2H), 1.48 (m, 2H). ^{13}C NMR (100 MHz, DMSO- d_6) δ 163.11, 160.68, 154.68, 148.14, 142.32, 140.23 (d), 139.54, 137.72, 136.24, 130.26 (d), 129.17, 128.16, 127.92, 124.89, 123.57, 121.18, 118.47, 117.54, 115.69 (d), 114.29 (d), 111.43, 108.42, 74.35, 42.75, 36.56, 28.75, 24.58, 21.60.


Synthesis of 3-((5-(3,4-dichlorobenzylthio)-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazol-3-yl)methyl)-1H-indole (19g)



19g

[0352] Prepared according to the **General Procedure 2C** from **15g** (519 mg, 0.89 mmol) and 3,4-dichlorobenzyl bromide (130 μ L, 0.89 mmol) to afford 538 mg (81%) of compound **19g** as a pale yellow foam: ^1H NMR (400 MHz, DMSO- d_6) δ 10.93 (s, 1H), 7.55 (d, J = 1.8 Hz, 1H), 7.45-7.00 (m, 23H), 6.90 (m, 1H), 6.54 (s, 1H), 4.29 (s, 2H), 4.18 (s, 2H), 3.68 (t, J = 7.6 Hz, 2H), 2.28 (t, J = 6.9 Hz, 2H), 1.50 (m, 2H). ^{13}C NMR (100 MHz, DMSO- d_6) δ 154.78, 147.98, 142.32, 139.54, 138.80, 137.75, 136.26, 130.83, 130.81, 130.38, 129.97, 129.19, 129.08, 128.16, 127.93, 126.71, 123.64, 121.18, 118.49, 117.58, 111.48, 108.36, 74.36, 42.77, 35.68, 28.78, 24.57, 21.64.

Synthesis of 3-((5-(3-bromobenzylthio)-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazol-3-yl)methyl)-1H-indole (20g)




20g

[0353] Prepared according to the **General Procedure 2C** from **15g** (510 mg, 0.88 mmol) and 3-bromobenzyl bromide (219 mg, 0.88 mmol) to afford 544 mg (83%) of **20g** as a pale yellow foam: ^1H NMR (400 MHz, DMSO- d_6) δ 10.92 (s, 1H), 7.48-7.00 (m, 24H), 6.92 (m, 1H), 6.53 (s, 1H), 4.28 (s, 2H), 4.17 (s, 2H), 3.68 (t, J = 7.8 Hz, 2H), 2.27

(t, $J = 7.1$ Hz, 2H), 1.47 (m, 2H). ^{13}C NMR (100 MHz, DMSO-d_6) δ 154.71, 148.11, 142.32, 140.27, 139.52, 137.74, 136.25, 131.54, 130.41, 130.16, 129.19, 128.17, 127.94, 127.84, 126.71, 123.60, 121.49, 121.19, 118.49, 117.56, 111.45, 108.42, 74.36, 42.77, 36.40, 28.74, 24.60, 21.61.


Synthesis of 3-(benzylthio)-5-(naphthalen-1-yl)-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazole (16h)



16h

[0354] Prepared according to the **General Procedure 2C** from **15h** (733 mg, 1.3 mmol) to afford 310 mg (37%) of compound **16h** as a white solid: ^1H NMR (400 MHz, DMSO-d_6) δ 7.98-7.92 (m, 2H), 7.53-7.45 (m, 4H), 7.33-7.19 (m, 15H), 7.00 (m, 1H), 6.92-6.88 (m, 6H), 6.21 (s, 1H), 4.37 (s, 2H), 3.46 (m, 2H), 2.02 (m, 2H), 1.39 (m, 2H). ^{13}C NMR (100 MHz, DMSO-d_6) δ 153.65, 149.32, 142.23, 139.04, 137.62, 137.32, 133.00, 131.46, 130.50, 129.16, 129.01, 128.69, 128.55, 128.48, 128.17, 127.98, 127.56, 127.34, 126.63, 125.28, 124.62, 124.55, 117.56, 74.29, 59.83, 43.43, 28.91, 24.32.


Synthesis of 2-(5-(benzylthio)-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazol-3-yl)-5-fluoro-1H-indole (16i)



16i

[0355] Prepared according to the **General Procedure 2C** from **15i** (340 mg, 0.58 mmol) to yield 156 mg (39%) of compound **16i** as a pale yellow foam: ^1H NMR (400 MHz, DMSO- d_6) δ 11.96 (s, 1H), 7.40-7.37 (m, 1H), 7.30-7.25 (m, 12H) 7.21-7.10 (m 4H), 7.01-6.99 (m, 7H), 6.74 (s, 1H), 6.58 (s, 1H), 4.38 (s, 2H), 3.96 (m, 2H), 2.43 (m, 2H), 1.78 (m, 2H). ^{13}C NMR (100 MHz, DMSO- d_6) δ 158.31, 155.99, 150.44, 148.67, 142.30, 139.27, 138.02, 137.09, 133.31, 129.21, 128.97, 128.51, 128.19, 128.01, 127.58, 125.55, 118.23, 113.05, 112.94, 111.74, 111.49, 105.27, 105.04, 101.53, 74.44, 43.89, 37.49, 28.54, 24.59.


Synthesis of 3-(benzylthio)-5-(4-fluorophenethyl)-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazole (16j)



16j

[0356] Prepared according to the **General Procedure 2C** from compound **15j** (740 mg, 1.29 mmol) and benzyl bromide (154 μL , 1.29 mmol) to afford 636 mg (74%) of **16j** as a white solid: ^1H NMR (400 MHz, DMSO- d_6) δ 7.39-7.35 (m, 9H), 7.25-7.19 (m, 8H) 7.05-6.97 (m, 8H), 6.59 (s, 1H), 4.28 (s, 2H), 3.65 (m, 2H), 2.96-2.84 (m, 4H), 2.35 (m, 2H), 1.65 (m, 2H). ^{13}C NMR (100 MHz, DMSO- d_6) δ 161.99, 159.59, 154.79, 148.18, 142.33, 139.57, 137.81, 137.28, 136.78, 130.29, 130.21, 129.21, 128.89, 128.44, 128.22, 128.01, 128.47, 117.79, 115.02, 114.81, 74.40, 42.42, 37.33, 31.49, 28.80, 26.25, 24.51.


Synthesis of 2-(5-(benzylthio)-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazol-3-yl)-1H-indole (16k)



16k

[0357] Prepared according to the **General Procedure 2C** from compound **15k** (590 mg, 1.04 mmol) and benzyl bromide (125 μ L, 1.04 mmol) to afford 210 mg (31%) of **16k** as a white solid: ^1H NMR (400 MHz, DMSO- d_6) δ 11.86 (s, 1H), 7.44-7.38 (m, 2H), 7.34-7.28 (m, 12H) 7.25-7.14 (m, 4H), 7.04-6.96 (m, 7H), 6.76 (s, 1H), 6.62 (s, 1H), 4.40 (s, 2H), 4.00 (m, 2H), 2.46 (m, 2H), 1.82 (m, 2H). ^{13}C NMR (100 MHz, DMSO- d_6) δ 154.95, 150.19, 142.20, 139.16, 137.85, 137.15, 133.11, 132.45, 129.19, 128.99, 128.58, 128.50, 128.10, 127.90, 127.66, 127.53, 127.40, 126.83, 125.39, 124.57, 117.97, 74.28, 43.82, 28.81, 24.50.


Synthesis of 3-((5-(Benzylthio)-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazol-3-yl)methyl)-5-fluoro-1H-indole (16l)



[0358] Prepared according to **General Procedure 2C** from cyclized compound **15l** (460 mg, 0.77 mmol) and benzyl bromide (92 μ L, 0.77 mmol) to afford 460 mg (87%) of the desired product **16l** as a yellow foam: ^1H NMR (400 MHz, DMSO- d_6) δ 11.05 (s, 1H), 7.41-7.36 (m, 10H), 7.30-7.21 (m, 1H), 7.23-7.20 (m, 2H), 7.15-7.04 (m, 11H), 6.91-6.85 (m, 1H), 6.56 (s, 1H), 4.26 (s, 2H), 4.15 (s, 2H), 3.61 (d, J = 7.6 Hz, 2H), 2.27 (d, J = 6.9 Hz, 2H), 1.46 (m, 2H). ^{13}C NMR (100 MHz, DMSO- d_6) δ 157.74, 155.44, 154.41, 148.39, 142.22, 139.22, 137.66, 137.21, 132.93, 129.18, 128.73,


128.31, 128.21, 127.99, 127.33, 127.02 (d), 125.71, 117.65, 112.49 (d), 109.47 (d), 108.73 (d), 103.35 (d), 74.51, 42.66, 37.60, 28.63, 24.44, 21.48, 20.78.

Synthesis of 3-((5-(3-Methoxybenzylthio)-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazol-3-yl)methyl)-1H-indole (21g)




[0359] Prepared according to **General Procedure 2C** from cyclized compound **15g** (500 mg, 0.86 mmol) and 3-methoxybenzyl bromide (121 μ L, 0.86 mmol) to afford 441 mg (73%) of **21g** as a yellow foam: ^1H NMR (400 MHz, DMSO- d_6) δ 10.93 (s, 1H), 7.47 (d, J = 7.8 Hz, 1H), 7.39-7.34 (m, 9H), 7.29 (d, J = 8.2 Hz, 1H), 7.23 (d, J = 1.4 Hz, 1H), 7.14 (d, J = 2.3 Hz, 1H), 7.05-7.00 (m, 8H), 6.90 (m, 1H), 6.82 (m, 1H), 6.74-6.71 (m, 2H), 6.52 (s, 1H), 4.25 (s, 2H), 4.17 (s, 2H), 3.65 (m, 2H), 3.62 (s, 3H), 2.25 (m, 2H), 1.47 (m, 2H). ^{13}C NMR (100 MHz, DMSO- d_6) δ 159.16, 154.57, 148.37, 142.31, 139.53, 138.66, 137.71, 136.24, 129.40, 129.17, 128.16, 127.92, 126.71, 123.57, 121.17, 120.93, 118.47, 117.55, 114.22, 113.04, 111.43, 108.46, 74.36, 54.92, 42.74, 37.35, 28.75, 24.60, 21.60.

Synthesis of 3-((5-(3-Methylbenzylthio)-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazol-3-yl)methyl)-1H-indole (22g)




22g

[0360] Prepared according to **General Procedure 2C** from cyclized compound **15g** (513 mg, 0.88 mmol) and 3-methylbenzyl bromide (119 μ L, 0.88 mmol) to afford 485 mg (80%) of **22g** as a yellow foam: ^1H NMR (400 MHz, DMSO- d_6) δ 10.93 (s, 1H), 7.47 (d, J = 7.8 Hz, 1H), 7.40-7.36 (m, 9H), 7.29 (d, J = 8.2 Hz, 1H), 7.22 (d, J = 1.4 Hz, 1H), 7.14 (d, J = 2.3 Hz, 1H), 7.05-6.90 (m, 12H), 6.52 (s, 1H), 4.23 (s, 2H), 4.17 (s, 2H), 3.65 (t, J = 7.6 Hz, 2H), 2.27 (t, J = 6.9 Hz, 2H), 2.13 (s, 3H), 1.45 (m, 2H). ^{13}C NMR (100 MHz, DMSO- d_6) δ 154.54, 148.41, 142.31, 139.56, 137.70, 137.56, 137.00, 136.25, 129.34, 129.17, 128.25, 128.16, 128.01, 127.92, 126.71, 125.84, 123.55, 121.17, 118.47, 117.53, 111.43, 108.46, 74.35, 42.71, 37.49, 28.72, 24.62, 20.79.



16a R = 3-indolyethyl	R' = Ph	21a R = 3-indolyethyl	R' = Ph
17a R = 3-indolyethyl	R' = 3-chlorophenyl	22a R = 3-indolyethyl	R' = 3-chlorophenyl
18a R = 3-indolyethyl	R' = 3-fluorophenyl	23a R = 3-indolyethyl	R' = 3-fluorophenyl
19a R = 3-indolyethyl	R' = 3,4-dichlorophenyl	24a R = 3-indolyethyl	R' = 3,4-dichlorophenyl
16b R = 2-quinolyl	R' = Ph	21b R = 2-quinolyl	R' = Ph
17b R = 2-quinolyl	R' = 3-indolyethyl	22b R = 2-quinolyl	R' = 3-indolyethyl
18b R = 2-quinolyl	R' = 3-bromophenyl	23b R = 2-quinolyl	R' = 3-bromophenyl
16c R = 2-naphthalyl	R' = Ph	21c R = 2-naphthalyl	R' = Ph
16d R = phenylethyl	R' = Ph	21d R = phenylethyl	R' = Ph
16e R = 3-indolyl	R' = Ph	21e R = 3-indolyl	R' = Ph
16f R = Ph	R' = Ph	21f R = Ph	R' = Ph
16g R = 3-indolymethyl	R' = Ph	21g R = 3-indolymethyl	R' = Ph
17g R = 3-indolymethyl	R' = 3-trifluoromethylphenyl	22g R = 3-indolymethyl	R' = 3-trifluoromethylphenyl
18g R = 3-indolymethyl	R' = 3-fluoro	23g R = 3-indolymethyl	R' = 3-fluoro
19g R = 3-indolymethyl	R' = 3,4-dichlorophenyl	24g R = 3-indolymethyl	R' = 3,4-dichlorophenyl
20g R = 3-indolymethyl	R' = 3-bromophenyl	25g R = 3-indolymethyl	R' = 3-bromophenyl
21g R = 3-indolymethyl	R' = 3-methoxyphenyl	26g R = 3-indolymethyl	R' = 3-methoxyphenyl
22g R = 3-indolymethyl	R' = 3-methylphenyl	27g R = 3-indolymethyl	R' = 3-methylphenyl
16h R = 1-naphthalyl	R' = Ph	21h R = 1-naphthalyl	R' = Ph
16i R = 5-fluoro-2-indolyl	R' = Ph	21i R = 5-fluoro-2-indolyl	R' = Ph
16j R = 4-fluoro-phenylethyl	R' = Ph	21j R = 4-fluoro-phenylethyl	R' = Ph
16k R = 2-indolyl	R' = Ph	21k R = 2-indolyl	R' = Ph
16l R = 3-(5-fluoro)indolymethyl	R' = Ph	21l R = 3-(5-fluoro)indolymethyl	R' = Ph


Synthesis of 3-(2-(4-(3-(1H-imidazol-4-yl)propyl)-5-(benzylthio)-4H-1,2,4-triazol-3-yl)ethyl)-1H-indole (AH-1-47)



AH-1-47

[0361] Prepared according to the **General Procedure 2E** from trityl protected **16a** (218 mg g, 0.32 mmol) to afford 69 mg (49%) of **AH-1-47** as a pale yellow solid: ^1H NMR (400 MHz, DMSO- d_6) δ 11.79 (bs, 1H), 10.83 (bs, 1H), 7.48 (s, 1H), 7.47 (d, J = 8.7 Hz, 1H), 7.35 (d, J = 8.2 Hz, 2H), 7.29-7.24 (m, 5H), 7.14 (d, J = 1.8 Hz, 1H), 7.08 (t, J = 7.3 Hz, 1H), 6.99 (t, J = 7.3 Hz, 1H), 6.76 (s, 1H), 4.31 (s, 2H), 3.65 (m, 2H), 3.10-2.97 (m, 4H), 1.72 (m, 2H). ^{13}C NMR (100 MHz, DMSO- d_6) δ 155.47, 148.09, 137.26, 136.19, 134.69, 128.91, 128.47, 127.45, 126.92, 122.65, 120.97, 118.32, 118.15, 113.16, 111.38, 42.68, 37.45, 29.25, 25.55, 22.68. LCMS (05-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 6.53 minutes, ESI m/z = 443.42 $[\text{M}+\text{H}]^+$. HRMS (ESI+): m/z calculated for $\text{C}_{25}\text{H}_{27}\text{N}_6\text{S}$ ($\text{M}+\text{H}$) + 443.2012, found 443.2000.

Synthesis of 3-(2-(4-(3-(1H-imidazol-4-yl)propyl)-5-(3-chlorobenzylthio)-4H-1,2,4-triazol-3-yl)ethyl)-1H-indole (AH-1-33)




AH-1-33

[0362] Prepared according to the **General Procedure 2E** from **17a** (320 mg g, 0.44 mmol) to give 80 mg (38%) of **AH-1-33** as a white solid: ^1H NMR (400 MHz, DMSO- d_6) δ 10.81 (s, 1H), 7.47-7.42 (m, 2H), 7.36-7.23 (m, 5H), 7.13 (d, J = 2.3 Hz, 1H)

), 7.07 (t, $J = 7.8$ Hz, 1H), 6.96 (t, $J = 7.8$ Hz, 1H), 6.70 (s, 1H), 4.30 (s, 2H), 3.66 (m, 2H), 3.08-3.04 (m, 2H), 2.99-2.95 (m, 2H), 2.37 (m, 2H), 1.71 (m, 2H). ^{13}C NMR (100 MHz, DMSO- d_6) δ 156.12, 148.37, 140.64, 136.70, 135.21, 133.39, 130.80, 129.23, 128.15, 127.87, 127.41, 123.15, 121.48, 118.84, 118.64, 113.68, 111.90, 43.17, 36.94, 29.64, 26.02, 23.17. LCMS (25-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 5.83 minutes, ESI $m/z = 477.34$ $[\text{M}+\text{H}]^+$. HRMS (ESI+): m/z calculated for $\text{C}_{25}\text{H}_{26}\text{ClN}_6\text{S}$ ($\text{M}+\text{H}$) + 477.1623, found 477.1633.


Synthesis of 3-(2-(4-(3-(1H-imidazol-4-yl)propyl)-5-(3-fluorobenzylthio)-4H-1,2,4-triazol-3-yl)ethyl)-1H-indole (AH-1-40)



AH-1-40

[0363] Prepared according to the **General Procedure 2E** from **18a** (250 mg, 0.36 mmol) to afford 80 mg (49%) of **AH-1-40** as a white solid: ^1H NMR (400 MHz, DMSO- d_6) δ 10.82 (s, 1H), 7.47 (s, 1H), 7.44 (d, $J = 7.8$ Hz, 1H), 7.33-7.28 (m, 2H), 7.16-7.03 (m, 5H), 6.97 (t, $J = 7.3$ Hz, 1H), 6.70 (s, 1H), 4.32 (s, 2H), 3.67 (m, 2H), 3.07 (m, 2H), 2.98 (m, 2H), 2.37 (m, 2H), 1.71 (m, 2H). ^{13}C NMR (100 MHz, DMSO- d_6) δ 156.10, 148.89, 140.89 (d), 136.71, 135.21, 130.92 (d), 127.42, 125.57, 125.54, 123.15, 121.47, 118.83 (d), 116.28 (d), 116.28 (d), 114.87 (d), 113.67, 111.90, 43.18, 37.04, 32.83, 29.64, 26.06, 23.18. LCMS (15-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 6.27 minutes, ESI $m/z = 461.39$ $[\text{M}+\text{H}]^+$. HRMS (ESI+): m/z calculated for $\text{C}_{25}\text{H}_{26}\text{FN}_6\text{S}$ ($\text{M}+\text{H}$) + 461.1918, found 461.1935.


Synthesis of 3-(2-(4-(3-(1H-imidazol-4-yl)propyl)-5-(3,4-dichlorobenzylthio)-4H-1,2,4-triazol-3-yl)ethyl)-1H-indole (AH-1-41)



AH-1-41

[0364] Prepared according to the **General Procedure 2E** from compound **19a** (450 mg g, 0.60 mmol) to afford 223 mg (73%) of **AH-1-41** as a white solid: ^1H NMR (400 MHz, DMSO- d_6) δ 10.82 (s, 1H), 7.57 (s, 1H), 7.53-7.43 (m, 3H), 7.34-7.24 (m, 2H), 7.13 (s, 1H), 7.05 (m, 1H), 6.95 (m, 1H), 6.71 (s, 1H), 4.31 (s, 2H), 3.69 (m, 2H), 3.05 (m, 2H), 2.98 (m, 2H), 2.37 (m, 2H), 1.72 (m, 2H). ^{13}C NMR (100 MHz, DMSO- d_6) δ 155.67, 147.71, 139.00, 136.20, 134.71, 130.88, 130.81, 130.55, 129.98, 129.30, 127.78, 127.55, 126.91, 122.64, 120.97, 118.32, 118.15, 113.17, 111.40, 42.71, 35.68, 29.16, 25.56, 22.64. LCMS (15-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 6.60 minutes, ESI m/z = 511.30 $[\text{M}+\text{H}]^+$. HRMS (ESI+): m/z calculated for $\text{C}_{25}\text{H}_{25}\text{Cl}_2\text{N}_6\text{S}$ ($\text{M}+\text{H}$) + 511.1233, found 511.1246.

Synthesis of 2-(4-(3-(1H-imidazol-4-yl)propyl)-5-(benzylthio)-4H-1,2,4-triazol-3-yl)quinoline (AH-1-84)




AH-1-84

[0365] Prepared according to the **General Procedure 2E** from compound **16b** (310 mg, 0.46 mmol) to give 49 mg (25%) of **AH-1-84** as a yellow solid: ^1H NMR (400 MHz, DMSO- d_6) δ 8.53 (d, J = 8.2 Hz, 1H), 8.30 (d, J = 8.7 Hz, 1H), 8.05 (d, J = 8.2 Hz,

1H), 7.93 (d, J = 8.2 Hz, 1H), 7.84-7.80 (m, 1H), 7.69-7.65 (m, 1H), 7.46-7.39 (m, 2H), 7.33-7.18 (m, 5H), 6.72 (s, 1H), 4.56 (m, 2H), 4.51 (s, 2H), 2.57 (m, 2H), 1.99 (m, 2H). ^{13}C NMR (100 MHz, DMSO- d_6) δ 171.70, 142.38, 140.66, 137.65, 136.27, 129.24, 128.22, 127.96, 126.95, 122.23, 120.98, 118.31, 118.22, 117.53, 113.49, 111.38, 74.39, 43.32, 34.14, 28.40, 25.17, 20.39. HRMS (ESI+): m/z calculated for $\text{C}_{24}\text{H}_{23}\text{N}_6\text{S}$ (M+H) + 427.1693, found 427.1699.


Synthesis of 2-(4-(3-(1H-imidazol-4-yl)propyl)-5-(2-(1H-indol-3-yl)ethylthio)-4H-1,2,4-triazol-3-yl)quinoline (AH.2.132)



AH.2.132


[0366] Prepared according to the **General Procedure 2E** from compound **17b** (400 mg, 0.55 mmol) to yield 31.2 mg (12%) of **AH.2.132** as a yellow solid: ^1H NMR (400 MHz, DMSO- d_6) δ 10.92 (s, 1H), 8.53 (d, J = 8.7 Hz, 1H), 8.32 (d, J = 8.7 Hz, 1H), 8.05 (d, J = 8.2 Hz, 1H), 7.94 (d, J = 8.7 Hz, 1H), 7.85 (m, 2H), 7.71-7.64 (m, 2H), 7.50 (s, 1H), 7.36 (d, J = 8.4 Hz, 1H), 7.25 (d, J = 2.3 Hz, 1H), 7.08 (m, 1H), 7.00 (m, 1H), 4.65 (s, 2H), 3.59 (m, 2H), 3.18 (m, 4H), 2.11 (m, 2H). ^{13}C NMR (100 MHz, DMSO- d_6) δ 171.70, 142.38, 140.66, 137.65, 136.27, 129.24, 128.22, 127.96, 126.95, 122.23, 120.98, 118.31, 118.22, 117.53, 113.49, 111.38, 74.39, 43.32, 34.14, 28.40, 25.17, 20.39. HRMS (ESI+): m/z calculated for $\text{C}_{24}\text{H}_{23}\text{N}_6\text{S}$ (M+H) + 427.169345, found 427.169942.

Synthesis of 2-(4-(3-(1H-imidazol-4-yl)propyl)-5-(3-bromobenzylthio)-4H-1,2,4-triazol-3-yl)quinoline (AH.2.160)



[0367] Prepared according to **General Procedure 2E** from derivative **18b** (265 mg, 0.35 mmol)) product **AH.2.160** as a white foam (74 mg, 41%): ^1H NMR (400 MHz, DMSO- d_6) δ 11.84 (s, 1H), 11.73 (s, 1H), 8.54 (d, J = 8.7 Hz, 1H), 8.31 (d, J = 8.7 Hz, 1H), 8.06 (d, J = 7.8 Hz, 1H), 7.93 (m, 1H), 7.85 (t, J = 6.8 Hz, 1H), 7.70 (d, J = 6.8 Hz, 1H), 7.64 (s, 2H), 7.48-7.42 (m, 3H), 7.28 (m, 1H), 6.81 (s, 1H), 4.58 (m, 2H), 4.52 (s, 2H), 2.55 (m, 2H), 2.01 (m, 2H). ^{13}C NMR (100 MHz, DMSO- d_6) δ 152.43, 152.09, 147.15, 146.58, 140.24, 137.43, 134.66, 131.71, 130.63, 130.42, 130.35, 129.13, 128.12, 127.99, 127.64, 127.38, 121.53, 119.90, 45.63, 35.79, 29.58. HRMS (ESI $^{+}$): m/z calculated for $\text{C}_{37}\text{H}_{35}\text{N}_6\text{S}$ ($M+H$) + 595.2630, found 595.2638.


Synthesis of 4-(3-(1H-imidazol-4-yl)propyl)-3-(benzylthio)-5-(naphthalen-2-yl)-4H-1,2,4-triazole (AH-1-75)



[0368] Prepared according the **General Procedure 2E** from **16c** (226 mg, 0.34 mmol) to afford 24 mg (32% yield) of **AH-1-75** as a white solid: ^1H NMR (400 MHz, DMSO- d_6) δ 8.12 (s, 1H), 8.01-7.95 (m, 3H), 7.67-7.65 (m, 1H), 7.59-7.57 (m, 2H), 7.39-7.16 (m, 6H), 6.63 (s, 1H), 6.41 (s, 1H), 4.41 (s, 2H), 3.93 (m, 2H), 2.27 (m, 2H), 1.75 (m, 2H). ^{13}C NMR (100 MHz, DMSO- d_6) δ 171.70, 142.38, 140.66, 137.65, 136.27,

129.24, 128.22, 127.96, 126.95, 122.23, 120.98, 118.31, 118.22, 117.53, 113.49, 111.38, 74.39, 43.32, 34.14, 28.40, 25.17, 20.39. HRMS (ESI+): m/z calculated for $C_{25}H_{24}N_5S$ (M+H) + 426.1747, found 426.1747.


Synthesis of 4-(3-(1H-imidazol-4-yl)propyl)-3-(benzylthio)-5-phenethyl-4H-1,2,4-triazole (AH-1-81)



AH-1-81

[0369] Prepared according to the **General Procedure 2E** from **16d** (300 mg, 0.46 mmol) to yield 83 mg (44%) of **AH-1-81** as a white solid: ^1H NMR (400 MHz, DMSO- d_6) δ 11.73 (s, 1H), 7.46 (s, 1H), 7.23-7.13 (m, 10H), 6.75 (s, 1H), 4.27 (s, 1H), 3.65 (m, 2H), 2.92-2.85 (m, 4H), 2.34 (m, 2H), 1.69 (m, 2H). ^{13}C NMR (100 MHz, DMSO- d_6) δ 155.05, 148.30, 140.69, 137.32, 134.81, 128.95, 128.54, 128.49, 128.41, 127.55, 126.24, 42.62, 37.46, 32.60, 29.13, 26.29. HRMS (ESI+): m/z calculated for $C_{23}H_{26}N_5S$ (M+H) + 404.1910, found 404.1903.

Synthesis of 3-(4-(3-(1H-imidazol-4-yl)propyl)-5-(benzylthio)-4H-1,2,4-triazol-3-yl)-1H-indole (AH-1-86)




AH-1-86

[0370] Prepared according to the **General Procedure 2E** from compound **16e** (390 mg, 0.6 mmol) to yield 154 mg (63%) of **AH-1-86** as a white solid: ^1H NMR (400 MHz, DMSO- d_6) δ 11.67 (s, 1H), 8.04 (d, J = 7.8 Hz, 1H), 7.71 (s, 1H), 7.51 (s, 1H), 7.48-7.46 (d, J = 7.8 Hz, 1H), 7.36-7.25 (m, 4H), 7.20 (t, J = 8.2 Hz, 1H), 7.12 (t, J = 8.3 Hz, 1H), 6.67 (s, 1H), 4.40 (s, 2H), 3.94 (m, 2H), 2.43 (m, 2H), 1.81 (m, 2H). ^{13}C NMR

(100 MHz, DMSO- d_6) δ 151.16, 148.37, 137.55, 135.93, 134.82, 129.01, 128.53, 127.52, 125.75, 125.02, 122.39, 120.91, 120.27, 111.85, 101.79, 43.63, 37.64, 28.89.

HRMS (ESI+): m/z calculated for $C_{23}H_{23}N_6S$ (M+H) + 415.1699, found 415.1699.


Synthesis of 4-(3-(1H-imidazol-4-yl)propyl)-3-(benzylthio)-5-phenyl-4H-1,2,4-triazole (AH-1-96)



AH-1-96

[0371] Prepared according to the **General Procedure 2E** from **16f** (400 mg, 0.65 mmol) to afford 113 mg (47%) of compound **AH-1-96** as a white solid: ^1H NMR (400 MHz, DMSO- d_6) δ 7.51-7.44 (m, 6H), 7.32-7.14 (m, 8H), 4.38 (s, 2H), 3.79 (m, 2H), 2.25 (m, 2H), 1.70 (m, 2H). ^{13}C NMR (100 MHz, DMSO- d_6) δ 155.05, 150.10, 147.85, 137.20, 134.86, 130.11, 129.09, 129.05, 128.61, 128.41, 127.86, 127.65, 127.27, 126.76, 48.71, 43.79, 37.42, 29.14. HRMS (ESI+): m/z calculated for $C_{21}H_{22}N_5S$ (M+H) + 376.1557, found 376.1590.

Synthesis of 3-((4-(3-(1H-imidazol-4-yl)propyl)-5-(benzylthio)-4H-1,2,4-triazol-3-yl)methyl)-1H-indole (AH-1-94)




AH-1-94

[0372] Prepared according to the **General Procedure 2E** from compound **16g** (605 mg, 0.9 mmol) to afford 305 mg (79%) of **AH-1-94** as a yellow solid: ^1H NMR (400 MHz, DMSO- d_6) δ 11.75 (s, 1H), 10.94 (s, 1H), 7.50 (s, 1H), 7.46 (d, J = 7.8 Hz, 1H), 7.32 (d, J = 7.8 Hz, 1H), 7.16-7.04 (m, 7H), 6.94 (t, J = 7.8 Hz, 1H), 6.69 (s, 1H), 4.25 (s, 2H), 4.15 (s, 2H), 3.58 (m, 2H), 2.28 (m, 2H), 1.54 (m, 2H). ^{13}C NMR (100 MHz,

DMSO- d_6) δ 154.70, 148.56, 137.34, 136.41, 134.81, 128.83, 128.48, 127.45, 126.81, 123.68, 118.65, 111.59, 108.36, 42.78, 37.88, 29.01, 23.54, 21.82. HRMS (ESI⁺): m/z calculated for $C_{24}H_{25}N_6S$ (M+H) + 429.1886, found 429.1856.


Synthesis of 3-((4-(3-(1H-imidazol-4-yl)propyl)-5-(3-(trifluoromethyl)benzylthio)-4H-1,2,4-triazol-3-yl)methyl)-1H-indole (AH.1.109)



AH.1.109

[0373] Prepared according to the **General Procedure 2E** from compound **17g** (400 mg, 0.54 mmol) to afford 106 mg (44%) of **AH.1.109** as a white foam: ^1H NMR (400 MHz, DMSO- d_6) δ 11.76 (s, 1H), 10.96 (s, 1H), 7.70 (s, 1H), 7.55-7.43 (m, 4H), 7.35-7.32 (m, 2H), 7.08-7.04 (m, 2H), 6.94 (m, 1H), 6.69 (s, 1H), 4.41 (s, 2H), 4.16 (s, 2H), 3.66 (m, 2H), 2.30 (m, 2H), 1.53 (m, 2H). ^{13}C NMR (100 MHz, DMSO- d_6) δ 154.73, 148.08, 139.19, 136.30, 134.69, 132.93, 129.36, 126.71, 125.48, 124.02, 123.57, 121.23, 118.53, 111.49, 108.28, 42.77, 36.46, 28.93, 21.67. HRMS (ESI⁺): m/z calculated for $C_{25}H_{24}F_3N_6S$ (M+H) + 497.1764, found 497.1730.


Synthesis of 3-((4-(3-(1H-imidazol-4-yl)propyl)-5-(3-fluorobenzylthio)-4H-1,2,4-triazol-3-yl)methyl)-1H-indole (AH.1.118)



AH.1.118

[0374] Prepared according to the **General Procedure 2E** from compound **18g** (500 mg, 0.73 mmol) to give 151 mg (47%) of **AH.1.118** as a yellow foam: ^1H NMR (400 MHz, DMSO- d_6) δ 11.75 (s, 1H), 10.94 (s, 1H), 7.49 (s, 1H), 7.42 (d, J = 7.8 Hz, 1H), 7.31 (d, J = 7.8 Hz, 1H), 7.15-6.91 (m, 7H), 6.69 (s, 1H), 4.30 (s, 2H), 4.16 (s, 2H), 3.66 (m, 2H), 2.28 (m, 2H), 1.55 (m, 2H). ^{13}C NMR (100 MHz, DMSO- d_6) δ 163.16, 160.74, 154.73, 148.27, 140.36, 140.28, 136.33, 134.72, 130.32 (d), 126.73, 124.93, 123.59, 121.27, 118.58 (d), 115.74 (d), 114.35 (d), 111.52, 108.34, 42.81, 36.70, 28.97, 21.72. HRMS (ESI+): m/z calculated for $\text{C}_{24}\text{H}_{24}\text{FN}_6\text{S}$ (M+H) + 447.1747, found 447.1762.


Synthesis of 3-((4-(3-(1H-imidazol-4-yl)propyl)-5-(3,4-dichlorobenzylthio)-4H-1,2,4-triazol-3-yl)methyl)-1H-indole (AH.1.116)



AH.1.116

[0375] Prepared according to the **General Procedure 2E** from **19g** (412 mg, 0.56 mmol) to afford 153 mg (41%) of compound **AH.1.116** as a yellow foam: ^1H NMR (400 MHz, DMSO- d_6) δ 11.76 (s, 1H), 10.95 (s, 1H), 7.57 (s, 1H), 7.51 (s, 1H), 7.45 (d, J = 7.8 Hz, 1H), 7.34 (d, J = 7.8 Hz, 1H), 7.27 (d, J = 8.2 Hz, 1H), 7.11-7.10 (m, 2H), 7.06 (t, J = 7.8 Hz, 1H), 6.93 (t, J = 7.7 Hz, 1H), 6.69 (s, 1H), 4.28 (s, 2H), 4.17 (s, 2H), 3.67 (m, 2H), 2.29 (m, 2H), 1.54 (m, 2H). ^{13}C NMR (100 MHz, DMSO- d_6) δ 154.78, 148.03, 138.96, 136.31, 134.68, 130.82, 130.38, 129.95, 129.06, 127.79, 127.55, 126.72, 123.60, 121.23, 118.55, 111.51, 108.26, 42.79, 35.83, 28.93, 21.72. HRMS (ESI+): m/z calculated for $\text{C}_{24}\text{H}_{23}\text{Cl}_2\text{N}_6\text{S}$ (M+H) + 497.1077, found 497.1076.


Synthesis of 3-((4-(3-(1H-imidazol-4-yl)propyl)-5-(3-bromobenzylthio)-4H-1,2,4-triazol-3-yl)methyl)-1H-indole (AH.1.112)



AH.1.112

[0376] Prepared according to the **General Procedure 2E** from compound **20g** (440 mg, 0.59 mmol) to yield 261 mg (88%) of **AH.1.112** as a white solid: ^1H NMR (400 MHz, DMSO- d_6) δ 11.73 (s, 1H), 10.93 (s, 1H), 7.505-7.30 (m, 5H), 7.15 (m, 1H), 7.07-7.03 (m, 3H), 6.93 (m, 1H), 6.69 (s, 1H), 4.28 (s, 2H), 4.15 (s, 2H), 3.66 (m, 2H), 2.28 (m, 2H), 1.54 (m, 2H). ^{13}C NMR (100 MHz, DMSO- d_6) δ 154.81, 148.30, 136.38, 134.78, 131.63, 130.54, 130.27, 127.93, 126.78, 123.64, 121.56 (d), 118.67 (d), 111.58, 108.37, 42.87, 36.56, 28.99, 21.75. HRMS (ESI $^+$): m/z calculated for $\text{C}_{24}\text{H}_{24}\text{BrN}_6\text{S}$ (M+H) + 507.0956, found 507.0961.

Synthesis of 4-(3-(1H-imidazol-4-yl)propyl)-3-(benzylthio)-5-(naphthalen-1-yl)-4H-1,2,4-triazole (AH.1.102)




AH.1.102

[0377] Prepared according to the **General Procedure 2E** from compound **16h** (264 mg, 0.40 mmol) to afford 77 mg (46%) of **AH.1.102** as a white foam: ^1H NMR (400 MHz, DMSO- d_6) δ 11.56 (s, 1H), 8.09 (d, J = 8.4 Hz, 1H), 8.00 (d, J = 7.8 Hz, 1H), 7.61-7.50 (m, 4H), 7.31-7.24 (m, 7H), 6.32 (s, 1H), 4.39 (s, 2H), 3.49 (m, 2H), 2.03 (m, 2H), 1.46 (m, 2H). ^{13}C NMR (100 MHz, DMSO- d_6) δ 153.76, 149.41, 137.35, 134.62, 133.12,

131.44, 130.66, 129.08, 128.81, 128.63, 127.63, 127.46, 126.72, 125.42, 124.63, 124.55, 43.66, 38.12, 29.15. HRMS (ESI+): m/z calculated for $C_{25}H_{23}N_5S$ (M+H) + 426.1774, found 426.1747.


Synthesis of 2-(4-(3-(1H-imidazol-4-yl)propyl)-5-(benzylthio)-4H-1,2,4-triazol-3-yl)-5-fluoro-1H-indole (AH.2.126)



AH.2.126

[0378] Prepared according to the **General Procedure 2E** from **16i** (123 mg, 0.18 mmol) to give 26 mg (33%) of compound **AH.2.126** as a white solid: ^1H NMR (400 MHz, DMSO- d_6) δ 12.06 (s, 1H), 9.04 (s, 1H), 7.47-7.25 (m, 8H), 7.07 (m, 1H), 6.81 (s, 1H), 4.46 (s, 2H), 4.09 (m, 2H), 2.68 (m, 2H), 1.93 (m, 2H). ^{13}C NMR (100 MHz, DMSO- d_6) δ 171.70, 142.38, 140.66, 137.65, 136.27, 129.24, 128.22, 127.96, 126.95, 122.23, 120.98, 118.31, 118.22, 117.53, 113.49, 111.38, 74.39, 43.32, 34.14, 28.40, 25.17, 20.39. HRMS (ESI+): m/z calculated for $C_{24}H_{23}N_6S$ (M+H)+ 427.169345, found 427.169942.


Synthesis of 4-(3-(1H-imidazol-4-yl)propyl)-3-(benzylthio)-5-(4-fluorophenethyl)-4H-1,2,4-triazole (AH.2.130)



AH.2.130

[0379] Prepared according to the **General Procedure 2E** from compound **16j** (585 mg, 0.88 mmol) to afford 84 mg (23% yield) of **AH.2.130** as a white solid: ^1H NMR (400 MHz, DMSO- d_6) δ 7.55 (m, 2H), 7.47-7.42 (m, 3H) 7.37-7.19 (m 15H), 7.04-7.00 (m, 6H), 6.48 (s, 1H), 4.41 (s, 2H), 3.81 (t, J = 7.8 Hz, 2H), 2.30 (t, J = 6.8 Hz, 2H), 1.70 (m, 2H). ^{13}C NMR (100 MHz, DMSO- d_6) δ 154.95, 150.19, 142.20, 139.16, 137.85, 137.15, 133.11, 132.45, 129.19, 128.99, 128.58, 128.50, 128.10, 127.90, 127.66, 127.53, 127.40, 126.83, 125.39, 124.57, 117.97, 74.28, 43.82, 28.81, 24.50. HRMS (ESI+): m/z calculated for $\text{C}_{24}\text{H}_{23}\text{N}_6\text{S}$ ($\text{M}+\text{H}$) $^+$ 427.169345, found 427.169942.


Synthesis of 2-(4-(3-(1H-imidazol-4-yl)propyl)-5-(benzylthio)-4H-1,2,4-triazol-3-yl)-1H-indole (AH.2.131)



AH.2.131

[0380] Prepared according to the **General Procedure 2E** from **16k** (150 mg, 0.23 mmol) to yield 47.2 mg (50%) of compound **AH.2.131** as a white solid: ^1H NMR (400 MHz, DMSO- d_6) δ 11.89 (s, 1H), 7.73 (s, 1H), 7.57 (d, J = 7.8 Hz, 1H), 7.43 (d, J = 8.2 Hz, 1H), 7.37-7.24 (m, 5H), 7.21-7.16 (m, 2H), 7.05 (m, 1H), 6.85 (s, 1H), 6.62 (d, J = 1.8 Hz, 1H), 4.44 (s, 2H), 4.08 (m, 2H), 2.55 (m, 2H), 1.87 (m, 2H). ^{13}C NMR (100 MHz, DMSO- d_6) δ 171.70, 142.38, 140.66, 137.65, 136.27, 129.24, 128.22, 127.96, 126.95, 122.23, 120.98, 118.31, 118.22, 117.53, 113.49, 111.38, 74.39, 43.32, 34.14, 28.40, 25.17, 20.39. LCMS (50-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 2.10 minutes, ESI m/z = 415.40 [$\text{M}+\text{H}$] $^+$. HRMS (ESI+): m/z calculated for $\text{C}_{24}\text{H}_{23}\text{N}_6\text{S}$ ($\text{M}+\text{H}$) $^+$ 427.169345, found 427.169942.


Synthesis of 3-((4-(3-(1H-imidazol-4-yl)propyl)-5-(benzylthio)-4H-1,2,4-triazol-3-yl)methyl)-5-fluoro-1H-indole (AH.2.145)



AH.2.145

[0381] Prepared according to **General Procedure 2E** from derivative **16I** (400 mg, 0.58 mmol)) product **AH.2.145** as a yellow foam (57 mg, 21%): ^1H NMR (400 MHz, DMSO- d_6) δ 11.97 (s, 1H), 11.08 (s, 1H), 7.52 (s, 1H), 7.36-7.32 (m, 1H), 7.23-7.12 (m, 6H), 6.92 (m, 2H), 6.72 (s, 1H), 4.27 (s, 2H), 4.15 (s, 2H), 3.62 (m, 2H), 2.30 (m, 2H), 1.55 (m, 2H). ^{13}C NMR (100 MHz, DMSO- d_6) δ 157.75, 155.46, 154.42, 148.46, 137.28, 134.68, 133.00, 128.77, 128.35, 127.36, 127.01 (d), 125.69, 112.55 (d), 109.52 (d), 108.63, 103.36 (d), 42.68, 37.69, 21.56. HRMS (ESI $^+$): m/z calculated for $\text{C}_{24}\text{H}_{24}\text{FN}_6\text{S}$ (M+H) + 447.1762, found 447.1787.


Synthesis of 3-((4-(3-(1H-imidazol-4-yl)propyl)-5-(3-methoxybenzylthio)-4H-1,2,4-triazol-3-yl)methyl)-1H-indole (AH.2.162)



AH.2.162


[0382] Prepared according to **General Procedure 2E** from derivative **AH-1-94** (441 mg, 0.63 mmol)) product **AH.2.162** as a yellow foam (151 mg, 53%): ^1H NMR (400 MHz, DMSO- d_6) δ 11.76 (s, 1H), 10.95 (s, 1H), 7.51-7.46 (m, 2H), 7.35 (d, J = 8.2 Hz, 1H), 7.08-7.02 (m, 3H), 6.97 (t, J = 7.8 Hz, 1H), 6.85 (s, 1H), 6.77-6.70 (m, 3H), 4.27 (s, 2H), 4.17 (s, 2H), 3.65 (m, 5H), 2.31 (m, 2H), 1.56 (m, 2H). ^{13}C NMR (100 MHz, DMSO- d_6) δ 159.18, 154.57, 148.44, 138.74, 136.29, 134.64, 129.43, 126.72, 123.52, 121.22,

120.95, 118.53, 114.22, 113.06, 111.46, 108.37, 54.93, 42.78, 37.45, 28.96, 24.57, 21.66. HRMS (ESI+): m/z calculated for $C_{37}H_{35}N_6S$ (M+H) + 595.2630, found 595.2638.
Synthesis of 3-((4-(3-(1H-imidazol-4-yl)propyl)-5-(3-methylbenzylthio)-4H-1,2,4-triazol-3-yl)methyl)-1H-indole (AH.2.165)



[0383] Prepared according to **General Procedure 2E** from derivative **AH.1.109** (421 mg, 0.61 mmol) to yield **AH.2.165** as a yellow foam (139 mg, 51%): ^1H NMR (400 MHz, DMSO- d_6) δ 11.75 (s, 1H), 10.94 (s, 1H), 7.50-7.45 (m, 2H), 7.37-7.18 (m, 2H), 7.07-6.92 (m, 6H), 6.69 (s, 1H), 4.23 (s, 2H), 4.16 (s, 2H), 3.64 (m, 2H), 2.30 (m, 2H), 2.17 (s, 3H), 1.54 (m, 2H). ^{13}C NMR (100 MHz, DMSO- d_6) δ 157.75, 155.46, 154.42, 148.46, 137.28, 134.68, 133.00, 128.77, 128.35, 127.36, 127.01 (d), 125.69, 112.55 (d), 109.52 (d), 108.63, 103.36 (d), 42.68, 37.69, 21.56. HRMS (ESI+): m/z calculated for $C_{37}H_{35}N_6S$ (M+H) + 595.2630, found 595.2638.

Synthesis of 3-((4-(3-(1H-imidazol-4-yl)propyl)-5-(4-bromobenzylthio)-4H-1,2,4-triazol-3-yl)methyl)-1H-indole (MS.1.22)




MS.1.22

[0384] Prepared according to **General Procedure E** from derivative **19o** (491 mg, 0.65 mmol) to give product **MS.1.22** as a yellow foam (169 mg, 51%): ^1H NMR (400 MHz, DMSO- d_6) δ 11.75 (s, 1H), 10.95 (s, 1H), 7.50 (s, 1H), 7.45 (d, J = 8Hz, 1H), 7.34

(d, $J = 8.4$ Hz, 1H), 7.30-7.17 (m, 3H), 7.10-7.04 (m, 4H), 6.94 (m, 1H), 4.21 (s, 2H), 4.16 (s, 2H), 3.59 (m, 2H), 2.28 (m, 2H), 1.53 (m, 2H). ^{13}C NMR (100 MHz, DMSO- d_6) δ 154.69, 148.16, 147.78, 136.98, 136.33, 134.68, 131.21, 130.88, 128.14, 127.90, 127.79, 127.55, 126.73, 126.67, 123.61, 121.21, 120.52, 118.54, 111.55, 108.21, 42.65, 36.89, 28.90, 21.79. HRMS (ESI+): m/z calculated for $\text{C}_{24}\text{H}_{24}\text{BrN}_6\text{S}$ ($\text{M}+\text{H}$) $^+$ 507.0961, found 507.0974.


Synthesis of Methyl 4-((4-(3-(1H-imidazol-4-yl)propyl)-5-((1H-indol-3-yl)methyl)-4H-1,2,4-triazol-3-ylthio)methyl)benzoate (MS.1.27)



MS.1.27

[0385] Prepared according to **General Procedure E** from derivative **20o** (395 mg, 0.54 mmol) to yield **MS.1.27** as a yellow foam (164 mg, 62%): ^1H NMR (400 MHz, DMSO- d_6) δ 11.76 (s, 1H), 10.95 (s, 1H), 7.69-7.67 (m, 2H), 7.50 (s, 1H), 7.45 (m, 1H), 7.35-7.28 (m, 3H), 7.11-7.05 (m, 2H), 6.95 (m, 1H), 6.67 (bs, 1H), 4.34 (s, 2H), 4.17 (s, 2H), 3.8 (s, 3H), 3.60 (m, 2H), 2.29 (m, 2H), 1.53 (m, 2H). ^{13}C NMR (100 MHz, DMSO- d_6) δ 165.90, 154.73, 148.08, 143.09, 136.32, 134.64, 129.24, 129.05, 128.51, 126.70, 123.59, 121.22, 118.51, 111.51, 108.20, 52.11, 42.69, 37.17, 28.90, 21.78. HRMS (ESI+): m/z calculated for $\text{C}_{26}\text{H}_{27}\text{N}_6\text{O}_2\text{S}$ ($\text{M}+\text{H}$) $^+$ 487.1911, found 487.1924.


Synthesis of 4-(3-(1H-imidazol-4-yl)propyl)-3-(3-methoxybenzylthio)-5-phenethyl-4H-1,2,4-triazole (MS.1.30)



MS.1.30


[0386] Prepared according to **General Procedure E** from derivative **17d** (441 mg, 0.63 mmol) to give product **MS.1.30** as a yellow foam: ^1H NMR (400 MHz, DMSO- d_6) δ 7.48 (s, 1H), 7.28-7.16 (m, 7H), 6.85-6.80 (m, 7H), 6.85-6.79 (m, 4H), 4.28 (s, 2H), 3.68 (m, 5H), 2.96-2.90 (m, 4H), 2.39 (m, 2H), 1.71 (m, 2H). ^{13}C NMR (100 MHz, DMSO- d_6) δ 159.18, 154.57, 148.44, 138.74, 136.29, 134.64, 129.43, 126.72, 123.52, 121.22, 120.95, 118.53, 114.22, 113.06, 111.46, 108.37, 54.93, 42.78, 37.45, 28.96, 24.57, 21.66. HRMS (ESI+): m/z calculated for $\text{C}_{24}\text{H}_{28}\text{N}_5\text{OS}$ ($\text{M}+\text{H}$) $^+$ 434.2009, found 434.2009.

Synthesis of 3-((4-(3-(1H-imidazol-4-yl)propyl)-5-(3-methylbenzylthio)-4H-1,2,4-triazol-3-yl)methyl)-6-fluoro-1H-indole (AH.2.182)



[0387] Prepared according to **General Procedure E** from derivative **17m** (445 mg, 0.63 mmol) to afford product **AH.2.182** as a yellow foam (129 mg, 44%): ^1H NMR (400 MHz, DMSO- d_6) δ 11.76 (s, 1H), 11.03 (s, 1H), 7.51 (s, 1H), 7.45 (m, 1H), 7.13-6.95 (m, 7H), 6.81 (m, 1H), 4.25 (s, 2H), 4.16 (s, 2H), 3.65 (m, 2H), 2.31 (m, 2H), 1.55 (m, 2H). ^{13}C NMR (100 MHz, DMSO- d_6) δ 160.16, 157.83, 154.50, 148.65, 137.71, 137.11, 136.30 (d), 134.75, 129.43, 128.33 (d), 127.84 (d), 126.74, 125.91, 124.24 (d), 123.65, 119.70 (d), 108.73, 107.28 (d), 97.62 (d), 42.81, 37.68, 28.95, 21.62, 20.96. HRMS (ESI+): m/z calculated for $\text{C}_{25}\text{H}_{26}\text{FN}_6\text{S}$ ($\text{M}+\text{H}$) $^+$ 461.1918, found 461.1926.


Synthesis of 3-((4-(3-(1H-imidazol-4-yl)propyl)-5-(benzylthio)-4H-1,2,4-triazol-3-yl)methyl)-6-fluoro-1H-indole (AH.2.178)



AH.2.178

[0388] Prepared according to **General Procedure E** from derivative **16m** (405 mg, 0.59 mmol) to give product **AH.2.178** as a yellow foam (112 mg, 43%): ^1H NMR (400 MHz, DMSO- d_6) δ 11.76 (s, 1H), 11.03 (s, 1H), 7.52 (s, 1H), 7.44 (m, 1H), 7.32-7.08 (m, 7H), 6.84 (m, 1H), 6.71 (s, 1H), 4.27 (s, 2H), 4.16 (s, 2H), 3.61 (m, 2H), 2.30 (m, 2H), 1.54 (m, 2H). ^{13}C NMR (100 MHz, DMSO- d_6) δ 160.11, 157.78, 154.46, 148.47, 147.79, 137.28, 136.26 (d), 134.72, 128.78, 128.37, 127.80, 127.56, 127.37, 126.67, 124.20 (d), 123.61, 119.66 (d), 108.64, 107.21 (d), 97.58 (d), 42.68, 37.72, 28.94, 21.64. HRMS (ESI+): m/z calculated for $\text{C}_{24}\text{H}_{24}\text{FN}_6\text{S}$ ($\text{M}+\text{H}$) $^+$ 447.1762, found 447.1757.

Synthesis of 4-(3-(1H-imidazol-4-yl)propyl)-3-benzyl-5-(benzylthio)-4H-1,2,4-triazole (AH.2.199)




AH.2.199

[0389] Prepared according to **General Procedure E** from derivative **17n** (200 mg, 0.32 mmol) to afford product **AH.2.199** as a white solid (72 mg, 59%): ^1H NMR (400 MHz, DMSO- d_6) δ 11.78 (s, 1H), 7.53 (s, 1H), 7.32-7.28 (m, 2H), 7.25-7.19 (m, 6H), 7.10 (m, 1H), 4.30 (s, 2H), 4.08 (s, 2H), 3.59 (m, 2H), 2.33 (m, 2H), 1.57 (m, 2H). ^{13}C

NMR (100 MHz, DMSO- d_6) δ 154.35, 148.67, 137.24, 136.17, 134.69, 128.83, 128.61, 128.44, 128.40, 127.42, 126.78, 42.74, 37.65, 30.44, 28.92. HRMS (ESI⁺): m/z calculated for $C_{25}H_{26}FN_6S$ ($M+H$)⁺ 461.1918, found 461.1926.


Synthesis of 4-(3-(1H-imidazol-4-yl)propyl)-3-benzyl-5-(benzylthio)-4H-1,2,4-triazole (AH.2.206)



AH.2.206

[0390] Prepared according to **General Procedure E** from derivative **18n** (200 mg, 0.30 mmol) to afford product **AH.2.206** as a white solid (39 mg, 31%): ¹H NMR (400 MHz, DMSO- d_6) δ 11.75 (s, 1H), 7.51 (s, 1H), 7.30-7.08 (m, 6H), 6.83-6.71 (m, 3H), 4.27 (s, 2H), 4.07 (s, 2H), 3.68 (s, 3H), 3.65 (m, 2H), 2.31 (m, 2H), 1.55 (m, 2H). ¹³C NMR (100 MHz, DMSO- d_6) δ 159.19, 154.34, 148.71, 138.73, 136.18, 134.69, 129.50, 128.60, 128.39, 126.77, 121.00, 114.27, 113.07, 54.98, 42.82, 37.51, 30.44, 28.93. HRMS (ESI⁺): m/z calculated for $C_{25}H_{26}FN_6S$ ($M+H$)⁺ 461.1918, found 461.1926.


General Procedure 2F: General Thiol Cross Coupling (to be inserted after General Procedure 2E on page 89).



[0391] In the main reaction flask a mixture of cyclized derivative **15m-o** (1 mmol), $Zn(OAc)_2$ (2 mmol), sodium dithionite ($Na_2S_2O_4$, 2 mmol), sodium *t*-butoxide (2.5 mmol), *N*-XantPhos (0.1 mmol) and $Pd_2dba_3 \cdot CHCl_3$ (0.05 mmol) was subjected to 3 vacuum/argon purge cycles and left under argon flow. In a separate flask, a mixture of

DMSO (15 mL) and the aryl halide (3-5 mmol) were sparged with dry Argon for 15 min and the mixture was transferred to the main reaction flask with a pressurized cannula. The reaction was heated at 90 °C for 16 hours thereafter. The mixture was cooled and partitioned with EtOAc (150 mL) and water (100 mL). The layers were separated and the EtOAc solution was washed with water (2 x 50 mL) and brine (50 mL). The EtOAc layer was dried (Na₂SO₄), filtered and concentrated to afford the desired aryl sulfide product.


Synthesis of 6-fluoro-3-((5-((4-fluorophenyl)thio)-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazol-3-yl)methyl)-1H-indole (68a)



68a

[0392] Prepared according to **General Procedure 2F** from 5-((6-fluoro-1H-indol-3-yl)methyl)-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazole-3-thiol (**15m**) (216 mg, 0.36 mmol) and 1-fluoro-4-iodobenzene (208 μ L, 400 mg, 1.80 mmol) using Zn(OAc)₂ (99 mg, 0.54 mmol), sodium dithionite (125 mg, 0.72 mmol), sodium t-butoxide (86 mg, 0.90 mmol), N-XantPhos (20 mg, 0.036 mmol) and Pd₂dba₃•CHCl₃ (10 mg, 0.018 mmol) to afford 307 mg of compound **68a** as an orange oil (this material was used in the next step without further purification): ¹H NMR (400 MHz, DMSO-d₆) δ 10.94 (bs, 1H), 7.71 (dd, *J* = 8.70, 5.10 Hz, 1H), 7.37 – 7.29 (complex overlapping m, 10H), 7.23 – 7.20 (m, 2H), 7.16 (d, *J* = 1.80 Hz, 1H), 7.07 (t, *J* = 8.70 Hz, 1H), 7.03 – 6.97 (m, 6H), 6.73 (dt, *J* = 8.70, 2.30 Hz, 1H), 6.48 (bs, 1H), 4.19 (s, 2H), 3.84 (apparent t, *J* ~ 7.00 Hz, 2H), 2.29 (t, *J* = 6.90 Hz, 2H), 1.49 (quint., *J* = 7.00 Hz, 2H). LCMS (40-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 8.60 min, ESI *m/z* = 693 [M+H]⁺.


Synthesis of 6-fluoro-3-((5-(p-tolylthio)-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazol-3-yl)methyl)-1H-indole (68b)



68b

[0393] Prepared according to **General Procedure 2F** from 5-((6-fluoro-1H-indol-3-yl)methyl)-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazole-3-thiol (**15m**) (300 mg, 0.50 mmol) and 4-iodotoluene (545 mg, 2.50 mmol) using $\text{Zn}(\text{OAc})_2$ (138 mg, 0.75 mmol), sodium dithionite (174 mg, 1.00 mmol), sodium t-butoxide (120 mg, 1.25 mmol), N-XantPhos (28 mg, 0.05 mmol) and $\text{Pd}_2\text{dba}_3 \cdot \text{CHCl}_3$ (26 mg, 0.025 mmol). Purification by flash chromatography (SiO_2 , 40:1 $\text{CH}_2\text{Cl}_2/\text{MeOH}$ to 20:1) afforded 247 mg (72% yield) of compound **68b** as a tan solid: ^1H NMR (400 MHz, $\text{DMSO}-d_6$, $t = 100^\circ\text{C}$) δ 10.70 (bs, 1H), 7.38 – 7.30 (complex overlapping m, 10H), 7.20 (bs, 1H), 7.11 (d, $J = 2.30$ Hz, 1H), 7.08 – 7.02 (complex overlapping m, 11H), 7.01 (d, $J = 2.30$ Hz, 1H), 6.71 (dt, $J = 9.00, 2.30$ Hz, 1H), 6.50 (bs, 1H), 4.18 (s, 2H), 3.85 (apparent t, $J \sim 7.30$ Hz, 2H), 2.23 (t, $J = 7.30$ Hz, 2H), 1.63 (quint., $J = 7.80$ Hz, 2H). LCMS (50-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 5.55 min, ESI $m/z = 689$ $[\text{M}+\text{H}]^+$.


Synthesis of 6-fluoro-3-((5-((3-methoxyphenyl)thio)-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazol-3-yl)methyl)-1H-indole (68c)



68c

[0394] Prepared according to **General Procedure 2F** from 5-((6-fluoro-1H-indol-3-yl)methyl)-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazole-3-thiol (**15m**) (300 mg, 0.50 mmol) and 3-bromoanisole (317 μ L, 468 mg, 2.50 mmol) using $\text{Zn}(\text{OAc})_2$ (138 mg, 0.75 mmol), sodium dithionite (174 mg, 1.00 mmol), sodium t-butoxide (120 mg, 1.25 mmol), N-XantPhos (28 mg, 0.05 mmol) and $\text{Pd}_2\text{dba}_3 \cdot \text{CHCl}_3$ (26 mg, 0.025 mmol). Purification by flash chromatography (SiO_2 , 40:1 $\text{CH}_2\text{Cl}_2/\text{MeOH}$ to 20:1) afforded 264 mg (75% yield) of compound **68c** as a tan solid: ^1H NMR (400 MHz, $\text{DMSO}-d_6$, $t = 25^\circ\text{C}$, peaks are broadened due to slow rotational interconversion) δ 10.96 (bs, 1H), 7.38 – 7.28 (complex overlapping m, 10H), 7.17 (bs, 2H), 7.07 (t, $J = 8.30$ Hz, 1H), 7.03 – 6.97 (m, 7H), 6.74 – 6.67 (m, 2H), 6.58 (m, 2H), 6.43 (s, 1H), 4.21 (s, 2H), 3.84 – 3.81 (m, 2H), 3.52 (s, 3H), 2.27 – 2.24 (m, 2H), 1.51 – 1.43 (m, 2H). ^{13}C NMR (100 MHz, $\text{DMSO}-d_6$) δ 160.21, 159.39 (d, $J_{\text{CF}} = 234$ Hz), 156.35, 146.13, 142.82, 140.08, 138.20, 136.62 (d, $J_{\text{CF}} = 4.40$ Hz), 134.55, 130.93, 129.67, 128.69, 128.46, 124.87 (d, $J_{\text{CF}} = 2.90$ Hz), 124.05, 120.09, 119.99 (d, $J_{\text{CF}} = 9.50$ Hz), 117.98, 113.71, 113.50, 109.00, 107.59 (d, $J_{\text{CF}} = 23.9$ Hz), 97.95 ($J_{\text{CF}} = 24.9$ Hz), 74.85, 55.59, 43.93, 29.51, 25.19, 22.38. LCMS (50-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 5.67 min, ESI $m/z = 705$ $[\text{M}+\text{H}]^+$.

Synthesis of 3-((4-(3-(1H-imidazol-4-yl)propyl)-5-((4-fluorophenyl)thio)-4H-1,2,4-triazol-3-yl)methyl)-6-fluoro-1H-indole (SK-I-128)




SK-I-128

[0395] Prepared according to **General Procedure 1D** from 6-fluoro-3-((5-((4-fluorophenyl)thio)-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazol-3-yl)methyl)-1H-indole (**68a**) (270 mg, 0.39 mmol) and afforded 77 mg (44% yield) of compound **SK-I-128** as a white solid: ^1H NMR (400 MHz, $\text{DMSO}-d_6$, $t = 30^\circ\text{C}$, peaks are broadened due to slow rotational interconversion and/or tautomeric equilibration) δ 11.73 (bs, 1H),

11.00 (bs, 1H), 7.48 (bs, 1H), 7.36 (apparent t, $J \sim 6.90$ Hz, 1H), 7.27 – 7.22 (m, 2H), 7.16 – 7.12 (m, 3H), 7.06 (bd, $J \sim 10.0$ Hz, 1H), 6.78 (bt, $J = 8.70$ Hz, 1H), 6.64 (bs, 0.6H), 6.46 (bs, 0.4H), 4.19 (s, 2H), 3.867 – 3.75 (bm, 2H), 2.38 – 2.25 (bm, 2H), 1.54 – 1.46 (bm, 2H). LCMS (50-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 2.05 min, ESI $m/z = 451$ $[M+H]^+$.


Synthesis of 3-((4-(3-(1H-imidazol-4-yl)propyl)-5-(p-tolylthio)-4H-1,2,4-triazol-3-yl)methyl)-6-fluoro-1H-indole (SK-I-130)



SK-I-130

[0396] Prepared according to **General Procedure 1D** from 6-fluoro-3-((5-(p-tolylthio)-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazol-3-yl)methyl)-1H-indole (**68b**) (162 mg, 0.24 mmol) and afforded 94 mg (88% yield) of compound **SK-I-130** as a white solid: ^1H NMR (400 MHz, DMSO- d_6 , $t = 100$ °C, peaks are broadened due to slow rotational interconversion and/or tautomeric equilibration) δ 11.43 (bs, 1H), 10.73 (bs, 1H), 7.41 (bs, 1H), 7.37 (dd, $J = 8.70, 5.50$ Hz, 1H), 7.12 – 7.06 (complex overlapping m, 5H), 7.04 (d, $J = 2.30$ Hz, 1H), 6.75 (dt, $J = 8.70, 2.30$ Hz, 1H), 6.61 (bs, 0.6H), 6.47 (bs, 0.4H), 4.19 (s, 2H), 3.89 – 3.81 (bm, 2H), 2.38 – 2.31 (bm, 2H), 2.22 (s, 3H), 1.69 – 1.60 (bm, 2H). LCMS (50-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 2.15 min, ESI $m/z = 447$ $[M+H]^+$.


Synthesis of 3-((4-(3-(1H-imidazol-4-yl)propyl)-5-((3-methoxyphenyl)thio)-4H-1,2,4-triazol-3-yl)methyl)-6-fluoro-1H-indole (SK-I-132)



SK-I-132

[0397] Prepared according to **General Procedure 1D** from 6-fluoro-3-((5-((3-methoxyphenyl)thio)-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazol-3-yl)methyl)-1H-indole (**68c**) (82 mg, 0.12 mmol) and afforded 49 mg (91% yield) of compound **SK-I-132** as a white solid: ^1H NMR (400 MHz, CD_3OD) δ 7.51 (d, $J = 1.40$ Hz, 1H), 7.29 (dd, $J = 8.70, 5.50$ Hz, 1H), 7.14 (t, $J = 7.80$ Hz, 1H), 7.00 (dd, $J = 10.0, 2.30$ Hz, 1H), 6.98 (s, 1H), 6.75 (dd, $J = 8.70, 2.30$ Hz, 2H), 6.71 – 6.67 (m, 1H), 6.64 (t, $J = 1.80$ Hz, 1H), 6.55 (s, 1H), 4.30 (s, 2H), 3.82 – 3.78 (m, 2H), 3.61 (s, 3H), 2.34 (t, $J = 7.40$ Hz, 2H), 1.53 (quint., $J = 7.80$ Hz, 2H). ^{13}C NMR (100 MHz, CD_3OD) δ 160.58, 159.99 (d, $^1J_{\text{CF}} = 235$ Hz), 156.74, 148.15, 136.87 (d, $J_{\text{CF}} = 12.4$ Hz), 134.64, 132.64, 130.25, 123.67 (d, $J_{\text{CF}} = 2.90$ Hz), 123.35, 120.83, 118.80 (d, $J_{\text{CF}} = 9.50$ Hz), 114.03, 113.45, 107.90, 107.45 (d, $J_{\text{CF}} = 24.9$ Hz), 97.12 (d, $J_{\text{CF}} = 25.9$ Hz), 54.44, 43.82, 28.86, 23.50 (broad), 22.08. LCMS (25-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 5.67 min, ESI $m/z = 463$ $[\text{M}+\text{H}]^+$.


Synthesis of 6-fluoro-3-((5-(pyridin-3-ylthio)-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazol-3-yl)methyl)-1H-indole (BN-VII-95)



BN-VII-95

[0398] Prepared according to **General Method 2F** from 5-((6-fluoro-1H-indol-3-yl)methyl)-4-(3-(1-trityl-1H-imidazol-4-yl)propyl)-4H-1,2,4-triazole-3-thiol (**15m**) (300 mg, 0.50mmol) and 3-iodopyridine (308 mg, 1.50 mmol) using Zn(OAc)₂ (138 mg, 0.75 mmol), sodium dithionite (174 mg, 1.00 mmol), sodium t-butoxide (120 mg, 1.25 mmol), N-XantPhos (28 mg, 0.05 mmol) and Pd₂dba₃•CHCl₃ (26 mg, 0.025 mmol). Trituration of the isolated residue with CH₂Cl₂ afforded ~350 mg of crude compound **BN-VII-95** as a tan solid: LCMS (50-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 3.38 min, ESI m/z = 676 [M+H]⁺. This material was taken on to the next step “as is.”

Synthesis of 3-((4-(3-(1H-imidazol-4-yl)propyl)-5-(pyridin-3-ylthio)-4H-1,2,4-triazol-3-yl)methyl)-6-fluoro-1H-indole (BN-VII-97)



BN-VII-97

[0399] Prepared according to **General Procedure 1D** from 6-fluoro-3-((5-(pyridin-3-ylthio)-4-(3-(1-trityl-1*H*-imidazol-4-yl)propyl)-4*H*-1,2,4-triazol-3-yl)methyl)-1*H*-indole (**BN-VII-95**) (350 mg, ≤ 0.5 mmol) and afforded 97 mg (45% yield for two steps) of compound **BN-VII-97** as a colorless glass: ^1H NMR (400 MHz, CD_3OD) δ 8.43 – 8.41 (m, 2H), 7.69 (dd, $J = 2.30, 1.30$ Hz, 1H), 7.67 (dd, $J = 2.30, 1.40$ Hz, 1H), 7.54 (d, $J = 0.90$ Hz, 1H), 7.34 – 7.32 (m, 1H), 7.30 (dd, $J = 8.70, 5.50$ Hz, 1H), 7.01 (dd, $J = 9.60, 2.30$ Hz, 1H), 7.01 (s, 1H), 6.77 – 6.72 (m, 1H), 6.60 (s, 1H), 4.31 (s, 2H), 3.89 – 3.85 (m, 2H), 2.38 (t, $J = 7.30$ Hz, 2H), 1.55 (quint., $J = 7.60$ Hz, 2H). ^{13}C NMR (100 MHz, CD_3OD) δ 159.97 (d, $^1J_{\text{CF}} = 235.8$ Hz), 156.76, 149.34, 148.34, 147.41, 138.23, 136.83 ($J_{\text{CF}} = 12.4$ Hz), 134.75, 129.86, 124.71, 123.74 (d, $J_{\text{CF}} = 2.90$ Hz), 123.36, 118.76 (d, $J_{\text{CF}} = 9.60$ Hz), 107.81, 107.46 (d, $J_{\text{CF}} = 24.9$ Hz), 97.14 (d, $J_{\text{CF}} = 25.8$ Hz), 43.84, 29.09, 23.58, 21.98. LCMS (15-95% acetonitrile in 0.05% TFA over 10 minutes) retention time = 5.63 min, ESI $m/z = 434$ $[\text{M}+\text{H}]^+$.

Example 3: Radioligand Binding Assay

[0400] Competitive radioligand binding experiments were performed using MEMBRANE TARGET Systems (Perkin-Elmer, Boston, MA) for human somatostatin receptors: SSTR1 (ES-520-M400UA), SSTR2A (ES-521-M400UA), SSTR3 (ES523-M400UA), SSTR4 (ES-524-M400UA) and SSTR5 (ES-522-M400UA) receptors. (See **Table 1**). Respective membrane receptor preparations were prepared in assay buffer (25 mM HEPES, 10 mM MgCl_2 , 1 mM CaCl_2 , 0.5% BSA, pH = 7.4) at a 1:150 dilution. Binding assays were performed using ^{125}I -Tyr-SRIF 14 (Perkin-Elmer, NEX 3890) dissolved in 1 mM HCl. Binding assays were performed in triplicate for each concentration of ligand in a total volume of 200 μL radioligand (25 μL ligand, 25 μL radioligand, 150 μL receptors) and incubated at room temperature for 90 minutes using a shaking table. Binding was terminated by filtration through GF/B glass fiber filters that were presoaked in 0.5% polyethyleneimine for a minimum of 4 hours. Filters were washed 9 x with 1000 μL ice cold wash buffer (50 mM Tris-HCl, pH = 7.4, 0.2% BSA). Filters were scored, transferred into plastic test tubes and counted in a gamma counter (Wizard2, Perkin-Elmer). Determination of the K_i for each compound was performed

using non-linear regression with GraphPad PRISM-5 software (GraphPad Software, Inc., La Jolla, CA).

Table 1. Competitive Radioligand Binding Data

Compound	SST1 (nM)	SST2 (nM)	SST3 (nM)	SST4 (nM)	SST5 (nM)
BN-VI-61	>10000	>10000	>10000	7.738	>10000
				9.325	
BN-VI-56	6929	>10000	>10000	5.087	>10000
				7.775	
BN-VI-62		>10000		37.52	
				47.28	
BN-VI-87		>10000		447.7	
BN-VI-89		6975		51.70	
BN-VI-97	5309	>10000	>10000	3.20	>10000
SM-I-26	>10000	>10000	>10000	11.95	>10000
				12.80	
SM-I-29		>10000		267.2	
SM-I-38	>10000	>10000	>10000	12.43	>10000
SM-I-50	4744	>10000	>10000	5.54	>10000
SM-I-55	>10000	>10000	>10000	16.20	>10000
SM-I-60	3172	>10000	6989	40.37	>10000
SM-I-76		>10000		11.02	
SM-I-92		>10000		6.979	
MM-I-17	>10000	>10000	>10000	21.47	>10000
MM-I-21	>10000	>10000	>10000	39.53	>10000
MM-I-26		>10000		945.3	
MM-I-36	4076	>10000		14.91	
MM-I-43		>10000		36.60	
MM-I-53		>10000		386.6	
MM-I-63		>10000		30.33	
MM-I-66	587.6	>10000	2335	0.8250	>10000
				0.8383	
MM-I-72	660.7	>10000		1.023	
MM-I-83		2080		1.036	
MM-I-87		3278		0.6726	
MM-I-89		>10000		2.966	
SK-I-16		>10000		1.719	
SK-I-22		7693		1.422	
SK-I-23	2576	>10000	>10000	2.219	>10000
SK-I-25		>10000		1.695	
SK-I-53	1716	7103	>10000	3.107	>10000
SK-I-55	1032	5,434	>10000	2.791	>10000
SK-I-56	1011	>10000	>10000	3.326	>10000
SK-I-57	365.3	1693	1129	1.759	>10000

SK-I-91	468.0	3,969	>10000	0.9025	>10000
SK-I-105	1,080	5,304	>10000	5.133	>10000
SK-I-119	4,336	>10000	>10000	57.05	>10000
SK-I-124	97.82	639.7	1736	0.7070	>10000
AH-1-33		>10000		92.84	
AH-1-40		>10000		90.18	
AH-1-41		>10000		78.80	
AH-1-47	4076 (3435-4835)	>10000	2414	31.05	>10000
AH-1-75		>10000		1347	
AH-1-81		>10000		213.6	
AH-1-84		>10000		959.2	
AH-1-86	>10000	>10000	>10000	76.14	>10000
AH-1-94	8591	>10000	>10000	20.87	>10000
AH-1-96		>10000		563.3	
AH.1.102		>10000		916.2	
AH.1.109		>10000		26.37	
AH.1.112		>10000		16.18	
AH.1.116		>10000		53.12	
AH.1.118		>10000		19.30	
AH.2.126		>10000		775.7	
AH.2.130		>10000		306.0	
AH.2.131		>10000		140.8	
AH.2.132	2134	>10000	>10000	27.32	>10000
AH.2.145		>10000		59.32	
AH.2.160		>10000		326.8	
AH.2.162	2250	>10000	>10000	16.51	>10000
AH.2.165	1644	>10000	>10000	13.76	>10000
MS.1.22	4645	7695	>10000	129.6	>10000
MS.1.27	>10000	>10000	>10000	152.2	>10000
MS.1.30	6,633	>10000	>10000	151.8	>10000
AH.2.178		>10000		12.29	
AH.2.182	2451	8094	5934	8.390	>10000
AH.2.199		>10000		80.75	
AH.2.206		301.4		596.7	
SK-I-128	314.6	2937	>10000	0.6318	>10000
SK-I-130	732.7	3918	5553	3.723	>10000
SK-I-132	655.7	2876	2912	0.6464	>10000

Example 4: Activity Assays

[0401] Measurement of forskolin stimulated inhibition of cAMP was performed via time-resolved fluorescence resonance energy transfer (TR-FRET) LANCE assay (AD0262, PerkinElmer Life Science, Inc., Boston MA). Recombinant Chinese hamster ovary (CHO-K1) cells expressing human somatostatin SSTR4 cells (ES-524-CF, PerkinElmer Life Science, Inc., Boston MA) were thawed (37 °C), resuspended in 10 mL

Hanks' balanced salt solution no phenol red (HBSS, Invitrogen, Carlsbad CA), and then centrifuged (150 x g, 5 minutes). Cellular pellet resuspended in stimulation buffer containing HBSS 1x, HEPES 5 mM, Protease free BSA 0.1 % (PerkinElmer), and 3-Isobutyl-1-methylxanthine 0.5 mM (pH 7.4) and seeded in 96-well plates at 4000 cells/well. LANCE cAMP assay was performed per manufacture instruction with assessment of respective compound, somatostatin-28 (Sigma-Aldrich Co., St. Louis, MO) as control agonist, against 5 μ M forskolin, performed in triplicate across concentration curve. Fluorescence signal was measured at 20 hours (excitation 340 nm and emission 665 nm, 400- μ s delay) via TR-FRET (FLUOSTAR Omega-F, BMG Labtech, Inc., Cary, NC). Data was calculated via GraphPad PRISM-5 software.

[0402] Measurement of β -arrestin was conducted with use of the PATHHUNTER eXpress SSTR4 CHO-K1 β -Arrestin GPCR Assay (93-0308E2, Discover Rx). PathHunter EXPRESS β -Arrestin SSTR4 cells (CHO-K1, DiscoverX) are engineered to co-express the PROLINK (PK) and the Enzyme Acceptor (EA) tagged β -Arrestin. Activation of the SSTR4-PK induces β -Arrestin-EA recruitment, forcing complementation of the two β -galactosidase enzyme fragments (EA and PK). Cells were thawed and diluted in cell-plating reagent, with subsequent plating in 96-well plate (100 μ L/well) and incubated at 37°C/5% CO₂ for 48 hours. Serial dilutions of control curve (somatostatin-28, Sigma-Aldrich Co., St. Louis, MO) and compound(s) being tested are added after 48 hours incubation. After subsequent incubation with control/compounds for 90 minutes, detection reagent is added followed by a 1 hour incubation. The resulting functional enzyme hydrolyzes substrate to generate a chemiluminescent signal which is measured (FLUOSTAR Omega-F, BMG Labtech, Inc., Cary, NC). Data was calculated via GraphPad PRISM-5 software.

Table 2. Activity Assay Data

Compound	EC ₅₀ cAMP (nM)
BN-VI-61	15.62
BN-VI-56	7.264
BN-VI-62	19.28
BN-VI-87	691.7
BN-VI-89	17.01


BN-VI-97	6.083
SM-I-26	16.51
	23.48
SM-I-38	21.02
SM-I-50	4.35
SM-I-55	8.811
SM-I-60	21.31
SM-I-76	10.69
SM-I-92	22.72
MM-I-17	17.31
MM-I-21	28.88
MM-I-36	54.96
MM-I-43	98.42
MM-I-53	254.5
MM-I-63	75.75
MM-I-66	0.5851
MM-I-72	3.324
MM-I-83	0.2756
MM-I-87	0.2495
MM-I-89	2.799
SK-I-16	1.756
SK-I-22	1.280
SK-I-23	7.271
SK-I-25	2.032
SK-I-53	5.972
SK-I-55	6.021
SK-I-56	5.630
SK-I-57	1.003
SK-I-91	3.173
SK-I-105	6.650
SK-I-119	77.72
SK-I-124	0.7253
AH-1-33	130.2
AH-1-40	213.5
AH-1-41	35.00
AH-1-47	85.19
AH-1-81	969.9
AH-1-86	104.6
AH-1-94	21.89
AH-1-96	3778
AH.1.109	38.49

AH.1.112	25.17
AH.1.116	44.02
AH.1.118	52.77
AH.2.126	1128
AH.2.130	2708
AH.2.131	142.8
AH.2.132	89.27
AH.2.145	46.94
AH.2.160	1399
AH.2. 162	13.96
AH.2.165	8.410
MS.1.22	165.5
MS.1.27	612.8
MS.1.30	289.6
AH.2.178	17.46
AH.2.182	10.00
AH.2.199	143.9
AH.2.206	301.4
SK-I-128	0.6186
SK-I-130	3.086
SK-I-132	0.9915

CLAIMS

What is claimed is:

1. A compound comprising Formula (I):



wherein

$\diagup \diagdown$ are independently a single bond or is absent;

A, B, and C are independently C, N, O, or S;

R^1 and R^7 are independently hydrogen, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted C_1 - C_6 alkyl, substituted or unsubstituted cycloalkyl, or substituted or unsubstituted fused ring system;

R^2 is substituted or unsubstituted C_1 - C_6 alkyl;


R^3 , R^4 , and R^5 are independently hydrogen, F, Cl, Br, I, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted amine, sulfoxide, sulfone, thiosulfinate, thiosulfonate, thioamide, sulfimide, sulfoximide, sulfonediimine, or sulfur halide;


R^6 and R^8 are independently hydrogen, F, Cl, Br, I, substituted or unsubstituted C_1 - C_6 alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted cycloalkyl; and

R^9 is a substituted or unsubstituted C_1 - C_3 alkyl;


with the proviso that when R^9 is C_2 alkyl, R^7 is not a 3,4-dichlorobenzene; or a pharmaceutically acceptable salt thereof.


2. The compound of claim 1, wherein  are each a single bond and A, B, and C are N.
3. The compound of claim 1 or 2, wherein R⁶ and R⁸ are independently hydrogen or substituted or unsubstituted C₁-C₃ alkyl.
4. The compound of claim 3, wherein R⁶ and R⁸ are hydrogen.
5. The compound of claim 3, wherein R⁶ and R⁸ are substituted or unsubstituted C₁-C₂ alkyl.
6. The compound of any one of claims 1 to 5, wherein R¹ and R⁷ are independently substituted or unsubstituted aryl or substituted or unsubstituted fused ring system.
7. The compound of claim 6, wherein R¹ is substituted or unsubstituted fused ring system.
8. The compound of claim 7, wherein R¹ is substituted or unsubstituted indole.
9. The compound of claim 6, wherein R⁷ is substituted or unsubstituted aryl.





10. The compound of claim 9, wherein R⁷ is .
11. The compound of claim 10, wherein R¹⁰, R¹¹, R¹², R¹³, and R¹⁴ is independently hydrogen, F, Cl, Br, I, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted amine, sulfoxide, sulfone, thiosulfinate, thiosulfonate, thioamide, sulfimide, sulfoximide, sulfonediimine, or sulfur halide.
12. The compound of claim 11, wherein R¹⁰, R¹¹, R¹², R¹³, and R¹⁴ is independently hydrogen, F, Cl, Br, I, CF₃, OCH₃, NO₂, OCH₂(C₆H₄), C₆H₄, SO₂CH₃, or OCF₃.


13. The compound of any one of claims 1 to 12, wherein R^2 is substituted or unsubstituted C_1 - C_3 alkyl.
14. The compound of claim 13, wherein R^2 is substituted or unsubstituted propyl.
15. The compound of claim 14, wherein R^2 is unsubstituted propyl.
16. The compound of any one of claims 1 to 15, wherein R^3 , R^4 , and R^5 are independently hydrogen, F, Cl, Br, I, or substituted or unsubstituted alkyl.
17. The compound of claim 16, wherein R^3 , R^4 , and R^5 are hydrogen.
18. The compound of any one of claims 1 to 17, wherein R^9 is methyl.
19. The compound of any one of claims 1 to 17, wherein R^9 is ethyl.
20. The compound of any one of claims 1 to 19, wherein the compound is selected from the group consisting of:















21. A compound comprising Formula (II):



wherein

$\diagup$ are independently a single bond or is absent;

A, B, and C are independently C, N, O, or S;

D is S, O, NR^{16} , or P;

R^1 and R^7 are independently hydrogen, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted C_1 - C_6 alkyl, substituted or unsubstituted cycloalkyl or substituted or unsubstituted fused ring system;

R^2 is substituted or unsubstituted C_1 - C_6 alkyl;

R^3 , R^4 , and R^5 are independently hydrogen, F, Cl, Br, I, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted amine, sulfoxide, sulfone, thiosulfinate, thiosulfonate, thioamide, sulfimide, sulfoximide, sulfonediimine, or sulfur halide.

R^6 and R^8 are independently hydrogen, F, Cl, Br, I, substituted or unsubstituted C_1 - C_6 alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted cycloalkyl;


R^9 and R^{15} are independently substituted or unsubstituted C_1 - C_6 alkyl; and

R^{16} is hydrogen, C_1 - C_6 alkyl, aryl, or benzyl;


or a pharmaceutically acceptable salt thereof.

22. The compound of claim 21, wherein $\diagup$ and $\diagdown$ are each a single bond and A, B, and C are N.
23. The compound of claim 21 or 22, wherein D is S.
24. The compound of any one of claims 21 to 23, wherein R^9 is a bond.
25. The compound of any one of claims 21 to 24, wherein R^{15} is unsubstituted C_1 - C_3 alkyl.
26. The compound of claim 25, wherein R^{15} is unsubstituted C_1 - C_2 alkyl.
27. The compound of any one of claims 21 to 24, wherein R^6 and R^8 are independently hydrogen or substituted or unsubstituted C_1 - C_3 alkyl.
28. The compound of claim 23, wherein R^6 and R^8 are hydrogen.
29. The compound any one of claims 21 to 28, wherein R^1 and R^7 are independently substituted or unsubstituted aryl or substituted or unsubstituted fused ring system.
30. The compound of claim 29, wherein R^1 is substituted or unsubstituted fused ring system.

31. The compound of claim 30, wherein R^1 is substituted or unsubstituted indole, substituted or unsubstituted naphthalene, or substituted or unsubstituted quinolone.
32. The compound of claim 29, wherein R^7 is substituted or unsubstituted aryl or substituted or unsubstituted indole.




33. The compound of claim 32, wherein R^7 is .
34. The compound of claim 33, wherein R^{10} , R^{11} , R^{12} , R^{13} , and R^{14} is independently hydrogen, F, Cl, Br, I, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted amine, sulfoxide, sulfone, thiosulfinate, thiosulfonate, thioamide, sulfimide, sulfoximide, sulfonediimine, or sulfur halide.
35. The compound of claim 34, wherein R^{10} , R^{11} , R^{12} , R^{13} , and R^{14} is independently hydrogen, F, Cl, Br, I, CF_3 , OCH_3 , NO_2 , $OCH_2(C_6H_4)$, C_6H_4 , SO_2CH_3 , or OCF_3 .
36. The compound of any one of claims 32 to 35, wherein R^2 is substituted or unsubstituted C_1 - C_3 alkyl.
37. The compound of claim 36, wherein R^2 is substituted or unsubstituted propyl.
38. The compound of claim 37, wherein R^2 is unsubstituted propyl.
39. The compound of any one of claims 21 to 38, wherein R^3 , R^3 , and R^4 are independently hydrogen, F, Cl, Br, I, substituted or unsubstituted alkyl.
40. The compound of claim 39, wherein R^3 , R^3 , and R^4 are hydrogen.
41. The compound of any one of claims 21 to 40, wherein the compound is selected from the group consisting of:




42. The compound of any one of claims 21 to 23, wherein R^{12} is an unsubstituted C_1 - C_3 alkyl.
43. The compound of claim 42, wherein R^{15} is unsubstituted C_1 - C_6 alkyl.
44. The compound of claim 43, wherein R^{15} is unsubstituted C_1 - C_3 alkyl.


45. The compound of any one of claims 42 to 44, wherein R^6 and R^8 are independently hydrogen or substituted or unsubstituted C_1 - C_3 alkyl.
46. The compound of claim 45, wherein R^6 and R^8 are hydrogen.
47. The compound of any one of claims 42 to 46, wherein R^1 and R^7 are independently substituted or unsubstituted aryl or substituted or unsubstituted fused ring system.
48. The compound of claim 47, wherein R^1 is substituted or unsubstituted fused ring system.
49. The compound of claim 48, wherein R^1 is substituted or unsubstituted indole.
50. The compound of claim 49, wherein R^7 is substituted or unsubstituted aryl.




51. The compound of claim 50, wherein R^7 is
52. The compound of claim 51, wherein R^{10} , R^{11} , R^{12} , R^{13} , and R^{14} is independently hydrogen, F, Cl, Br, I, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted amine, sulfoxide, sulfone, thiosulfinate, thiosulfonate, thioamide, sulfimide, sulfoximide, sulfonediimine, or sulfur halide.
53. The compound of claim 52, wherein R^{10} , R^{11} , R^{12} , R^{13} , and R^{14} is independently hydrogen, F, Cl, Br, I, CF_3 , OCH_3 , NO_2 , $OCH_2(C_6H_4)$, C_6H_4 , SO_2CH_3 , or OCF_3 .
54. The compound of any one of claims 21 to 53, wherein R^2 is substituted or unsubstituted propyl.
55. The compound of claim 54, wherein R^2 is unsubstituted propyl.

56. The compound of any one of claims 21 to 55, wherein R^2 , R^3 , and R^4 are independently hydrogen, F, Cl, Br, I, substituted or unsubstituted alkyl.
57. The compound of claim 56, wherein R^2 , R^3 , and R^4 are hydrogen.
58. The compound of any one of claims 21 to 57, wherein the compound is selected from the group consisting of:







59. A compound according to any one of claims 1-58 for use as a medicament for the treatment of pain or inflammation.
60. A method for the treatment of pain or inflammation which comprises administering to a subject in need thereof a therapeutically effective amount of a compound according to any one of claims 1-58.
61. A pharmaceutical composition containing a compound according to any one of claims 1-58 and a pharmaceutically acceptable carrier.